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Abstract 
The synthesis of glycolipids as potential anti-bacterial agents and glycolipid mimetics is the 
main focus of the research presented in this thesis. A variety of glycolipids based around an 
aspartic acid, aliphatic or aromatic scaffold were investigated. 
Chapter 1 describes the biological importance of glycolipids and how they can be utilised as 
anti-adhesion agents and immunomodulators. The concept of multivalency is also discussed, 
with specific examples relating to the anti-adhesion approach. 
A variety of O-glycolipids based around an aspartic acid scaffold were constructed in chapter 2. 
Based on a modular approach, a diverse range of glycolipids were synthesised. They exhibited 
variations in hydrocarbon chain length, number of hydrocarbon chains, connectivity of 
carbohydrate moiety and the carbohydrate moiety used. Although originally designed to act as 
immunomodulators their ability to inhibit bacterial adhesion in immunocompromised 
individuals was also investigated. Furthermore the glycolipids were tested as low molecular 
weight organogelators (LWOG), and promising results were obtained.  
Chapter 3 deals with the synthesis of O- and N-glycolipids built around an aliphatic core. 
Initially the synthesis proved problematic but success was achieved utilising DMTMM as the 
coupling reagent. Similarly to the aspartic acid analogues, the glycolipids exhibited variation in 
the chemical nature of the spacer groups used to link the carbohydrate to the aliphatic core. 
The O- and N-glycolipids were synthesised with a view to examine their ability to inhibit 
bacterial adhesion in Cystic Fibrosis (CF) patients.  
The synthesis of a range of glycolipids based around an aromatic core is discussed in chapter 4. 
Again variation in the linker utilised to connect the carbohydrate moiety and the aromatic core 
is explored. This time the importance of the presence of the hydrocarbon chain was also 
investigated. Therefore variation in the connectivity of the lipidic chain is explored, and 
analogues of varying hydrocarbon chain length were synthesised. The O- and N-glycolipids 
were synthesised as potential anti-adhesion agents in order to determine a structural activity 
relationship. 
The biological evaluation of selected glycolipids is discussed in chapter 5. Selected aspartic 
acid, aliphatic and aromatic glycolipids are investigated as potential inhibitors of Burkholderia 
multivorans adhesion to a model of lung epithelial cells of CF patients. Promising preliminary 
results were obtained for both a mono- and di-valent aromatic-based glycolipid. 
 
 v 
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1.1 Glycolipids and their biological importance 
Glycolipids, as their name implies, are lipids that are attached to a carbohydrate moiety.[1] 
Glycolipids are amphiphilic in nature, and can be divided into different sub-classes depending 
on 1) the organism in which they are found,[2] and 2) their structure and function.[3] Glycolipids 
found in animals generally belong to the glycosphingolipid family and are important 
membrane components (Figure 1.1).[3] Glycolipids found in plants generally belong to the 
glycoglycerolipids family.[2]  
 
Figure 1.1 General structure of glycoglycerolipids and glycosphingolipids. 
Glycolipids are an essential component of cell membranes[4] and are normally found at the 
outer surface. They play a vital role in a number of cellular functions, including cell adhesion, 
cell-cell communication, signal transduction, protein sorting[2] and cell pathogen  
interactions.[4-5]  
The hydrophobic lipid part of the glycolipid buries itself in the outer lipid layer of the cell 
membrane, whereas the hydrophilic carbohydrate portion extends from the phospholipids 
bilayer into the aqueous environment outside the cell.[6] It can then act as a recognition site for 
specific chemicals, help maintain the stability of the membrane and also play a role in tissue 
formation.[6-7]   
1.2 Glycolipids as potential anti-adhesion agents 
1.2.1 Anti-adhesion therapy 
The alarming rate at which bacterial antibiotic resistance is increasing has made it vital to 
intensify the search for new means of combating bacterial infections.[8] A strategy which does 
not kill the pathogens but still interferes with their pathogenicity may provide a much needed 
alternative.[9] One such approach, which has proved highly promising, is anti-adhesion 
therapy.[8-9] 
 
 The anti-adhesion approach inhibits bacterial adhesion to the host cell by using agents 
(particularly carbohydrate) to bind to the adhesin proteins present on the pathogen, therefore 
preventing the bacteria from attaching to the carbohydrates present on the surface of the cell 
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(Scheme 1.1). Bacterial adhesion is often the prerequisite for the later stages of infection 
including colonisation and invasion of tissues, thus this approach is highly advantageous. The 
non-adhering bacteria can then be removed by the regular cleansing mechanisms of the 
body.[9]  As the bacteria are not killed, but rendered ineffective, they are not under selection 
pressure and as a result, bacterial resistance to these anti-adhesive drugs evolves slowly.[10] 
 
 
Scheme 1.1 Bacterial adhesion to the cell can result in infection (left). Free carbohydrates binding to the 
pathogen (right) prevent bacterial adhesion to the cells, therefore preventing infection.
[9]
 
 
The key to using carbohydrates for the anti-adhesion approach is that, when the bacteria 
mutate and lose their affinity for the carbohydrate drug (i.e become resistant), they also lose 
their ability to bind to the native carbohydrates present on host cells.[11] Also, as many of the 
saccharides that inhibit bacterial adhesion are found on cell surfaces or in body fluids, they are 
unlikely to be toxic or immunogenic and are ideal for using as anti-adhesion agents.[12] Another 
benefit comes from the specificity exhibited by the bacterial adhesins. Individual microbe 
species bind to different carbohydrate sequences, therefore the carbohydrate-based drugs can 
be used to target only the species that requires elimination. This is not the case with 
conventional antibiotics, which can also kill and target non-pathogenic, normal microbial 
flora.[13]  
An important hurdle in the development of this area is the limited affinity of monovalent 
carbohydrates for the target proteins that are often multivalent. Multivalent inhibitors seem a 
logical step to overcome the limitation.[9] 
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1.2.3 The multivalent glycoside effect 
Protein-carbohydrate interactions are responsible for the initiation of a number of crucial 
events in a variety of biological processes including cell–cell communication, fertilisation, host–
pathogen interactions, and immune response.[14] However, a major problem lies in the fact 
that individual carbohydrates tend to bind weakly to their complementary multivalent 
proteins.  To overcome this, multivalent scaffolds containing a number of carbohydrates have 
been utilised.[15] It is has been shown that multivalent glycosides bind with greater affinities to 
their polyvalent protein receptors.[16] This phenomenon, which was first noted by Lee and co-
workers is known as the ‘‘cluster’’ or ‘‘multivalent’’ glycoside effect,[17] and has found a wide 
range of applications in biology and medicine. Some examples are discussed below. 
Adhesin proteins present on uropathogenic Escherichia coli recognise and bind to galabiose 
(Gal-α1-4Gal)-containing structures present on cell surfaces. It is by this mechanism that the 
bacteria adhere to the host cells. Pieters and coworkers synthesised a variety of galabiose 
containing multivalent glycoconjugates 1.1-1.4 (Figure 1.2) and investigated their potential as 
inhibitors of  E. coli adhesion.[18] They also investigated their potential anti-adhesion properties 
against Streptococcus suis. 
 
Figure 1.2 Variety of galabiose multivalent ligands tested as potential inhibitors of  E. coli adhesion to 
host cells.
[18] 
A number of assays were performed, and it was found that the mono- and multivalent 
galabiose derivatives 1.1-1.4 inhibited bacterial adhesion in a concentration-dependent 
manner. The multivalent effect was also prominent as the octavalent derivative 1.4 proved to 
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be a much better inhibitor than the tetravalent derivative 1.3, which was in turn superior to 
the bivalent derivative 1.2 and so on (Table 1.1). Interestingly, the multivalent effect was much 
more pronounced for the inhibition of S. suis adhesion in comparison to the E. coli.  
 E. coli 
Relative 
potency 
E. coli 
potency per 
sugar 
S. suis 
Relative 
potency 
S. suis 
potency per 
sugar 
Monovalent (1.1) 1.0 1.0 1.0 1.0 
Divalent (1.2) 2.6 1.3 13 6.7 
Tetravalent (1.3) 7.7 1.9 250 63 
Octavalent (1.4) 43 5.3 310 39 
Table 1.1. The relative inhibitory potency [IC50 (monovalent compound)/IC50 (multivalent compound)] of 
galabiose derivatives in surface plasmon resonance (SPR) adhesion assay with E. coli and S. suis. To 
calculate the potency per sugar unit, the relative potency was divided by the valency of the compound. 
Pieters and his group have carried out much research in this area and have synthesised a 
variety of different ligand collections consisting of compound with varying valency.[18-19] Each 
collection is based around the same dendrimer scaffold but contains different carbohydrate 
moieties and also different linker structures.[19] One such example is the synthesis of a variety 
of lactose-containing dendrimers 1.5-1.9 (Figure 1.3), with each one exhibiting a different 
valency. The ability of the ligands to bind the cholerae toxin B (CTB) subunit were evaluated.[20] 
 
Figure 1.3 Variety of lactose multivalent ligands tested as potential binders of the cholerae toxin B 
subunit.
[20]
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As with the previous example, the multivalent effect is extremely evident. All multivalent 
derivatives were able to bind to the CTB and therefore led to an increase in inhibition of 
bacterial binding to the host cells (Table 1.2). They also found that the binding of CTB 
increased with increasing valency. As expected, the octavalent ligand 1.7 displays the strongest 
binding with a Kd of 33 mM. Surprisingly the results for the monovalent ligand 1.9 were also 
quite promising, as it had a Kd of 248 mM, making it 73 times more potent than lactose alone. 
Pieters et al. suggest that this increase in affinity is due to additional interactions which can 
occur between the aglycone and the protein. The difference in binding affinity between the 
mono- 1.9 and di-valent ligand 1.5 is only very minimal. This could be due to the linker length, 
as it may not have allowed both carbohydrate moieties to bind simultaneously to adjacent 
subunits. This highlights the importance of considering binding site spacing when designing 
dendrimers for multivalent inhibition.[21] 
Compound Kd[µm] Relative potency  Relative potency per 
lactose 
Lactose 18000 1 1 
1.8 2700 7 7 
1.9 248 73 73 
1.5 235 77 38 
1.6 99 182 46 
1.7 33 545 68 
Table 1.2 Apparent dissociation constants of the binding of various lactose derivatives to CTB. 
1.2.4 Glycoconjugates as inhibitors of Burkholderia cenocepacia adhesion 
Burkholderia cenocepacia complex (Bcc) is a group of opportunistic pathogens associated with 
infections in immunocompromised individuals which have underlying lung disease e.g. CF 
(discussed further in Chapter 5, section 5.1).[22] Bcc is often resistant to common antibiotics, 
and therefore utilising multivalent carbohydrates as inhibitors of the bacterial adhesion would 
be highly advantageous. 
McClean and co-workers previously showed that terminal galactose-containing glycolipids 
present on the surface of the host cell mediate bacterial adhesion and therefore facilitate the 
invasion of the lungs.[23] With this in mind, ligands containing terminal galactose moieties could 
potentially be utilised to reduce bacterial adhesion. One such example comes from Murphy 
and co-workers.[24] Bivalent lactosides 1.10-1.12 (Figure 1.4) were synthesised and tested as 
potential inhibitors of Burkholderia multivorans bacterial adhesion. Results showed that 
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lactoside 1.10 strongly inhibited the binding of B. multivorans to lung epithelial cells at a range 
of concentrations. In comparison, the more rigid derivative 1.11 was unable to inhibit 
adhesion. In fact, at certain concentrations it led to an increase in bacterial adhesion to the 
epithelial cells. Finally the tertiary amide derivative 1.12 decreased attachment at low 
concentrations, but at higher concentrations, it led to an increase in bacterial attachment.[24] 
 
Figure 1.4 Selection of bivalent lactosyl glycoconjugates synthesised and tested against B. multivorans. 
One of the soluble lectins (discussed in detail in chapter 5) of Burkholderia cenocepacia is 
BC2L-A, and it has been shown to exhibit a strong affinity for α-D-mannosides, with methyl α-
D-mannopyranoside displaying a Kd value of 2µm.
[25] Lameignere et al. tested a variety of α-D-
mannosides and investigated their affinity for the BC2-A lectin (Figure 1.5).  The bivalent 
compound 1.15 with a rigid linker displayed high binding affinities in comparison to the more 
flexible bivalent derivative 1.14 and the trismannoside 1.16, which both only exhibited 
moderate affinities. The rigid compound 1.15 had an affinity ten times greater than the flexible 
compound 1.14 and it is believed this difference is due to the inability of the flexible 
compound to cross-link the lectins. It was observed that both the flexible derivative 1.14 and 
the trismannoside 1.16 bind as monomers. Lameignere et al. postulated that the flexible 
compound 1.14 can fold on the BC2L-A structure and as a result, it does not interact with 
neighbouring proteins. If this is the case, a rigid linker which efficiently presents the second 
mannose far from the first binding site can result in a higher cross-linking effect, and therefore 
resulting in higher affinities. 
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Figure 1.5 Selection of α-D-mannosides tested for the affinity for the BC2L-A lectin.
[25]
 
1.2.5 Glyconjuagates as inhibitors of Pseudomonas aeruginosa adhesion 
P. aeruginosa is an opportunistic pathogen associated with causing chronic airway infections in 
immunocompromised individuals, most notably cystic fibrosis patients. P. aeruginosa contains 
two lectins, LecA and LecB, which play a major role in the infection process.[22] It has been 
shown that LecA recognises galactose derivatives and LecB recognises fucose derivatives. 
Glycoconjugates containing galactose and fucose have exhibited a therapeutic effect against P. 
aeruginosa pneumonia in both mice models[26] and cystic fibrosis patients.[27] 
A variety of multivalent glycoconjugates have been synthesised for inhibiting the binding of 
LecA to galactosylated surfaces and some representative examples 1.17-1.19 are shown in 
Figure 1.6. Similarly, a variety of multivalent glycoconjugates have been found to be LecB high 
affinity ligands and again representative examples are shown in Figure 1.6. 
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Figure 1.6 Representative examples of multivalent glycoconjugates 1.17,
[28]
 1.18 (monomer, from which 
polymer was synthesised)
[29]
 and 1.19
[30]
 which are LecA high affinity ligands. Representative examples 
of multivalent glycoconjugates 1.20
[31]
 and 1.21
[32]
 which are LecB high affinity ligands. 
 
1.3 Glycolipids as immunomodulators 
1.3.1 The immune response 
The human mammalian immune system has two components; the innate or non-specific 
immune system and the adaptive or specific immune system.[33] The innate immune system is 
the first line of defence against invading pathogens and foreign bodies (Table 1.3). The 
adaptive immune system is the second line of defence and only comes into effect if the innate 
immune system is overwhelmed or circumvented. Both immune systems utilise cellular and 
humoral components to carry out their protective function, however the innate immune 
system also includes physical barriers such as skin. The innate immune system provides a fast, 
non-specific response to an unknown pathogen. In comparison, the adaptive immune system 
provides a slower specific response as it needs to produce lymphocytes with specific antigen 
receptors such as T-cells receptors (TCR). As these lymphocytes can retain a memory of the 
invading organism, the host can recognise these pathogen if re-infected and therefore produce 
a faster response.[34] 
Chapter 1:                                                                                                                                                  Introduction 
 
 
10 
 
 
Innate or non-specific immunity  Adaptive or specific immunity 
Reponse is antigen-independent Reponse is antigen-dependent 
Fast response Slow response 
Not antigen-specific Antigen specific 
No immunologic memory Immunologic memory 
Table 1.3 Key differences between innate and adaptive immunity. 
1.3.2 Natural Killer T-Cells 
Natural killer T (NKT) cells are a subset of T cells, which share characteristics of both Natural 
Killer (NK) cells and T-cells.[35] T-cells recognise fragments of foreign molecules that are 
presented to the host by antigen-presenting cells (APC).[36] The major difference between T-
cells and NKT cells is that T-cells detect antigens presented by conventional major 
histocompatibility (MHC) molecules, whereas, NKT cells recognise lipid antigens presented by 
the non-traditional MHC molecule CD1d.[37] CD1d is a member of the CD1 family. The binding 
of the NKT cells and the CD1d protein leads to the rapid secretion of cytokines.[36] Cytokines 
are small, cell-signalling proteins used extensively in intercellular communication and they are 
secreted by a number of cells. The secretion of cytokines is discussed more in the next section. 
1.3.3 α-Gal-Cer  
In 1993, during a screen for reagents that prevent tumour metastases in mice, researchers at 
the Pharmaceutical division of the Kirin Brewery company reported the isolation of 
Agelasphin-9b from a marine sponge, Agelas mauritianus.[38] Although work had previously 
been carried out on sponges of this type, this isolation was of significant interest as the 
compound displayed potent anti-tumor and immunostimulatory properties. Various structure-
activity studies were carried out and as a result the candidate molecule for immunology 
researchers became the synthetic material, known as KRN7000 or αGalCer (Figure 1.7).[36]  
 
Figure 1.7 Structure of KRN7000 (synthethic α-GalCer compound) and Agelasphin 9b (one of the original 
compounds isolated from the Agelas mauritianus).
[36]
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Numerous mechanistic immunological studies have shed some light onto the mode of action of 
α-GalCer. It has been shown that two consecutive cellular recognition events are necessary to 
exhibit activity.[36, 39] First, the α-GalCer binds to the CD1d protein, forming a binary complex. 
This binary complex is then recognised by the T cell receptor (TCR) located on the surface of 
the invariant natural killer T (iNKT) cells to form the active ternary complex. This recognition 
leads to the activation of the immune response through the secretion of cytokines.[36, 39-40] The 
secretion of  a range of cytokines including interferon-γ (IFNγ) (TH1 cytokine) and interleukin-4 
(TH2 cytokine) is initiated by the iNKT cells.
[40] TH1 cytokines are believed to be involved in 
antitumor and antimicrobial activity, whereas TH2 cytokines may play a role in alleviating 
autoimmune diseases.[41]  
 
Although promising results for KRN7000 were observed in pre-clincial trials on mice,[42] phase 1 
clincal trials on 24 patients suffering from refractory solid tumours didn’t give promising 
results. In fact, the patients showed no partial or complete response to the treatment.[43] As a 
result, clinical trials were terminated.  Another complication that has hampered the use of 
KRN7000 as a therapeutic agent is the fact that it leads to the release of both TH1 and TH2 
cytokines. It has been revealed that, when released together, their effects oppose one 
another, and can lead to unpredictable biological responses.[40] Therefore the main focus on 
current KRN7000 research is to find a synthetic analogue that can effectively activate iNKT cells 
but with a bias towards either a TH1 or TH2 response. 
1.3.4 Synthetic analogues of α-GalCer 
Since its discovery, numerous analogues of KRN700 have been synthesised. The main sites of 
modifications are highlighted in Figure 1.8 and representative examples are discussed below 
(Figure 1.9).  
 
Figure 1.8 Modifications investigated on KRN7000. 
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In glycolipid 1.22 Lee and colleagues replaced the amide functionality of the phytosphingosine 
backbone with a triazole ring containing a long hydrocarbon chain.[44] In vivo studies were 
performed on mice, and they found that the analogue exhibited an improved bias towards TH2 
cytokine production compared to KRN7000. Another promising analogue is the β-glycolipid 
1.23. Although evidence suggests that β-glycolipid analogues have potential as immune 
regulating compounds, there has been little interest in the synthesis and evaluation of such 
analogues. In vitro studies on glycolipid 1.23 showed it to be a promising anti-tumour agent.[45] 
In the final glycolipid analogue shown, 1.24, an aromatic group together with a long alkyl chain 
was introduced at the amino acid functionality.[46] This resulted in an increase bias towards TH1 
cytokine production in comparison to KRN7000. 
 
Figure 1.9 Synthetic analogues of the glycolipid KRN7000 with modifications of the amide functionality 
1.22,
[44]
 anomeric linkage 1.23
[45]
 and lipid chain 1.24.
[46]
 
 
The hydroxy group on the C-6 position of galactose is the only sugar alcohol not involved in any 
hydrogen bonding between α-GalCer and the CD1d protein. For this reason huge interest lies 
in the synthesis of analogues with modifications in this position[47]. Two examples are shown 
below in Figure 1.10; a 6-ureido analogues with a bulky 1-naphthyl group linked to the 6’-
ureido-6’deoxy-αGalCer 1.26,[48] and a highly soluble analogue which has an acetamide group 
in the C6 position of galactose and a cis-double bond in the acyl chain of KRN7000 1.25.[49] 
Compound 1.25 was shown to activate both murine and human NKT cells more effectively 
than KRN7000. 1.26 showed a slight TH1 bias with IFN-γ stimulation comparable or possibly 
greater than KRN7000 with reduced IL-4 production.[47] However a stronger TH1 bias was 
obtained with the 3-CF3, 4-Cl benzamide substituent 1.27
[48] on the 6-position. The compound, 
1.27, induced IFN-γ levels comparable to α-GalCer and only marginal levels of IL-4. 
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Figure 1.10 Modifications of the 6-position of the galactose moiety in α-GalCer which led to improved 
immunological activity. 
 
1.4 Thesis objectives 
 
As discussed previously, glycolipids are extremely important and are involved in a variety of 
biological processes. Despite this, their structural complexity and amphiphilic nature can make 
isolation and synthesis problematic. With this in mind, the efficient synthesis of glycolipid 
mimetics which resemble naturally occurring glycolipids is advantageous and could provide a 
useful tool in aiding investigation into their biological relevance. We aimed to synthesise a 
collection of glycolipid mimetics and investigate their potential as both anti-adhesion agents 
and immunomodulators.  
The alarming rate at which bacterial antibiotic resistance is increasing, especially among Gram-
negative bacteria (GNB), has made it vital to intensify the search for new means of combating 
bacterial infections.[8] We wanted to investigate the ability of the selected glycolipids to inhibit 
the adhesion of Burkholderia multivorans to the epithelial cells of patients with cystic fibrosis 
(CF), thus, reducing bacterial infections. This approach is extremely valuble as there are no 
drugs againist resistant GNB currently in development.[50] 
 
Although numerous multivalent ligands have been examined as potential inhibitors of bacterial 
adhesion, limited examples of glycolipids have been investigated for this purpose. We wanted 
to explore how the lipidic component of the glycolipid may influence the bacterial adhesion 
process. There are a number of reasons as to how the lipidic component may influence the 
biological activity of the compounds. They are lipophilic and may insert into the cell membrane 
of the cells. This could result in the glycolipids aiding the adhesion of the bacteria to the host 
cells by acting as a bridge between the bacteria and the cell. The presence of lipidic chains may 
also lead to increased steric hinderence. This could affect both the conformation of the 
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molecule and also how it interacts with the bacterial lectin involved in the adhesion process. 
Finally, the presence of lipidic chains may lead to the formation of micelles. This would result 
in a supramolecular, multivalent presentation of the glycolipids to the bacteria and may lead to 
an increased biological activity. 
Our investigation focused around the construction of galactosyl ligands, as it has been shown 
that terminal galactosyl-containing glycolipids mediate bacterial adhesion to the host cells.[23] 
Structural information on the bacterial lectin involved in the adhesion process is limited, 
therefore the rationale design of synthetic anti-adhesion ligands is extremely difficult. For this 
reason, a wide range of structurally diverse glycoconjugates have been examined in an 
attempt to identify possible structural requirements necessary to exhibit anti-adhesion 
properties.  
Our research focused on the synthesis of glycolipids around an aspartic acid scaffold (chapter 
2), malonyl scaffold (chapter 3) or an aromatic core (chapter 4). Representative based 
examples have been investigated as potential inhibitors of bacterial adhesion and preliminary 
results are discussed in chapter 5. 
During the course of our research it was observed that some of the glycolipids had the ability 
to act as low molecular weight gelators (LMWG). This was further investigated and the results 
are presented in chapter 2. 
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2.1 Amphiphilic glycolipids 
Amphiphilic compounds such as glycolipids are used as surfactants in industry. Due to the 
unique physicochemical properties that arise from the coexistence of the hydrophilic head 
group and the hydrophobic moiety, surfactants reduce the interfacial tension and facilitate the 
formation of emulsions between immiscible liquids of different polarities. They can also be 
adsorbed between different phases (e.g. liquid-liquid or liquid-solid) and reduce the tension 
between these phases. Owing to these properties, surfactants are utilised in the polymer, 
plastic, textile, paper, cosmetics and pharmaceutical industries.[51]  
The majority of commercial surfactants are chemically synthesised from petroleum 
derivatives[52] and prolonged usage can lead to significant environmental problems. As a result 
of this, surfactants which are derived from natural products pose fewer environmental 
problems and as a result are of great interest.[51b] Biosurfactants are surfactants produced by 
microorganisms. As they are extracted from renewable sources, have high purity, low toxicity, 
and are biodegradable, they are extremely advantageous, and this has led to huge commercial 
interest.[53] Examples of biosurfactants include glycolipids, lipopeptides, fatty acids and 
phospholipids. Due to their biocompatibility, biological activities, biodegradability and 
physicochemical properties glycolipids are the most widely used surfactants in the cosmetic 
industry. Examples of types of glycolipid biosurfactants include sophorolipids, rhamnolipids 
and mannosylerythritol lipids (Figure 2.1).[51b]  
 
Figure 2.1 Examples of structures of sophorolipids, rhamnolipids and mannosylerythritol lipids extracted 
from microorganisms.
[51b]
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2.2 Gelator molecules 
In the 1920’s, J.Lloyd made a predictive statement whereby he described gel as materials 
“easier to recognize than define”.[54] In the years that followed various definitions were 
presented.  Nowadays it is generally accepted that gels are solid-like materials comprised of an 
elastic cross-linked network and a solvent (major component). By weight gels are mostly liquid, 
yet they behave like solids due to the entrapment of the solvent in a three-dimensional gelator  
network within the liquid.[55] Gels can be formed via self-assembly (supramolecular gels) or via 
polymerisation of the gelator (polymer gels) molecule. A supramolecular gel, is a semi solid 
material which is composed of gelator molecules in relatively low concentrations. In the 
presence of an appropriate solvent, a supramolecular gelator can prevent liquid flow as a 
result of surface tension. This surface tension is caused by self-assembly which leads to an 
extensive three dimensional network of intertwined gelator fibre.[54]  Polymer gels are created 
from two components: a polymer network and a solvent. A polymer network envelops the 
liquid and prevents it from escaping. The properties of a gel depend largely on the structure of 
the gelator network that makes up the gel and the interaction of the network and the 
solvent.[56]   
2.2.1 Low molecular weight gelators (LMWG) 
Low molecular weight gelators (LMWGs) have received a great deal of interest in recent years 
due to their potential for creating novel soft materials which have applications in the 
environmental, cosmetics, and biomedical industries. LMWG are small molecules which can 
self-assemble through noncovalent interactions to form fibrous networks which are able to 
entrap solvent molecules in their matrix. This leads to the formation of thermally reversible 
supramolecular gels, which can occur in both organic solvents (organogels) and aqueous 
solutions (hydrogels).[57] The non-covalent interactions involved in gel formation include H-
bonding, π stacking, electrostatic interactions and Van der Waals forces.[58] These gels are 
usually prepared by heating the gelator in an appropriate solvent and cooling the resulting 
supersaturated solution to rt. When the hot solution is cooled, the molecules start to 
condense and there are three possible outcomes (Figure 2.2): (1) a highly ordered aggregation 
which results in the formation of crystals; (2) a random aggregation which results in an 
amorphous precipitate; or (3) an aggregation process intermediate between these two, which 
yields a gel.[55]  
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Figure 2.2 Schematic representation of gelation process.
[59]
 
Organogels are of interest due to their potential uses as sensors, cosmetics, separation 
systems, biomimetics and templates for material synthesis. Arguably the most important 
application of organogels is for drug delivery.[58b] 
Low molecular weight organogelators (LMWOG) can be further divided into two main groups, 
H-bond gelators and non H-bond gelators.[58b, 58c] H-bonding is responsible for gelation when 
induced by compounds containing amide bonds such as peptides[60] and compounds which 
contain hydroxyl groups such as carbohydrates.[61] On the other hand, cholesterol 
derivatives,[62] anthracene and tropone derivatives are classified as non-H bond gelators.[58b] 
2.2.1.1 The non-covalent interactions involved in gel formation 
H-bonding interactions take place between an electron-rich heteroatom and electron-deficient 
hydrogen. The group that provides the hydrogen atom is termed the hydrogen bond donor 
(HBD) and the heteroatom that receives the hydrogen is known as the hydrogen bond 
acceptor.[63] H-bonding between the gelator molecules themselves and also between the 
gelator molecule and the solvent can play a role in the formation of a gel.[64] 
Van der Waals forces are another important non-covalent interaction which plays a role in the 
formation of gels.[65] The electron density of the hydrophobic regions of a molecule is never 
evenly distributed. Instead, transient areas of higher and lower electron density exist. This 
leads to temporary dipoles being present in the molecule. The presence of these transient 
dipoles can induce dipole formation in the hydrophobic region of another molecule. The 
interaction between these two dipoles is what is known as Van der Waals forces.[63] 
2.2.2 Non-carbohydrate gelators 
There are many examples of LMWGs described in the literature. Initially, most were discovered 
through serendipity rather than design. However, due to an increased interest in this field, 
researchers are now attempting to synthesise “designed” gelators to examine the relationship 
between chemical structure and gelation ability.  
Super-saturated 
solution 
Crystal 
Gel 
Precipitate 
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Although we are primarily interested in carbohydrate-based gelators there are many examples 
in the literature of non-carbohydrate gelators. As can be seen from the representative 
examples shown in Figure 2.3, many LMWGs contain either an aromatic ring or an amide bond. 
 
Figure 2.3 Chemical structure of some representative examples of  LMWG: cholesterol derivative 2.1,
[66]
 
hydrazine derivative 2.2,
[67]
 fatty acid amide 2.3
[68]
 and a L-alanine derivative 2.4.
[58b]
 
2.2.3 Carbohydrate-based gelators 
The presence of stereogenic centres has been shown to affect the ability to form gels.[69] 
Chirality also  plays a crucial role and is involved in the assembly processes that take place on 
surfaces to form supramolecular gels.[58b] For these reasons carbohydrates have commonly 
been used in the synthesis of LMWGs. They are also naturally abundant and can be selectively 
functionalised because they contain multiple chiral centres.[57]  Wang et al. have found that 
glucose is a versatile building block for synthesising carbohydrate organogelators, as 
substituted products can be obtained easily by selectively functionalising the anomeric 
position and the 4- and 6- hydroxyl groups.[57] Examples of these functionalised glucose 
derivatives, 2.5 and 2.8, are shown in Figure 2.4. Amino acids are also popular in the synthesis 
of LMWGs as they allow for the introduction of hydrocarbon chains (important for non-polar 
Van der Waal type interactions) and also the formation of amide bonds (2.6 and 2.7 Figure 
2.4). Finally, selected triazole-containing molecules 2.9 have also proven to be efficient 
gelators. 
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Figure 2.4 Chemical structure of carbohydrate-based gelators, a functionalised glucose 2.5,
[57]
 a 
glycolipid amino acid 2.6,
[70]
 a glycolipid aspartic acid derivative 2.7,
[71]
 a simpler functionalised glucose 
2.8,
[72]
 and a maltose compound containing a triazole and azobenzene moiety 2.9.
[73]
 
2.3 Glycomimetics 
Glycomimetics are small organic molecules that have structures similar to carbohydrates, but 
with some modification which normally results in improved pharmacological properties. They 
are designed to mimic the bioactive function of naturally occurring carbohydrates and yet 
address the drawbacks of carbohydrate leads, namely their low bioavailability and insufficient 
drug-like properties.[74] Strong interest lies in the rational design of glycomimetic drugs as 
alternatives to complex and naturally occurring oligosaccharides. Glycomimetic drugs currently 
approved and on the market include glycosidase inhibitors that prevent the digestion of 
carbohydrates for the treatment of diabetes (Voglibose)[75] and also prevent influenza virus 
infections (Oseltamivir).[76] Other examples include carbohydrate-derived drugs that are used 
to treat Gaucher’s disease (Miglustat),[77] and epilepsy (Topiramate).[78] The structures of these 
compounds are shown in Figure 2.5.  
 
Figure 2.5 Examples of some glycomimetic drugs currently on the market. Their trade name is given in 
brackets.
[74]
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2.3.1 Glycolipid mimetics 
Glycolipids contain one or more saccharide units linked to a hydrophobic lipid chain. Due to 
their involvement in a variety of processes in bacteria, plants and animals, there is strong 
interest in, not only the synthesis of naturally occurring glycolipids, but also the design and 
preparation of glycolipid mimetics. Glycolipids are structurally complex, therefore their 
synthesis can often be demanding. This is why simpler mimetics of naturally occurring 
glycolipids are advantageous. As glycolipids can interact with both the polar and non-polar 
regions in their receptors, they often exhibit high activity in many biological processes such as 
inhibition of microbial adhesion.[79] Moreover, due to their amphiphilic nature, glycolipids can 
form supramolecular structures, such as micelles or liposomes[80] (section 2.1.3), and this 
feature may be employed for drug delivery approaches[81] or to enhance biological activity 
through multivalent presentation of carbohydrate ligands.[82] 
There are limited examples of glycolipid mimetics reported in the literature. In one such 
example, Dubber et al. synthesised a variety of functionalised glycolipid mimetics, including a 
variety of monosaccharide building blocks.[79] Their structures can be seen in Figure 2.6. 
 
Figure 2.6 Series of glycolipid mimetics synthesised by Dubber et al.
[79]
 
More examples of simple glycolipid mimetics are shown in Figure 2.7.  Escherichia coli urinary 
tract infections are initiated by adhesion of uropathogenic bacteria to uroplankinreceptors in 
the uroepithelium. This adhesion is mediated by the FimH adhesin which is located at the tips 
of the mannose-binding type 1 pili. Blocking of bacterial adhesion is achieved by binding these 
pili with a functionalised free mannose structure therefore preventing infection. Bouckaert et 
al. synthesised glycolipid mimetics 2.14-2.23 and investigated their potency as FimH 
antagonists.[83] Experiments showed heptyl α-D-mannopyranoside as the best binder. 
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Figure 2.7 Glycolipid mimetics against E. Coli urinary tract infections.
[83]
 
An example of a more structurally complicated glycocluster mimetic is shown below (Figure 
2.8). This novel palmitylated cluster 2.23 exhibits surfactant properties which was determined 
by surface tension measurements of aqueous solutions.[84] 
 
Figure 2.8 Example of surfactant glycocluster mimetic 2.23.
[84]
 
2.3.2 Glycosphingolipid glycomimetics 
Glycosphingolipids (GLS) consist of glycosylated sphingolipids. They are bioactive molecules 
which are ubiquitous in eukaryotic cell membranes. They are essential to many biological 
processes such as cell signalling, proliferation, differentiation and cell recognition. They also 
play a role in cell pathogen interactions. Due to their biological importance and complexity the 
preparation of synthetic analogues of GLS is highly advantageous.[85]   
Due to the range of therapeutic applications displayed by the synthetic glycosphingolipid 
KRN7000 (discussed in Chapter 1), much research has centred on synthesising mimetics of this 
compound. In addition to the examples described earlier, Kinjo and colleagues synthesised a 
carboxylic glycosphingolipid 2.24 (Figure 2.9) and observed that the compound displayed 
improved iNKT cell stimulatory properties compared to the parent compound.[35] Franck and 
Tsuji reported the synthesis of  α-C-galactosylceramide 2.25, and provided evidence that the  
C-analogue is superior to the O-analogue in both immunological activity and stability.[36] 
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Figure 2.9 Synthetic α-GalCer analogue KRN700 1.2, Glycosphingolipid mimetic 2.24
[35]
 with improved 
immunological activity and α-C-galactosylceramide derivative 2.25.
[36] 
2.4 Chapter objective 
This chapter deals with the synthesis of a variety of L-aspartic acid O-linked glycolipids, as 
mimetics of glycolipids and more specifically glycosphingolipids. Although glycosphingolipids 
have been shown to exhibit a variety of biological activities, the isolation and purification of 
natural glycosphingolipids has proven very difficult. For this reason, synthetic mimetics are 
extremely advantageous.  As peptide coupling methodologies are well developed, we chose to 
base our approach on amino acids, and more specifically on aspartic acid. We chose aspartic 
acid as it features an acid group on its side chain and a carboxylic acid and amino group at the 
α-carbon and therefore would allow the introduction of functionality easily. Owing to this, it 
would provide access to a range of structurally diverse glycoconjugates which could be 
investigated for potential biological activities. We followed a modular approach utilising a key 
set of protection, deprotection and coupling strategies which allowed us to achieve diversity 
easily and also enable sufficient scale up. We aimed to synthesise a collection of compounds 
which exhibited variations in hydrocarbon chain length, quantity of hydrocarbon chains, 
connectivity of carbohydrate moiety and variation in the carbohydrate moiety used.  Our 
objective was to examine if and how these changes affected the biological and 
physicochemical properties of the glycolipids. 
The core building block structure can be seen in Figure 2.10. It is clear that the aspartic acid 
linker would remain constant in all analogues and that variation could be achieved at three 
potential sites. 
 
Figure 2.10 Core building block structure of L-aspartic acid O-linked glycolipids. 
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The structures of the desired glycolipids are shown in Figure 2.11. Variation site 1 allowed for 
differences in the carbohydrate moiety used. In most cases, a galactosyl moiety was used, 
however a lactosyl moiety (as in 2.32) and a functionalised galactose moiety (as in 2.30) were 
also exploited. The carbohydrate connectivity could also be modified (as in 2.31), where the 
carbohydrate moiety was replaced by a C-14 lipidic chain. Variation site 2 allowed for changes 
in the hydrocarbon chain length. Analogues with a short C-10, medium C-16 and large C-24 
hydrocarbon chain were prepared. Variation site 3 allowed different amines to be coupled to 
the α-carboxylic acid. In most cases, tetradecylamine was used. This position also allowed for 
the number of hydrocarbon chains coupled to be varied. Glycolipid 2.29 has a slightly different 
structure to the others in that there are two galactosyl moieties coupled to the aspartic acid 
core and only one hydrocarbon chain. 
 
Figure 2.11 Structure of glycolipid analogues 2.26-2.32 generated from an aspartic acid core. 
During the course of the synthesis it was observed that some of the analogues where able to 
induce gelation of the solvents used in their purification. As a result, these amphiphilic 
glycolipids were investigated as LMWGs in a range of organic solvents of different polarities. 
We envisaged that hydrocarbon chain length, number of hydrocarbon chains present, and 
general conformational differences would influence the gelation ability. Finally, the ability of 
the glycolipids to form giant unilamellar vesicles (GUV’s) to further examine their potential as 
biomedical agents was investigated by Urzula Miggis in the laboratory of Dr. Jennifer Mc 
Manus in NUI Maynooth. 
Varying number of hydrocarbon 
chains and carbohydrates present 
Varying  hydrocarbon chain length 
Varying carbohydrate moiety present 
Varying carbohydrate  
connectivity 
Carbohydrate 
functionalisation 
Chapter 2:                                                                                                   Alkyl glycolipids as novel soft materials 
 
 
 
25 
 
2.5 The synthesis of first generation aspartic acid-based β-O-glycolipids 2.26, 
2.27 and 2.28  
The structures of the L-aspartic acid-based O-glycolipids 2.26, 2.27 and 2.28 were designed to 
act as glycosphingolipid mimetics, where the sphingosine backbone of the glycosphingolipids 
would be replaced by an acylated amino acid core. The idea was to introduce a spacer group 
that would allow the functionalisation of the glycolipids with two hydrocarbon chains. The 
naturally occurring amino acid L-aspartic acid was chosen as it features an acid group on its 
side chain, which would allow for connectivity to the galactosyl moiety through the formation 
of an amide bond. It also contains a carboxylic acid and amino group at the α-carbon which 
would allow for the introduction of hydrocarbon chains through the formation of amide bonds. 
The tetradecylamide hydrocarbon chain remained constant in analogues 2.26-2.28 to mimic 
the sphingosphine hydrocarbon chain length in glycosphingosines (Figure 2.12).  
 
Figure 2.12 General structure of glycosphingosines. 
Initial investigations led us to design the synthetic pathway as in Scheme 2.1 whereby the 
easily accessible β-O-ethyl-galactosyl amine 2.33 and the commercially available protected 
aspartic acid derivative 2.37 would serve as suitable building blocks. The tetradecylamide chain 
would be introduced first using standard peptide coupling conditions. The deprotection of the 
N-Boc protecting group would provide the free amine which would allow for introduction of 
the second hydrocarbon chain, again using standard peptide coupling conditions. Finally, 
deprotection of the benzyl ester protecting group would yield the free acid in the aspartic acid 
building blocks 2.34-2.36 which is ready for coupling with galactosyl amine 2.33, again using 
standard coupling conditions. In this way a range of analogues could be synthesised in a 
straightforward manner by exploiting a key set of protection/deprotection and coupling 
strategies which are already widely accepted and utilised. 
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Scheme 2.1 Key building blocks and intermediates for the synthesis of glycolipids 2.26-2.28. 
2.5.1 Initial synthesis of β-O-glycolipid 2.26 
Amide bond formation is one of the most commonly used transformations in the synthesis of 
pharmaceuticals, fine chemicals and polymers.[86] Amides are widely utilised as they are more 
stable to hydrolysis than esters, yet still accepted to be biodegradable. It is estimated that 
more than 25% of known drugs contain an amide bond.[86] For this reason, there are a plethora 
of methods for amide bond formation reported in the literature.[87] The most frequently used 
procedures for amide formation involve the reaction of an amine (including ammonia) with 
either activated carboxylic acid derivatives or reaction with carboxylic acids mediated by a 
coupling reagent. Various different coupling methodologies have been developed using azides, 
active esters, acyl halides, anhydrides, carbodiimides, immonium and aminium salts to name 
but a few. The use of acid chlorides and activated esters is discussed in chapter 4, however for 
the purpose of this chapter only aminium coupling reagents will be discussed. TBTU (O-
benzotriazol-1-yl)-1,13,3-tetrametyluronium hexaflourophosphate) (Scheme 2.2) is an 
extremely popular aminium coupling reagent. It was originally believed to have an uronium 
structure but crystallography data and solution studies revealed it actually has an aminium 
structure.[88] TBTU is commonly used in conjunction with HOBt. HOBt acts as a racemisation 
suppressant, therefore when used together minimal racemisation occurs in the amide bond 
formation. HOBt is also used in conjunction with a variety of other carbodiimde coupling 
reagents such as DCC.  
A reaction mechanism for the coupling of a carboxylic acid and an amine with TBTU and HOBt 
is proposed in Scheme 2.2. The mechanism proceeds with the attack of the carboxylate anion 
(generated in basic conditions) at the TBTU aminiuim carbocation to form an active ester 
species. Subsequent attack of the HOBt to the electrophilic carbon of the active ester, again in 
basic conditions yields a second active ester intermediate which then reacts with the amine to 
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lead to the formation of a new amide bond. However, it is important to highlight, that this is 
not the only pathway possible and the amide product can be formed via a number of routes. 
Direct attack of the amine at the acylaminium intermediate (active ester 1) generating the 
amide product is also possible. Finally, the carboxylate anion can also attack the active ester to 
form an anhydride, which can subsequently react with the amine to form the amide product.  
 
Scheme 2.2 Mechanism of TBTU and HOBt coupling reagents to form a new amide bond. 
It was decided to use the TBTU/HOBt coupling methodology as there are many advantages 
over the use of other standard reagents, including the easy removal of by-products. 
2.5.1.1 Synthesis of galactosyl amine 2.33 
The synthesis of β-galactosyl amine 2.33 was attempted through a variety of synthetic routes 
(Schemes 2.3-2.5). The first route examined (Scheme 2.3) involved the use of the well-
established trichloroacetimidate donor developed by Schmidt and colleagues in 1980.[89] Due 
to their excellent yields and stereoselectivities, trichloroacetoimidates are well regarded and 
extensively used in carbohydrate chemistry.[90] The galactosyl trichloroacetimidate donor 2.40 
was prepared as described in the literature from 1,2,3,4,6-penta-O-acetyl-β-D-galactose 
2.38.[91] Selective deacetylation of the anomeric position of the galactose pentacetate, using 
Me2NH, yielded the galactose hemiacetal 2.39. The free hydroxyl group of the hemiacetal 
intermediate 2.39 was then treated with trichloroacetonitrile and DBU to yield the α-galactosyl 
trichloroacetimidate 2.40 exclusively. The α-anomer, which is the thermodynamically favoured 
product, is obtained due to the use of a strong base (DBU) for deprotonation of the anomeric 
hydroxyl group. The glycosylated product 2.41 was obtained in 40% yield, by reacting the 
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glycosyl donor (2.40) and the glycosyl acceptor N-Boc ethanolamine under Lewis acid (TMSOTf) 
activation. The final step involved the deprotection of the N-Boc protecting group using TFA to 
yield the free amine 2.33 in 93% yield. Although the synthesis was successful, it was found that 
excess acid from the final deprotection step was hampering successive reactions which 
involved basic conditions. For this reason it was decided to investigate an alternative synthetic 
route. 
 
Scheme 2.3 Reagents and conditions: i) Me2NH, CH3CN, rt, 24 h, 91%; ii) CCl3CN, DBU, DCM, 3Å MS, N2, 
3.5 h, 83%; iii) 0.04 N TMSOTf, tert-Butyl N-(2-hydroxyethyl)carbamate, 3Å MS, DCM, 0
o
C-rt, N2, 18 h, 
40%; iv) TFA, DCM, rt, 3 h, 93%. 
In order to optimise the reaction and also to shorten the reaction steps required, we decided 
to attempt the direct activation of the 1,2,3,4,6-penta-O-acetyl-β-D-galactose 2.38 using the 
Lewis acid BF3.O(Et)2 as the promoter (Scheme 2.4).
[92] This time, in order to avoid acidic 
deprotection conditions, an acceptor which had the amine protected as a benzyloxy 
carbamate (N-CBz) was utilised. The galactoside 2.42 was obtained in 36% yield. It was 
observed that the use of BF3.O(Et)2 may have been too harsh for the acetyl protecting groups 
as 1H NMR analysis showed a partially deacetylated galactoside product was also isolated. 
Reacetylating the resulting crude mixture using Ac2O and pyridine for 1 h led to an improved 
yield of 57% of the desired glycoside 2.42.  The final step involved hydrogenolysis of the N-CBz 
protecting group using Pd/C which afforded the free amine product 2.33 in 91% yield. 
 
Scheme 2.4 Reagents and conditions: i) 1) BF3.OEt2, benzyl N-(2-hydroxyethyl)carbamate, DCM, rt, 16 h, 
2) Ac2O, Pyr, 1 h, 57%;  ii) Pd/C, H2, EtOH, rt, 4 h, 91%. 
 
Galactosyl amine 2.33 was obtained in only moderate yields using carbamate protected (N-Boc 
or N-CBz) ethanolamines as the glycosyl acceptors. It is possible that these may be quite 
deactivating towards glycosylation. For this reason it was decided to attempt the synthesis of 
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the amine 2.33 via one more synthetic approach (Scheme 2.5). As in the previous route, the 
glycosylation reaction was carried out directly from the 1,2,3,4,6-penta-O-acetyl-β-D-
galactoside 2.38  under Lewis acid BF3.O(Et)2 activation. This time, 2-chloroethanol was used as 
the glycosyl acceptor and a few changes were made regarding the addition of BF3.O(Et)2. 6 eq 
were used instead of the 3 eq used previously, and it was added in a 50% solution of BF3.O(Et)2 
in DCM at 0 oC over a period of 30 min. The desired galactoside 2.43[93] was obtained in 78% 
yield, and no partially deacetylated product was detected by TLC. The reaction was repeated 
using 3 eq of BF3.O(Et)2 added dropwise over 30 min and a similar result was observed. The 
chloride group of glycoside 2.43 was then substituted with an azido moiety by reaction of NaN3 
in DMF at 110 oC, to yield the galactosyl azide intermediate 2.44[93] in 81% yield. The final step 
involved the reduction of the azide to the amine using H2, Pd/C in EtOH to yield the free amine 
2.33 in 89% yield.  
 
 
Scheme 2.5 Reagents and conditions: i) BF3.OEt2, 2-chloroethanol, DCM, rt, 16 h, 78%;  ii) NaN3, DMF, 
110 
o
C, 3 h, 81%; iii) Pd/C, H2, EtOH, rt, 16 h, 89%. 
 
Although similar yields were obtained for the glycosylation reactions in route one (scheme 2.3) 
and route three (scheme 2.5), route three required less steps and was therefore more 
efficient. Another advantage of route three is that the galactose azide 2.44 could also be 
utilised as a synthetic intermediate. For these reasons route three was chosen as the optimum 
synthetic route. 
2.5.1.2 Synthesis of acylated aspartic acid glycolipid 2.50 
The synthesis of the L-aspartic acid derivative 2.50 commenced with the amide coupling of the 
commercially available N-Boc-L-aspartic acid-4-benzyl ester 2.45 with tetradecylamine using 
TBTU and HOBt (Scheme 2.6). This reaction was initially carried out in the presence of a base 
(NEt3) to yield the desired product 2.46
[94] in 87% yield. Subsequent removal of the N-Boc 
protecting group with TFA afforded the amine 2.47 which was acylated with decanoic acid 
using the above mentioned TBTU/HOBt methodology to give derivative 2.48 in 94% yield. 
Hydrogenolysis of the side chain benzyl ester of glycoside 2.48, (carried out at 50 oC to 
enhance solubility) afforded the desired L-aspartic acid building block 2.49, which was then 
coupled to the primary amine galactosyl derivative 2.33 to yield the acetylated glycolipid 2.50 
in 60% yield. 
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Scheme 2.6 Reagents and conditions: i) TBTU, HOBt, C14H29NH2, NEt3, DMF, 4 Å MS, N2, rt, 18 h, 87%; ii) 
TFA, DCM, rt, 1.5 h, 93%; iii) TBTU, HOBt, CH3(CH2)8COOH, NEt3, DMF, 4 Å MS, N2, rt 16 h, 94%; iv) H2, 
Pd/C, EtOAc, 50 
o
C, 4 h, 85%; v) TBTU, HOBt, 2.33, NEt3, DMF, 4 Å MS, N2, 50 
o
C, 16 h, 60%. 
 
However, the 1H NMR spectrum of glycolipid 2.50 showed distinct duplication of the expected 
signals in a 1:1 ratio (Figure 2.13). Duplication of the amide protons is the most obvious, but 
the signals corresponding to the β-protons* and also the anomeric proton (H-1) suggested the 
presence of a mixture of diastereoisomers.  
 
Figure 2.13 
1
H NMR spectrum of β-O-glycolipid 2.50 (CDCl3, 300 MHz). The duplication of signals 
suggests the presence of a mixture of diastereoisomers. 
To rule out possible conformational exchange equilibria, variable temperature 1H NMR spectra 
of compound 2.50 were recorded in d6-DMSO. No coalescence of the signals was observed at 
temperatures as high as 80 oC. This suggested that at some point during the synthesis of the 
glycolipid racemisation had occurred, and glycolipid 2.50 was in fact, a mixture of 
diastereoisomers.  
H-1 
NH1 
NH3 β-H* β-H* NH2 α-H* 
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It is believed that the unexpected racemisation of the chiral carbon of the L-aspartic acid 
derivative 2.50 takes place in the first step of the synthesis upon activation of the α-carboxylic 
acid. Although the use of TBTU and HOBt as coupling reagents is commonplace in peptide 
synthesis, the activation of the α-carboxylic acid using these conditions may increase the 
acidity of the α- proton and it may be abstracted in the presence of a base such as NEt3. This is 
further supported by the disappearance of the optical activity of compound 2.46 [[α]22D = 0 (c 
1.55, CHCl3)]. If the coupling reaction is repeated in the absence of NEt3 (Scheme 4.5), a 
specific optical rotation value of [[α]22 D
 = +2.5 (c 1.55, CHCl3)] is obtained for the L-enantiomer, 
compound 2.51. Most of the published procedures reporting amide bond formation of N-Boc 
aspartic acid 2.45 involve the use of carbodiimide-type coupling reagents,[95] formation of 
activated esters, such as pentafluorophenyl derivatives,[96] or mixed anhydrides.[97] The 
coupling of the aspartic acid building block 2.45 has been reported in the literature using the 
conditions described above. However, to the best of our knowledge no compromise of the 
optical purity of the resulting aspartate derivatives when using uronium-type reagents (such as 
TBTU or HBTU) has been explicitly reported prior to our report.[94, 98]  
The L-enantiomeric glycolipid 2.55 was obtained from repeating the synthetic sequence as 
described above, but in this case the initial coupling reaction was carried out in the absence of 
base. Although this route allowed access to sufficient amounts of diastereomerically pure 2.55, 
the initial coupling of the α-carboxylic acid results in a lower yield in the absence of NEt3 
(Scheme 2.7).  
 
Scheme 2.7 Reagents and conditions: i) TBTU, HOBt, C14H29NH2, DMF, rt, 16 h, 37%; ii) TFA, DCM, rt,    
83%; iii) (1) TBTU, HOBt, C10H20O2, NEt3, DMF, rt, 62%; (2) H2, Pd/C, EtOAc, 50 °C, 76%; iv) TBTU, HOBt, 
2.33, NEt3, DMF, 50 °C, 69%. 
 
The 1H NMR spectrum of the diastereomerically pure glycolipid 2.55 is shown in Figure 2.14. 
This time no duplication of the expected signals was observed, confirming the presence of a 
single diastereoisomer 2.55. 
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Figure 2.14 
1
H NMR spectrum of glycolipid 2.55 (CDCl3, 300 MHz) with characteristic signals assigned. 
Solvent under peak at 1.25 affecting intergration. 
2.5.2 Alternative route to form β-O-glycolipid 2.26-2.28 
Upon these unexpected drawbacks, we decided to use an alternative synthetic approach as in 
Scheme 2.8. We chose to introduce the galactosyl moiety early on in the synthesis so we could 
observe if racemisation was occurring by 1H NMR analysis. For this reason, the commercially 
available N-Boc-L-aspartic acid-1-benzyl ester 2.56 was utilised. In this starting material the 
carboxylic acid at the α-carbon is benzyl ester protected and the side chain is a free carboxylic 
acid. In order to maintain the L-configuration at the α-position of the aspartic acid derivative 
2.26, upon activation with TBTU/HOBt, we chose to carry out this step in the absence of base. 
 
Scheme 2.8 Alternative synthetic approach for β-O-glycolipid 2.26. 
The synthesis proceeded with the coupling of the galactosyl amine 2.33 and the N-Boc-L-
aspartic acid-1-benzyl ester 2.56, using TBTU/HOBt to give the orthogonally protected 
compound 2.57 in 76% yield (Scheme 2.9). Deprotection of the benzyl ester was performed 
using H2 and Pd(C) in EtOAc and the resulting crude carboxylic acid 2.48 was carefully reacted 
with tetradecylamine using TBTU/HOBt system. To avoid racemisation of the chiral carbon in 
this crucial step, the reaction was carried out in the absence of base. Under these conditions, 
diastereomerically pure glycolipid 2.59 was successfully obtained, albeit in a moderate yield of 
56%. Subsequent removal of the N-Boc protecting group with TFA afforded the amine 2.60 
which was acylated with pre-activated decanoic acid using the above mentioned TBTU/HOBt 
methodology. The diastereomerically pure, protected glycolipid 2.55 was successfully obtained 
in 63% yield.  
NH3 
 
 
NH2 
 
 
NH1 
 
 
H-1 
 
 
α-H* 
 
 
β-H* 
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Chapter 2:                                                                                                   Alkyl glycolipids as novel soft materials 
 
 
 
33 
 
 
Scheme 2.9 Reagents and conditions: i) TBTU, HOBt, NEt3, DMF, 4 Å MS, N2, rt, 16 h, 76%; ii) H2, Pd/C, 
EtOAc, rt, 4 h, 90%; iii) TBTU, HOBt, C14H29NH2, DMF, 4 Å MS, N2, rt, 16 h, 56%; iv) TFA, DCM, 50 
o
C, 1.5 h, 
74%; v) TBTU, HOBt, CH3(CH2)8COOH, DMF, 4 Å MS, N2, rt, 16 h, 63%. 
 
Structural elucidation of the acetyl protected glycolipid 2.55 was carried out and we observed 
that the 1H NMR spectrum obtained was identical to the spectrum shown in Figure 2.14. This 
proved that carrying out the synthesis via a different approach still yielded the desired product 
2.55. 
Finally, selective deprotection of the acetyl protecting groups was performed under mildly 
basic conditions. Catalytic NEt3 in a heterogenous solvent system (DCM/MeOH/H2O, 1:2:1) at 
40 oC afforded the deprotected glycolipid 2.26 as a white precipitate in 83% yield (Scheme 
2.10). Mild deprotection conditions were chosen preferentially over the harsher, but more 
commonly employed Zémplen conditions,[99] which may have resulted in degradation of the 
glycolipid. 
 
Scheme 2.10 Reagents and conditions: i) NEt3, DCM/MeOH/H2O, 40 
o
C, 18 h, 83%. 
 
The best solvent for 1H NMR analysis of the deprotected glycolipids, in terms of solubility and 
resolution, was found to be d5-Pyr. The 
1H NMR of the O-glycolipid 2.26, is shown in Figure 
2.15. Characteristic peaks are highlighted, including the amide protons (NH), the anomeric 
proton (H-1), and the α* and β*-protons. 
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Figure 2.15 
1
H-NMR spectrum of deprotected glycolipid 2.26 (d5-Pyr, 300 MHz) with characteristic 
signals assigned. 
2.5.3 Synthesis of β-O glycolipid 2.27 and 2.28 
The synthesis of glycolipids 2.27 and 2.28 began from the synthetic intermediate 2.60, which 
was used previously. The free amine 2.60 was acylated with either hexadecanoyl chloride or 
tetracosanoic acid using the TBTU/HOBt methodology, to yield diastereomerically pure 
glycolipid 2.61 (87% yield) and glycolipid 2.62 (40% yield), respectively (Scheme 2.11). The 
moderate yield of 2.62 is due to the poor solubility of tetracosanoic acid in DMF. 
 
Scheme 2.11 Reagents and conditions: i) NEt3, CH3(CH2)14COCl, DCM, N2, rt, 16 h, 87%; ii) NEt3, 
DCM/MeOH/H2O, 40 
o
C, 18 h, 52% ;  iii) TBTU, HOBt, NEt3, DMF, 4 Å MS, N2, rt, 6 h, 40%; iv) NEt3, 
DCM/MeOH/H2O/THF, 40 
o
C, 18 h, 38%. 
Deprotection of the O-glycolipid 2.61 using NEt3 afforded the novel O-glycolipid 2.27 as a white 
precipitate in a moderate yield of 52% (Scheme 2.11). The 1H NMR spectrum of O-glycolipid 
2.27 is displayed in Figure 2.16.  Characteristic peaks are highlighted in the figure, including the 
NH NH1 α-H* 
H-1 β-H* 
ppm 
3
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amide protons (NH), the anomeric proton (H-1), and the α* and β*-protons. Again the best 
solvent for 1H NMR analysis, in terms of solubility and resolution, was found to be d5-Pyr. 
 
Figure 2.16 
1
H NMR spectrum of glycolipid 2.27 (d5-Pyr, 300 MHz) with characteristic peaks assigned. 
Presence of solvent effecting integration of H-1 and α-H. 
Deprotection of tetracosanoyl derivative 2.62 proved a lot more difficult. The mildly basic 
conditions of NEt3 in a heterogenous solvent mixture, which had worked for glycolipids 2.26 
and 2.27, was unsuccessful. Although partial deacetylation was observed by TLC, full 
deprotection was not achieved. Other common methods were also attempted such as 
Zémplen conditions and reaction with hydrazine, but these proved to be too harsh and 
degradation of compound 2.62 was observed in both cases. We believed that the problems 
encountered were due to poor solubility of the partially deacetylated compound, as the 
reaction mixture became cloudy after overnight stirring. Upon careful consideration the mild 
conditions of NEt3 in MeOH/H2O/DCM was reinvestigated and the solvent systems were varied 
in an attempt to achieve greater solubility. This time THF (1 mL) was added to the already 
heterogenous solvent system of DCM, H2O and MeOH (1 mL, 1 mL, 2 mL).  As before, a 
precipitation, which was assumed to be the partially deprotected glycolipid, was observed 
after 1 h (reaction mixture became cloudy). The reaction was continued and 1 mL of THF was 
added every time a precipitate was formed. This process continued for 72 h until no starting 
material could be visualised by TLC. The reaction was quenched by evaporation and triturated 
using DCM/Et2O to yield the desired fully deprotected compound 2.28 as a white solid in 38% 
yield. 
Due to the extremely poor solubility of glycolipid 2.28, structural elucidation was very difficult. 
Like glycolipids 2.26 and 2.27, glycolipid 2.28 was partially soluble in d5-Pyr, therefore 
1H NMR 
analysis was carried out and the structure confirmed. The 1H NMR spectrum of O-glycolipid 
β-H* 
H-1 
α-H* 
NH NH1 
NH 
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2.28 is displayed in Figure 2.17.  Characteristic peaks are highlighted in the Figure, including 
the amide protons, the anomeric proton, and α and β-protons. 
Insufficient material was soluble in d5-Pyr to enable us to obtain a clear 
13C NMR spectrum. 
However comparisons of the 1H NMR spectrum to the shorter chain analogues 2.26 and 2.27, 
gave sufficient evidence that the desired compound 2.28 was present. This was further 
confirmed by HR-MS analysis. 
 
Figure 2.17 
1
H NMR spectrum of deprotected glycolipid 2.28 (d5-Pyr, 300 MHz) with characteristic peaks 
assigned. Solvent under peak at ~1.25 ppm affecting integration. 
2.6 Synthesis of second generation glycolipids  
2.6.1 Synthesis of bivalent β-O-glycolipid 2.29 
Due to the solubility issues encountered with the previous glycolipids 2.26-2.28, we wished to 
investigate alternative glycolipid structures. As aspartic acid contains two carboxylic acid 
groups there are two potential sites for acylation. We wanted to investigate if acylating at both 
sites with the galactosyl amine (therefore having only one lipidic chain present) would improve 
solubility and lead to different physicochemical properties and self-assembly behaviour. 
Glycolipid 2.29 was prepared as a representative example (Figure 2.18). 
 
Figure 2.18 Structural comparison between the structure of glycolipids 2.26 and 2.29. 
 
The synthesis started with galactosylated carboxylic acid intermediate 2.58 synthesised 
previously as described in section 2.5.2. Coupling of the free acid building block 2.58 with the 
galactosyl amine 2.33 using TBTU/HOBt methodology afforded 61% of the bivalent molecule 
β-H* 
H-1 α-H* 
NH 
NH NH1 
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2.63 (Scheme 2.12).  Subsequent removal of the N-Boc protecting group with TFA afforded the 
amine 2.64 which was acylated with hexadecanoyl chloride in the presence of base. The 
diastereomerically pure protected glycolipid 2.65 was successfully obtained in 58% yield. Due 
to the increased solubility of glycolipid 2.65 the removal of the acetyl protecting groups 
proceeded very smoothly and the deprotected bivalent β-O-glycolipid was obtained as a white 
solid in 86% yield. The 1H NMR spectrum of the deprotected bivalent β-O-glycolipid 2.29 is 
shown in Figure 2.19. 
 
Scheme 2.12 Reagents and conditions: i) TBTU, HOBt, DMF, 4 Å MS, N2, rt, 18 h, 61%; ii) TFA, DCM, rt, 
3.5 h, 61%; iii) NEt3, CH3(CH2)14COCl, DCM, N2, rt, 16 h, 58%; iv) NEt3, DCM/MeOH/H2O, 40 
o
C, 18 h, 86%. 
 
 
 
Figure 2.19 
1
H NMR spectrum of deprotected bivalent β-O-glycolipid 2.29 (d5-Pyr, 300 MHz). 
2.6.2 Synthesis of β-O-glycolipid 2.31 
A further structural variation was investigated around the aspartic acid linker. We wanted to 
examine if varying the position of both the galactosyl moiety and the tetradecyl chain would 
affect the physicochemical properties and gelation ability. Therefore, we attempted the 
synthesis of β-O-glycolipid 2.31, which differs from glycolipid 2.55 as the galactose moiety is in 
the C-4 position of the aspartic acid rather than the C-1 position. Compared to glycolipid 2.55, 
the lipid chains are no longer branching off from the same carbon (Figure 2.20).  
NH’s α-H* 
H-1 
β-H* β-H* 
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Figure 2.20 Comparison between the structure of glycolipids 2.55 and 2.31. 
The synthesis proceeded with the coupling of tetradecylamine and the commercially available 
N-Boc-L-aspartic acid-1-benzyl ester 2.56 using TBTU/HOBt in DMF to give the orthogonally 
protected compound 2.66 in 84% yield (Scheme 2.13). Removal of the N-Boc protecting group 
with TFA afforded the amine 2.67 which was acylated with hexadecanoyl chloride using base 
to give compound 2.68. Deprotection of the benzyl ester was performed using H2 bubbled 
through a solution of 2.68 in EtOAc at 50 oC in the presence of Pd(C). The resulting carboxylic 
acid 2.69 was carefully reacted with the galactosyl amine 2.33 again using the TBTU/HOBt 
system. To avoid racemisation of the chiral carbon in this crucial step, the reaction was carried 
out in the absence of external base. Under these conditions, diastereomerically pure 2.31 was 
successfully obtained, in a moderate yield of 63%. Despite the moderate yield of the final step, 
all other synthetic steps exhibited high yields, we therefore concluded that the synthetic 
approach was advantageous. 
 
Scheme 2.13 Reagents and conditions: i) TBTU, HOBt, DMF, 4 Å MS, N2, rt, 18 h, 84%; ii) TFA, DCM, ,2.5 
h, 73%; iii) TBTU, HOBt, CH3(CH2)14COCl, DMF, 4 Å MS, N2, rt, 16 h, 87%; iv) H2, Pd/C, EtOAc, 50 
o
C, 4 h, 
94%; v) TBTU, HOBt, 2.33, DMF, 4 Å MS, N2, rt, 18 h, 63%. 
 
The 1H NMR spectrum of glycolipid 2.31 can be seen in Figure 2.21.  Characteristic signals are 
assigned which include the amide protons (NH), the anomeric proton (H-1), and the α* and β*-
protons. The 1H NMR spectrum shows no evident differences to the corresponding one of 
glycolipid 2.55. 
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Figure 2.21 
1
H NMR spectrum of acetylated β-O-glycolipid of 2.31 (CDCl3, 300 MHz). 
2.6.3 Synthesis of disaccharide β-O-glycolipid 2.32 
The next synthesis investigated was the disaccharide aspartic acid derivative 2.32. Like the 
previous mimetics discussed, this variation was chosen as we wanted to examine whether the 
presence of a disaccharide (a higher percentage of polarity) would influence gelation ability in 
a range of solvents of different polarities, including H2O. Initial investigations led us to 
approach the synthesis via a modular approach as shown in Scheme 2.14, whereby the easily 
accessible β-O-ethyl-lactosyl amine 2.70 and aspartic acid derivative 2.35 would serve as 
suitable building blocks.  
 
Scheme 2.14 Aspartic acid 2.35 and lactosyl amine 2.70 building blocks used for the synthesis of 
glycolipid 2.32. 
2.6.3.1 Synthesis of Lactosyl amine 2.70 
The synthesis followed the same methodology as the galactosyl amine 2.33 described in 
section 2.2.1.1. The hydroxyl groups of commercially available D-lactose 2.72 were acetylated 
and a direct glycosylation reaction with 2-chloroethanol was carried out on the anomeric 
position of the per-acetylated donor 2.72 (Scheme 2.15). This yielded 47% of the β-lactoside 
2.73 exclusively. A substitution reaction was then performed and the chloride atom of the 
ethyl linker was replaced with an azide group. Hydrogenolysis afforded the final lactosyl amine 
2.70 in 73% yield. 
α-H* NH1 
NH 
β-H* H-1 
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Scheme 2.15 Reagents and conditions: i) NaOAc, Acetic anhydride, 0-110 
o
C, 18 h, 80%; ii) 2-
chloroethanol, BF3.O(Et2), DCM, N2, rt, 16 h, 47%; iii) NaN3, DMF, 110 
o
C, 3 h; 74% iv) H2, Pd/C, EtOH,       
5 h, 73%. 
2.6.3.2 Synthesis of aspartic acid building block 2.35 
The synthesis commenced with the same reaction conditions that were initially used for the C-
10 glycolipid 2.26 (section 2.5.1.2, Scheme 2.7). Coupling of the free amine building block 2.52 
with hexadecanoyl chloride afforded 68% of the desired compound 2.75 (Scheme 2.16).  
Subsequent removal of the benzyl ester protecting group with H2 bubbled through Pd/C 
afforded the free acid aspartic acid building block 2.35. The free acid 2.35 was coupled with 
the lactosyl amine 2.70 using TBTU/HOBt coupling methodology (Scheme 2.16). The 
enantiomerically pure protected glycolipid 2.32 was successfully obtained in 29% yield. The 
poor yield was due to poor solubility of the aspartic acid building block 2.35 with the long 
hydrophobic chains. The 1H NMR spectrum of O-glycolipid 2.32 is displayed in Figure 2.22.  
Characteristic peaks are highlighted in the figure, including the amide protons, the anomeric 
proton, and the α and β-protons. Deprotection of glycolipid 2.32 was attempted using NEt3 in a 
heterogenous solvent system however full deprotection, without degradation of the 
compound, could not be achieved. 
 
 
Scheme 2.16 Reagents and conditions: i) TBTU, HOBt, CH3(CH2)14COCl, NEt3, DMF, N2, rt, 68%; ii) H2, 
Pd/C, EtOAc, 50 °C, 5 h, 90%; iii) TBTU, HOBt, NEt3, DMF, 50 °C-rt, 18 h, 29%. 
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Figure 2.22 
1
H-NMR spectrum of acetylated disaccharide glycolipid 2.70 (CDCl3, 300 MHz) with 
characteristic peaks assigned. 
2.6.4 Synthesis of C-6 functionalised β-O-glycolipid 2.30 
Literature research has shown that there is a great deal of interest in compounds which form 
gels as a result of an external stimulus.[67, 73] One way this can be achieved is by functionalising 
the gelator molecule with a group that can be activated by external conditions and therefore 
lead to stimuli responsive gels. One example that is commonly reported in the literature is the 
use of azobenzenes. Azobenzenes undergo photoreversible cis-trans isomerism: trans-cis 
isomerisation is achieved by UV irridation and cis-trans isomerisation takes place upon visible 
light irradation. Many groups have exploited this ability and produced gelator molecules 
containing azobenzene whereby the gels collapse under UV irradiation and reform by visible 
light irradiation.[55]   
Another approach reported by Miravet and Escuder[100] involves the synthesis of reactive gels. 
Using this method, the already assembled gels can be further reacted with other functional 
groups to produce new gel materials that have different properties to that of the original gel. 
This means the pre-assembled gel acts as scaffold for the synthesis of the new gel.  
Some selected examples are shown below in Scheme 2.17. The reactive organogel 2.76 was 
reacted with a variety of primary amines to obtain a number of new bis-urea gel materials 
2.77-2.79 which exhibited increased thermal stability. 
β-H* 
α-H* 
NH1 NH3 NH2 
ppm 
β-H* 
H-1 
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Scheme 2.17 Synthesis of a variety of new bis urea gels 2.77-2.79 from reactive organogel 2.76.
[100]
 
We wanted to examine if functionalising the C-6 position on the galactose moiety of the 
glycolipid 2.27 would result in different physicochemical properties and self-assembly 
behaviour. Our aim was to investigate if we could improve gelation ability or synthesise a 
stimuli responsive gelator by replacing the hydroxyl group on the C-6 position of galactose with 
a variety of functional groups, which could lead to a reactive organogel system. 
As we had previously synthesised the free acid aspartic acid building block 2.35 featuring both 
the tetradecyl and hexadecanoyl chain (discussed in section 2.2.6), it was decided to use this 
building block and again follow a modular approach. This way we could focus on the 
functionalisation of the carbohydrate moiety.  
As aromatic groups have been reported to stabilise gel formation as a result of π-π stacking,[73] 
our initial idea was to introduce a group capable of forming a triazole moiety into the C-6 
position of the analogue. In order to achieve this, it was decided to functionalise the C-6 
position of the galactose with an alkyne group. The alkyne moiety of the galactose could then 
react with an azide-containing molecule in a 1,3 dipolar cylcoaddition to form the desired 
triazole functionality.  
For this synthesis the free hydroxyl groups at the C-2, C-3 and C-4 positions need to be 
protected (to prevent unwanted coupling reactions) and the C-6 position needs to bear a free 
hydroxyl group. Fernández  et al. demonstrated selective deprotection of a  primary C-6 
trimethyl silyl (TMS) ether  in the presence of secondary TMS groups on galactose.[101] Jervis et 
al. further proved this methodology.[40] Owing to their ease of introduction into the galactose 
starting material, the ability to selectively deprotect the primary silyl ether at the C-6  and 
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finally, due to the ease with which the remaining silyl ether groups can be removed when 
required, protection with TMS group appeared to be ideal for this type of approach. 
The synthetic approach had to be considered carefully. Introduction of an alkyne group, such 
as propiolic acid, to the selectively TMS protected galactoside could be carried out via a 
Steglich esterification. This would yield a functionalised galactose building block such as 2.80 
ready for coupling with the free acid aspartic acid derivative 2.35. The alkyne of glycolipid 2.81 
could then react with an azide-containing molecule in a 1,3 dipolar cylcoaddition, in the 
presence of a Cu(I) source, to form the desired triazole functionality. The initial synthetic 
pathway can be seen below in Scheme 2.18. 
 
Scheme 2.18 Key building block in the synthesis of glycolipid 2.78. 
2.6.4.1 Attempted synthesis of C-6 functionalised galactose building block 2.83 
The synthesis of galactosyl amine 2.83 started with the acetylated galactosyl azide building 
block 2.44 (discussed previously in section 2.5.1.1), which was deprotected using methanolic 
NaOMe (Scheme 2.19). The resulting compound 2.82 was then reacted with 
chlorotrimethylsilane and hexamethyl disilazane in pyridine to yield compound 2.83 in 76% 
yield. Selective deprotection of the TMS  ether  in the C-6 position using acetic acid in 
MeOH/acetone afforded the alcohol 2.84 in 75% yield. The final step was the Steglich 
esterification with propiolic acid, N,N'-dicyclohexylcarbodiimide (DCC) and 4-
dimethylaminopyridine (DMAP) in DCM. However, no desired product 2.85 was obtained. This 
reaction was repeated in the absence of DMAP but still remained unsuccessful. Instead, due to 
the presence of the labile TMS ethers, a complicated mixture of products and deprotected 
galactose azide 2.82 was obtained. It is possible that the primary alcohol of the galactose was 
attacking the terminal alkyne of the propiolic acid in a Micheal type reaction and therefore 
preventing the formation of the product 2.85. There are examples of this type of reactivity in 
the literature and ways to circumvent this problem include cooling the reaction, and also 
allowing the alcohol to react with the DCC and DMAP prior to addition of the alkyne.[102] Both 
conditions were attempted but again, no product was obtained. 
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Scheme 2.19 Attempted synthesis of galactosyl azide building block 2.83 Reagents and conditions: i) 
NaOMe, DCM, MeOH, N2, rt, 1 h, 91%; ii) TMSCl, HMDS, pyr, 0 
o
C-> rt, overnight, 76%; iii) AcOH, 
acetone:MeOH, 2 h, 75%; iv) propiolic acid, DCC, DMAP, DCM, N2, rt/0 
o
C. 
 
Due to the problems encountered above, possibly due to the side reactivity of propiolic acid, it 
was decided to instead attempt to incorporate the azide functionality onto the C-6 position of 
the galactoside building block. As the molecule already contained an azide group, which 
needed to be reduced to the free amine for coupling to the aspartic acid, we needed to 
introduce an orthogonal group that could be converted to the azide at a later stage. For this 
reason we chose to functionalise the galactoside 2.87 with bromoacetic acid. The revised 
synthetic route can be observed below in Scheme 2.20. The synthesis started with the C-6 free 
hydroxyl galactoside 2.84 (discussed above). Steglich esterification with bromoacetic acid this 
time afforded the desired functionalised product 2.86 in 61% yield. The 1H NMR spectrum of 
the galactosyl azide building block 2.86 is shown below in Figure 2.23.  
Scheme 2.20. Reagents and conditions: i) DCC, DMAP, DCM, N2, rt/0 
o
C, 18 h, 61%; ii) (1) 2% TFA in DCM, 
1 h, 96%; (2) Dowex, MeOH, 1 h, 98%. 
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Figure 2.23 
1
H NMR spectrum of galctosylazide building block 2.86. 
Owing to the constraints of working with the labile TMS protecting groups, it was decided to 
attempt their removal at this point and then reprotect the sugar hydroxyl groups using a more 
robust protecting group. The use of acetyl protecting groups was investigated for comparison 
with the glycolipid described in earlier sections. Initial deprotection of the remaining TMS 
ethers was achieved using a 2% solution of TFA in DCM to yield compound 2.87. However, 
reprotection using acetyl protecting conditions to give galactoside 2.88 could not be achieved. 
A number of common acetylation conditions were attempted including; acetic anhydride and 
pyridine, acetic anhydride, pyridine and DMAP, and acetyl chloride and NEt3. All reactions were 
carried out at both rt and reflux but in all cases, no desired product was obtained. We believed 
that this may have been due to residual acid from the preceeding deprotection step. 
Therefore, we attempted the deprotection using the milder conditions of Dowex in MeOH, as 
Gervay–Hague and Witschi had reported the successful deprotection of TMS ethers on a 
similar substrate using the same conditions.[103] Again the desired deprotected product 2.90 
was obtained, however acetylation still remained unsuccessful. 
As a result of these setbacks, we again had to address our synthetic approach. We opted to 
maintain the TMS protected galactose moiety 2.86 and carry on with the synthesis. The 
functionalised galactosyl azide 2.86 was reduced to the amine using, Pd/C in EtOAc and 
subsequently in situ coupled to the aspartic acid building block 2.35 using TBTU/HOBt 
methodology. Unfortunately, under these conditions no desired product 2.89 was obtained 
(Scheme 2.21). 
2.86 
H-1 
Si(CH3)3 
ppm 
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Scheme 2.21 Attempted synthesis of C-6 functionalised glycolipid 2.89 Reagents and conditions: i) (1) H2, 
Pd/C, EtOAc, 2.5 h; (2) HOBt, TBTU, NEt3, DMF, N2, rt, 16 h. 
Instead, the product of these reactions appeared to have an acetyl group in the C-6 position of 
the galactose as in glycolipid 2.30 (Figure 2.24), and cleavage of the TMS ethers was also 
observed. We postulated that the bromo-carbon bond had undergone hydrogenolysis when 
reduction of the azide was taking place, as many examples of halogen hydrogenolysis  have 
been carried out with Pd/C in the literature.[104] Structural elucidation using 1H NMR, 13C NMR 
spectroscopy and HR-MS confirmed the presence of compound 2.30. The 1H NMR spectrum of 
this compound is shown below (Figure 2.25), with characteristic peaks assigned.  
 
Figure 2.24 Structure of glycolipid 2.30 obtained from the hydrogenolysis of 2.89 and subsequent in situ 
coupling with the aspartic derivative 2.35. 
 
Figure 2.25 
1
H NMR spectrum of functionalised glycolipid 2.30 (d5-Pyr, 300 MHz). 
 
 
 
 
CH3 of OAc* 
NH 
NH NH 
α-H 
ppm 
* 
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2.7 Gelation and self-assembly properties of β-O-glycolipids 2.26-2.32 
As discussed earlier, the ability of a molecule to induce gelation of a certain solvent has a wide 
range of applications in the chemical industry including their use as soft materials, drug 
delivery systems and H2O purification systems. During the synthesis of glycolipid 2.27 we 
observed that it was able to induce gelation in certain solvents used for chromatographic 
purification.  This serendipitous observation prompted us to review the literature and 
recognise the potential applications of O-glycolipid 2.27 to act as a LMWG. With this in mind 
we decided to examine the gelation abilities of a range of different glycolipids, and investigate 
some of the structural features that may affect gelation ability including hydrophobic chain 
length, and the effect of chirality. All of the compounds tested are amphiphilic in nature and 
feature the presence of one or two saturated hydrocarbon chains varying in length. 
2.7.1 Gelation and self-assembly properties of first generation of β-O-glycolipids  
Our aim was to investigate how alterations in the glycolipid structure could influence their 
ability to induce gelation (Figure 2.26). We also wanted to examine if changes in the glycolipid 
structure affected the stability of the gels. The first variation investigated was hydrophobic 
chain length. As discussed previously, (section 2.2.1.1), Van der Waals forces of hydrophobic 
regions in a molecule play a role in the formation of gels. Therefore, we strived to determine if 
the length of the hydrophobic chain influenced self-assembly and gelation ability of the 
glycolipids. For this comparison, we chose glycolipid 2.55 which contained the C-10 chain and 
glycolipid 2.61 which contained the C-16 chain. The second structural feature chosen to 
examine was how chirality in the molecule altered gelation ability. For this, we chose to 
compare the diastereomerically pure glycolipid 2.26 and the mixture of diastereomers, 
glycolipid 2.90. The final variant we opted to assess was how the presence of acetyl or 
hydroxyl groups affected the solubility, and therefore changed self-assembly behaviour. H-
bonding between gelator moleules and also between the gelator molecule and the solvent are 
important in gel formation. It was belived the presence of the hydroxyl groups would lead to 
more H-bond donors being available for H-bonding and therefore, could result in more 
thermally stable gels. For this evaluation we compared the acetyl protected glycolipid 2.61, 
and the deprotected glycolipid 2.27. 
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Figure 2.26 Structure of compounds 2.26, 2.27, 2.55, 2.61, and 2.90 tested for their gelation ability in a 
variety of organic solvents. 
Gelation tests were performed using an “inverted test-tube method” as described by Tanake 
et al.[105] The glycolipids and solvents (20 mg mL-1) were placed in screw cap glass vials and 
heated until all solid had dissolved (apart from the insoluble compounds). The solution was 
then cooled to rt and left to stand for 2 h. Their gelation ability was assessed by inverting the 
vials and examining the absence of the gravitational flow of solvents. If the solvent did not flow 
upon inversion, but instead remained at the bottom of the vial, the molecule was classified as 
a gelator. If there was gravitational flow of liquid upon inversion of the vial, the compound was 
determined to be a non-gelator. Based on our observations, the term non-gelator was further 
categorised. If the compound was determined to be a non-gelator and dissolved fully in the 
solvent, it is classified as soluble in the gelation table. However, if the glycolipid never 
solubilised in the solvent, it was classified as insoluble in the gelation table. Another term used 
is aggregates, which implies that the glycolipid was initially soluble in the given solvent but 
upon standing at rt it precipated as a more defined, self-assembled structure. The final term 
utilised is partial gelation. In some cases we found that, although there was a presence of 
liquid flow upon inversion of the vial, small localised gelled areas could also be observed.  
Images of the self-assembly behaviour in different solvents are portrayed in Figure 2.27. 
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Gelation of 2.55 and 2.61 in MeCN                Gelation of  2.26 and 2.27 in toluene        Gelation of 2.61 and 2.31 in MeOH 
                          
        Aggregates of 2.55 in EtOH                  Aggregates of 2.55 in MeOH        Partial gelation of 2.55 in hexane 
Figure 2.27 Images of self-assembly of selected glycolipids in various solvents. 
The ability of the glycolipids to induce gelation was tested in a variety of organic solvents and 
the results are presented in Table 2.1. The minimum gelation concentrations (MGC) were also 
calculated for all gelators in their various solvents. The MGC indicates the minimum 
concentration of gelator molecule (mg) required to induce full gelation in a given volume of  
solvent (1 mL).[106]  
2.31 2.55 2.61
1 
2.26 2.27 2.61 
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 DCM Toluene MeCN MeOH EtOH H2O EtOAc Hexane CHCl3 
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Table 2.1 Gelation abilities of glycolipids in various solvents. All compounds were tested using the inverted test tube method at 20 mg mL-1. Values refer to critical gel 
concentration (MGC) (mg per mL). Aggregates=A, Gelation=G, Partial Gelation=P.G, Insoluble=I, Soluble=S, Partial soluble=P.S.
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2.7.1.1 SEM on O-glycolipids 2.55, 2.61, and 2.90 
Scanning Electron microscopy (SEM) is a technique commonly employed to give information 
about a samples morphology. To gain a microscopic insight into the self-assembled structures 
of 2.55 and 2.61 when acting as LMWGs, the morphologies of galactosyl aspartic acid 
derivatives were observed by SEM as xerogels using the drop casting method. The drop-cast 
technique involved the gelling of a small amount of solvent directly onto the silicon wafer used 
in SEM analysis. The corresponding xerogel was formed by allowing the sample solvent to 
evaporate at rt overnight. 
The SEM images of the xerogel from MeCN of glyolipid 2.55 are shown in micrograph A and B 
of Figure 2.28. The SEM image in micrograph A shows that evaporation of the solvent leaves 
behind a porous structure characteristic of xerogels. On magnification, the formation of a 
network of thick fibres, which enables the trapping of solvent and leads to the formation of 
the gel can be observed (micrograph B). These observations are in line with those reported, as 
SEM images of organogelators are commonly encountered as three dimensional fibrous 
networks.[107]  A very different morphology is observed when examining the aggregates formed 
by glycolipid 2.55 in EtOH. Micrograph B (Figure 2.29) depicts a very compact three 
dimensional network containing long thin fibrils that are woven tightly together with a defined 
structure. Again, this is in line with morphologies described in the literature and it is believed 
that these thinner fibrils can further aggregate forming highly entangled and more dense 
fibrous bundles.[68] No pores can be observed in the SEM image of the aggregates and this 
explains why gelation is not observed in this solvent.  These pores represent pockets where 
the solvent becomes trapped as the gel is being formed and remain visible after the solvent 
has evaporated. 
                     
                   MeCN xerogel of glycolipid 2.55           Magnification of MeCN xerogel of glycolipid 2.55 
Figure 2.28 SEM micrographs of xerogel of glycolipid 2.55 in MeCN. 
A
0 
B 
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          Aggregates of   glycolipid 2.55 in EtOH              Aggregates of glycolipid 2.55 in EtOH 
Figure 2.29 SEM micrographs of aggregates of glycolipd 2.55 in EtOH. 
Remarkably, the mixture of diastereoisomeric glycolipids 2.90 was capable of inducing the 
gelation of CHCl3, whereas the single diastereoisomer 2.26 was insoluble in this solvent. The 
SEM images of the xerogel of glycolipids 2.90 in CHCl3 are shown below in Figure 2.30. Again, 
the images depict the formation of a three dimensional fibrous network, however, this time 
the fibrils are much thinner and the structure is much more porous in comparison to the 
images of the xerogel of 2.55 in MeCN (Figure 2.28). 
             
          Xerogel of glycolipid 2.90 in CHCl3                Magnification of xerogel of glycolipid 2.90 in CHCl3 
Figure 2.30 SEM micrographs of xerogel of glycolipid 2.90 in CHCl3. 
It is very clear from the above images that the morphology of the xerogels differs greatly 
depending on both the molecule inducing gelation and the solvent used for gelation. The single 
diastereoisomer, protected C-10 glycolipid 2.55, forms much thicker fibres with the pores very 
evenly distributed. In contrast, the deprotected mixture of diastereoisomeric C-10 glycolipids 
2.90 appears to form a three dimensional network saturated with pores formed by much 
A 
A
0 
B 
B 
      100 µm            30 µm       
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thinner fibrils. This is supported by data from gelation Table 2.1 which shows that although the 
deprotected glycolipids 2.26, 2.27 and 2.90 exhibit self-assembly behaviour in certain solvents, 
in general, the protected compounds 2.55 and 2.61 induce gelation in a wider variety of 
solvents.  However, we observed that the deprotected glycolipids formed more stable gels 
than their acetylated counterparts. This implies that H-bonding of the free hydroxyl on the 
galactose moiety may be important in the self-assembly process. This was further supported 
by examination of the gel-sol transition temperature (Tgs). The formation of all the gels was 
found to be thermo-reversible, i.e. they turned into solutions upon heating and slowly gelled 
upon cooling. The gel-sol transition temperature indicates the temperature for the phase 
transition at which the gel breaks down and changes back into a solution. For the gel of the 
protected glycolipid 2.61 in toluene, the Tgs was observed to be 36 
oC, however, the gel of the 
deprotected glycolipid 2.27 in the same solvent showed a Tgs of 46 
oC.  
The SEM micrograph of the xerogel of C-16 glycolipid 2.61 in MeCN is similar to that of 
glycolipid 2.55 (Figure 2.31). Micrograph A shows the presence of numerous pores distributed 
on an otherwise dense structure. On magnification (40 µm) we can see that the self-
association leads to an ordered three dimensional network made up of thick fibres interwoven 
to form solvent pores (Micrograph B).  Micrograph A and B of Figure 2.32 show the xerogel of 
glycolipid 2.61 in EtOH. This time a very different morphology is observed. Although thick 
fibres and large solvent pores can still be observed, we also see the presence of globular 
domains dotted throughout the structure.  
           
                Xerogel of glycolipid 2.61 in MeCN           Magnification of xerogel of glycolipid 2.61 in MeCN 
Figure 2.31 SEM micrographs of xerogel of glycolipid 2.61 in MeCN. 
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          Xerogel of glycolipid 2.61 in EtOH              Magnification of xerogel of glycolipid 2.61 in EtOH 
Figure 2.32 SEM micrographs of Xerogel 2.61 in EtOH. 
These micrographs provide an excellent example of how morphology of the xerogels differs 
depending on both the glycolipid inducing gelation and the solvent involved in the self-
assembly process. In comparison to the C-10 glycolipid 2.55, the C-16 glycolipid 2.61 forms a 
complex three dimensional structure with much thicker fibres, tightly interwoven to form 
smaller pores. The results presented in Table 2.1 show that the C-16 glycolipid 2.61 is able to 
induce gelation in a wider variety of solvents (toluene, MeOH, EtOH and MeCN) than its C-10 
counterpart 2.55 (MeCN). The ability of the glycolipid 2.61 to induce gelation in EtOH is 
particularly interesting as EtOH is a biocompatible solvent therefore, the organogelator could 
potentially be used in drug delivery systems. These results indicate the importance of non-
polar, Van der Waals type interactions caused by the hydrocarbon chains, in the self-assembly 
process. In polar and non-polar solvents, the longer the alkyl chain, the better the molecule is 
at inducing gelation in the selected example. The importance of non-polar interactions was 
further cemented by comparison of the Tgs of the C-10 2.55 and C-16 2.61 glycolipids in MeCN, 
which were found to be 15 oC and 52 oC, respectively. This showed that the C-16 induced gels 
had a greater thermal stability. This is in line with what is reported in the literature. Zweep et 
al.[65] reported that the MGC and Tgs of a group of cyclohexane-based bisamide organogelators 
in polar solvents, increased with increasing alkyl chain length. They postulated that it was as a 
result of increased gelator-gelator interactions together with decreasing interactions between 
the hydrophobic chains and the polar solvent molecules. 
 
A
0 
B 
      100 µm             50 µm       
Chapter 2:                                                                                                   Alkyl glycolipids as novel soft materials 
 
 
 
55 
 
2.7.1.2 Spectroscopic studies on glycolipid 2.55 and 2.61 
As discussed above, interactions between the gelator compound and solvent are crucial in the 
self-assembly and gelation process. In order to gain insight into the role of the gelator 
molecules in this regard, a series of spectroscopic studies using different techniques were 
performed. 
The first spectroscopic technique we used was 1H NMR analysis. H-bonding has been shown to 
play an important role in the self-assembly process and we sought to examine if H-bonding 
could be observed in our samples.  Concentration studies were carried out and 1H NMR spectra 
on the C-10 glycolipid 2.55 in CDCl3 were recorded at different concentrations. The variation in 
the chemical shifts of the signals corresponding to the different N-H protons of glycolipid 2.55 
were examined (Figure 2.33). The bottom spectrum represents the least concentrated sample 
and the top spectrum represents the most concentrated sample. The biggest change observed 
relates to the amide connecting the galactosyl moiety to the aspartic acid side chain (labelled 
N-H1). It resonates at  6.26 ppm in the dilute sample and shifts to a higher chemical shift of 
6.37 ppm in the more concentrated sample. This implies that the amide is involved in 
intermolecular H-bonding, which could be contributing to self-assembly of the molecule. As 
CHCl3 is a relatively non-polar solvent, H-bonding between the glycolipid is accentuated. 
Intramolecular H-bonding may be taking place in amides labelled N-H2 and N-H3, as the 
resonances for the amides of both the tetradecyl and decanoic chain occur at relatively high 
chemical shift.  
 
Figure 2.33 
1
H NMR concentration studies on 2.55 in CDCl3: a) 2 mg mL
-1
, b) 4 mg mL
-1
, c) 6 mg mL
-1
, d) 9 
mg mL
-1
, e) 12 mg mL
-1
. 
 
N-H1 N-H2
 
 N-H1 
N-H3
 
 N-H1 
a 
b 
c 
d 
e 
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Although H-bonding of glycolipid 2.55 is detected in CHCl3, self-assembly behaviour is not 
observed (i.e. no gel or aggregates are formed). CHCl3 is a non-polar solvent and this may 
result in the glycolipid 2.55 being almost too soluble when dissolved in it. As a result, the 
glycolipid may be extremely solvated leading to a reduction in gelator-gelator interactions, 
therefore, resulting in no self-assembly behaviour.  
In order to further  examine the interaction between the solvent and gelator molecule we 
compared the 1H NMR spectra of 2.55 in CDCl3 (where it is soluble), CD3CN (where it acts as a 
gelator) and MeOD (where aggregates are formed) (Figure  2.34). Clear differences between 
the spectra are evident, with the most obvious being the shifting of the amide protons. When 
comparing the values of the 1H NMR spectra recorded in CDCl3 and CD3CN a change in the 
values of the chemical shifts for the amide protons is observed (Table 2.2).  
 CDCl3 (ppm CD3CN (ppm) ∆ δ= (ppm) 
N-H1 6.30 6.60 0.30 
N-H2 7.11 6.82 0.29 
N-H3 7.44 7.06 0.38 
H-1 4.53 4.62 0.09 
α-H 4.66 4.57 0.09 
β-H 2.77, 2.45 2.55 0.22, 0.10 
 
Table 2.2 Chemical shifts for selected protons in CDCl3 and CD3CN. 
MeCN is a polar, aprotic solvent which can act as an H-bond acceptor and compete for H-
bonding with the amides of the glycolipid. This may result in some of the intermolecular and 
intramolecular H-bonds between the gelator molecules being broken and therefore results in 
the values for the      N-H signals shifting to a lower chemical shift. This does not rule out H-
bonding completely, but merely implies that different interactions can take place in MeCN, 
resulting in the glycolipid 2.55 being able to adopt a different conformation, leading to 
differences in chemical shifts, most notably with the β-protons. This conformational difference 
observed in MeCN allows non-polar interactions (due to the hydrocarbon chains) to become 
more prominant and leads to the formation of gels.  
When comparing the 1H NMR spectra of 2.55 CD3CN and MeOD only minor differences are 
observed, however, the outcome is completely different (gel in MeCN and aggregates in EtOH). 
MeOH is a polar protic solvent, acting as both a H-bond donor and acceptor. This means it can 
compete even more severely than MeCN for H-bonding with the amides of the molecule. As 
before, this leads to a non-polar interaction becoming more important, however, in this case 
the glycolipid is solvated differently. As MeOH is more polar than MeCN, glycolipid 2.55 is likely 
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to be more insoluble in MeOH. This may result in the non-polar interactions being too strong, 
leading to the formation of a three dimensional network which is not robust enough to entrap 
solvent molecules and thus leading to the formation of aggregates.   
 
Figure 2.34 
1
H NMR spectrum of 2.55 in CDCl3 (green) versus CD3CN (red) and MeOD (blue). 
In addition, FT-IR analysis was performed as it is extremely sensitive to H-bonding interactions. 
The self-assembly behaviour of the C-10 aspartic acid derivative 2.55 and C-16 aspartic acid 
derivative 2.61 were investigated to examine the possibility that an intermolecular H-bonding 
network was contributing to gelation. When comparing the FT-IR spectra of the LMWG in 
solution and in the gel phase, the differences in the frequencies of some bands can be 
attributed to differences in H-bonding patterns.[61] For C-10 derivative 2.55 the sample was 
dissolved in MeCN, heated, and FT-IR analysis was performed in real time as the gel was being 
formed. The FT-IR spectra can be seen in Figures 2.35 and 2.36. The frequencies of the 
functional groups in the gel state (green line) were compared to those in the solution state 
(pink line). Significant differences in both wavenumbers and band intensity were observed. In 
the spectrum of the MeCN gel the emergence of two broad N-H amide bands at 3614 and 3552 
cm-1 is an indication that H-bonding of the compound 2.55 is playing a significant role in the 
gelation process. Similarly, one of the bands belonging to the carbonyl amides of the solution 
spectrum (1673 cm-1) has increased in intensity and shifted to a lower frequency (1635 cm-1). A 
low frequency shift is indicative of H-bonding in the formation of the gel of 2.55 in MeCN. 
These data correlates well with those reported in the literature.[108] 
 
β-H α-H 
β-H 
α-H 
N-H3 
β-H 
N-H2 
N-H1 
N-H3 
N-H2 
N-H1 
β-H 
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Figure 2.35 FT-IR spectra of glycolipid 2.55, from solution to gel in MeCN, spectra recorded at intervals 
of 2 min. The pink line indicates first measurement (solution) while the green line indicates final 
measurement (gel). The MeCN background is subtracted. 
 
 
Figure 2.36 Zoomed in FT-IR spectra of the carbonyl region of 2.55, showing difference in intensities 
between solution and gel state. 
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For the C-16 derivative 2.61 the sample was dissolved in MeCN, heated, and FT-IR analysis was 
performed in real time as the organogel was being formed. The FT-IR spectra can be seen in 
Figure 2.37. The bands corresponding to certain functional groups in the gel state (black line) 
were compared to those in the solution state (red line). In this case, the differences in both 
wavenumbers and band intensity between the gel and solution phase spectra were less 
noticeable. The C-16 aspartic acid derivative 2.61 is an extremely good gelator and always 
gelled almost instantaneously, it is therefore assumed that there was not sufficient time to 
obtain a spectrum before gelation occurred. This explains why differences between the 
spectra are not as clear. In the spectrum of the gel phase the emergence of a broad N-H amide 
band at 3615 cm-1 is representative for the formation of H-bonds involving organogelator 2.61. 
In this case, little or no difference can be seen in the carbonyl amides between the gelled and 
solution spectra. In fact, besides the appearance of the broad peak at 3615 cm-1 no differences 
can be observed between the two spectra. However, the carbonyl amide appears at a 
frequency of 1643 cm-1 which is in the region that implies it is participating in H-bonding. 
 
Figure 2.37 FT-IR spectra of LMWG 2.61 formation from solution to gel in MeCN. The red line indicates 
first measurement (solution) while the black line indicates final measurement (gel). 
The role of H-bonding in the gelation process was further investigated by an experiment which 
showed the competing effects of solvent on the protected C-10 derivative 2.55. As indicated 
earlier in Table 2.1, glycolipid 2.55 formed aggregates in 100% EtOH, however, in 100% MeCN 
gelation was observed (Figure 2.38). The self-assembly behaviour in varying percentages of 
MeCN and EtOH was then investigated and the results can be seen in Table 2.3. 
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Glycolipid Amount MeCN (mL) EtOH (mL) Result 
20 mg 100% - Gelation 
20 mg 90% 10% Gelation 
20 mg 80% 20% Gelation 
20 mg 50% 50% Soluble 
20 mg - 100% Aggregates 
 
Table 2.3 Gelation results of glycolipid 2.55 in varying percentages of MeCN an EtOH. 
 
                                                                                                    
       100% MeCN                                   50% EtOH, 50% MeCN                                    100% EtOH 
        Gelation             Soluble                    Aggregates 
Figure 2.38 The competing effects of EtOH and MeCN on glycolipid 2.55. 
As stated already, EtOH is a polar, protic solvent and it can be considered as a “competing” 
solvent. It has the ability to act as a H-bond donor and acceptor. In EtOH, the H-bonding 
between the amides of the glycolipid is being interrupted by H-bonding between the glycolipid 
and the solvent. Also, the glycolipid is more insoluble in EtOH than it is in MeCN, leading to 
differences in the solvation of the glycolipid, which can lead to increased gelator-gelator 
interactions. As a result the glycolipid is subjected to different interactions when EtOH is the 
solvent. A fine balance between H-bonding, non-polar interactions and solubility is required in 
order for the self-assembly process to lead to gelation. In the MeCN:EtOH 1:1 mixture this 
balanced is not achieved, therefore, the glycolipid remains in solution. In this mixture, the 
solvent nature and composition leads to the glycolipid again being solvated in a different 
manner. The H-bonding ability of EtOH may interefere with H-bonding occurring between the 
amides of the glycolipids. Similarily, the increased solvation (due to the MeCN) may lead to 
decreased Van der Waals forces between the lipidic portions of the glycolipids. All this 
suggests that in this mixture of solvents the interactions required to induce gelation are 
prohibited and the self assembly process required to induce gelation does not occur. 
The formation of organogels involves gelator-gelator interactions and solvent-gelator 
interactions.[109] H-bonding and Van der Waals interactions seem to be the most important 
interactions contributing to the self-assembly and gelation process of the glycolipids described. 
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Solubility also plays a crucial role because if the molecule is really soluble it can become 
effectively solvated and therefore, prevent the gelator-gelator interactions.  In the above 
glycolipids the carbohydrate moiety and the aspartic acid linker provide the source for H-
bonding donors and acceptors, whereas the lipidic chains are responsible for the non-polar 
Van der Waals type interactions.  
2.7.2 Gelation and self-assembly properties of second generation β-O-glycolipids 
In order to support the results discussed above a second generation of potential 
organogelators were synthesised and investigated (Figure 2.39). Initially we set out to examine 
the importance of the sugar moiety in the gelation process. For this investigation two non-
glycosidic controls were examined: compound 2.75, which was an intermediate in the 
synthesis of the disaccharide 2.32 (Section 2.6.3.2) and compound 2.91, which was easily 
synthesised by the reaction of hexadecanoyl chloride and propyl amine.  
We also wanted to examine whether the number of monosaccharide’s and type of linkage 
present affected the gelation ability. Therefore, compound 2.65 was synthesised (Figure 2.39), 
which has two galactosyl moieties and only the C-16 chain (section 2.2.5). Compound 2.31 was 
also synthesised, which had the galactose moiety linked through the C-1 position of the 
aspartic acid linker instead of the C- 4 position, as in previous examples (section 2.5.2 and 
section 2.5.3). Another variation we wanted to investigate was whether changing the 
carbohydrate moiety affected the gelation ability. Compound 2.32 was synthesised for this 
comparison, which has a lactose moiety and two hydrophobic chains (section 2.2.6). Finally, 
we wanted to examine if functionalising the C-6 position on the galactose moiety of the C-16  
aspartic acid derivative 2.61, as described earlier (Section 2.5.3), affected its gelling ability 
(compound 2.30, section 2.6.4). 
 
Figure 2.39 Second generation of potential aspartic acid derived LWMGs. 
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The gelation ability of the above compounds was tested in a range of solvents using the 
inverted test tube method as described in section 2.3.1. The results are presented in Table 2.4 
below. 
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 DCM Toluene MeCN MeOH EtOH H2O EtOAc Hexane CHCl3 
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P.S 
 
G(6) 
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G(8) 
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G(35) 
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S 
 
G(16) 
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S 
 
S 
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S 
 
A 
 
P.G 
 
G(20) 
 
I 
 
S 
 
I 
 
S 
 
 
 
S 
 
G(10) 
 
A 
 
G(10) 
 
G(8) 
 
I 
 
S 
 
P.G 
 
S 
Table 2.4 Gelation abilities of second generation glycolipids in various solvents. All compounds were tested using the inverted test tube method at 20 mg mL-1. Values 
refer to Minimum Gelation concentration (mg mL
-1
). Aggregates=A, G=Gelation, P.G= Partial Gelation, Insoluble=I, Soluble=S, Partially soluble=P.S, Non-tested = -.
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A number of conclusions could be drawn from the results. 
i) The galactosyl moiety was required in order to increase the stability of the gel, although not 
necessarily to induce its formation. Although the non-glycosidic controls 2.89 and 2.75 still 
possessed some self-association behaviour (2.91 gelled in toluene and 2.75 gelled in EtOH) 
it was observed that the thermal stability of the gels was much lower, so much so that even 
holding the vial could cause the gel to collapse.  
ii) We also concluded that Van der Waals non-polar interactions were extremely important in 
the gelation process, and two lipidic chains were necessary for gelation. Compound 2.65, 
which contained one lipidic chain, did not exhibit any self-association behaviour, whereas 
compound 2.32 which contained two lipid chains and a lactosyl moiety, exhibited similar 
behaviour to the galactosyl derivatives which contained two lipidic chains 2.55 and 2.61. Gel 
formation was observed in MeCN, MeOH and EtOH. The gels were also very stable, with Tgs 
values of 45 oC in MeCN, and 47 oC in EtOH, which is slightly lower than the Tgs value of 52 
oC 
obtained for the galactose C-16 derivative 2.61. 
iii) Regarding the differences observed when altering the sugar moiety, the lactose derivative 
2.32 gelled in the same solvents as 2.61 (its galactosyl counter-part). However it had 
significantly lower MGC values in MeOH and MeCN, which is beneficial (i.e. a lower 
concentration of compound was required to induce gelation).  
iv) The position of the sugar moiety in the aspartic acid scaffold also influenced the self-
assembly behaviour. Compound 2.31 exhibited self-assembly behaviour in a variety of 
solvents including, EtOH, MeOH and toluene and exhibited lower MGC values than 2.61. 
However the thermal stability of the EtOH gel was much lower, with a Tgs value of 33 
oC 
compared to 2.61 (Tgs of 42 
oC). 
v) The final conclusion drawn was that functionalising the C-6 position of the galactose moiety 
did affect its gelation ability. Although the molecule did act as a LMWG in toluene its MGC 
was much higher than its fully deprotected counterpart 2.27, which was less beneficial as a 
higher concentration of compound was required to induce gelation. 
2.7.3 Ability of selected O-glycolipids to act as hydrogelators 
A hydrogel may be defined as a semi-solid formulation having an external aqueous phase which is 
immobilised within the available spaces of a three dimensional network structure.[110] As a result of 
their high H2O content they are extremely biocompatible and therefore, have been considered for 
use in a wide range of biomedical and pharmaceutical applications. Applications of hydrogels include 
contact lenses, biosensors, sutures, dental materials, and controlled drug delivery devices.[111] 
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In 2011 work by Kar et al.[112] demonstrated the transformation of an organogel to a hydrogel by 
using simple protecting group removal. They reported the development of a series of amino 
acid/peptide-based amphiphilic molecules which could induce gelation of both H2O and organic 
solvents. If the molecule contained a tert-butyloxycarbonyl (t-Boc) protecting group at the primary 
amine of the hydrophilic ethyleneoxy unit at the C terminus, the compound acted as an 
organogelator. Whereas deprotection of the N-Boc moiety under acidic conditions to yield the 
primary amine resulted in the molecule acting as a hydrogelators (Scheme 2.22).  
 
Scheme 2.22 Example of transformation between organogelator and hydrogelators.
[112]
 
Due to the high biocompatibility and numerous applications of hydrogels, it was decided to test the 
potential of our glycolipids to act as hydrogelators. Their gelation ability was tested as previously 
described[105] and the results are presented in Table 2.5. Initially, all compounds tested were 
insoluble in H2O, and no hydrogels were formed. It was believed that the long hydrophobic chains 
were driving the high insolubility and therefore, they could not interact with the solvent to form the 
complex, three dimensional structures required to form a gel. Due to the previous positive results 
obtained with EtOH, it was decided to test the ability of the compounds to induce gelation in a 
mixture of EtOH and H2O. These conditions proved slightly more successful. Glycolipid 2.31 and 2.55 
induced gelation in a 1:1 mixture of H2O /EtOH. Varying the proportions of a H2O /EtOH mixture was 
attempted but only the 1:1 ratio induced full gelation. These optimised conditions were investigated 
for all glycolipids described earlier, however only glycolipid 2.31 and 2.55 induced gelation.
   TFA 
Dry DCM 
Boc Anhydride 
Basic Medium 
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 H2O H2O /EtOH 
(1:1) 
 H2O H2O /EtOH 
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Table 2.5 Gelation abilities of second generation glycolipids in various solvents. All compounds were tested using the inverted test tube method at 20 mg mL-1. Values 
refer to Minimum Gelation concentration (mg mL
-1
). Aggregates=A, G=Gelation, P.G= Partial Gelation, Insoluble=I, Soluble=S, Partially soluble=P.S.
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Liu et al.[67] recently published an article highlighting the ability of ultrasonication to induce 
gelation in some cases. They found that a selection of hydrazide compounds could not induce 
gelation in polar solvents by the usual heating and cooling process. However if the cooling 
process was carried out in the presence of ultrasound, stable gels were formed. With this in 
mind, we decided to again test the ability of the glycolipids to induce the formation of 
hydrogels. This time we allowed the cooling process to occur in the presence of ultrasound. 
However, as before, the formation of hydrogels was still not observed for all compounds 
investigated (Table 2.5). Using ultrasound it was found that the deprotected glycolipids, 2.26 
and 2.27, were able to induce gelation in MeOH, which they had not been able to do using the 
heating and cooling method. The thermal stability of the gels was greatly increased in MeOH 
(carried out under same conditions). The Tgs value of the C-16 derivative 2.27 was 70 
oC in 
MeOH and only 46 oC in toluene.  
A summary of all Tgs values is shown in table 2.6. 
Compound Solvent Tgs 
 
Toluene 36 oC 
 
Toluene 46 oC 
 
MeCN 15 oC 
2.61 MeCN 52 oC 
 
MeCN 45 oC 
 
EtOH 33 oC 
2.61 EtOH 42 oC 
 
MeOH 70 oC 
Table 2.6 Comparison of Tgs values of various glycolipids in different solvents. 
Chapter 2:                                                                                                   Alkyl glycolipids as novel soft materials 
 
 
 
68 
 
2.8 Incorporation of glycolipid 2.55 into a giant unilamellar vesicle (GUV) 
Amphiphilic glycolipids assemble into a variety of structures in aqueous solution (Figure 2.40). 
The shape of thestructures depends mainly on the geometry and properties of the lipids 
involved in their formation. The most commonly occurring aggregates include a bilayer, micelle 
and liposome.[80] The lipid molecules are organized in such way that the hydrophilic head 
groups are in contact with the aqueous solution and the hydrophobic tails are interacting with 
each other. 
 
Figure 2.40 Shapes of lipid aggregation in an aqueous environment.
[113]
 
Micelles are mainly formed by lipids with large head groups and one hydrocarbon chain, which 
is usually unsaturated and pointing towards the centre of the structure. Bilayers and liposomes 
are formed by lipid amphiphiles containing two fatty acid chains.[80] 
A vesicle is a lipid bilayer rolled up into a spherical shell. The centre of the vesicle is H2O filled 
and is surrounded by a single lipid bilayer (unilamellar vesicle) or by more than one 
(mutilamellar vesicle).[114] Giant unilamellar vesicles (GUVs) range in size from 1-300 µm[81] and 
were first observed by Bangham in the 1950’s.[115] Their size allows for their manipulation by 
micropipettes and visualisation under light microscope.  GUVs are extensively used in studying 
the physical and chemical properties of biological membranes.  The vesicle membrane mimics 
the lipid bilayer of the plasma membrane and they can be utilised to study biochemical 
reactions and self-assembly processes that occur on the membrane.[116] 
Vesicles are also used as drug delivery vehicles. They can be prepared from lipids naturally 
occurring in mammalian cells, which make them highly biocompatible.[81] Also, incorporation of 
receptors, ligands, addressins, poly-ethylene glycol (PEG) and other molecules would allow for 
the targeting of a specific site or organ within the body. The incorporation of certain glycolipids 
into the vesicles allow for targeting specific tissues or cells (for example cancer or metastatic 
cells). Interesting examples include the development of liposomes containing carbohydrate-
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functionalised β-cyclodextrins designed for drug delivery into liver cells,[117] and GUVs 
containing glycolipid specific for activated platelets which is a promising method for drug 
delivery in cardiovascular diseases.[118] 
In view of the ability of our synthetic glycolipids to self-assemble, and in order to expand the 
scope of the applications, the formation of GUVs in the presence of these compounds was 
explored. The acetylated glycolipid 2.55 was successfully incorporated into GUVs formed with 
DOPC, DPPC and cholesterol. In studies carried out by Ms Urzsula Miggas and Dr. Jennifer 
McManus at NUI Maynooth, a series of phase condensation phenomena, which is believed to 
be induced by the presence of the glycolipid, were observed at the surface of the GUVs. 
Detailed investigations are currently underway. 
2.9 Conclusion 
Despite the initial problem of racemisation that occurred during the synthesis of acylated 
aspartic acid derivative 2.34, careful consideration of the synthetic approach resulted in the 
synthesis of the diastereomerically pure aspartic acid derivatives, 2.26-2.28. Following the 
same modular approach, we described the successful synthesis of a variety of L-aspartic acid 
derivatives, 2.29-2.32, utilising a key set of reaction conditions.  
The gelation abilities of a range of glycolipid derivatives were examined in a variety of solvents, 
and some of the structural features that may affect gelation ability, including hydrophobic 
chain length and chirality, were investigated. We found that the acetylated galactosyl C-16 
analogue 2.61 and the acetylated lactosyl C-16 analogue 2.32 were the best gelators as they 
were able to induce gelation in the widest number of solvents. The lactosyl derivative 2.32 
exhibited lower MGC values in MeOH and MeCN than its galactosyl counterpart 2.61, 
however, the galactosyl derivative produced more thermally stable gels.  
Spectroscopic analysis provided evidence for the importance of H-bonding and non-polar Van 
der Waals interactions in the self-assembly and gelation process. However, we also confirmed 
that solvation and solubility plays a crucial role. A fine balance between all these factors is 
necessary to induce effective gelation. 
Sructural analysis indicated that, for the glycolipids investigated, two lipidic chains were crucial 
for the self assembly process. This was evident as when a derivative containing two galactose 
moieties and one lipidic chain 2.29 was investigated no self-assembly or gelation was 
observed. The C-16 derivatives always performed better than their C-10 counterparts and this 
suggested that  Van der Waals forces are also important in the self assembly process as the 
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hydrophobic chain length can influence the gelation ability.  The acetylated analogues were 
able to induce gelation in a wider variety of solvents than the free hydroxyl analogues which 
indicated that a certain degree of solubility is required for the self-assembly process. Finally, 
we determined that although the carbohydrate moiety was not necessarily required to induce 
gelation however, it was required for stability. As the control compounds 2.89 and 2.77 both 
formed gels which collapsed upon moving of the vial. 
The ability of the glycolipids to acts as hydrogels was also examined. Although none of the 
glycolipids were able to induce gelation in H2O, we found that with 1:1 mixtures of EtOH and 
H2O the acetylated galactose C-10 derivative 2.55 was able to induce gelation with an 
extremely low MGC value of 4 mg mL-1.  
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3.1 Introduction 
Due to the presence of two carboxylic acid side groups, which can be easily functionalised, 
malonic acid is an ideal scaffold for the synthesis of a wide range of divalent molecules. Owing 
to the short methylene linker connecting the two acid groups, there is provision for access to 
short bivalent glycoconjugates. Also, further functionalisation can be achieved at the α carbon, 
with the possibility of adding side groups or alkyl chains depending on the compound of 
interest. 
 
 
Figure 3.1 Structure of malonic acid and sites for functionalisation. 
Despite the fact that malonic acid and its various esters are readily available and easily 
functionalised, there are limited examples of malonamide synthesis reported in the literature. 
More specifically, examples of malonamides used as glycoconjugate scaffolds are limited. The 
synthesis of malonate derivatives is somehow more common, however, again reports in the 
literature are sparse. 
3.1.1 Malonates and their potential application 
Malonate esters have been used extensively as intermediates in the synthesis of complex 
molecules. In many cases, one carboxylic acid is lost through decarboxylation and this 
phenomenon is discussed further in section 3.2.1.1. The synthesis of simple malonate esters is 
discussed below. Sbardella et al.[119] synthesised a series of long chain alkylidenemalonates 3.1-
3.5 (Figure 3.2) and examined their potential as modulators of histone acetyltransferases 
(HATs). Compounds 3.1-3.5, are structurally related and simplified analogues of anacardic acid, 
which is a known inhibitor of HATs.  
 
Figure 3.2 Structure of long chain alkylidenemalonates 3.1-3.5, and Anacardic acid (a known HAT 
inhibitor).
[120]
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During nucleosome assembly, DNA repair and other genomic processes, HATs regulate 
transcription and histone deposition by acetylating the ɛ-amino groups of specific lysines in 
histones.[121] They are also responsible for acetylating transcription factors (e.g. p53)[122] and 
other nuclear proteins (e.g. α-tubulin).[123] A limited number of HAT inhibitors have been 
identified.  
The compounds 3.1-3.5 were pre-screened for their effects on cell-cycle and apoptosis 
induction in the human leukemia cell line U937. The inhibiting capability of the more active 
derivatives was then investigated against HAT enzymes.  Malonates 3.1 and 3.2 were able to 
both arrest cell cycle and induce apoptosis, whereas the other derivatives had very minimal 
effects. Pentadecylidenemalonate 3.2 was further identified as the first molecule able to both 
activate and inhibit HATs.[119] 
Kolb and Meier also published a report on the synthesis of a series of malonate derivatives 
bearing long aliphatic chains ranging in length from C6-C16 (Figure 3.3).
[124]  
 
Figure 3.3 Malonate-derived monomers 3.6-3.11.
[124]
 
These alkyl malonate derivatives had a completely different application and were polymerised 
to yield polyesters and polyamides. The use of degradable polymers has become very topical in 
order to minimise polymer waste management caused by non-degradable polymers. Due to 
their biodegradability, biocompatibility, hydrolytic degradability and suitable mechanical 
strength, synthetic aliphatic polyesters are promising candidates for degradable polymer 
materials.[124-125] 
3.1.2 Non-carbohydrate-based malonamides 
Malonamides are derivatives of malonic acid, whereby an amide functionality replaces the 
carboxylic acid groups. The hydrolysis of malonamides does not proceed as easily as that of 
malonate esters, therefore, they have not been exploited as synthetic intermediates.  Some 
selected examples of non-carbohydrate malonamides are discussed below. 
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 A family of N,N’-di-substituted malonamides were prepared as potential silver(I)-selective 
chelating ligands, and a selection of representative examples are shown in Figure 3.4.[126] 
Figure 3.4 Disubstituted malonamides as potential silver(I) selective ligands.
[126] 
Metal-selective ligands have applications in solvent extraction and Daubinet and Kaye aimed to 
develop ligands capable of extracting silver(I) selectively from ore-leached solutions containing 
metal-based contaminates. Initial results indicated that although substituted malonamides 
3.12-3.16 exhibited some selectivity for silver(I) over copper(II) and lead(II), 3.12 gave the best 
results as it exhibited remarkably high selectivity and excellent efficiency.[126a] A second 
generation of analogues was synthesised and examined (representative examples 3.17-3.19), 
however, the original substituted malonamides  proved to be more efficient ligands.[126b] 
Fioravanti et al. discussed the use of Meldrum’s acid as a scaffold to obtain non-symmetric 
disubstituted malonyl peptides (Scheme 3.1).[127]  They aimed to further functionalise these 
disubstituted malonyl peptides and synthesise malonyl dehydro peptides, using Knoevenagel 
reactions (Scheme 3.1), which could be potential scaffolds for peptidomimetics.[128] 
 
  
Scheme 3.1 Synthesis of malonyl peptides and malonyl dehydro peptides as potential scaffolds for the 
construction of peptidomimetics.
[127]
 
 
Chapter 3:                                 Synthesis of malonamide glycoconjugates as potential anti-adhesion agents 
 
 
75 
 
The use of natural peptides is limited by their poor bioavailability and susceptibility to 
proteolysis. Therefore, the synthesis of peptidomimetics, by structural manipulation of the 
natural peptide backbone, is highly advantageous. One modification that can be made in the 
peptide chain is reversal of the amide bond. This alteration increases the peptides resistance 
to biodegradation without decreasing the receptor binding ability and biological response.  
Some selected examples of malonyl dehydro peptides are shown in Figure 3.5. These can be 
regarded as important synthetic targets, not only for the construction of novel 
peptidomimetics but also for their potential biological applications. Also, due to the double 
bond, they can be further functionalised to synthesise more complex molecules. Figure 3.5 
also highlights the difference between natural dehydro peptides and the synthetic malonyl 
dehydro peptides.[128] 
 
Figure 3.5 Selected examples of synthesised malonyl dehydro peptides, and the difference between 
malonyl dehydro peptide and natural dehydro peptide.
[127-128]
 
 
It is important to highlight that more complicated bicyclic malonamides have also been utilised 
in the literature, surprisingly, however, examples are limited. One such example, reported by 
Parks et al., involves the synthesis of a series of 6,6-bicyclic malonamides as ligands for the 
binding of f-block metals (Figure 3.6).[129]  
 
Figure 3.6 Selection of 6,6-bicyclic ligands synthesised as potential ligands for the binding of f-block 
ions.
[129] 
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3.1.3 Carbohydrate-based malonamides 
As stated previously, there are a limited examples of carbohydrate-based malonamides 
reported in the literature. Kato et al. described the synthesis of bis(α-D-
mannopyranosyl)malonamide 3.27 which was further reacted with C60 to afford the fullerene 
glycoconjugate 3.28 (Figure 3.7).[130]  
 
Figure 3.7 Structure of carbohydrate malonamide 3.27 and protected and deprotected fullerene sugar 
3.28, 3.29, synthesised from bis(α-D-mannopyranosyl)malonamide 3.27 and C60.
[130]
 
The first fullerene sugars were described by Vaselle and Diederich in 1992,[131] and since then a 
variety of fullerene glycoconjugates have been designed and characterised. They are extremely 
important as they have potential applications in both the biomedical and materials 
industries.[130]  
Another paper which was published by Isaad et al.[132] concerns the synthesis of carbohydrate-
based malonamides. However, in this case the sugars are utilised to aid the water solubility of 
naturalised dyes.  Disperse dyes are commonly used in the dyeing of many materials.  Due to 
their insoluble nature in water, however, additives are regularly used in conjunction with the 
dyes to enable them to approach the hydrophobic fibres and dye them.[133] This practice 
causes great concern owing to the large quantities of additives that are necessary for dyeing in 
water and also because of the environmental impact of both the dyes and the additives. Isaad 
et al.[132] have developed a new class of dyes termed “naturalised dyes” which reduce 
enviromental impact, as no additives are required for the dyeing process. This also enables the 
dyeing processs to be carried out at lower temperatures and over a shorter period of time.  
Two potential soluble naturalised dyes were synthesised[132]: the mono-glyconjugated 
derivative, 3.30, and the double-glycoconjugated dervativ 3.31 (Figure 3.8). 
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Figure 3.8 Structure of mono and double-glycoconjugated dyes 3.30 and 3.31.
[132]
 
The mono-glycoconjugate 3.30 was still insoluble in water, however, the double-
glycoconjugate 3.31 was water soluble. A mixed derivative, which has one lactose and one 
galactose moiety attached, was also synthesised but exhibited limited solubility in water. This 
shows that a minimum percentage weight of 50% of the glycidic moiety is required for 
solubility, since at 40% they are still completely insoluble.[132] 
3.2 Chapter Objective 
This chapter deals with the synthesis of a variety of malonamide glycoconjugates as potential 
anti-adhesion agents. Although examples of similar compounds are minimal in the literature, 
we chose malonamides as we envisaged a symmetric, aliphatic scaffold that could be easily 
functionalised. As stated previously, malonic acid is an ideal building block in the synthesis of 
these bivalent aliphatic ligands. It features two carboxylic acid side groups and an acidic          
α-proton and therefore, allows the easy introduction of functionality. Owing to this, it would 
provide access to a range of structurally diverse glycoconjugates which could be investigated 
for potential biological activities. The design of the ligands involved the use of an aliphatic 
scaffold that would enable the synthesis of a bivalent galactose system but also allow for the 
introduction of a lipidic chain. As with the previous chapter, we followed a modular approach 
utilising a key set of reaction conditions which allowed us to achieve diversity quickly and 
easily, and also allowed for sufficient scale up.  
 
The core building block structure can be seen in Figure 3.9. It is clear from the figure that the 
malonyl backbone would remain constant in all analogues and that variation could be achieved 
at three potential sites. 
 
3.30 
3.31 
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Figure 3.9 Core scaffold utilised for the synthesis of malonamide glycoconjugates. 
 
Promising anti-adhesion activity has been achieved using a variety of synthetic multivalent 
compounds, and there are numerous examples discussed throughout this report.  However, in 
most of these cases, the structure of the bacterial lectin of interest is known. This makes the 
discovery of efficient synthetic ligands simpler, as they can be specifically designed for 
optimum binding. In our case, minimal structural information is known about the bacterial 
lectins of Burkholderia. Multivorans which are involved in the recognition of glycolipids present 
on the surface of the cell. This makes the design of synthetic ligands as anti-adhesion agents 
extremely difficult. For this reason, we chose to synthesise a variety of structurally diverse 
ligands, and aimed to examine their structure-activity relationships.  
 
For the purpose of our research, we chose to investigate how linker length, chemical structure 
and flexibility influenced the presentation of the carbohydrate moieties and thus, the 
biological activity. For this reason, variation site 1 always remained as a galactosyl moiety, 
although it could be expanded to a different carbohydrate moiety if required. At variation site 
2, a C-10 lipidic chain was kept constant but again it could be altered to a hydrophobic chain of 
varying length if desired.  The main variations focused on the chemical structure of the linker. 
We aimed to examine three types of amide linkage between the galactosyl moiety and the 
malonyl backbone. In the first linkage envisaged, the galactosyl moiety is coupled directly to 
the malonyl scaffold via an N-glycosidic bond (compound 3.32, Figure 3.10). For the second 
linkage, we intended to utilise an ethyl linker functionalised with a primary amine to connect 
the galactose and malonyl backbone via an amide bond (compound 3.33, Figure 3.10). The 
final linker we aimed to investigate exploits a triazole moiety to pin the galactose moiety and 
the malonyl building block (3.34, Figure 3.10). 
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Figure 3.10 Structures of galactosyl malonamides 3.32-3.34. 
3.3 The synthesis of malonyl-based glycoconjugates 3.32, 3.33 and 3.34 
The malonyl-based N-glycoconjugates 3.22 and O-glycoconjugates 3.33 and 3.34 were 
designed to act as potential anti-bacterial agents. Their biological activitiy will be discussed in 
Chapter 5 (section 5.7). A suitable starting material for their synthesis is methyl malonate 3.35, 
as it features an acidic α-proton, which would allow for the introduction of a hydrocarbon 
chain. It also contains two ester groups on its side chain, which upon hydrolysis would allow 
for connectivity to the galactosyl moiety through the formation of an amide bond. 
 
Two routes for the synthesis of the bivalent aliphatic glycoconjugates were explored: 1) 
alkylation of the α-proton followed by the amide coupling of the desired amine and the free 
carboxylic acid groups, or 2) amide coupling with the desired amine, followed by alkylation of 
the α-carbon.  
 
Initial investigations led us to design the synthetic pathway shown in Scheme 3.2, whereby the 
easily accessible amines and the commercially available dimethyl malonate 3.35 would serve 
as suitable building blocks. The decyl chain would be introduced first via alkylation of the              
α-carbon. Subsequent hydrolysis of the methyl esters would provide the carboxylic acid side 
groups which would allow for introduction of the galactosyl moiety using standard peptide 
coupling conditions. Based on this approach, a variety of analogues could be easily synthesised 
by utilising a key set of reaction conditions which are already widely accepted and utilised. 
 
 
Scheme 3.2 Intial synthetic route for synthesis of glycoconjugates 3.32-3.34. 
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3.3.1 Attempted synthesis of β-O-glycoconjugate 3.33 via alkylation followed by amide 
coupling 
The malonamide O-glycoconjugate 3.33 was designed as a flexible molecule. We believed that 
the ethyl linker would allow for a certain amount of flexibility of the galactosyl moieties.  
The synthesis commenced with the alkylation of the commercially available dimethyl malonate 
3.35 with 1-bromodecane using K2CO3 to give ester 3.37 (Scheme 3.3).
[134] Hydrolysis, utilising 
15% NaOH in EtOH, afforded the di-acid 3.36, which was ready for coupling with the galactosyl 
amine 2.33 using standard TBTU/HOBt methodology, as discussed previously (Chapter 2, 
section 2.5). Unfortunately, this coupling reaction did not yield the desired product 3.38. 
 
Scheme 3.3 Reagents and conditions: i) CH3(CH2)9Br, K2CO3, CH3CN, 80 
o
C, 36 h, 80%;  ii) 15% NaOH, 
EtOH, 80 
o
C, 18 h, 50%; iii) HOBt, TBTU, DMF, NEt3, N2, rt, 16 h, 78%. 
Instead, the major product obtained appeared to be the decarboxylated derivative 3.39. The 
1H NMR spectrum of 3.39 is shown in Figure 3.11 with characteristic peaks assigned. The signal 
corresponding to the α-proton is absent from the 1H NMR spectrum, and instead the 
methylene protons* can be seen resonating at 2.16-2.12 ppm. This was very much unexpected 
because although decarboxylation can occur in the presence of base, it usually requires 
thermal conditions.[135] The coupling reaction was repeated, this time in the absence of base 
but nonetheless the decarboxylated product 3.39 was obtained.  
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Figure 3.11 
1
H NMR spectrum of decarboxylated derivative 3.39 (300 MHz, CDCl3). 
To rule out possible steric issues arising from the bulky carbohydrate, a test reaction was 
carried out. Propyl amine was reacted with the malonyl backbone 3.36, under the same 
conditions but again the 1H NMR spectrum indicated that only one propyl group had been 
attached. This result indicated that steric issues were not the problem and that 
decarboxylation was occurring due to some other factor. 
3.3.2 Decarboxylation of malonic acid derivatives 
It is well established that malonic acid derivatives can undergo decarboxylation to form 
carboxylic acids (Scheme 3.4).[135-136] In fact, it is this feature which makes malonic acids such 
useful synthetic reagents in what has famously being named the Malonic Ester Synthesis 
(MES).[137] The MES reaction mechanism is described below (Scheme 3.4). The malonic ester 
3.40 is first alkylated using mild basic conditions to yield derivative 3.41. Hydrolysis promoted 
by either acidic or basic conditions, affords the di-carboxylic acid 3.42 which can then undergo 
thermal decarboxylation to yield the enol 3.43 and CO2. In the final step, the enol tautomerises 
to the carboxylic acid derivative 3.44.[135] 
NH 
H-1 
CH3  
of chain 
* 
1
st
 CH2*  
of chain 
3.39 
Chapter 3:                                 Synthesis of malonamide glycoconjugates as potential anti-adhesion agents 
 
 
82 
 
Scheme 3.4 Synthesis of carboxylic acid derivatives via malonic ester alkylation, hydrolysis and 
decarboxylation, i.e. the malonic ester synthesis.
[135] 
As a result of this phenomenon it was decided to re-examine the hydrolysis step of our 
synthetic route and ensure decarboxylation was not occurring at this point. The 1H NMR 
spectrum of the alkylated malonic acid 3.36 exhibited a signal for the α-proton at 3.44 ppm 
(Figure 3.12), while the 2D COSY spectrum showed distinct coupling between the α-proton and 
first methylene of the decyl chain (Figure 3.13). The presence of the compound was also 
confirmed by HR-MS analysis. As stated already, the α-proton resonates downfield at 3.44 ppm 
in the carboxylic acid derivative 3.36, whereas the first methylene proton of the 
decarboxylated derivative 3.39 (Figure 3.11) resonates upfield at 2.12 ppm. 
Figure 3.12 
1
H NMR spectrum of the malonyl backbone 3.36 (MeOD, 300 MHz). 
 
 
 
 
α-H* 
1
st
 CH2 of 
chain 
CH3 of chain 
3.36 
* 
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Figure 3.13 
1
H NMR COSY spectrum of carboxylic acid derivative 3.36 which shows the α-proton 
coupling to the first methylene  of the decyl chain (300 MHz, CDCl3). 
This confirmed that the decarboxylation was in fact occurring during the amide coupling 
reaction between the galactosyl amine 2.33 and the malonyl backbone 3.36.  
As mentioned above, this decarboxylation of malonic acids via Malonic Ester Synthesis has 
been exploited for the synthesis of substituted carboxylic acids since 1901.[138] On the other 
hand, the synthesis of amides from malonyl esters never emerged as a universal and efficient 
methodology. Recently, Majahan et al. reported a general methodology for the synthesis of 
amides utilising malonic esters.[137] Originally they were attempting to synthesise the indole 
alkaloid derivative 3.47 using intramolecular, copper-catalysed α-arylation of malonates 3.46. 
However, they observed the formation of decarboxylated product 3.45 instead of the alkaloid 
derivative 3.47 (Scheme 3.5).  
 
Scheme 3.5 Reagents and conditions: i) CuI (0.10 equiv.), 2-picolinic acid (0.20 equiv.), Cs2CO3 (3.0 
equiv.), 1,4-dioxane, rt to 70 
o
C, 4 h.
[137]
 
This serendipitous discovery led them to explore this reaction further and examine both the 
cause of decarboxylation and its potential as a method for amide bond formation. The 
methodology worked very well for aromatic, hetero-aromatic, primary and secondary amines, 
however, the conditions did not tolerate the formation of aliphatic amines. Further studies of 
the reaction and the conditions required for decarboxylation found that the base Cs2CO3 was 
α-proton 
1
st
 CH2 of decyl chain 
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responsible, although some heterocylic amines, such as 2-aminopyridine, yielded the 
decarboxylated amide without the addition of Cs2CO3.                            
Although this report shows that decarboxylation can occur with amides derived from malonic 
esters, to the best of our knowledge decarboxylation under the coupling conditions utilised 
has not been reported in the literature to date. 
3.3.3 Attempted Knoevenagel synthesis of β-O-glycoconjugate 3.43 via alkylation followed 
by amide coupling 
As a result of the problems encountered above, the synthetic route was readdressed and a 
new approach was taken. We wanted to investigate if the presence of a double bond in the 
hydrophobic chain could lessen the risk of decarboxylation during the coupling step. With this 
in mind, a Knoevenagel condensation between the ester 3.35 and an aliphatic aldehyde 
(dodecanal), was attempted (Scheme 3.6).  
 
Scheme 3.6 Knoevenagel condensation between dodecanal and dimethyl malonate 3.35. 
The Knoevenagel condensation is widely utilised as a carbon-carbon bond forming reaction in 
organic synthesis.[139] The reaction is generally catalysed by weak organic bases such as amines, 
ammonia and ammonium salts,[140] but acidic conditions can also be exploited.[139] There are 
numerous synthetic conditions reported in the literature, however, conventional reagents 
used as catalysts in this reaction include piperidine,[141] aluminium oxide[142] and lithium 
bromide.[143] Although there are many examples of Knoevenagel condensations carried out 
with aromatic aldehydes, the literature on the condensation with aliphatic aldehydes is a lot 
sparser. In fact there are only isolated reports of the condensation reaction between aliphatic 
aldehydes and malonic esters,[139, 144] and even fewer between aliphatic aldehydes and the 
poorly reactive malonamides.[128] The biggest challenge lies in the fact that reaction conditions 
seem to require optimisation for each specific substrate.[139] 
A variety of reaction conditions were attempted for this transformation and the results are 
summarised in Table 3.1. After extensive optimisation, the desired product 3.48 was isolated in 
38% yield (Table 3.1, entry 6), when acetic acid and piperidine were used as catalysts. The 
purification of 3.48 was complicated by the presence of excess of unreacted aldehyde, which 
hampered separation by chromatography. 
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 Table 3.1 Various reaction conditions attempted for the Knoevenagel condensation between 3.35 and dodecanal.
Entry Reagents Conditions Molecular 
Sieves (4 Å) 
Reaction Time Product 
1 Piperidine (1 drop) 
Acetic Acid[119] 
(1 drop) 
3.35 (1 eq) and C11H23CHO (1 eq) at 0 
oC. 
  
Reagents added 0 oC for 45 min, then rt. 
Yes (added 
after 45 min) 
3 h 3.35 
C11H23CHO 
2 LiBr (0.5 eq) 
Acetic anhydride[145] (4.4 
eq) 
3.35 (1.5 eq) and reagents refluxed at 80 oC for 3 h.  
 
C11H23CHO (1 eq) added and stirred for further 2 h. 
No 5 h 3.48:3.35  
(10:1 ratio) 
C11H23CHO 
3 LiBr (0.2 eq) 
Acetic anhydride[140] (2 
eq) 
3.35 (1 eq) and reagents refluxed at 80 oC for 4 h.  
C11H23CHO (3 eq) added and stirred for 2 h. 
No 6 h 3.48:3.35  
(8:1 ratio) 
C11H23CHO 
4 Acetic Acid (0.2 eq) 
Piperidine (0.2 eq) 
 
3.35 (1 eq) and C11H23CHO (1.1 eq).  
 
Reagents added and stirred at rt overnight. 
Yes (from 
start) 
16 h 3.48:3.35  
(1: 2 ratio) 
C11H23CHO 
5 Acetic Acid (1 eq) 
Piperidine (1 eq) 
 
3.35 (1 eq) and C11H23CHO (1.1 eq).  
 
Reagents added and stirred at 90 oC overnight. 
Yes (from 
start) 
16 h Decomposed 
6 Acetic Acid (2 drops) 
Piperidine 
(2 drops) 
 
3.35 (1 eq) and C11H23CHO (1.1 eq) on ice.  
 
Reagents added and stirred at 0 oC for 45 min. Sieves added 
and stirred at rt overnight. 
Yes (after 45 
min) 
16 h 3.48 (38%) 
C11H23CHO 
DCM, N2 
3.35 
3.48 
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3.3.4 Hydrolysis of alkylidenmalonate 3.48 
The next step required hydrolysis of the methyl esters in 3.48 to yield the carboxylic acid 
derivative 3.49. Unfortunately, problems were again encountered.  Various hydrolysis 
conditions were examined, which included the use of LiOH, NaOH or formic acid but in all 
cases the compound appeared to decompose. Ester hydrolysis is a widely utilised reaction in 
organic synthetic chemistry and the transformation is most commonly carried out under basic 
conditions such as NaOH or LiOH (Scheme 3.7). These hydroxides have high basicity and 
nucleophilicity and therefore, can be classed as unsuitable reagents when sensitive subtrates 
are being hydrolysed.[145] In our case, the presence of the double bond seemed to induce the 
degradation of the molecule, and a complex crude 1H NMR spectrum that no desired product 
or decarboxylated product was obtained. 
 
Scheme 3.7 Reagents and Conditions: i) Piperidine, CH3COOH, C11H23COH, 0 
o
C-rt, 18 h, 38%; ii) see Table 
3.1. 
Based on this information, a milder hydrolysis method was obviously required. In 1960, 
Elsinger et al. reported the selective hydrolysis of methyl esters using lithium iodide.[146] Since 
then, there has been a number of reports on the use of lithium salts for the mild hydrolysis of 
esters.[145, 147] Lithium iodide is a mild, neutral reagent and therefore, can hydrolyse esters in 
the presence of a variety of functional groups.  
With this in mind, hydrolysis of the alkylidene malonate 3.48 was attempted using lithium 
iodide. At first, the results appeared promising, but upon closer inspection the crude mixture 
was extremely complex and purification proved difficult. We next investigated a one pot 
reaction, whereby the alkylidene malonate 3.48 was hydrolysed and coupled to the galactosyl 
ethyl amine 2.33 in situ (Scheme 3.8). Unfortunately, the reaction did not proceed as expected. 
The crude sample appeared to consist of a variety of unknown compounds. Upon purification 
by column chromatography the major product was identified as the decarboxylated derivative 
3.50, which was confirmed by HR-MS. The presence of the double bond did not appear to 
lessen the risk of decarboxylation as expected. Instead, the alkene chain was also lost. This was 
unexpected, and as the reaction was carried out in situ, it is difficult to identify whether it 
occurred during the hydrolysis or coupling reaction.  
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Scheme 3.8 Reagents and Conditions: i) LiI, EtOAc, N2, 60 
o
C, overnight; ii) HOBt, TBTU, NEt3, 2.33, DMF, 
rt, 16 h, 63%. 
3.3.5 Amidation reactions of malonic esters 
To circumvent the problems we again had to alter our synthetic method. The amidation of 
malonic esters has been previously reported[126]  and provides a convenient route for accessing 
malonamides from malonic esters. Our initial approach involved the amidation of 
ethanolamine with the alkylated malonic ester 3.37 (Scheme 3.9) which could be later reacted 
with two galactosyl donors in a glycosylation reaction to give compound 3.38. 
Scheme 3.9 Reagents and conditions: i) NH2CH2CH2OH, DCM, rt, 3 days, 62%. 
Amidation of the alkylated malonic ester 3.37 afforded the desired N,N-bis(2-
hydroxyethyl)malonamide 3.52 in 62% yield after a period of three days (Scheme 3.9). 
Unfortunately, compound 3.52 was found to be extremely insoluble in all organic solvents 
tested, which made any further reactions practically impossible. As a result of this, a different 
approach was taken. This time the amidation reaction was performed on the diethyl malonate 
prior to alkylation (Scheme 3.10). We believed this would alleviate solubility issues and enable 
further functionalisation. 
Scheme 3.10 Reagents and conditions: i) NH2CH2CH2OH, rt, 2 h, 85%. 
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Starting from diethyl malonate 3.53 the desired N,N-bis(2-hydroxyethyl)malonamide 3.54 was 
obtained in 85% yield. While 3.54 exhibited improved solubility in relation to the alkylated 
derivative 3.52, it was still limited to a number of solvents including DMF and THF. The next 
step, which was the glycosylation reaction, raised more problems. Although various synthetic 
approaches were examined the desired bis-galactosylated product 3.55 could not be obtained. 
With Schmidt glycosylation conditions (see Chapter 2, section 2.5.1.1), a mixture of 
compounds, which could not be identified, were observed. Direct glycosylation from the β-
pentacetate galactoside 2.38 was also attempted but no reaction appeared to take place and 
only starting material was observed in the crude mixture. A direct amidation reaction between 
diethyl malonate 3.53 and the galactose ethyl amine 2.33 was also attempted, but even after 3 
days TLC analysis indicated that only starting material was present. 
3.3.6 Malonyl chloride and malonic acid as pecursors for the synthesis of malonamides 
The report by Kato et al. (discussed in section 3.1.3) described the synthesis of mannose 
malonamides from malonic acid 3.56 using standard peptide coupling conditions.[130] This led 
us to examine the synthesis of galactosyl malonamides from malonic acids (Scheme 3.11). We 
then attempted to form the galactosyl malonamide 3.57 first, with alkylation of the α-carbon 
to introduce the aliphatic chain being carried out at a later stage. 
 
Scheme 3.11 Reagents and Conditions: i) HOBt, TBTU, DIPEA, 2.33, N2, 0 
o
C-rt, 16 h, 72%. 
Despite our renewed optimism, we did not obtain the di-substituted product 3.57. Instead, we 
again isolated the decarboxylated derivative 3.50 in a high yield of 72%. The synthesis was 
carried out as per standard peptide coupling conditions, i.e. activation of the acid with HOBt, 
TBTU and DIPEA prior to addition of the amine. As it is possible that decarboxylation occurred 
during this activation process, the reaction was repeated with no prior activation, but, as 
before, the decarboxylated product was obtained and no di-substituted product 3.57 
observed. 
In order to examine the effect of base on decarboxylation, the reaction was repeated in the 
presence of NEt3. Similar results were observed and although the decarboxylated product 3.50 
was still the major product, small amounts of the disubstituted product 3.57 could be detected 
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in the 1H NMR spectrum. The presence of the di-substituted product was confirmed by HR-MS. 
Optimisation of the reaction failed to improve on this result and even at reduced temperatures 
(-10 oC) the decarboxylated derivative 3.50 was the major product. Kato et al. did not report 
any observation of decarboxylation and appear to only obtain disubstituted product. 
Therefore, our observations were highly unexpected. 
We next looked to malonyl chlorides as precursors for the synthesis of di-substituted 
galactosyl malonamides, as these type of transformations have been previously reported in 
the literature.[148] Malonyl chloride 3.58 was reacted with the galactosyl amine 2.33, in the 
presence of base (NEt3) and yielded both the disubstituted 3.57 and decarboxylated 
derivatives 3.50 in a 1:1 ratio (Scheme 3.12). Various purification methods were attempted, 
including recrystallisation and column chromatography, but the two compounds could not be 
separated. HR-MS confirmed the presence of both products. 
 
Scheme 3.12 Reagents and Conditions: i) 2.33, DCM, NEt3, N2, 0 
o
C-rt, 16 h, 60%. 
As before, the effect of base on the reaction was examined, and the reaction was repeated 
using DIPEA. No improvement on the efficiency of the system was observed, and in fact the 
yield decreased to 45%. The reaction was also attempted at lower temperatures (-10 oC), and 
this time improvements were achieved. The ratio of desired product 3.57 to decarboxylated 
product 3.50 increased from 1:1 to 1.5:1.  Further enhancement could be achieved when the 
reaction time was reduced from 16 h to 4 h, and the ratio increased to 4:1. No further 
improvements were achieved, and again purification was unsuccessful.Thus, it was decided to 
continue on with the synthesis, and to attempt the alkylation on the mixture of 3.57 and 3.50. 
As only the disubstituted derivative 3.57 was expected to undergo alkylation, we hoped 
purification may be simpler after this step. 
Initially, we followed the same alkylation procedure as previously discussed in section 3.2.1 
and the mixture of products was reacted with 1-bromodecane using K2CO3 (Scheme 3.13).  
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Scheme 3.13 Reagents and condition: i) CH3(CH2)9Br, K2CO3, CH3CN, 80 
o
C, 36 h. 
These conditions proved ineffective as no product was isolated and only starting material 
recovered. However, this is not surprising, as the amide groups are less electron withdrawing 
than the original esters and this results in the reduced acidity of the α-proton. Therefore, a 
stronger base is required for deprotonation. With this in mind, the reaction was repeated, this 
time using NaH as the base, but this led to the partial decomposition of compound 3.57. 
Degradation of the bisamide 3.57 was also observed when Knoevenagel condensation was 
attempted, using all the conditions described in Table 3.1. 
3.4 Synthesis of O-glycoconjugate 3.33 
With so many problems to contend with, a change of approach was considered. We finally 
decided to investigate if coupling conditions other than TBTU/HOBt or acid chlorides would 
reduce or even eliminate decarboxylation. Rather than using other conventional coupling 
reagents, such as carbodimides, we focused on the use of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-
4-methylmorpholinium chloride (DMTMM), which has previously been used in the synthesis of 
malonamide glycoconjugates.[132] 
3.4.1 DMTMM as an alternative peptide coupling reagent 
DMTMM has been highlighted as an effective activating agent for amide bond formation and 
peptide synthesis.[149] Although initially reported by Kaminski et al. in 1998,[150] it was not until 
Kunishima and co-workers[151] optimised its usage that it began receiving interest as an 
alternative reagent for amide bond formations. 
DMTMM, which is a white solid, is synthesised by the reaction of 2-chloro-4,6-dimethoxy-
1,3,5-triazine (CDMT) with N-methylmorpholine (NMM) in THF at rt (Scheme 3.14). It is 
extremely easy to purify as the solid product precipitates readily. However, it can be unstable 
and can only be stored and used for one month after synthesis. As shown below, it can 
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undergo demethylation at the morpholinium nitrogen when suspended in DCM, while in THF it 
was found to be stable with only 13% DMTM detected after 13 h (Figure 3.14).[151b] 
 
Scheme 3.14 Reagents and conditions: i) THF, rt, 30 min, 100%, ii) rt, DCM, 3 h, 100%. 
The reaction mechanism is similar to other activating agents. The DMTMM reacts with the 
carboxylate ion 3.59 in a SNAr transformation to form the activated ester 3.62 (Scheme 3.15), 
and regenerated NMM 3.63. The amine then attacks and displaces the activated ester to form 
the amide 3.64 and the triazinone by-product 3.65. 
Scheme 3.15 Mechanism of DMTMM activated coupling.
[151]
 
The synthesis started with alkylated malonic acid 3.36 as described in section 3.2.1. The acid 
3.36 was coupled to the galactosyl amine 2.33 using DMTMM and NMM and to our delight the 
desired bis-substituted product 3.38 was obtained (Scheme 3.16), albeit in a low yield of 30% 
and with a number of impurities. In the procedure reported by Isaad and co-workers,[132] NMM 
and DMTMM were utilised, however, it is known from the mechanism that NMM is generated 
during the reaction. For this reason, the reaction was repeated without the addition of base 
and this resulted in both an increase in yield (55%) and a decrease in side-product formation. 
 
Scheme 3.16 Reagents and Conditions: i) 1) DMTMM, NMM, THF, 16 h, rt, 37%; or DMTMM, THF, 16 h, 
55%; ii) NEt3, DCM/MeOH/H2O, 40 
o
C, 18 h, 78%. 
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The deprotection of the malonyl-based glycoconjugate 3.38 using NEt3 afforded the novel       
O-glycoconjugate 3.33 as a white precipitate in a yield of 78% (Scheme 3.16). The 1H NMR 
spectrum of O-glycoconjugate 3.33 is displayed in Figure 3.14 and diagnostic signals, including 
the amide protons (N-H), the anomeric (H-1) proton and the α-proton*, are assigned. 
Figure 3.14 
1
H NMR spectrum of deprotected O-glycoconjugate 3.33 (300 MHz, d5-Pyr). 
3.5 Synthesis of N-glycoconjugate 3.32 
Once a successful synthetic route was established, the preparation of the other malonamides 
could be attempted. The malonamide glycoconjugate 3.32 was designed to act as a more rigid 
molecule compared to the O-glycoconjugate 3.33. The galactose moiety is directly linked to 
the malonyl backbone via an N-glycosidic bond. This should exert a certain degree of rigidity in 
the molecule, as rotation around the amide bond is limited, thus restricting the conformation 
of the molecule and locking the presentation of the galactosides. 
3.5.1 Synthesis of galactosyl amine 3.66 
The synthesis of the known galactosyl amine 3.66 began with the reaction of the per-
acetylated galactosyl donor 2.38 with TMSN3, promoted by the Lewis acid SnCl4 to yield    91% 
of the β-galactosylazide 3.67 (Scheme 3.17). Reduction of the azide by hydrogenation 
catalysed by Pd/C afforded the galactosyl amine 3.66 in 97% yield.[152] 
 
Scheme 3.17 Reagents and Conditions: i) SnCl4, TMSN3, DCM, N2, 18 h, 91%; ii) H2, Pd/C, EtOAc, rt, 16 h, 
97%; iii) 3.66, DMTMM, THF, rt, 18 h, 56%; iv) NEt3, DCM/MeOH/H2O, 40 
o
C, 18 h, 93%. 
NH 
H-1 
α-H* 
NH 
[ppm] 
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The galactosyl amine 3.66 was then coupled to the alkylated malonic acid 3.36, using DMTMM 
as the activating agent, and the N-glycoconjugate 3.68 was obtained in 56% yield. Finally, 
selective deprotection of the acetyl protecting groups, using catalytic NEt3 in a heterogenous 
solvent system (DCM/MeOH/H2O, 1:2:1) at 40 
oC, afforded the novel N-glycoconjugate 3.32 as 
a white precipitate in 93% yield (Scheme 3.17). These mild deprotection conditions were 
attempted as we feared that harsher conditions, such as those employed in Zémplen 
deprotection, may result in degradation of the glycolipid. The 1H NMR spectrum of the N-
glycoconjugate 3.32, is shown in Figure 3.15 with characteristic peaks highlighted. 
Figure 3.15 
1
H NMR spectrum of deprotected N-glycoconjugate 3.32 (300 MHz, d5-Pyr).  
3.6 Synthesis of Malonyl-based O-glycoconjugate 3.44  
As with the N-glycoconjugate 3.32 and O-glycoconjugate 3.33, malonyl-based                             
O-glycoconjugate 3.34 was designed to act as a potential inhibitor of bacterial adhesion (see 
Chapter 5). A very different extended linker can be observed in this molecule. Like the 
malonamide glycoconjugate, 3.33, it contains the ethyl chain which should allow for a certain 
degree of conformational flexibility. However, it also contains a triazole moiety, which could 
influence both the biological activity and conformation of the molecule.  Promising anti-
microbial results of a triazole-containing glycolipid 3.69 on the bacterium P. aeruginosa were 
reported by Marotte et al. (Figure 3.16).[31]  
 
Figure 3.16 Triazole glycolipid 3.69 which showed promising anti-adhesion activity towards                      
P. aeruginosa.
[31]
 
 
 
 
4 
3.69 
NH NH 
α-H* H-1 
1
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 CH2  
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We intended to synthesise the triazole-containing glycoconjugate 3.34 and then compare its 
ability to inhibit bacterial adhesion with that of glycoconjugates 3.32 and 3.33. Ultimately we 
wanted to probe whether introducing aromaticity into the linker of the glycolipid structure 
would affect its anti-microbial properties. 
The synthesis commenced with the coupling of 3-aminopropyne to the malonic acid building 
block 3.36, utilising DMTMM as the activating agent. This resulted in the alkylated alkyne 
malonamide 3.70 (Scheme 3.18). A subsequent Huisgen cycloaddition (discussed in detail in 
Chapter 4, section 4.4.1) between the galactosyl azide 3.67  and the malonamide alkyne 3.70, 
which was catalysed by CuSO4 .5H2O and sodium ascorbate, afforded the 1,4-disubstituted 
1,2,3-triazole O-glycoconjugate 3.71 in 58% yield.   
 
Scheme 3.18 Reagents and Condition: i) Propargylamine, DMTMM, THF, rt, 16 h, 78%; ii) CuSO4.5H2O, 
sodium ascorbate, DCM/H2O/Acetone, 18 h, 58%; ii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 89%. 
Selective deprotection of the O-glycoconjugate 3.71 using NEt3 yielded the novel                      
O-glycoconjugate 3.34 as a white precipitate in 98% yield. The 1H NMR spectrum is displayed in 
Figure 3.17.  Characteristic peaks are highlighted in the figure, including the amide protons 
(NH), triazole proton (CN3CH) and α-proton*.  
Figure 3.17 1H NMR spectrum of deprotected O-glycoconjugate 3.34 (300 MHz, d5-Pyr). 
NH 
CN3CH 
H-1 
α-H* 
Chapter 3:                                 Synthesis of malonamide glycoconjugates as potential anti-adhesion agents 
 
 
95 
 
3.7 Conclusion 
The synthesis of the malonyl-based glycoconjugates proved more problematic than 
anticipated, and a variety of synthetic routes were attempted. The main problem encountered 
was decarboxylation. We found that although the decarboxylation of malonic acids is widely 
reported in the literature, it generally occurs during the hydrolysis step. This was not the case 
for the compounds discussed above as the decarboxylation step appeared to occur during 
amide bond formation. To the best of our knowledge no decarboxylation has previously been 
reported using the HOBt/TBTU methodology utilised here. Amidation reactions overcame this 
decarboxylation, however, the resulting compounds were extremely insoluble and unreactive. 
A variety of precursors, including malonyl chloride and malonic acid, were utilised, and 
although some success was achieved, alkylation with the lipid chain then proved difficult due 
the decreased acidity of the α-proton. 
 
Finally, the malonyl-based glycoconjugates 3.32-3.34 were successfully synthesised by using 
DMTMM as an alternative coupling reagent. Following this approach, no decarboxylation was 
observed. Glycoconjugates exhibiting a variety of linkages to the malonyl backbone were 
explored, and we found that the best yields were achieved with the triazole-containing 
derivative 3.34. The ability of selected malonamides to inhibit bacterial adhesion was also 
investigated and the results are discussed in Chapter 5.  
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4.1 Introduction 
Cell surface carbohydrates are important in initiating a vast number of biological and 
pathological processes.[153] More specifically, carbohydrate-protein interactions are often 
responsible for mediating the early stages of the infection process for bacterial pathogens.[22, 
153] One drawback in the synthesis of carbohydrate-based anti-infection agents lies in the fact 
that individual carbohydrates tend to bind weakly to their corresponding  polyvalent protein 
receptors.[15] This can be overcome by utilising multivalent carbohydrate ligands which 
generally result in greater affinity of binding[15-16] (discussed in detail in Chapter 1 section 
1.2.3).  
In complex, multiantennary oligosaccharides, only a small number of the carbohydrate 
residues are directly involved in the protein-carbohydrate interactions. It is believed that the 
remaining sugars have a purely structural role. It has been suggested that they may act as 
spacers and ensure optimal protein-carbohydrate interactions by maintaining the sugar 
epitopes at an appropriate distance. In theory, this suggests that the saccharide moieties 
responsible for structure could be replaced by other rigid molecules such as aromatic 
scaffolds.[154] 
Glycoconjugates built around a benzene core are widely explored in the literature. Depending 
on the analogue utilised, they can lead to the synthesis of divalent, trivalent, tetravalent and 
even hexavalent molecules. They also allow for the linkage between the sugar moiety and the 
aromatic scaffold to be varied (e.g. N-, O-, S- or C- linked), and therefore, various reaction 
conditions can be exploited. 
One benzene derivative which has received a great deal of attention is benzene-1,3,5-
tricarboxylic acid (trimesic acid, Figure 4.1). Trimesic acid has been widely utilised as an 
aromatic scaffold for the synthesis of multivalent glycoconjugates. Due to the presence of the 
three carboxylic acid side groups, which can be easily functionalised, it is an ideal scaffold for 
the synthesis of a wide range of trivalent molecules through the formation of amide bonds. 
 
Figure 4.1 Benzene-1,3,5-tricarboxylic acid (trimesic acid). 
Carboxylic acid 
groups 
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4.2 Aromatic-based glycolipids and their biological importance 
As benzene derivatives are readily available and easily functionalised there are numerous 
examples of glycoconjugates based on aromatic scaffolds reported in the literature.  
4.2.1 Synthesis and application of divalent glycoconjugates 
Depending on the valency of the glycoconjugate of interest, different reaction conditions can 
be exploited. For example, Roy et al.[155] and van Doren et al.[156] both reported the synthesis of 
a divalent biaryl glucoside 4.3, yet they both used different synthetic strategies (Scheme 4.1). 
Van Doren et al. utilised a double Lewis acid-catalysed glycosidation (reaction a) and the 
glucoside 4.3 was obtained in 47% yield, whereas Roy et al. utilised an Ullman-type reductive 
homocoupling (reaction b), and improved this yield to 81%. Glucoside 4.3 displayed strong 
binding affinities towards the plant lectin Concanavalin A (Con A). 
 
Scheme 4.1 Synthesis of divalent aryl glucoside 4.3 using either a) a double Lewis acid-catalysed 
glycosidation
[156]
 or b) an Ullman-type reductive homocoupling strategy.
[155]
 
 Another example of divalent glycoconjugates based around an aromatic scaffold comes from 
Pagé and Roy.[157]  They reported the synthesis of two, divalent, mannopyranoside clusters 4.5 
and 4.6 and investigated their binding affinities towards Con A and pea lectins. Both ligands 
were designed to display similar structural features by utilising the same aromatic core, one 
linked via an aryl spacer and the other via a heteroaliphatic spacer.  
 
Figure 4.2 Divalent mannopyranoside clusters 4.5 and 4.6 investigated for their binding affinities 
towards Con A and pea lectins.
[157]
 
Both divalent compounds were shown to exhibit greatly improved affinities towards the plant 
lectins, in comparison to the monosaccharide standards (Table 4.1). However, the effect was 
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more prominent for the tetravalent lectin (Con A) over the divalent pea lectin. Con A exists as 
tetramers at physiological pH, which enables the formation of a stable, cross-linked lattice with 
the mannosylated clusters 4.5 and 4.6. This is not the case for the divalent pea lectin and 
therefore may explain the difference in affinities.  
Compound Con A 
IC50 (µm) 
Relative 
Potency 
Pea Lectin 
IC50 (µm) 
Relative  
Potency 
Methyl α-D-Man 924 1.0 3850 1.0 
pNO2-Ph α-D-Man 106 8.7 1500 2.6 
Allyl α-D-Man 261 3.5 940 4.1 
4.5 30.5 30.3 185 20.8 
4.6 36.8 25 575 6.7 
Table 4.1 Affinities of bivalent mannosylated clusters 4.5 and 4.6 and their monosaccharide 
counterparts against plant lectins, Con A and pea lectin. 
 
Aiming to investigate how scaffold flexibility and spatial arrangement of ligands may affect 
their inhibitory potency against Viscum album agglutinin and human galectins, a variety of 
divalent lactosyl glycoconjugates-based around an aromatic core were synthesised by Murphy 
and co-workers (scaffolds 1.10-1.12 and 4.7-4.11, Figure 4.3).[158] 
 
Figure 4.3 Selection of bivalent lactose glycoconjugates 1.10-1.12 and 4.9-4.11 synthesised and tested 
against Viscum album agglutinin and human galectins.
[158]
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A number of assays were carried out in order to correlate structural features with bioactivity 
and a number of conclusions were reached. It was found that the bivalent lactose 
glycoconjugates were less effective at interfering with glycoprotein binding to the plant toxin 
than to human lectins. Solid phase and cell surface experiments showed that structural 
differences in the compounds (secondary amide in 1.11 versus tertiary amide in 1.12), as well 
as where the lactose moieties were placed around the common core (substitution at the 6, 4 
or 3 position on glucose, 4.7-4.9 respectively), had an influence on binding properties to 
galectin-3 and galectin-4. This was due to both changes in geometry and inter-epitopes’ 
distance. Significantly, the constrained compound 1.12 displayed the best inhibition with 
truncated galectin-3 and galectin-4. Conversely, glycoconjugates which were highly flexible 
exhibited notable ability to protect human cells from plant toxin binding. Results also showed 
that the more rigid structures led to a loss in biological activity as the acyclic compound 4.11 
displayed more optimum activity than the cyclic 4.10 molecule againist all lectins 
investigated.[158] 
4.2.2 Synthesis and applications of trivalent glycoconjugates 
Due to the easy functionalisation of commercially available trimesic acid and trimesoyl chloride 
there are a wide range of trivalent glycoconjugates reported in the literature. Selected 
examples based on the common core 4.12 can be seen below in Figure 4.4.  
 
Figure 4.4 Examples of aromatic trivalent glycoconjugates 4.12-4.16 built around trimesic acid.
[31, 159]
 
The Stoddart group reported one of the first glycoclusters built around benzene-1,3,5 
tricarboxylic acid 4.13 in the late 1990’s.[159a] Since then, a variety of trivalent glycoclusters 
bearing more complex epitopes such as lactosides 4.14,[159b] Lewisa diasaccharides 4.15[31] and 
modified galactoside mimetics 4.16[159c] have been synthesised. Reaction of N,N,N-tripropargyl-
1,3,5-carboxamidobenzene with the corresponding azido glycosides using CuAAC methodology 
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afforded the trivalent glycoconjugates 4.14-4.16 in high yields. The inhibitory properties of 
these glycoclusters towards different galectins and bacterial lectins have been investigated. 
Trivalent lactoside 4.14 exhibited high affinity against galectin-1 and -3, and IC50 values implied 
enhanced activity compared to free lactose.[159b] Lewisa disaccharide derivative 4.15 was tested 
for its inhibitory properties towards PA-IIL, which is a fucose binding lectin found in P. 
aeruginosa. Results showed, however, that the trivalent glycocluster did not exhibit higher 
affinity over the Lewisa trisaccharides or their PEGylated dimers.[31] The Chabre and Roy 
group[159c] then attempted to combine aromatic glycomimetics and multivalency in order to 
synthesise glycoclusters with increased potency and affinities towards the PA-IL bacterial 
lectin, which is a glucose binding lectin. They synthesised 4.16 by reacting the propargylated C-
galactoside, which contained hydrophobic aglycones in the anomeric position, to the 
elongated triazide derivative of trimesic acid again using CuAAC methodology. The presence of 
aglycones has led to enhanced binding properties and experiments have shown a 127-fold 
overall enhancement of affinity towards PA-IL compared to the controls. This experiment 
highlighted the benefits of utilising both glycomimetics and multivalency in the synthesis of 
carbohydrate ligands.[154, 159c] 
Not all linkages to the core aromatic scaffold occur via the formation of amide bonds. 
Alternative linkages such as ethers, as in the general core structure 4.17, have also been 
utilised and some examples are shown in Figure 4.5.[160] 
 
Figure 4.5 Selection of trivalent glycoconjugates 4.18 and 4.19 where an ether linkage connects the 
aromatic scaffold and the glucosides.
[160]
 
 
A large selection of glycoconjugates were synthesised in the group of Chabre and evaluated as 
potential inhibitors of the interaction between biotinylated plant, human and chicken galectins 
and the surface-immobilised asialofetuin (ASF).[154]  Derivative 4.19 showed the best results 
against the full length chicken galectin-3, with a 10-fold improvement in affinity when 
compared to derivative 4.18 and a 63- and 18-fold enhancement when compared to the 
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controls, lactose and 2’-fucosyllactose.[160] Similar results were also observed for the human 
galectins but the enhancements were not as distinct. 
4.2.3 Synthesis and applications of oligovalent glycoconjugates 
By utilising a variety of benzene derivatives a large selection of diverse glycoconjugates with 
varying valencies can be synthesised quite easily. This highlights the advantages of building 
glycoconjugates around an aromatic core, as it allows for flexibility in both the number of 
epitopes added, and the connectivity between the glycan and aromatic scaffold.  A selection of 
multivalent glycoconjugates can be seen in Figure 4.6. 
 
 
Figure 4.6 Selected examples of tetravalent 4.20 and 4.21,
[161]
hexavalent 4.22 and 4.23,
[161]
 and 
octadecavalent 4.24
[162]
 glycoconjugates. 
 
Santoyo-Gonzalez et al. synthesised a variety of multivalent mannose (α-Man)-containing 
glycoconjugates which centred around either an aliphatic, aromatic, or carbohydrate core.  
Two tetravalent compounds (4.20 and 4.21) and two hexavalent compounds (4.22 and 4.23) 
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derivatives based around an aromatic core can be seen in Figure 4.6. The ability of the 
glycoconjugates to bind Con A was evaluated and results showed that the aromatic conjugates 
exhibited enhanced binding in comparison to their aliphatic counterparts and also that the 
aromatic thioglycosides analogues 4.21 and 4.23 showed more promising results.[161] 
 
The octadecavalent glycocluster  4.24 was synthesised by Roy et al. as part of a study in order 
to examine the effects of multivalent mannose glycoconjugates on bacterial adhesion.[162] 
Initial results against the BclA lectin of Burkholderia cenocepacia showed that some of the 
ligands had micromolar affinities towards the lectin, and that these affinities increased with 
increasing valency.[154] 
4.2.4 Synthesis and applications of glycolipids based around an aromatic core 
Although there are many examples of aromatic-based glycoconjugates reported in the 
literature,[154, 163] examples of analogues which contain both a carbohydrate moiety and a 
lipidic chain are limited. Some monovalent examples can be seen below in Figure 4.7. 
 
Figure 4.7 Examples of glycolipid analogues possessing one carbohydrate moiety and either one 
(4.328,
[164]
 4.31-4.34
[164]
), two (4.25-4.27
[165]
), or three 4.29
[164]
 lipidic chains. 
 
Analogues 4.25-4.27 were synthesised by Tamiaki et al. The glycolipids were incorporated into 
a L-α-phosphatidylcholine liposome and were able to interact with a specific lectin to form 
liposomal assemblies.[165] In order to assist in the understanding of protein-carbohydrate 
interactions, the remaining glycolipid analogues 4.28-4.34 were synthesised as models for 
natural glycolipids.[164] 
 
The literature is even sparser with regards to multivalent aromatic glycoconjugates possessing 
a lipidic chain. One example involves the synthesis of a divalent neoglycopeptide possessing a 
tetradecylamine chain, 4.35, is shown in Figure 4.8.[153] Glycolipid 4.35 was investigated as a 
potential inhibitor of the binding of verotoxin globotriosylceramide (Gb3) and showed 
promising results (IC50 = 0.2 mM). 
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Figure 4.8 Example of divalent glycoconjugate possessing a lipidic chain.
[153]
 
4.3 Chapter objective 
This chapter deals with the synthesis of a variety of aromatic-based glycolipids as potential 
inhibitors of bacterial adhesion. As can be seen from the introduction, there are extensive 
examples of these types of compounds reported in the literature, and huge interest lies in the 
synthesis of glycoconjugates built around an aromatic scaffold. We chose an aromatic-based 
core as we required a rigid scaffold for comparison against the more flexible aliphatic 
derivatives described in chapter 3. The objective was to introduce an aromatic scaffold that 
would allow the synthesis of a bivalent galactosyl ligand but also enable for the introduction of 
a lipidic chain.  As discussed previously, trimesic acid and its derivatives are ideal building 
blocks in the synthesis of aromatic glycoconjugates. Another appropiate building block for this 
purpose is the aniline derivative, 5-aminoisophthalic acid, which features two carboxylic acid 
side groups and a primary amine. This allows for the easier sequential functionalisation of 
different positions in the aromatic core. Owing to this, both building blocks would provide 
access to a range of structurally diverse glycolipids which could be investigated for potential 
biological activities. As before, the aim was to adopt a modular approach utilising a key set of 
reaction conditions which would enable us to achieve diversity quickly and easily, and also 
allow for sufficient scale up.  
 
The core building block structures can be seen below in Figure 4.9, where it is clear that the 
aromatic core would remain constant in all analogues and that variation could be achieved at 
three potential sites. 
 
Figure 4.9 Core scaffold utilised for the synthesis of aromatic-based glycoconjugates. 
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As stated previously, structural information on the bacterial lectins involved in the adhesion 
process of B. multivorans is limited, so the rational design of synthetic ligands as anti-adhesion 
agents is extremely difficult. For this reason, we aimed to synthesise a variety of ligands and 
examine how the structure influences the biological activity. As with the aliphatic bivalent 
ligands (discussed in chapter 3), we sought to investigate how linker length, structure and 
flexibility influenced the presentation of the carbohydrate moieties and thus the biological 
result. In addition, we intended to examine whether hydrophobic chain length also played a 
role in the activity of the aromatic glycoconjugates. For this reason, variation site 1 always 
remained as a galactosyl moiety, although it could be extended to a different carbohydrate 
moiety if required. At variation site 2, a hydrophobic chain of varying length (C-3 compared to 
C-16 and C-14) was utilised.  As before, the main variation focused on the chemical structure of 
the linker. In order to investigate how linker flexibility/rigidity and length affected the 
conformation and thus the biological activity, we aimed to synthesise a variety of structurally 
diverse glycoconjugates with different amide linkages between the galactosyl moiety and the 
aromatic backbone.  
 
In the first type of linkage envisaged, the galactosyl moiety is coupled directly to the aromatic 
scaffold via an N-glycosidic bond (4.36, 4.37, Figure 4.10). For the second type of spacer we 
intended to utilise an ethylene group functionalised with a primary amine to connect the 
galactose and aromatic core via an amide bond (4.38, 4.39, Figure 4.10). With the third type of 
linker, we aimed to exploit both a triazole moiety and an ethylene group to join the galactose 
moiety and the aromatic building block (4.40, 4.41, Figure 4.10). In the fourth type of linkage 
we looked at connecting the galactose to the aromatic scaffold again via an N-glycosidic bond 
and a triazole moiety (4.42, Figure 4.10). For the final linkage, a glycine-based spacer and an 
ethylene group were exploited to link the aromatic backbone to the carbohydrate moiety 
(4.43, Figure 4.10). 
 
The ability of the glycoconjugates to act as potential inhibitors of bacterial adhesion was 
investigated and the results are discussed in chapter 5 (section 5.8). In order to test the 
multivalent effect we also synthesised a monovalent version of the glycolipid which showed 
the most promising results (4.44, Figure 4.10). 
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Figure 4.10 Structure of glycoconjugates 4.36-4.44 generated from an aromatic core. 
 
4.3 The synthesis of the first generation of glycolipids 4.38 and 4.39 based on 
aromatic scaffolds 
The aromatic-based O-glycolipids analogues 4.38 and 4.39 were designed to act as potential 
anti-bacterial agents (see chapter 5). Initially the readily available trimesoyl chloride was 
chosen as the starting material, as it features three acid chloride side groups which would 
allow for the formation of amide bonds with galactosyl moieties featuring amino groups. 
Trimesic acid was also utilised, as it contains three carboxylic acid groups which could be 
activated and again, would enable easy functionalisation. As trimesoyl chloride and trimesic 
acid were utilised in the synthesis of the first generation derivatives, all first generation 
glycolipids are connected to the lipidic chain via an amide bond of the form ArCONHR (4.45 a, 
Figure 4.11). In contrast, 5-aminoisophatlic acid is used in the synthesis of the second 
generation derivatives, therefore, the lipidic chain is linked to the aromatic scaffold via an 
amide bond of the form ArNHCOR (4.45 b, Figure 4.11). These different amide bond forms lead 
to differences in the distribution of the electron density on the aromatic ring. The anilide of 
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the second generation derivatives can donate electrons into the aromatic ring leading to more 
electron-rich aromatic rings in comparison to the first generation derivatives.  
Figure 4.11 Contrasting amide bond formation of first generation 4.45 a and second generation 
glycolipids 4.45 b. 
Initial investigations led us to design the synthetic pathway as shown in Scheme 4.2, whereby 
the easily accessible β-O-galactosyl amine 2.33 and the commercially available trimesoyl 
chloride 4.46 would serve as suitable building blocks. The tetradecylamine chain would be 
introduced first by careful stoichiometric adjustment, followed by an in situ reaction with the 
galactosyl amine to yield the desired glycoconjugate 4.38 in one easy step. Based on this 
approach a variety of analogues could be synthesised, although the formation of side products 
may complicate the purification of the desired products. 
 
Scheme 4.2 Initial synthetic route for synthesis of glycoconjugate 4.38. 
4.3.1 Synthesis of O-glycoconjugate 4.38 
The aromatic O-glycoconjugate 4.38 was designed as a flexible ligand (Figure 4.12). We 
believed that the ethylene linker would allow for a certain amount of flexibility for the 
presentation of the galactosyl moieties. 
 
Figure 4.12 Structure of β-glycoconjugate 4.38. 
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4.3.1.1 Initial synthesis of aromatic backbone 4.47 utilising trimesoyl chloride 
The synthesis of the aromatic backbone 4.47 commenced with the reaction of tetradecylamine 
with the commercially available trimesoyl chloride 4.46 using NEt3 (Scheme 4.3). To promote 
reaction with only one of the three acid chlorides, an in situ reaction with the galactosyl amine 
2.33 (whose synthesis was discussed in section 2.5.1.1) was carried out. This afforded the 
desired bivalent glycoconjugate 4.48, albeit the yield was very low and a variety of by-products 
were also obtained.   
 
Scheme 4.3 Reagents and Conditions: i) 1) NH2C14H29 (1 eq), NEt3, THF, N2, 0 
o
C- rt, 3 h, 2) 2.33 (2 eq), 
NEt3, THF, N2, rt, 16 h, 8%. 
 
This result was not totally surprising. There are many examples reported in the literature 
which utilise trimesoyl chloride for the synthesis of functionalised aromatic analogues.[159c, 166] 
In most examples, however, all three acid chloride groups are being reacted with the same 
amine. In our case, selective functionalisation is challenging, as two different amines are being 
utilised and this can therefore lead to a mixture of products. 
 
The main product isolated was the tri-tetradecyl substituted derivative 4.50 (Figure 4.13). The 
benzene derivative, containing one galactose moiety and two lipidic chains, 4.49, was also 
obtained. 
Figure 4.13 Structure of by-products isolated from reaction of trimesoyl chloride with tetradecylamine 
and the galactosyl amine 2.33. 
 
With this in mind, we decided to readdress our synthetic approach and a variety of different 
reactions and conditions were attempted. The results are summarised in Table 4.2.  
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Entry NH2C14H29 Addition conditions Galactose ethyl amine 
2.33 
Addition conditions Solvent MeOH Product 
1 1 eq added over 3 h at 0 oC 
at high dilution 
N/a N/a THF No 4.50 
(56%) 
2 0.33 eq added over 3 h at 0 oC 
at high dilution 
N/a N/a THF No 4.50-4.52 
(did not isolate) 
3 0.33 eq over 3 h at 0 oC 
at high dilution 
N/a N/a THF Yes 4.53-4.55 
(could not separate) 
4 1 eq added second after 2.33 
at medium dilution 
2 eq added first over 3 h at O oC 
at high dilution 
THF No 4.50, 4.49, 4.48 
(39%, 22%, 18%) 
5 0.33 eq added first over 3 h at O oC 
at high dilution 
2 eq added second, quickly at rt 
at low dilution 
THF No 4.50, 4.49, 4.48 
(6:2:1 ratio) 
6 1 eq added first over 3 h at O oC 
at high dilution 
2 eq added second, quickly at rt 
at low dilution 
DCM No 4.50, 4.49, 4.48 
(8:1:0.5 ratio) 
Table 4.2 Reaction conditions attempted for the formation of divalent glycolipid 4.48 
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Additional by-products formed during the attempted synthesis of glycolipid 4.48 are shown in 
Figure 4.14. 
 
Figure 4.14 Additional products formed in the synthesis of glycolipid 4.48 using a variety of reaction 
conditions. 
 
For our next approach, the synthesis again started with the trimesoyl chloride, but unlike 
previously we attempted to isolate the diacid mono-tetradecyl derivative 4.52 prior to reaction 
with the galactose ethyl amine 2.33 (Table 4.2, entry 1). The reaction was carried out in a 1:1 
ratio of trimesoyl chloride and tetradecylamine and this time the addition of the amine was 
carried out at a high dilution over a period of 3 h at 0 oC.  Nevertheless, upon purification the 
tri-substituted derivative 4.50 was still isolated as the major product. The reaction was 
repeated, using a 3:1 ratio of trimesoyl chloride to tetradecylamine. We hoped this would 
lessen the formation of the tri-substituted derivative 4.50 (Table 4.2, entry 2).  Under these 
conditions the results slightly improved and the mono-, di- and tri-substituted products 4.50-
4.52 were obtained. However, we hypothesised that the acid chlorides had hydrolysed during 
isolation of the products and this led to difficulties in purification. HR-MS confirmed this 
hydrolysis.  
 
Due to the purification problems posed by the hydrolysis of the acid chlorides, a new approach 
was required. The reaction was carried out as before (3:1 ratio), but this time MeOH was 
added to the crude mixture after the reaction was complete (Table 4.2, entry 3).  We believed 
that the addition of MeOH would result in the formation of methyl esters, which may enable 
more efficient separation of the reaction products. To our delight a white solid precipitated 
upon addition of the MeOH, and a large singlet at 4 ppm in the 1H NMR spectrum indicated the 
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presence of methyl esters. Unfortunately, purification still proved problematic. Although the 
presence of the mono-substituted 4.54 and di-substituted 4.55 products were confirmed by 
HR-MS, the compounds could not be separated using column chromatography as the two 
products eluted together.  
 
Finally, we reverted back to the original one pot reaction method, and attempted to optimise 
the reaction conditions.  A number of variations were examined including addition order and 
alteration of the number of eq. and solvent used (Table 4.2, entries 4-6). Even with the 
alterations in the reaction conditions, the tri-substituted tetradecyl derivative was always the 
major product 4.50. This led us to believe that the poor nucleophilicity of the galactose ethyl 
amine 2.33 may also be a factor in the poor yields of the product.  
 
As a result of the problems encountered it was decided to re-address the synthetic route. In 
order to avoid preferential formation of the tri-substituted product 4.50, we attempted to 
temporarily protect one of the carboxylic acids groups as a benzyl ester, which could be 
removed at a later stage. 
 
For this approach, phenylmethanol was reacted with trimesoyl chloride 4.46 in the presence of 
base (Scheme 4.4). The reaction was carried out in a 1:1 ratio and as before the benzyl alcohol 
was added in high dilution at 0 oC over a period of 3 h. An in situ reaction with the galactose 
ethyl amine 2.33 was then performed (the galactosyl amine 2.33 was added in very low 
dilution very quickly in order to increase the chance of reaction with the acid chloride).The 
desired di-substituted galactose glycoconjugate 4.56 was obtained in 7% yield. 
 
Scheme 4.4 Reagents and Conditions: i) 1) C6H5CH2OH (1 eq), DIPEA, THF, N2, 0 
o
C- rt, 3 h, 2) 2.33 (2 eq), 
DIPEA, THF, N2, rt, 16 h, 7%. 
 
Nonetheless, a low yield was again observed and implied that the nucleophilicity of the 
galactose ethyl amine 2.33 was a problem.  Following on from this, the next reaction 
attempted was between phenylmethanol and trimesoyl chloride followed by the in situ 
addition of tetradecylamine (Scheme 4.5). Nevertheless, like with so many previous reactions, 
1H NMR analysis indicated that a mixture of products 4.57-4.59 formed and which could not be 
separated. 
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Scheme 4.5 Reagents and Conditions: i) 1) C6H5CH2OH (2 eq), DIPEA, THF, N2, 0 
o
C- rt, 3 h, 2) NH2C14H29 (1 
eq), DIPEA, THF, N2, rt, 16 h. 
 
4.3.1.2 Attempted Synthesis of Aromatic backbone 4.47 utilising trimesic acid 
The results from the experiments above show that the trimesoyl chloride seems to be 
extremely susceptible to reaction with the tetradecylamine and phenylmethanol. The high 
reactivity of acid chlorides is widely reported in the literature, and supports why they are 
commonly utilised in amide bond forming reactions.[167]  Nonetheless, one drawback lies in 
their susceptibility to hydrolysis. In our case, the high reactivity of the trimesoyl chloride is a 
disadvantage, as it means achieving selective mono-substitution may be difficult.  Trimesic acid 
has also been widely utilised in the synthesis of aromatic glycoconjugates.[163b, 168] Therefore, 
we again re-addressed our synthetic approach and attempted using trimesic acid as an 
alternative to trimesoyl chloride. The idea was to activate only one of the three carboxylic acid 
side groups, therefore, making mono-substitution more likely. Two approaches were 
attempted: i) activation via standard HOBt, TBTU methodology, and ii) activation via formation 
of one acid chloride.  
 
The activation of carboxylic acids using HOBt and TBTU was previously discussed in Chapter 2 
(section 2.5.1). The formation of acid chlorides is one of the easiest ways to activate a 
carboxylic acid and make it more susceptible to nucleophilic attack.[87] Reagents commonly 
used to generate acid chlorides from their corresponding acids include thionyl chloride,[169] 
oxalyl chloride,[170] phosphorus oxychloride[171] and phosphorus pentachloride. In our case, 
oxalyl chloride with catalytic DMF was used. The mechanism is shown in Scheme 4.6. 
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Scheme 4.6 Mechanism of acid choride formation using oxalyl chloride and catalytic DMF. 
 
In the first step, the oxalyl chloride 4.61 reacts with DMF 4.60 to yield the iminium 
intermediate 4.62, with loss of CO, CO2and Cl
- which then reacts with the carboxylic acid 4.63 
to form the acid chloride 4.64 and the regenerated DMF catalyst. 
 
Scheme 4.7 depicts the outcome of attempted activation of one of the carboxylic acids of 
trimesic acid 4.65 utilising both acid chloride formation (reaction conditions i) or HOBt/TBTU 
methodology (reaction conditions ii). The active intermediates generated would be the 
corresponding acid chloride 4.66 and active ester 4.67, respectively. 
 
 
Scheme 4.7 Reagents and Conditions: i) 1) Oxalyl choride, DMF, DCM, N2,  0 
o
C, 1 h, 2) NH2C14H29, NEt3, 0 
o
C- rt, 16 h; ii) HOBt (1 eq), TBTU (1 eq), DMF, NEt3, N2, 10 min, 2) NH2C14H29, 16 h. 
 
In both cases, we encountered the same problems as before. The crude mixtures showed a 
number of products, and 1H NMR analysis indicated the presence of both the mono-
substituted 4.52 and di-substituted 4.51 compounds. In order to fully confirm the presence of 
the two compounds we decided to react both crude mixtures with propargylamine using HOBt 
and TBTU in the presence of base, and attempt separation afterwards (Scheme 4.8). 
 
Chapter 4:                Synthesis of glycolipids based on aromatic scaffolds as potential anti-adhesion agents 
 
 
114 
 
 
Scheme 4.8 Reagents and conditions: i) 1) HOBt (3 eq), TBTU (3 eq), DMF, NEt3, N2, 10 min, 2) 
HCCCH2NH2 (3 eq), 16 h, 8% and 11%. 
 
The reaction confirmed what we had expected and both the mono-substituted tetradecyl 
derivative 4.68 and the di-substituted tetradecyl derivative 4.69 were observed in the crude 
reaction mixture. Unfortunately, purification still proved difficult. Integration of the 
corresponding signals in the 1H NMR spectrum implied that the di-substituted derivative 4.69 
was obtained in a slightly higher conversion of 11% in comparison to 8% of the mono-
substituted product 4.52, but the low yields demonstrated the difficulties in the approach. 
 
4.3.1.3 Synthesis of glycolipid 4.48 via pentafluorophenyl (PFP) esters 
Further literature research led to our interest in the use of activated esters in amide bond 
forming reactions. Activated esters are extremely advantageous as they can be isolated and 
purified. This means they can be synthesised in advance and stored over a period of time.[87] 
They are generally prepared using standard ester-formation reagents such as DCC and DIC.[172] 
Activated esters react more cleanly with amines under mild conditions and therefore produce 
fewer side reactions during coupling.[167] One of the most commonly used active esters is 
pentafluorophenyl esters,[173] which have been commonly utilised since they were first 
reported in 1974.[174]  
 
Owing to this, we attempted to synthesise the pentafluorophenyl ester of aromatic diacid 
4.70. We hoped that subsequent reaction with the galactose ethyl amine 2.33 would thus lead 
to an improved yield of the desired bivalent glycolipid 4.48. The synthesis commenced with 
the selective activation of trimesic acid (discussed previously, section 4.3.1.2) using HOBt and 
TBTU to give diacid 4.70. This time, the HOBt/TBTU, base and tetradecylamine were added to 
trimesic acid solution portion-wise. The resulting crude reaction mixture was dissolved in dry 
THF along with pentafluorophenol, and DIC was added dropwise at 0 oC.[175] Following column 
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chromatography the desired mono-substituted, di-activated derivative 4.71 was obtained in 
24% yield over two steps (Scheme 4.9). Formation of a number of other by-products, including 
the corresponding tri-pentaflurophenyl ester, was also observed, albeit, the products were not 
isolated. 
 
Scheme 4.9 Reagents and Conditions: i) 1) HOBt, TBTU, DMF, NEt3, N2, 10 min, NH2C14H29, 16 h 2) THF, C6F5OH, 
DIC, 0 
o
C – rt, 3 h, 24% over two steps; ii) 2.33, THF, NEt3, N2, 16 h, 47%; iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 
h, 78%. 
 
The pentafuorophenyl ester derivative 4.71 was then reacted with the galactosyl amine 2.33 in 
the presence of base to yield the divalent galactose glycolipid 4.48 in an improved yield of      
47%. Finally, selective deprotection of the acetyl groups using catalytic NEt3 in a 
heterogeneous solvent system (DCM/MeOH/H2O, 1:2:1) at 40 
oC afforded the novel O-
glycoconjugate 4.38 as a white precipitate in 78% yield (Scheme 4.9). As discussed in earlier 
chapters, mild deprotection conditions were attempted as we feared the harsher conditions, 
such as Zémplen conditions, may result in degradation of the glycolipid. The 1H NMR spectrum 
of the deprotected O-glycoconjugate, 4.38, is shown in Figure 4.15, with characteristic peaks 
such as the amide (NH), aromatic (ArH*), anomeric (H-1) and tetradecyl protons highlighted. It 
is clear from the 1H NMR spectrum that the desired bivalent glycolipid has been synthesised, 
since all expected peaks are present and integrate correctly. For example, the anomeric proton 
of the galactose moiety (labelled H-1 on 1H NMR spectrum) integrates for two protons, 
indicating that two galactose moieties are in fact present. In comparison, the terminal methyl 
group of the tetradecyl chain integrates for three protons confirming the presence of only one 
hydrocarbon chain. 
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Figure 4.15 
1
H NMR spectrum of bivalent deprotected O-glycolipid 4.38 (300 MHz, d5-Pyr). 
 
4.3.2 Synthesis of O-glycoconjugate 4.39 
In order to investigate the effect of the hydrocarbon chain length on the activity of the 
glycoconjugate, the aromatic O-glycoconjugate 4.39 was synthesised (Figure 4.16). Again It 
was designed to act as a flexible molecule utilising the same ethyl linker as glycoconjugate 
4.38, though this time the glycolipid contains a short C-3 hydrophobic chain instead of the 
longer C-14 one.  
 
Figure 4.16 Structure of β-O-glycoconjugate 4.39. 
4.3.2.1 Synthesis of aromatic core 4.72 
We followed the same approach as discussed above for the synthesis of glycoconjugate 4.38 
and utilised the active pentafluorophenyl esters to attain coupling to the galactose ethyl amine 
2.33. The synthesis started with nucleophilic addition of propylamine to trimesoyl chloride in 
the presence of base. As before, the propylamine was added in high dilution, at 0 oC over a 
period of 3 h. An in situ reaction with pentafluorophenol yielded the aromatic scaffold 4.72, 
but in a low yield of 20% (Scheme 4.10). 
 
Scheme 4.10 Reagents and Conditions: i) DIPEA, NH2C3H7, THF, N2, 0 
o
C, 3 h, 2) C6F5OH, DIPEA, rt, 16 h, 
20% over two steps. 
H-1 
N-H1 N-H2 
CH3 of       
C-14  
chain  
Ar-H* 
1
st
 CH2 of    
C-14 chain 
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Surprisingly, the main product isolated was the aromatic derivative containing three 
pentafluorophenyl esters 4.73. This was in complete contrast to what was previously 
observed, as usually the tri-amide was found to be the major product. We chose to use this to 
our advantage and reacted the tri-pentafluorophenyl derivative 4.73 with 1 eq of propylamine 
in the presence of base. To our delight, the desired mono-substituted derivative 4.72 was 
attained in a high yield of 88% (Scheme 4.11). 
 
Scheme 4.11 Reagents and Conditions: i) DIPEA, NH2C3H7, THF, N2, 0 
o
C, 16 h, 88%; ii) 2.33, DIPEA, THF, N2, rt, 
18 h, 40% (4.74) and 36% (4.75); iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 98%. 
 
The desired short chain, bivalent galactose glycoconjugate 4.74 was obtained in a moderate 
yield of 40% by reaction of the galactose ethyl amine 2.33 with the pentafluorophenyl ester 
4.72 in the presence of base (Scheme 4.11). A monovalent galactose derivative 4.75, with one 
pentafluorophenol ester still remaining, was also isolated but in a lower yield of 30%. This 
again highlighted the poor nucleophilicity of the galactose ethyl amine 2.33. This monovalent 
derivative 4.75 was also a very interesting product, as it meant the synthesis of asymmetric 
glycoconjugates may also be possible, following this approach. This was investigated and is 
discussed in section 4.9. 
 
Deprotection of the aromatic-based glycoconjugate 4.74 using NEt3 afforded the novel O-
glycoconjugate 4.39 as a white precipitate in 98% yield. The 1H NMR spectrum of O-
glycoconjugate 4.39 is displayed in Figure 4.17, with significant peaks, including the amide 
(NH), anomeric (Ar-H) and aromatic (H-1) protons, highlighted. 
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Figure 4.17 
1
H NMR spectrum of bivalent deprotected O-glycolipid 4.39 (300 MHz, d5-Pyr). 
4.4 The synthesis of first generation triazole containing glycolipids 4.40 and 4.41 
based on aromatic scaffolds  
As part of our on-going studies into the potential anti-microbial activity of bivalent aromatic 
glycoconjugates, we were interested in synthesising the 1,4 di-substituted 1,2,3-triazole O-
glycolipids 4.40 and 4.41 (Figure 4.18). There are many examples of triazole-containing 
compounds, as discussed in the introduction to this chapter, and in most cases high affinities 
towards the lectin of interest were observed. 1,4-Disubsituted 1,2,3-triazoles are of high 
biological interest as they possess high chemical stability, display aromatic character and can 
act as hydrogen bond acceptors.[176] This means they can mimic the electronic properties and 
atom arrangement of peptide bonds, without being susceptible to hydrolytic cleavage.[177] 
Ultimately, these glycoconjugates 4.40-4.41 were designed to probe how introducing 
aromaticity into the linker may affect their anti-microbial activity. 
 
As with the glycoconjugates discussed previously, the O-glycoconjugates 4.40 and 4.41 are 
linked to the aromatic scaffold via an ethylene chain which should allow for a certain degree of 
conformational flexibility. The spacer also contains a triazole moiety which can impart a certain 
amount of rigidity to the molecule. Therefore, the presence of the triazole moiety could 
influence the conformation of the glycoconjugate and thus its biological activity. Glycolipids 
4.40 and 4.41 (Figure 4.18) differ only by the length of lipidic chain attached, as again we 
wanted to investigate how hydrophobic chain length influenced anti-microbial activity. 
 
H-1 
NH1 and 
NH2 
Ar-H’s * 
1
st
 CH2 of 
C-3 chain 
CH3 of C-3 
chain 
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Figure 4.18 Structure of triazole-containing glycoconjugates 4.40 and 4.41. 
4.4.1 Cu catalysed azide-alkyne cycloaddition (CuAAC) 
The synthesis of 1,4 di-substituted 1,2,3-triazoles occurs via a copper(I) catalysed azide-alkyne 
cycloaddition (CuAAC) reported independently by the Meldal group in Denmark,[178] and 
Sharpless and Fokin in the U.S.[179] Prior to their reports, the uncatalysed Huisgen 1,3-dipolar 
cycloaddition was utilised in the synthesis of substituted triazoles. However, it had many 
drawbacks.[180] The Huisgen 1,3-dipolar cylcoaddition required high temperatures, long 
reaction times and provided mixtures of 1,4- and 1,5-triazole regioisomers (4.78 and 4.79, 
respectively). In contrast, the copper catalysed reaction transforms organic azides (4.77) and 
terminal alkynes (4.76) into the 1,4 di-substituted 1,2,3-triazoles (4.78) exclusively, without the 
need for elevated temperatures (Scheme 4.12).[176] 
 
 
Scheme 4.12 Huisgen 1,3-dipolar cycloaddition of azides and alkynes usually requires prolonged heating 
and results in mixtures of both 1,4-and 1,5-regioisomers (bottom), whereas CuAAC produces only 1,4- 
di-substituted-1,2,3-triazoles in excellent yields at rt (top). 
 
The proposed mechanism for the CuAAC reaction is shown in Scheme 4.13.[181] The classicial 
thermal cycloaddition proceeds via a concerted mechanism, however, DFT calculations 
provided evidence that the CuAAC reaction follows a stepwise mechanism.[182] 
∆ 
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Scheme 4.13 Outline of plausible mechanism for the Cu(I) catalysed reaction between organic azides 
and terminal alkynes.
[183]
 
 
π coordination of the terminal alkyne to a copper(I) species to form the copper(I) acetylide 
complex 4.81 initiates the catalytic cycle. As a result, the alkyne proton becomes more acidic 
and can therefore be abstracted (generally under basic conditions) to form the δ–acetylide 
intermediate 4.82. In the next step, a copper ion coordinates to the azide group as shown in 
transition states 4.83 and 4.84.[182] Kinetic studies and structural evidence suggest that the 
acetylide and azide may not be bound to the same copper atoms as in 4.83, but instead to two 
different copper atoms as in 4.84.[178] During the transition state, two possibilities for 
coordination and delivery of the azide to the alkyne have been suggested 4.85 or 4.86. It is 
believed that complexation between the azide and copper atom leads to the azide being 
susceptible to nucleophilic attack at the secondary carbon of the acetylide, generating the 
regioselective metallocene intermediates 4.85 and 4.86. Ring contraction yields the metallated 
triazole 4.87. Finally, electrophilic attack at the triazole yields the desired 1,2,3-triazole 4.80, 
with dissociation leading to the regeneration of the copper catalyst, thus ending the catalytic 
cycle.[181-183] 
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4.4.2 Synthesis of β-O-glycoconjugate 4.40 
The synthesis began with the reaction of trimesoyl chloride and benzyl alcohol using DIPEA, 
followed by an in situ reaction with propargylamine to yield the di-alkynyl derivative 4.88 in a 
low yield of 20% (Scheme 4.14). As discussed for the previous reactions, the mono-substituted 
alkynyl derivative 4.89 was also isolated, albeit in a lower yield of 9%. 
 
Scheme 4.14 Reagents and Conditions: i) 1) C6H5CH2OH (1 eq), THF, DIPEA, N2, 0 
o
C, 3h, 2) NH2CH2CCH (2 
eq), DIPEA, rt, 16 h, 20%; ii) 2.44, CuSO4.5H2O, Sodium ascorbate, DCM/Acetone/H2O, 20 h, 58%; iii) 
H2, Pd/C, EtOAc, 4-48 h. 
 
A subsequent CuAAC reaction with the galactosyl azide 2.44 (previously synthesised in Chapter 
2, section 2.5.1.1) using a promoter system of CuSO4.5H2O and sodium ascorbate, afforded the 
1,4-di-substituted 1,2,3-triazole glycolipid 4.90 in a regiospecific manner and in a moderate 
yield of 58%. Unfortunately, the next step which involved hydrogenolysis of the benzyl ester 
using H2 and Pd/C, proved unsuccessful. The reaction was attempted at rt, with bubbling H2 
through the reaction mixture and utilising EtOH as the solvent, but in all cases the desired 
product 4.91 was not obtained. Instead, only the starting material 4.90 was isolated. Increasing 
the reaction temperature to 50 oC also proved unsuccessful and a further increase to 70 oC 
resulted in the degradation of compound 4.90. 
 
As a result of the problems encountered our synthetic approach was modified. It was decided 
to utilise the di-alkynyl derivative 4.68 discussed previously in section 4.2.1, however, this time 
the compound was synthesised via an alternative method. Trimesoyl chloride was reacted 
directly with the tetradecylamine followed by the addition of propargylamine after a period of 
3 h. Nonetheless, a mixture of products was obtained and isolation of the desired derivative 
4.68 was complicated by the presence of side-products. However, as 1H NMR spectral analysis 
indicated that the desired di-alkynyl 4.68 was the major product the crude mixture was 
reacted on without further purification. A CuAAC reaction with the galactose ethyl azide 2.44, 
using CuSO4.5H2O and sodium ascorbate as promoters afforded the desired bivalent galactose 
glycolipid 4.92 in 54% yield. Global deacetylation using catalytic NEt3 in a heterogenous solvent 
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system (DCM/MeOH/H2O, 1:2:1) at 40 
oC afforded the novel O-glycoconjugate 4.40 as a white 
precipitate in 90% yield (Scheme 4.15). 
Scheme 4.15 Reagents and conditions: i) NH2C14H29, THF, DIPEA, N2, 0 
o
C, 3h, NH2CH2CCH, DIPEA, rt, 16 
h; ii) 2.44, CuSO4.5H2O, Sodium ascorbate, DCM/Acetone/H2O, 20 h, 54% over two steps; iii) NEt3, 
DCM/H2O/MeOH, 40 
o
C, 20 h, 90%. 
 
The 1H NMR spectrum of β-O-glycolipid 4.40 can be seen in Figure 4.19. Characteristic peaks, 
including the anomeric proton (H-1),aromatic protons (Ar-H*), amide protons (N-H), and 
triazole protons (CCHN3*), are assigned.  
 
Figure 4.19 
1
H NMR spectrum of bivalent deprotected O-glycolipid 4.40 (300 MHz, d5-Pyr). 
4.4.3 Synthesis of β-O-glycoconjugate 4.41 
Following the same approach as described above, the synthesis of glycoconjugate 4.41 
proceeded smoothly. Propylamine was added over a period of 3 h to trimesoyl chloride 4.46 in 
the presence of base. An in situ reaction with propargylamine afforded a mixture of products 
which was used without further purification (Scheme 4.16).  A successive Cu(I) catalysed 
cycloaddition using a promoter system of CuSO4.5H2O and sodium ascorbate yielded 57% of 
the protected β-O-glycoconjugate 4.95. Finally, selective deprotection using the mild 
conditions of NEt3 in a heterogeneous solvent system (DCM/MeOH/H2O, 1:2:1) led to the 
synthesis of the deprotected, bivalent β-O-glycoconjugate 4.41 in a high yield of 93%. The 1H 
NMR spectrum of O-glycoconjugate 4.41 is displayed in Figure 4.20 with significant peaks 
assigned. 
 
H-1 
CCHN3* 
Ar-H* 
N-H2 
N-H1 
* * 
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Scheme 4.16 Reagents and conditions: i) NH2C3H7, THF, DIPEA, N2, 0 
o
C, 3h, NH2CH2CCH, DIPEA, rt, 16 h; 
ii) 2.44, CuSO4.5H2O, sodium ascorbate, DCM/Acetone/H2O, 20 h, 57%; iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 
20 h, 93%. 
 
 
Figure 4.20 
1
H NMR spectrum of bivalent deprotected O-glycolipid 4.41 (300 MHz, d5-Pyr). 
4.5 The synthesis of the second generation of glycolipids-based on aromatic scaffolds 
4.36 and 4.37 
When trimesoyl chloride and trimesic acid were exploited in the synthesis of the aromatic 
glycoconjugates, a variety of side-products, which complicated purification and reduced the 
yield, was always observed. Although the desired products were still obtainable, we opted to 
construct an alternative approach and investigate methods to potentially reduce this by-
product formation, therefore making the synthesis more efficient. 
 
The use of aniline derivatives in the synthesis of aromatic glycoconjugates is well reported in 
the literature.[93, 153, 172] We therefore chose 5-aminoisophthalic acid as our aromatic building 
block starting material. This way, functionalisation with the lipidic chain could be achieved 
prior to coupling of the galactosyl moieties. The revised synthetic route can be seen in Scheme 
4.17. This alternative approach would also provide access to an important building block 4.96, 
which could be easily functionalised with a variety of carbohydrate-based amines to yield a 
number of structurally diverse glycoconjugates. 
H-1 
CCHN3* 
Ar-H* 
N-H2 
N-H1 
4.41 
* * 
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Scheme 4.17 Revised synthetic approach for the synthesis of the second generation of glycoconjugates-
based around an aromatic scaffold. 
 
As well as exhibiting different connectivity in the amide linkage to the hydrocarbon chain, the 
N-glycoconjugates 4.36 and 4.37 (Figure 4.21) were designed to act as more rigid ligands than 
the ones described in the previous sections, since the galactose is connected to the aromatic 
core directly via an N-glycosidic bond.  As before, in order to investigate how chain length 
influenced the biological activity C-16 and C-3 hydrocarbon derivatives were synthesised. 
 
 
Figure 4.21 Structure of second generation N-glycolipids 4.36 and 4.37. 
4.5.1 Synthesis of N-Glycoconjugate 4.36 
The synthesis of the galactose amine 3.66 was discussed previously in Chapter 3 (section 
3.5.1).  
Hexadecanoyl chloride was reacted with 5-aminosophthalic acid 4.97 in the presence of base 
to yield the di-acid building block 4.96 in 81% yield (Scheme 4.18). The di-acid derivative was 
then activated using DMF and oxalyl chloride to yield the di-acid chloride intermediate. A 
succeeding in situ reaction with the galactose amine 3.66 yielded the N-glycoconjugate 4.98 in 
a moderate yield of 45%. Finally, selective deprotection using the mild conditions of catalytic 
NEt3 led to 93% of the desired deprotected N-glycoconjugate 4.36. 
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Scheme 4.18 Reagents and conditions: i) ClCOC15H31, NEt3, THF, DMF, N2, 18 h, 81%; ii) 1) Oxalyl chloride, 
DMF, DCM, N2,  0 
o
C, 1 h, 2) 3.66, NEt3, 0 
o
C- rt, 16 h, 45% over two steps; iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 93%. 
 
The 1H NMR spectrum of the deprotected N-glycoconjugate 4.36 is shown in Figure 4.22 with 
characteristic peaks assigned. It is clear from the 1H NMR spectrum that the anilide proton of 
the second generation derivatives resonates at a higher ppm, in comparison to the lipidic 
amide of the first generation derivatives.  We can also see a difference in the chemical shift of 
the methylene protons of the lipidic chain. The first methylene group resonates further upfield 
at a lower ppm of 2.52 than what was observed for the first generation derivatives (3.70 ppm). 
Figure 4.22 
1
H NMR spectrum of bivalent deprotected N-glycolipid 4.36 (300 MHz, d5-Pyr). 
4.5.2 Synthesis of N-glycoconjugate 4.37 
The synthesis of the shorter chain N-glycolipid 4.37 proceeded via a similar route as discussed 
earlier. 5-Aminoisophthalic acid 4.97 was reacted with propionic chloride and afforded the di-
acid 4.99 in 89% yield (Scheme 4.19). 1H NMR spectral analysis also indicated the presence of 
some propionic acid. Purification proved unsuccessful so it was decided to proceed on with the 
crude compound 4.99. The di-acid derivative was coupled to the galactose amine 3.66 using 
HOBt/TBTU methodology and the protected, bivalent glycoconjugate 4.100 was acquired in a 
low yield of 20%. The low yield indicated that both the electrophilicity of the carbonyl carbon, 
and nucleophilicity of the amine are extremely important in the synthesis of aromatic 
glycoconjugates. Due to the higher yield achieved in the synthesis of the C-16 derivative, 
discussed in section 4.5.1, it was believed that converting the acids into acid chlorides is the 
Ar-H* 
N-H1 
N-H2 
CH3 of 
chain 
1
st
 CH2 
of chain 
2
nd
  CH2 
of chain 
4.36 
H-1 
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optimum approach. Nevertheless, as we had obtained enough sample to carry out biological 
analysis no further optimisation of the reaction was attempted.  
 
Scheme 4.19 Reagents and Conditions: i) ClCOC2H5, NEt3, THF, DMF, N2, 18 h, 89%; ii) HOBt, TBTU, NEt3, 
DMF, N2, 3.66,  rt, 16 h, 20%; iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 96%. 
 
Global deprotection was achieved using catalytic NEt3 in a heterogeneous solvent system to 
yield the deprotected N-glycoconjugate 4.37 in 96% yield. The 1H NMR spectrum can be seen 
in Figure 4.23, with significant peaks including the anomeric proton (H-1), amide protons (N-H) 
and aromatic protons (Ar-H) highlighted. 
 
 
Figure 4.23 
1
H NMR spectrum of bivalent, deprotected N-glycolipid 4.37 (300 MHz, d5-Pyr). 
4.6 The synthesis of the second generation triazole containing glycolipid 4.42 based 
on an aromatic scaffold 
Similarly to the first generation of 1,4-di-substituted 1,2,3-triazole O-glycoconjugates discussed 
previously in section 4.4, the N-glycoconjugate 4.42 (Figure 4.24) was designed to act as a 
potential inhibitor of bacterial adhesion. In this case, the N-glycoconjugate 4.42 was intended 
to act as a more rigid molecule than glycolipids 4.40 and 4.41, as no ethyl linker is used and the 
galactose moiety is directly attached to the triazole moiety via an N-glycosidic bond. As 
discussed previously, glycoconjugates containing triazole moieties are of high biological 
interest. 
 
N-H2 N-H1 
Ar-H* 
H-1 
Chapter 4:                Synthesis of glycolipids based on aromatic scaffolds as potential anti-adhesion agents 
 
 
127 
 
 
Figure 4.24 Structure of second generation 1,4-di-substituted 1,2,3-triazole glycoconjugate 4.42. 
 
The synthesis started with the di-acid 4.96 intermediate synthesised previously in section 
4.4.1. Coupling of the free acid building block 4.96 with propargylamine using TBTU/HOBt 
methodology afforded the di-alkyne intermediate 4.101 in 62% yield (Scheme 4.20). A 
subsequent CuAAC reaction with the galactosyl azide 3.67 (previously synthesised in Chapter 
3, section 3.5.1) using a promoter system of CuSO4.5H2O and sodium ascorbate afforded the 
1,4-di-substituted 1,2,3-triazole N-glycolipid 4.102 in a regiospecific manner and in a moderate 
yield of  58%. The monovalent derivative 4.103 was also isolated in 22% yield. Again, this was 
extremely interesting as it could be employed as a precursor in the synthesis of asymmetric 
aromatic glycoconjugates. Finally, mildly basic cleavage of the acetyl protecting groups was 
performed with catalytic NEt3 in a heterogeneous solvent system (DCM/MeOH, H2O, 1:2:1) at 
40 oC to yield the divalent N-glycolipid 4.42 in a 98% yield after 18 h. 
 
 
Scheme 4.20 Reagents and conditions: i) HOBt, TBTU, NEt3, DMF, N2, NH2CH2CCH, rt, 16 h, 62%; ii) 3.67, 
CuSO4.5H2O, Sodium ascorbate, DCM/Acetone/H2O, 20 h, 58%;  iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 98%. 
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Structural elucidation was carried out and the 1H NMR spectrum of deprotected glycolipid 4.42 
is shown in Figure 4.25. Characteristic signals, including the anomeric proton (H-1), aromatic 
(Ar-H) protons, amide protons (NH) and the triazole proton (CCHN3), are highlighted in the 
figure. 
 
 
Figure 4.25 
1
H NMR spectrum of bivalent deprotected N-glycolipid 4.42 (300 MHz, d5-Pyr). 
4.7 The synthesis of second generation glycoconjugate 4.43 based on  an aromatic 
scaffold 
As mentioned previously, the exact structure of the bacterial receptor of B. multivorans which 
is involved in the adhesion process is not known. This makes the design of synthetic ligands 
difficult, and instead a variety of ligands have to be synthesised and evaluated.  It is very clear 
from Figure 4.26 that the chemical nature of the linker groups between the aromatic core and 
the galactosyl moieties are significantly different for all glycoconjugates designed. This should 
be reflected in a different three-dimensional presentation of the carbohydrate epitopes in 
each of the glycoconjugates. However, precise structural information on these ligands would 
require crystallography data and conformational studies.  It is also clear from Figure 4.26 that 
an obvious relationship between linker length and resulting flexibility/rigidity of the ligands 
cannot be realised. A more “extended” structure would not necessarily present the galactose 
groups at a further distance from each other.  
 
H-1 
CCHN3 
Ar-H* N-H2 N-H1 
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Figure 4.26 Difference between linker flexibility/ridigity and distance between the galactose epitopes. 
 
With these observations in mind, glycoconjugate 4.43 (Figure 4.26) was designed. The 
galactose molecule is linked to the aromatic core via an ethylene chain and a glycine amino 
acid. The presence of the second peptide bond may impart additional conformational 
constraints to the glycoconjugate, which could influence the presentation of the galactose 
epitopes compared to the triazole-containing glycolipids 4.40 and 4.42. 
4.7.1 Initial synthesis of glycoconjugate 4.43 
The synthesis of glycoconjugate 4.43 commenced with the amide coupling of the commercially 
available N-Boc-glycine 4.104 with the galactose ethyl amine 2.33 using TBTU and HOBt 
(Scheme 4.21). The desired galactose building block 4.105 was afforded in 62% yield. 
Subsequent removal of the N-Boc protecting group with TFA afforded the amine 4.106 which 
was then reacted with di-acid aniline derivative 4.96, synthesised previously (section 4.5.1). 
Unfortunately, the reaction was unsuccessful and a mixture of inseparable compounds was 
obtained.  
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Scheme 4.21 Reagents and Conditions: i) HOBt, TBTU, DMF, NEt3, N2, 16 h, rt, 62%; ii) TFA, DCM, 0 
o
C – 
rt, 5 h, 74%; iii) 1) 4.96, oxalyl chloride, DMF, DCM, N2,  0 
o
C, 1 h, 2) 4.106, NEt3, 0 
o
C- rt, 16 h. 
It is possible that unfavourable intramolecular H-bonding (Figure 4.27) was occurring in the 
free amine derivative 4.106.  This H-bonding leads to a decrease in the nucleophilicity of the 
amine 4.106 and therefore could explain why the reaction did not proceed as expected.  
 
Figure 4.27 Unfavourable intramolecular H-bonding of amine derivative 4.106. 
 
1H NMR spectral analysis provided an indication for this H-bonding. In the 1H NMR spectrum of 
the N-Boc derivative 4.105 the sugar amide * resonates at 6.5 ppm, whereas, in the 1H NMR 
spectrum of the free amine derivative 4.106 the amide peak shifts upfield to 7.5 ppm. 
 
To circumvent this problem, we altered our synthetic route. The reaction was repeated but 
this time the coupling of the free amine 4.106 to di-acid aniline derivative 4.96 was attempted 
using HOBt and TBTU in DMF. As DMF is a polar aprotic solvent we hoped that it would 
compete with these intramolecular H-bonds therefore increasing the nucleophilicity of the 
amine.   Unfortunately, this proved fruitless and again a mixture of products was observed in 
the crude sample. Column chromatography was attempted and a small amount of potential 
product 4.107 was isolated, although some impurities still remained.  
4.7.2 Attempted synthesis of glycoconjugate 4.43 using pentafluorophenyl esters 
Due to the problems encountered above, we opted to alter our synthetic approach and 
convert the di-acids 4.96 into activated pentafluorophenyl esters. The diacid 4.96 was reacted 
with pentafluorophenol and DIC and the di-ester derivative 4.108 was obtained in a moderate 
yield of 46% (Scheme 4.22). Remarkably, a subsequent reaction with the free amine 4.106, in 
the presence of base, yielded the mono-substituted galactose derivative 4.109, exclusively. 
Although unexpected, this was extremely interesting and again provided a potential building 
block for the synthesis of asymmetric aromatic glycoconjugates (discussed in section 4.9). We 
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decided to further explore this reaction and found that if the reaction mixture was heated to 
50 oC, the di-substitued derivative 4.107 was obtained. However, a number of side-products 
were also obtained and purification proved unsuccessful. 
Scheme 4.22 Reagents and Conditions: i) C6F5OH, DIC, DIPEA, THF, N2, 0 
o
C, 1 h, rt, 4 h, 46%; ii) 4.106, 
DIPEA, THF, N2, 16 h, rt, 45%. 
 
4.7.3 Synthesis of glycoconjugate 4.43 
With so many problems to contend with, a complete change of approach was considered and 
it is shown in Scheme 4.23. The di-acid C-16 aniline 4.96 was first reacted with the HCl salt of 
the glycine benzyl ester 4.110 to yield the bi-substituted amide derivative 4.111. 
Hydrogenolysis of the benzyl ester using H2 and Pd/C catalyst afforded the novel di-acid 
compound 4.112 in 78% yield. The di-acid 4.112 was then reacted with the galactose ethyl 
amine 2.33 using HOBt and TBTU to yield the desired bivalent glycoconjugate 4.107, albeit in a 
low yield of 15%. Global deprotection was achieved using catalytic NEt3 to afford the 
deprotected glycoconjugate 4.43 in quantitative yield.  
 
Scheme 4.23 Reagents and conditions: i) TBTU, HOBt, NEt3, DMF, N2,  NH2CH2COOCH2C6H5.HCl, rt, 16 h, 
54%; ii) H2, Pd/C, EtOAc, 78%; iii) TBTU, HOBt, NEt3, DMF, N2, 2.33, rt, 18 h, 15%; iv) NEt3, 
DCM/H2O/MeOH, 40 
o
C, 20 h, quant. 
 
The 1H NMR spectrum of the deprotected, bivalent galactose derivative can be seen in Figure 
4.28, and characteristic peaks including the aromatic protons (Ar-H), amide protons (NH) and 
anomeric protons (H-1) are highlighted.  
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Figure 4.28 
1
H NMR spectrum of bivalent, deprotected O-glycolipid 4.43 (300 MHz, d5-Pyr). 
4.8 The synthesis of monovalent aromatic glycolipid 4.44 
The concept of multivalency has been previously discussed in detail in Chapter 1 and also 
briefly in the introduction to this chapter. There are many reviews on the topic published in 
the literature.[184] In order to confirm that a true multivalent effect was occurring for our 
bivalent, aromatic glycoconjugates, it was necessary to synthesise a monovalent derivative for 
direct comparison. As will be discussed in Chapter 5, the rigid, aromatic, bivalent 
glycoconjugate 4.36 gave the most promising anti-microbial results. Therefore, we opted to 
attempt the synthesis of a monovalent comparison for glycoconjugate 4.36 (Figure 4.29). 
 
 
Figure 4.29 Bivalent 4.36 and monovalent 4.44 version of rigid aromatic glycoconjugate. 
 
The synthesis proceeded smoothly following a similar approach as used for the synthesis of 
4.36 (section 4.5.1). 3-Aminobenzoic acid 4.113 was reacted with hexadecanoyl chloride in the 
presence of base to yield 75% of the mono-acid building block 4.114 (Scheme 4.24).  The 
mono-acid derivative was then reacted with the galactose amine 3.66 using HOBt and TBTU to 
attain the monovalent N-glycoconjugate 4.115 in a moderate yield of 65%. Finally, selective 
deprotection using the mild conditions of catalytic NEt3 led to the desired deprotected N-
glycoconjugate 4.44 in 92% yield. The 1H NMR spectrum of the deprotected monovalent 
glycoconjugate 4.24 with characteristic peaks assigned is shown in Figure 4.30. 
4.34 
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Scheme 4.24 Reagents and conditions: i) ClCOC15H31, NEt3, THF, DMF, N2, 18 h, 75%; ii) HOBt, TBTU DMF, 
N2, NEt3, 3.66, rt, 16 h, 65%; iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 99%. 
 
 
Figure 4.30 
1
H NMR spectrum of monovalent deprotected N-glycolipid 4.44 (300 MHz, d5-Pyr). 
4.9 The synthesis of non-symmetrical glycolipids based on an aromatic scaffolds 
4.116 and 4.117 
During the synthesis of bivalent glycolipids 4.39 and 4.43 we found that the mono 
pentafluorophenyl esters 4.75 and 4.109 could also be isolated and purified (section 4.3.2 and 
section 4.7.2, respectively). This led us to examine the possibility of synthesising non-
symmetrical, aromatic glycoconjugates, which could be of high biological interest. 
 
Figure 4.31 Monovalent derivatives isolated during the synthesis of bivalent glycoconjugates. 
 
As discussed previously, individual carbohydrate interactions with their complementary 
protein, which are essential for a number of biological processes, tend to be very weak. To 
overcome this, multivalent carbohydrate systems have been widely explored,[154] and it has 
been shown that mutivalency generally leads to increased binding affinities.[15] To date, most 
interest has centred around the synthesis of multivalent systems composed of identical 
carbohydrate entities linked to an appropriate scaffold.[154]  Although beneficial and successful, 
H-1 
N-H 
N-H* 
4.44 
* 
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this approach does not take the glycoheterogeneity of carbohydrate-protein binding into 
account. In order to understand this biological heterogeneity further, efficient methodologies 
for the successful synthesis of scaffolds displaying different carbohydrate ligands 
(heteroglycans, heteroglycoclusters and heteroglycoassemblies) are of extreme importance.[15] 
Some examples are shown in Figure 4.32. 
 
 
Figure 4.32 Examples of selected heteroglycans, Lindhorst et al. 4.123,
[185]
 Roy et al. 4.121.
[186]
  Aizpurua 
et al. 4.118-4.120,
[187]
  and Santoyo-Gonzalez et al. 4.122.
[188] 
 
In 2002, Lindhorst and co-workers successfully synthesised a novel hetero-glycocluster 4.123 
using an approach based on the orthogonal derivatisation of D-galactose to attach different 
carbohydrate moieties.[185] Later, in 2007, Roy et al. explored the possibility that 
heteromultivalent glycoconjugates may be able to cross-link two different lectins, if each of 
the lectins was specific for one of the saccharide units.[186] They successfully demonstrated this 
principle and the heteromultivalent glycodendrimer 4.121, which contained four α-fucose and 
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four β-galactose residues on opposite sides of the scaffold, displayed fast cross-linking abilities 
with both the PA-IL and PA-IIL P. aeruginosa ligands. In 2010, Aizpurua et al. published the first 
report on the synthesis of non-symmetrical bis(1,2,3-triazoles).[187] Some selected examples of 
the non-symmetrical bis(1,2,3-triazoles) they synthesised included compounds 4.118-4.120 
(Figure 4.32). Santoyo-Gonzalez and co-workers exploited the CuAAC reaction to synthesise 
multivalent heteroglycans incorporating two different monosaccharides, including D-mannose, 
D-glucose, D-glucosamine, onto a variety of scaffolds.[188] One such example of a 
pentaerythritol scaffold bearing 2 α-mannose and 2 α-glucose moieties is glycocluster 4.122. 
The ability of the compounds to bind Con A was evaluated and it was found that even though 
α-mannose is a much better ligand than α-glucose for binding Con A, the relative potency per 
α-mannose unit was 1.5-fold higher for the (αMan)2(αGlc)2 derivative as compared to the 
(αMan)4 homoconjugate. 
4.9.1 Synthesis of non-symmetrical aromatic glycolipid 4.116 
As stated above, during the synthesis of the bivalent glycoconjugate 4.39 the monovalent 
counterpart 4.75 was also isolated.  The clear differences between the 1H NMR spectra of the 
two compounds can be seen in Figure 4.33. The red spectrum corresponds to the protected 
divalent glycoconjugate 4.74, and shows that in this case the aromatic protons appear 
equivalent and resonate together as a broad singlet at 8.35 ppm. In contrast the blue 
spectrum, which corresponds to the monovalent derivative 4.75, shows that the aromatic 
protons no longer appear equivalent. The aromatic H1 and H2 atoms are now in close 
proximity to the electron-withdrawing penatfluorophenyl ester and, as a result, they have 
shifted to a higher ppm value of 8.77. The H3 atom remains in a similar environment as in 
compound 4.74 and therefore shifts upfield only slightly to 8.44 ppm.  
 
 
Figure 4.33 
1
H NMR spectra of divalent glycoconjugate 4.74 (red) and its monovalent counterpart 4.75 
(blue). 
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Although the synthesis of heteroglycans is advantageous, we decided to continue with the 
galactose moiety and synthesise a non-symmetrical molecule containing two galactose 
moieties connected to the aromatic backbone via a different linker. The compound we aimed 
to synthesise was glycolipid 4.116, which was a hybrid between glycoconjugate 4.39 and 4.41 
(Figure 4.34). 
 
Figure 4.34 Structure of non-symmetrical glycolipid 4.116, which is a cross between glycolipids 4.30 and 
4.32. 
When carrying out the synthesis of the divalent glycolipid 4.39, a 30% yield of the monovalent 
counterpart 4.75 was obtained. Aiming to improve this yield, the reaction was repeated using 
less equivalents of galactose ethyl amine 2.33, and with dropwise addition of the amine to the 
reaction mixture (Scheme 4.25). Nevertheless the yield only increased to 36%, and no bivalent 
glycolipid 4.39 was detected by 1H NMR spectral analysis. The monovalent derivative 4.75 was 
reacted with propargylamine to afford the alkyne intermediate 4.124 in 66% yield. A 
subsequent CuAAC reaction with the galactosyl azide 2.44 using a promoter system of 
CuSO4.5H2O and sodium ascorbate afforded the non-symmetrical glycolipid 4.116 in a 
regiospecific manner and in a good yield of 72%. Removal of the acetyl protecting groups of 
glycolipid 4.116 was not attempted in this case as the compound would not be tested for anti-
microbial activity. 
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Scheme 4.25 Reagents and Conditions: i) 2.33, DIPEA, THF, N2, rt, 18 h, 36%; ii) ) NH2CH2CCH, THF, 
DIPEA, N2, rt, 3h, 66%;  ii) 2.44, CuSO4.5H2O, sodium ascorbate, DCM/Acetone/H2O, 20 h, 72%. 
 
Although the non-symmetrical glycolipid 4.116 contains two galactose moieties, this approach 
proves that the synthesis of a variety of heteroglycans can be easily achieved by simply varying 
the carbohydrate azide utilised in the CuAAC reaction. The 1H NMR spectrum of the protected 
glycolipid 4.116 is shown in Figure 4.35 with characteristic signals assigned. 
 
Figure 4.35 
1
H NMR spectrum of non-symmetrical glycolipid 4.116 (300 MHz, CDCl3). 
4.9.2 Synthesis of non-symmetrical aromatic glycoconjugate 4.117 
Like glycoconjugate 4.116, non-symmetrical glycolipid 4.117 was designed to be a hybrid 
between two previously synthesised glycoconjugates, 4.42 and 4.43 (Figure 4.36). We wanted 
to synthesise a non-symmetrical molecule whereby the two galactose moieties where 
connected to the aromatic scaffold via a different linker. The idea was to prove that this 
methodology would be effective, and that the monovalent derivatives could be utilised to 
synthesise a variety of diverse heteroglycans.  
4.116 
H-1 and H-1’ CONHCH2 N-H N-H 
N-H 
CCHN3 Ar-H* 
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Figure 4.36 Structure of non-symmetrical glycolipid 4.117, which is a cross between glycolipids 4.42 and 
4.43. 
As mentioned previously (section 4.7.2), the monovalent counterpart 4.109 was obtained 
exclusively in a 45% yield while trying to synthesise the bivalent glycine derivative 4.43. Again 
this was evident from the 1H NMR spectrum (Figure 4.37).  Due to the electron-withdrawing 
pentafluorophenyl ester group the aromatic protons of the monovalent derivative 4.109 (red) 
reasonates at a higher chemical shift compared to the bivalent derivative 4.107 (blue). 
 
Figure 4.37 
1
H NMR spectra of divalent glycoconjugate 4.107 (blue) and its monovalent counterpart 
4.109 (red). 
 
The synthesis of the non-symmetrical glycolipid 4.117 started with the reaction of the 
monovalent derivative 4.109 with propargylamine using NEt3 to yield the alkynyl derivative 
4.125 in 68% yield (Scheme 4.26). The alkyne derivative was then reacted with galactose azide 
3.67 in a Cu(I) catalysed azide-alkyne cylcoaddition, and the protected non-symmetrical 
glycolipid 4.126 was attained in 65% yield. Global acetyl deprotection was achieved using 
catalytic NEt3 in a heterogeneous solvent system, to give the final deprotected, non-
symmetrical glycolipid 4.117 in 88% yield. 
4.109 
Ar-H 
Ar-H Ar-H Ar-H 
4.107 
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Scheme 4.26 Reagents and Conditions: i) NH2CH2CCH, THF, DIPEA, N2, rt, 3h, 68%;  ii) 3.67, CuSO4.5H2O, 
Sodium ascorbate, DCM/Acetone/H2O, 20 h, 65%; iii) NEt3, DCM/H2O/MeOH, 40 
o
C, 20 h, 88%. 
 
The 1H NMR spectrum of the deprotected glycolipid can be seen in Figure 4.38. Characteristic 
signals are highlighted including the amide protons (NH), the triazole proton (CN3CH), the two 
anomeric protons (H-1 and H-1’) and finally the aromatic protons (Ar-H). 
 
 
Figure 4.38 
1
H NMR spectrum of bivalent glycolipid 4.117 (300 MHz, d5-Pyr). 
4.10 The synthesis of glycoconjugates with more complex carbohydrate epitopes 
Finally, it was decided to attempt the synthesis of aromatic glycoconjugates with more 
complex carbohydrate moieties present, and investigate how this would affect the binding to 
the bacterial proteins and thus influence the biological activity.  We chose the disaccharide 
galabiose (also known as Gal(α,1-4)gal), as it contains a terminal galactose moiety which 
should be recognised by the bacterial proteins (Figure 4.39). Glycoconjugates-containing this 
disaccharide have been shown to be inhibitors of both E. coli and S. suis adhesins.[10] There are 
many examples of both monovalent and multivalent glycoconjugates-containing galabiose 
reported in the literature and in many cases they have been utilised to inhibit bacterial 
adhesion to human cells.[10, 22, 189]  
H-1 H-1 CN3CH Ar-H* NH N-H4 
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Figure 4.39 Representative examples of monovalent 4.128
[10]
 and bivalent 4.127
[190]
 glycoconjugates- 
containing the dissacharide galabiose which have been utilised to inhibit bacterial adhesion to human 
cells. 
 
Initial investigations led us to design the synthetic pathway shown in Scheme 4.27, whereby 
the easily accessible glycosyl donor 4.129 and acceptor 4.130 would serve as suitable building 
blocks in the synthesis of the novel galabiose diasaccharide 4.131. The carbohydrate moiety 
could then be coupled to the aromatic backbone 4.96, synthesised previously in section 4.5.1, 
to yield the more complex glycoconjugate 4.132. Galabiosyl azide 4.131 could also be used as a 
building block in the synthesis of other glycoconjugates using the methodologies discussed in 
the previous sections. 
 
Scheme 4.27 Proposed synthetic pathway for the synthesis of the more complex bivalent 
glycoconjugate 4.132. 
 
4.10.1 Synthesis of glycosyl donor 4.129 
Following a procedure reported by Wang et al., the known compound 4.129 was successfully 
synthesised.[191] Commercially available β-D-Galactose pentacetate 2.38 was reacted with p-
toluenethiol under Lewis acid BF3.O(Et)2 activation and the desired galactoside 4.133 was 
obtained in 69 % yield (Scheme 4.28). Global deprotection using  methanolic NaOMe afforded 
the deprotected compound 4.134 which was subsequently reacted with NaH and benzyl 
bromide to attain the benzylated glycosyl donor 4.129[192] in a yield of 80%.  
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Scheme 4.28 Reagents and conditions; i) BF3.OEt2, p-toluenethiol, DCM, 0 
o
C - rt, 20 h, 69%; ii) NaOMe, 
DCM, MeOH, N2, rt, 1 h, 85%; iii) NaH, BnBr, DMF, N2, 0 
o
C – rt, 18 h, 80%. 
 
4.10.2 Synthesis of glycosyl acceptor 4.130 
The synthesis of the known compound 4.130 commenced with the deprotection of the 
galactose azide 3.67 which was previously discussed in Chapter 3, section 3.2.6.1 (Scheme 
4.29). Following a literature procedure, the hydroxyl groups at the C-4 and C-6 position of the 
resulting compound 4.135 were selectively protected using  a benzylidene acetal to give 
intermediate 4.136.[193] The remaining hydroxyl groups were then benzoylated by treatment 
with benzoyl chloride in pyridine, and the desired galactoside 4.137 was obtained in 75% yield.  
When benzyl groups are present on the acceptor, they increase its nucleophilicty and lead to 
higher yields in glycosylation reactions. However, Ohlsson and Nilsson reported a series of α-
galactosylations using a variety of acceptors, and a donor closely related to 4.129. They found 
that although the yields were higher when the acceptor contained all benzyl groups, the α/β 
selectivity was much lower. They achieved the best results utilising the acceptor 4.130, with a 
yield of 67% and a α/β selectivity of 25:1.[189] Regioselective reduction of the benzylidene 
under acidic conditions by NaCNBH3 initially proved unsuccessful. However following a 
procedure reported by Xia et al., whereby methyl orange was used as a pH indicator[194], the 
known galactosyl acceptor 4.130[189] was obtained in a yield of 73%. This compound is 
mentioned in the literature but no experimental data is given. The 1H NMR spectrum of the 
acceptor 4.130 is shown in Figure 4.40. 
 
Scheme 4.29 Reagents and conditions; i) NaOMe, DCM, MeOH, N2, rt, 1 h, 83%; ii) C6H5CH(OCH3)2, 
CH3C6H4SO3H, DMF, N2, 20 h, NEt3, 83%; iii)  C6H5COCl, Pyr, 0 
o
C – rt, 16 h, 84%; iv) NaCNBH3, HCl, methyl 
orange, THF, rt, 4 h, 73%. 
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Figure 4.40 
1
H NMR spectrum of glycosyl acceptor 4.130 (300 MHz, CDCl3). 
4.10.3 α-Galactosylation between glycosyl donor 4.129 and glycosyl acceptor 4.130  
The next step was the α-galactosylation between the glycosyl donor 4.129 and acceptor 4.130. 
Following a procedure from Ohlsson and Magnusson the galactosylation was carried out at       
-55 oC using a promoter system of TMSTOf and NIS in a mixture of DCM and Et2O.
[195] The 
galabiose diasaccharide 4.131 was obtained in 41% yield (Scheme 4.30). The 1H NMR spectrum 
of compound 4.131 is shown in Figure 4.41. Unreacted donor and acceptor were also 
recovered, however, interestingly only small amounts of the β-diasaccharide were recovered 
(< 1%).  
Figure 4.41 
1
H NMR spectrum of protected galabiose derivative 4.131 (300 MHz, CDCl3). 
 
The α-anomer 4.131 was found to be the major product as the non-ester benzyl protecting 
groups do not allow for neighbouring group participation. This means that the glycosylation 
reaction can follow either a SN1 or SN2 mechanism, which can result in a mixture of anomers. 
By controlling the temperature, solvent and reaction conditions used, the formation of one 
anomer over the other can be favoured.[196] However, this can be extremely difficult and thus 
OH 
H-1 OBn 
H-1’ 
Ar of 
OBn 
4.130 
H-1 
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in the majority of cases the synthesis of 1,2-trans glycosides (β-anomer) involves simpler 
purification of products and more efficient procedures than for the corresponding 1,2-cis 
glycosides (α-anomer). Other groups have previously synthesised the Gal(α, 1-4)gal linkage and 
optimum conditions have already been established.[195] 
The next synthetic steps required careful consideration. The reduction of the azide in 4.131 to 
the amine group was required for coupling to the aromatic scaffolds; however, the benzyl and 
benzoyl groups also needed to be removed. The deprotection conditions of the benzoyl groups 
are quite harsh and require reflux in NaOMe. If this was carried out after the coupling reaction 
we would risk hydrolysis of the newly formed amide bonds. With this in mind, we decided to 
first remove the benzoyl groups and then reduce the azide. Deprotection of the benzoyl 
groups by refluxing with NaOMe yielded 91% of compound 4.138. Subsequent hydrogenolysis 
using H2 and Pd/C led to both the reduction of the azide and removal of the benzyl groups, and 
afforded a 98% yield of compound 4.139. 
Scheme 4.30 Reagents and conditions; i) TMSOTf, NIS, DCM, Et2O, Ar, -55 
o
C, 2 h, 41%; ii) NaOMe, 
MeOH, 90 
o
C, 4 h, 91%; iii) H2, Pd/C, MeOH, HCl, 2 h, 98%. 
Unfortunately, the final step, which involved coupling of the free amine 4.139 to the aromatic 
backbone proved extremely problematic.  For our first attempt, the aromatic scaffold was 
activated using TBTU/HOBt, followed by addition of the galabiosyl amine 4.139 (Scheme 4.31). 
The reaction was unsuccessful and a complex mixture of products was obtained. The reaction 
was repeated but this time the carboxylic acids were converted into acid chlorides prior to 
addition of the amine, nevertheless, the desired product was not obtained.  On closer 
inspection, we observed that the galabiosyl amine 4.139 was extremely insoluble and was 
therefore posing problems for the reaction. 
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Scheme 4.31 Reagents and conditions: i) 1) HOBt, TBTU, DMF, NEt3, N2, 16 h; or 2) Oxalyl chloride, DMF, 
DCM, N2,  0 
o
C, 1 h, 4.216, 0 
o
C- rt, 16 h. 
 
To circumvent this problem, we re-addressed our synthetic route and attempted the reduction 
of the azide in compound 4.138 using Ph3P (Scheme 4.32). With this method, only the azide 
would be reduced and the benzyl groups would remain intact, therefore improving the 
solubility in organic solvents. The reaction appeared to go to completion, however, when 
purification was attempted the galabiosyl amine 4.140 could not be eluted from the column. A 
variety of solvent systems were attempted and NEt3 was also added but this was to no avail. It 
was decided to repeat the reaction and carry on the synthesis without further purification. 
Unfortunately, this approach was also unsuccessful and when both reaction conditions 
(HOBt/TBTU or oxalyl chloride mediated couplings) were re-attempted, similar results were 
observed. The 1H NMR spectrum showed a complex mixture of products, including unreacted 
starting material 4.215. 
 
Scheme 4.32 Reagents and conditions: i) PH3P, THF, H2O, rt, 18 h. 
As reviously stated, numerous times throughout this chapter the electrophilicity of the 
carbonyl carbon of the aromatic scaffold and the nucleophilicity of the carbohydrate amine is 
extremely important in the synthesis of aromatic scaffolds. The reaction conditions appear to 
be substrate specific, consequently attaching a more complex epitope such as galabiose would 
require careful optimisation that will be carried out in the future.  
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4.11 Spectroscopic analysis on selected glycolipids 
During the synthesis of some of the glycolipids described so far, we observed that the 1H NMR 
spectra appeared to vary greatly with concentration. In order to gain a further insight into this 
phenomenon, a series of spectroscopic studies were performed.  
Concentration studies were carried out on a selection of glycolipids including first generation 
glycoconjugates 4.48 and 4.93, and second generation glycoconjugates 4.109, 4.125 and 4.126 
(Figure 4.42). With these studies, we expected to get some information on how the molecule 
conformation was influenced by the chemical nature of the linkers and also whether the amide 
bond form of the lipidic chain (i.e. first generation analogues versus second generation 
analogues) influenced conformation. 
 
 
Figure 4.42 First generation glycolipids 4.48 and 4.93, and second generation glycolipids 4.109, 4.125 
and 4.126 selected for spectroscopic analysis. 
 
4.11.1 Concentration studies on first generation glycolipids 4.48 and 4.116 
Concentration studies were carried out and 1H NMR spectra of the C-14 flexible glycolipid 4.48 
in CDCl3 were recorded at different concentrations. The variation in the chemical shifts of the 
signals corresponding to the different N-H signals in glycolipid 4.48 was examined (Figure 
4.43). The bottom spectrum represents the least concentrated sample (blue) and the top 
spectrum represents the most concentrated sample (black). It is very clear that minimal 
differences are observed between the spectra. The tetradecyl amide proton (N-H2) resonates 
at 6.77 ppm in the most dilute spectrum and 6.81 ppm in the most concentrated spectrum. 
This implies that this amide may be weakly involved in intermolecular H-bonding. An even 
smaller shift is observed for the sugar amide proton (N-H1), which resonates at 6.99 ppm in 
the dilute spectrum and only moves to 7.0 ppm in the more concentrated sample.  
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Figure 4.43 
1
H NMR concentration studies on 4.48 in CDCl3: a) 4 mg mL
-1
, b) 9 mgmL
-1
, c) 13 mg mL
-1
, d) 
16 mg mL
-1
, e) 23 mg mL
-1
. 
 
Conversely, much bigger differences are observed between the dilute (blue) and concentrated 
(pink) spectra of the more rigid, triazole-containing glycolipid 4.116 in CDCl3 (Figure 4.44). 
Clear differences between the chemical shifts of the amide protons can be seen in the least 
concentrated sample (bottom), and the most concentrated sample (top). 
 
Figure 4.44 
1
H NMR concentration studies on 4.116 in CDCl3: a) 4 mg mL
-1
, b) 8 mg mL
-1
, c) 11 mg mL
-1
, 
d)  18 mg mL
-1
. 
 
The biggest change observed relates to the amide proton connecting the triazole moiety to the 
aromatic scaffold (N-H1). It resonates at 7.56 ppm in the dilute sample and shifts to a higher 
ppm value of 7.88 in the more concentrated sample. This implies that the amide is involved in 
intermolecular H-bonding. As CHCl3 is a non-polar solvent, H-bonding between the glycolipid is 
accentuated. The tetradecyl amide proton (N-H2) also shifts to a higher ppm value going from 
the dilute spectra to the more concentrated. It resonates at 6.62 ppm in the dilute spectrum 
and 6.85 ppm in the concentrated spectra. Interestingly, the aromatic protons shift to a lower 
N-H1 
N-H2 
H1, H2, H3 
a 
b
  a 
c 
d 
e 
a 
b 
c 
d 
N-H2 
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N-H1 
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ppm value with increasing concentration. This could imply that the aromatic rings are 
participating in aromatic π stacking interactions.[197]   
4.11.2 Concentration studies on second generation glycolipids 4.109, 4.125 and 4.126 
The second generation derivative 4.109 showed even bigger variations in the chemical shifts of 
the signals corresponding to the different amide protons. Most notably, the anilide proton 
exhibited the biggest variation, as the more acidic NH protons exhibit the stronger H-bonds.[198]  
As before, concentration studies were carried out and 1H NMR spectra of the monovalent 
pentafluorophenyl derivative 4.109 in CDCl3 were recorded at different concentrations. The 
variation in the chemical shifts of the signals corresponding to the different protons in 
glycolipid 4.109 was examined (Figure 4.45).  
The bottom spectrum represents the least concentrated sample (blue) and the top spectrum 
represents the most concentrated sample (green). Full NMR analysis was carried out by Dr. 
John O’Brien in Trinity College Dublin, and enabled assignation of all signals. 
Figure 4.45 
1
H NMR concentration studies on 4.109 in CDCl3: a) 5 mg mL
-1
, b) 10 mg mL
-1
, c)  15 mg mL
-1
. 
Similar studies were carried out on monovalent glycolipid 4.125 and the non-symmetrical 
glycolipid 4.126 and the variation in chemical shifts is summarised in Table 4.3. As with  
glycolipid 4.109, the resonances for the anilide proton showed the highest chemical shift 
variation (Figure 4.46). This is not the case for the first generation derivatives where much 
smaller chemical shift differences are observed for the tetradecyl amide proton. While the 
pentafluorophenyl derivative 4.109 and divalent galactosyl 4.126 showed similar variation 
patterns in the chemical shifts for the amide protons, the signals corresponding to the 
monovalent, non-symmetrical glycolipid 4.126 registered the most significant differences in 
the dilute and concentrated spectra. This implies that compound 4.126 may participate more 
readily in intermolecular associations, mediated to some extend by H-bond formation. 
NH-1 NH-2 NH-3 
NH-3 
NH-3 
H3 H2
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Glycolipid 
N-H1 
Dilute 
ppm 
N-H1 
Conc. 
ppm 
∆ 
ppm 
N-H2 
Dilute 
ppm 
N-H2 
Conc. 
ppm 
∆ 
ppm 
N-H3 
Dilute 
ppm 
N-H3 
Conc. 
ppm 
∆ 
ppm 
N-H4 
Dilute 
ppm 
N-H4 
Conc. 
ppm 
∆ 
ppm 
 
 
6.57 
 
6.73 
 
 
0.16 
 
7.46 
 
7.67 
 
0.21 
 
8.10 
 
8.99 
 
0.89 
 
------ 
 
------ 
 
------- 
 
 
6.69 
 
6.97 
 
0.28 
 
7.53 
 
8.13 
 
0.60 
 
8.12 
 
8.97 
 
0.85 
 
7.09 
 
 
7.56 
 
 
0.49 
 
 
6.86 
 
7.01 
 
0.15 
 
8.09 
 
8.228 
 
0.19 
 
8.38 
 
8.75 
 
0.37 
 
7.83 
 
7.96 
 
0.13 
Table 4.3 Summary of 
1
H NMR  spectral concentration studies which shows the variations in the chemical shift of the different N-H signals in both dilute and concentrated samples.
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Figure 4.46 Differences in the chemical shift of the lipidic amides for the first generation derivative 
4.116 and the second generation derivatives 4.109 and 4.126. 
We can therefore conclude that the type of amide linkage between the lipidic chain and the 
aromatic scaffold does play a role in H-bonding ability and thus it contributes to the 
intermolecular interactions between the ligands. A much bigger chemical shift difference is 
observed for the second generation derivatives, whereby the lipidic chain is linked to the 
aromatic scaffold via an amide bond of the form ArNHCOR, in comparison to the first 
generation glycolipids which are connected to the lipidic chain via an amide bond of the form 
ArCONHR.  
Another conclusion which can be drawn from these data is that the subsitutents present 
around the aromatic core also influence the glycolipids ability to form intermolecular 
associations. With the flexible first generation molecule 4.48, minimal differences between the 
amides resonances were observed in the dilute and concentrated spectra. The triazole-
containing molecule 4.116 exhibited higher chemical shift differences, but the real substituent 
effect can be observed in Table 4.3. The difference in the chemical shift of the amides varied 
depending on whether the pentafluorophenyl ester, alkyne group, or galactosyl triazole were 
present.  
4.12 Conclusions 
A collection of bivalent, aromatic glycoconjugates 4.36-4.44 were successfully synthesised.  
Linkers of varying structure, length and flexibility were exploited to produce a range of 
glycolipids which offered different presentations of the carbohydrate moiety, thus potentially 
leading to different biological activities. Two different aromatic scaffolds were also employed, 
1) trimesic acid and it derivatives and 2) 5-aminoisophthalic acid, and this led to different 
amide bond forms being utilised to connect the lipidic chain (ArCONHR, or ArNHCOR). The use 
∆ ppm = 0.23 ∆ ppm = 0.89 
∆ ppm = 0.37 
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of 5-aminoisophatlic acid proved to be the more efficient synthetic approach, exhibiting higher 
yields and a decrease in side-product formation. 
Following a modular approach, two non-symmetrical glycoconjugates 4.116 and 4.117 were 
successfully synthesised and using this synthetic route a variety of bivalent heteroglycans 
could also be potentially prepared. 
Spectroscopic analysis was carried out on selected glycolipids and it was found that the first 
and second generation derivatives behaved quite differently in solution in chloroform. In both 
cases, the lipidic amide appeared to participate in intermolecular H-bonding, however the 
anilide proton of the second generation glycolipids exhibited the highest chemical shift 
difference in 1H NMR concentration studies. This may imply that the glycoconjugates are 
involved in intermolecular association as a result of both H-bonding and aromatic interactions.  
Studies towards the synthesis of glycoconjugates containing more complex carbohydrate 
epitopes such as galabiose, has been investigated. However, further optimisation will be 
necessary.  
Finally, for comparison with the bivalent ligands, a monovalent derivative was synthesised and 
the ability of selected aromatic glycoconjugates to inhibit bacterial adhesion was investigated. 
The results are discussed in chapter 5.    
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5.1 Cystic Fibrosis 
Cystic fibrosis (CF) is a genetic, life-threatening disease that causes severe lung damage by the 
recurrence of lower respiratory tract infections.[199] It is the most common autosomal recessive 
disease in people of European ancestory and it affects 1 in 2500-3000 live births.[200] It is 
caused by a mutation in a CFTR gene which encodes the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein.[201] Both enviromental and inherited factors determine 
the severity and course of the disease, and it can even differ between siblings that exhibit the 
same mutations.[202] Cystic fibrosis does not only affect the respiratory tract but it also leads to 
the impairment of other organs including the pancreas, sweat glands, vas deferens, bile duct 
and the large and small bowel.[201] 
5.1.1 CFTR protein 
The CFTR protein (found in the apical plasma membrane) is a member of the ATP-binding 
cassette (ABC) superfamily of proteins[203] and primarily regulates the movement of chloride 
ions across epithelial membranes. It also regulates the transport of other ions, including 
sodium.[204] This regulation of the movement of chloride and sodium ions is extremely 
important, as it aids in the clearance of mucus by controlling the volume of liquid present on 
the airway surfaces.[205] 
 
Mutations in the CFTR gene disrupt the function of the chloride and sodium channels. This 
leads to a decrease in chloride secretion into the airways and an increase in sodium absorption 
from the airways.[204] As a result,  the airway mucous becomes dehydrated, and therefore leads 
to the accumulation of mucous which is unusually thick and sticky. This mucous clogs the 
airways leading to breathing difficulties and susceptibility to bacterial infections.[206] 
 
Several different mutations of the CFTR gene can occur and each mutation leads to a different 
defect in the CFTR protein. These different defects can result in a milder or more severe form 
of the disease.[201] The most common mutation which accounts for about two-thirds of 
mutated alleles in northern Europe and America,  is the deletion of phenylalanine at position 
508 (∆F508).[201] ∆F508 results in a mutant CFTR protein that does not properly fold and 
therefore is degraded by the cell. In general, mutations in CFTR gene lead to the production of 
proteins which are misfolded. The cell protein quality control recognises this misfolded protein 
and either retains and degrades it, or the abnormal protein is trafficked to the apical plasma 
membrane where it functions abnormally (Figure 5.1).[203]  
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Figure 5.1 In a normal cell (left), the CFTR protein is synthesised in the rough endoplasmic reticulum, 
glycosylated in the Golgi apparatus and then transported to the apical plasma membrane where it 
functions as a ion channel regulator. The diagram on the right shows two possible outcomes that can 
occur with mutations in the CF gene. (1) The mutation can lead to protein mis-folding, e.g., the 
ΔF508 mutation. When this occurs the CFTR is degraded intracellularly and no protein is transported to 
the apical plasma membrane. (2) With other mutations, the abnormal protein is still processed and 
transported to the apical plasma membrane where it functions abnormally.
[203]
 
5.1.2 CF and bacterial infections 
Chronic pulmonary infections caused by bacterial pathogens are the leading cause of death 
among CF patients.[208] Commom bacterial pathogens found in CF airways include P. 
aeruginosa and B. cepacia complex.[209] B. cepacia complex (Bcc) is a group of opportunistic 
pathogens classified into at least 17 species. However, with regards to CF infections, B. 
cenocepacia and B. multivorans are the most significant.[208] Although Pseudomonas infections 
are much more common in CF patients, Bcc is much more worrying as it is particularly virulent 
in the CF airway and is often more difficult to eradicate.[204] Many of the Bcc species are highly 
transmissible and exhibit resistance to multiple antibiotics.[201] Once a CF patient becomes 
colonised with Bcc the infection is rarely eradicated, and can occasionally lead to the 
deterioration of the patient.[201, 204] For these reasons, Burkholderia is a pathogen which cannot 
be ignored. 
5.2 Burkholderia cencocepacia complex (Bcc) 
Bcc is a group of genetically distinct and ubiquitous Gram-negative bacteria. Although known 
to be beneficial to the environment they are also associated with causing severe lung 
infections in immunocompromised individuals.[210]  
B. cepacia was originally identified by Walter H. Burkholder over 50 years ago as a plant 
pathogen which caused onion rot. Since then, many environmental benefits have been 
discovered. Bcc can prevent certain plant diseases (including root-rot[211]), inhibit the growth of  
Chapter 5:                                               Evaluation of glycolipids as potential inhibitors of bacterial adhesion 
 
154 
 
 
mould on fruit,[212] act as a chemical fungicide and utilise many different carbon compounds as 
energy sources.[213] Some Bcc strains can even increase crop production by acting as nitrogen 
fixers[214] (Figure 5.2). Despite its obvious enviromental advantages, the pathogenesis of Bcc in 
susceptible individuals still remains a major concern, and the risks of using Bcc strains in 
agriculture remains uncertain.   
 
Figure 5.2 Enviromental advantages and worrying pathogenesis of the B. cepacia complex.
[215]
 
As stated earlier, the P. aeruginosa pathogen accounts for the majority of infections in CF 
patients, in fact only 3.5% of CF infections worldwide are due to Bcc.[216] Although the 
incidence of Bcc infections is much lower than the more common P. aeruginosa, patients 
colonised with Bcc suffer a more rapid decline in health and for this reason Bcc infections are 
particularly feared by CF patients and their carers.[208, 216] Intially, B. cenocepacia was the most 
common species isolated from CF patients. However, more recently, short term segregation 
reduced the patient-to-patient transmissibility of B. cenocepacia.  As B. multivorans can be 
acquired from the environment, it has surpassed B. cenocepacia and become the most 
common Bcc species isolated in CF patients in both America and the United Kingdom.[217]  
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5.2.1 Virulence of Bcc 
There are many reasons why Bcc is such a virulent group of pathogens. Firstly, they are 
intrinsically resistant to most antimicrobial treatments available, including aminoglycosides, 
quinolones, polymyxins and β-lactams.[218] Even more , increased resistance is observed upon 
formation of Bcc biofilms in vitro.[219] This resistance can be attributed to:    1) the presence of 
various efflux pumps which can remove antibiotics from the cell, 2) the formation of biofilms, 
which leads to decreased contact between the antibiotics and the cell surface and 3) 
decreased permeability of the cell membrane making it less susceptible to the antibiotic.[204] 
Secondly, Bcc strains are highly transmissible between CF patients.[216] In one instance, a strain 
of B. cenocepacia (ET12) was isolated from patients residing on different sides of the 
Atlantic.[215] Although it is believed that transmission results from direct contact, the exact 
method by which Bcc spreads between CF patients is not known. Finally, infection with Bcc 
strains can lead to the ‘cepacia syndrome’. The cepacia syndrome results in a rapid decline in 
the patient’s health and can even lead to death. It occurs when the bacteria enters the 
bloodstream and is characterised by fever, pneumonia, septicemia and bacteremia.[210, 220] 
Bcc strains can also exhibit a wide variety of virulence factors which enhance its pathogenicity. 
These include the lipopolysaccharide, secretion of proteins, iron acquisition, formation of 
biofilm, adhesion proteins and quorum sensing.[215-217] The lipopolysaccharide can lead to the 
induction of a strong immune response that results in damage of the host cell,[210] it also plays 
a role in antimicrobial peptide resistance.[221] Quorum sensing is the phenomenum by which 
bacterial cells can communicate with each other. Acyl-homoserine lactones (AHLs), which are 
cell-cell signalling molecules, are released by the bacterial cells and then can diffuse into 
neighbouring cells where they can modulate gene expression including many virulence 
associated genes.[215] 
5.3 Bacterial adhesion to cell surfaces 
Infectious diseases occur when microorganisms colonise host surfaces and grow to a sufficient 
number to produce clinical symptoms.[8] For colonisation to occur, pathogens must adhere to 
the cell surface so that they do not become washed away by the body’s regular cleansing 
mechanisms.[222] Therefore, the adhesion of pathogenic organisms to host tissues is often the 
prelude for the majority of infectious diseases.[222b] As stated previously, this adhesion is 
largely governed by protein-protein and/or protein–carbohydrate interactions and determines 
the species specificity of many pathogens and also their preference for certain tissue types.[9] 
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One of the phenomena leading to bacterial adhesion involves binding of lectin proteins, 
present on the surface of the infectious organism, to the carbohydrate portion of glycolipids 
and glycoproteins present on the surface of the host tissues.[12, 222b] Lectins are structurally 
diverse molecules, they are of non-immune origin and do not include enzymes.[8] Lectins have 
shallow binding sites but yet are highly specific in their recognition of multivalent complex 
carbohydrates. They contain a carbohydrate-binding domain (CRD) and binding occurs largely 
due to hydrogen-bonding between the backbone and side chain carbonyl groups of the protein 
and the hydroxyl groups of the carbohydrate molecules and non-polar interactions with 
lipophilic side chains.[6]  
 
For our research, we are primarily interested in the inhibition of the adhesion of bacterial 
pathogens. Bacterial lectins are called adhesins and like all lectins they mediate binding to the 
host cell surface through recognition and binding of specific carbohydrate structures.[8] They 
can be described as a bacterial virulence factor due to their ability to mediate adhesion and 
mutants deficient in the lectin proteins are often unable to initiate infection.[12, 222b] Bacterial 
lectins are generally surface-bound and are typically found in fimbriae or pilli.[12]  
Studies as far back as 1979 have shown that soluble carbohydrates recognised by the bacterial 
surface lectins block the adhesion of bacteria to animal cells in vitro.[222b, 223] Sharon et al. found 
that upon co-administration of methyl α-mannoside and type 1 fimbriated E. coli into the 
urinary bladder of mice, the rate of urinary tract infection decreased by two thirds.[223] This 
research showed the potential in using carbohydrates to block bacterial adhesion and led to 
the examination of new therapies for combating bacterial infections. 
5.3.1 Bcc invasion of epithelial cells 
Bcc adheres to host epithelial cells using both protein and glycolipid receptors which are 
present on the host cell membrane.[216] However the exact mechanisms employed by Bcc 
strains to invade the lung epithelial cells are not well understood. There is also some 
disagreement in the literature. In studies performed by Sylvester et al., it was found that Bcc 
strains bind preferentially to galactose-containing glycolipids, particularly globosides Gb2 and 
Gb3,[224] whereas Krivan et al. found preferential binding to galactose-containing asialo-GM1 
and asialo-GM2.[225] Neither study showed structural data for the receptors playing a role in 
invasion of the epithelial cell. 
Developing on these findings, McClean and co-workers were the first group to provide direct 
evidence that galactose-containing glycolipids played a role in the invasion of Bcc isolates into 
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epithelial cells.[23] They found that preincubation of the lung epithelial cells with either α-
galactosidase or β-galactosidase resulted in complete inhibition of invasion by the B. 
multivorans isolate LMG13010 and the B. cenocepacia isolate BC7. These results clearly 
demonstrate that both terminal α- and β-galactose-containing receptors are involved in the 
invasion process.[23] In another study, McClean and co-workers[226] tested the ability of simple 
sugars (galactose, glucose, mannose, lactose and xylitol) to block the receptors  on the 
bacterial cell, thus inhibiting subsequent binding to the host cell. It was found that competition 
with lactose was the most effective, however, high concentrations (mmol range) were 
required. In a follow on study, the same research group reported that glycoconjugates-
containing terminal galactose moieties displayed promising anti-adhesion activity and were 
able to reduce B. multivorans adherence to lung epithelial cells (discussed in Chapter 1, section 
1.2.4).[24] With this in mind, the design of galactose-containing glycolipids, which could 
potentially inhibit bacterial adherence to lung cells of CF patients, and thus reduce infection, is 
extremely beneficial and could lead to new therapeutic approaches. 
5.4 Chapter Objective 
This chapter deals with the biological evaluation of a variety of aromatic, aliphatic and aspartic 
acid-based glycolipids as potential inhibitors of bacterial adhesion. Based on the anti-adhesion 
approach we wanted to investigate the structure-activity relationship of the selected 
glycolipids. The work was undertaken in the laboratory of Dr. Siobhan McClean at the Institute 
of Techonology Tallaght, Dublin. As discussed previously, the use of carbohydrates to inhibit 
bacterial adhesion, and thus reduce infection, is extremely advantageous, and there are 
numerous examples reported in the literature. However, there are limited examples of 
compounds containing both a bivalent carbohydrate system and a hydrophobic lipidic chain. 
Furthermore, to the best of our knowledge there are no examples of these bivalent glycolipid 
compounds being utilised as potential inhibitors of bacterial adhesion. We hypothesise that 
the presence and length of the lipidic chain would influence the aggregation of the 
glycoconjugates in an aqueous environment, and thus influence the presentation of the 
carbohydrate-binding epitopes. 
As discussed earlier, we chose to base our glycolipid analogues around an aromatic, aliphatic 
or amino acid core (Figure 5.3). The idea was to introduce a scaffold that would allow the 
synthesis of a bivalent galactose system but also enable the introduction of a lipidic chain. The 
rigid aromatic compounds could serve as a good comparison to the more flexible aliphatic-
based glycolipids. 
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Figure 5.3 General structures of aromatic-based glycolipids (A), aliphatic-based glycolipids (B) and 
aspartic acid glycolipids (C). 
 
As the lectins of the B. multivorans (which recognises glycolipids present on the host cell 
surface) have not been identified, the rational design of synthetic ligands is extremely difficult. 
With this in mind, we decided to synthesise a range of glycolipids of diverse chemical structure 
and investigate how core scaffold, distance between epitopes, linker length and structure, and 
flexibility influenced the conformation of the ligand and therefore the presentation of the 
carbohydrate moieties and thus the biological activity. In other words, we wanted to 
investigate how the structure of the glycolipid affected its biological activity. We also wanted 
to examine if the presence of the lipidic chain influenced the biological outcome.  
 
As can be seen from Figure 5.3, all of the chosen glycolipids contained a terminal galactose 
moiety. This was due to the work by McClean et al. (discussed in section 5.3.1) which showed 
that terminal galactose-containing glycolipids present on the host cell mediated adhesion of 
Bcc isolates and facilitated invasion of the lung epithelial cells. We aimed to examine the ability 
of our synthetic, soluble glycolipids to bind preferentially to the galactose receptors present on 
the bacterial pathogen, therefore preventing them from binding to the galactosides on the 
surface of the host cell. In other words, we aimed to prevent colonisation using the anti-
adhesion approach. 
5.5 Anti-adhesion assay 
Biological evaluation was carried out using the clinically relevant LMG13010 isolate. This is a 
representative strain of B. multivorans and is the most frequently acquired Bcc species in the 
last decade. The human epithelial cells (CFBE41o-) used were donated by Dr. Dieter Gruenert 
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of California Pacific Medical Centre Research Institute, San Francisco, USA. The cells are 
transformed human bronchial epithelial cells expressing the ∆F508 mutation of the CF 
transmembrane conductance regulator (CFTR) gene). Therefore, they display the most 
common mutation observed in CF patients (75% worldwide).  
The bacteria were pre-treated with the glycolipids, applied to the cells and the percentage of 
bacterial adhesion to the epithelial cells evaluated. Epithelial cells incubated with bacteria 
alone were utilised as a control, and the% of inhibition of adhesion was calculated. 
5.6 Biological evaluation of glycolipids 2.26 and 2.29 based on aspartic acid scaffolds  
To examine the potential of aspartic acid-based glycolipids to inhibit bacterial adhesion to the 
lung epithelial cell, O-glycolipids, 2.26 and 2.29, were chosen as representative examples. The 
C-10 derivative 2.26 was chosen as a representative example as solubility issues were 
encountered with the C-16 and C-23 derivatives. In order to examine the multivalent effect, 
bivalent glycolipid 2.29 was also chosen. The results are presented below in Figure 5.5. 
 
Figure 5.4 Structure of aspartic acid O-glycolipids 2.26 and 2.29 selected for biological evaluation. 
 
Figure 5.5Adhesion of LMG13010 bacteria to lung epithelial cells upon treatment with either O-
glycolipid 2.26 or 2.29. Bars represent the mean% binding relative to inhibitor-free control (100%) from 
four separate experiments for each monosaccharide. Error bars represent the standard error of the 
mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 using a one-way ANOVA and Tukey’s post-test, 
compared to inhibitor-free control. 
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The results indicate that at all concentrations investigated, the O-glycolipid 2.26 appeared to 
aid bacterial adhesion to the epithelial cells. This phenomenon has been previously reported in 
the literature and presumably occurs by the glycolipid acting as a ‘bridge’ between the bacteria 
and the host cell.[24] The highest increase in bacterial adhesion (186%) was observed at 25 µm 
(p = 0.003). Glycolipid 2.26 is the only glycolipid tested which presents two lipidic chains. As 
the concentration increases above 25 µm, a decrease in this effect is observed. This could be 
due to the ability of this compound to self-assemble into aggregates that precipitate out of 
solution, as discussed in chapter 2.   
Slightly more promising results were observed for the bivalent O-glycolipid 2.29.  At a higher 
concentration of 100 µm bacterial adhesion to the epithelial cell significantly decreased to     
40% (p = 0.003). In contrast, at a lower concentration of 5 µm, the glycolipid 2.29 appeared to 
aid adhesion as bacterial adhesion increased to 169% (p = 0.03). Statistically significant effects 
were not observed at all other concentrations examined. The significant decrease in bacterial 
adherence at 100 µm supports the hypothesis that the bacteria binds to glycolipids present on 
the host cell surface. With this in mind, it is possible to postulate that synthetic, soluble 
glycolipids can be used to bind to the bacterial lectins, reducing their ability to adhere to the 
host cell and rendering them ineffective. 
As the bivalent glycolipid 2.29 gave better results, we can postulate that the presence of two 
carbohydrates favours anti-adhesion and also that the hydrophobic chains affects the 
biological outcome. The long hydrophobic chains may penetrate into the phospholipid bilayer 
of the cell membrane exposing the galactose moieties on the surface of the cell. The galactose 
moieties could then be recognised by the glycolipid receptors present on the bacterial 
pathogen, and therefore facilitate adhesion. 
In order to ensure that the observed biological activity was due to decreased adhesion of the 
bacteria to the epithelial cells, as opposed to the glycolipids killing the bacteria, mimimum 
inhibitory concentration studies were also carried out. The desired glycolipid was applied to 
the bacteria at a range of concentrations. The control consisted of the bacteria with no 
glycolipid applied. The bacterium was incubated for 24 h at 37 oC and the absorbance was 
read. The% survival was calculated based on the control. The results are shown in Figure 5.6.  
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Figure 5.6 Survival of bacteria after overnight incubation (37 
o
C) with bivalent glycolipid 2.29. Bars 
represent the mean% survival relative to inhibitor-free control (100%) from four separate experiments 
for disaccharide 2.29. Error bars represent the standard error of the mean (SEM).  
Statistically significant effects were not observed at all concentrations examined. This indicates 
the bacteria survival after overnight incubation with the glycolipid 2.29 is similar to the 
inhibitor-free control. These data also indicates that the biological activity observed was a real 
anti-adhesion effect. 
5.7 Biological evaluation of glycolipids 3.32 and 3.34 based on aliphatic scaffolds  
To examine the potential of aliphatic bivalent glycolipids to inhibit bacterial adhesion to the 
lung epithelial cell, N-glycolipids 3.32 and 3.34 (Figure 5.7) were chosen as representative 
examples.  
Figure 5.7 Structure of aliphatic N-glycolipids 3.32 and 3.44 selected for biological evaluation. 
We chose N-glycolipid 3.34 to investigate if introducing a triazole moiety into the molecule 
would influence the biological activity, as has been reported in the literature.[31] Due to the 
isosteric relationship between 1,4-di-substituted 1,2,3-triazoles and the amide bond, many 
biological applications for triazole-containing molecules have been explored.[227] The results 
are presented in Figure 5.8. 
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Figure 5.8 Adhesion of LMG13010 bacteria to lung epithelial cell upon treatment with either N-glycolipid 
3.42 or 3.44. Bars represent the mean% binding relative to inhibitor free control (100%) from four 
separate experiments for each disaccharide. Error bars represent the standard error of the mean (SEM). 
*P < 0.05, **P < 0.01, ***P < 0.001 using a one-way ANOVA and Tukey’s post-test, compared to 
inhibitor free control. 
Preliminary results indicate that the 1,2,3-triazole moiety did in fact influence the biological 
activity, as the triazole-containing N-glycolipid 3.34 gave more promising results than the N-
glycolipid 3.32. Although only minimal, and not statistically significant (p = 0.5), a reduction in 
bacterial adhesion to the epithelial cells was observed at all concentrations tested in 
comparison to glycolipid 3.32. The more rigid N-glycolipid 3.32 appeared to aid the adhesion 
process at all concentrations, except at 5 µm. The highest increase in bacterial adhesion to the 
host cell is observed a 250 µm (127%, p = 0.002). As with the aspartic acid glycolipids 2.26 and 
2.29 (discussed in section 5.5) the 3.32 molecule could be acting as a “bridge” between the 
bacteria and the host cell and facilitating adhesion. Also It is believed that when a high 
concentration of glycolipids is present the bacteria can utilise them as a carbon source to 
provide energy. 
Unlike the aspartic acid glycolipids 2.26 and 2.29 previously discussed, the results do not 
follow the expected concentration-dependent pattern. In fact for the triazole-containing 
glycolipid 3.34, glycolipid concentration had a limited effect on the results, and similar 
adhesion levels were observed at all concentrations examined.  
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As before, inhibitory concentration studies were also carried out, and the results are shown in 
Figure 5.9. High survival rates of bacteria were achieved after overnight incubation with the 
corresponding glycolipid. One way ANOVA shows no statistically significant difference between 
the inhibitor free control and the bacteria incubated with varying concentrations of the 
glycolipids 3.32 and 3.34. These results indicate that the glycolipids 3.32 and 3.34 slightly 
interfere with bacterial adhesion to the epithelial cell, but exhibit no toxicity towards the 
bacteria.  
 
Figure 5.9 Survival of bacteria after overnight incubation with glycolipids 3.33 and 3.34. Bars represent 
the mean% survival relative to inhibitor free control (100%) from four separate experiments for each 
disaccharide. Error bars represent the standard error of the mean (SEM).  
5.8 Biological evaluation of glycolipids based on aromatic scaffolds 4.27-4.34. 
To examine the potential of aromatic-based glycolipids to inhibit bacterial adhesion to the lung 
epithelial cell, a wide variety of structurally diverse molecules were analysed. In order to 
compare how linker length and structure, and also flexibility influenced the presentation of the 
carbohydrate moieties and thus the biological activity, glycolipids-containing structurally 
diverse linkers were evaluated.  
5.8.1 Rigid N-glycolipids 4.36 and 4.37 versus flexible O-glycolipids 4.38 and 4.39 
The rigid N-glycolipids 4.36 and 4.37 served as a good comparison to the more flexible O-linked 
glycolipids 4.38 and 4.39. We also wanted to examine how hydrophobic chain length alters the 
biological activity so both short (4.27 and 4.39) and long (4.36 and 4.38) chain derivatives were 
synthesised (Figure 5.10). The effect of the aromatic scaffold (trimesic derivatives 4.36 and 
4.39, versus isophatlic derivatives 4.37 and 4.38) were also evaluated. The assay was 
performed as before and the results are presented in Figure 5.11.  
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Figure 5.10 Structures of aromatic, rigid N-glycolipids 4.36 and 4.37, and flexible O-glycolipids 4.38 and 
4.39 selected for biological evaluation. 
 
Figure 5.11 Adhesion of LMG13010 bacteria to lung epithelial cell upon treatment with either N-
glycolipid 4.36 or 4.37, or O-glycolipid 4.38 or 4.39. Bars represent the mean% binding relative to 
inhibitor-free control (100%) from four separate experiments for each bivalent glycolipid. Error bars 
represent the standard error of the mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 using a one-way 
ANOVA and Tukey’s post-test, compared to inhibitor free control. 
The results show that the C-16 rigid glycolipid 4.36 displayed optimum biological activity. At all 
concentrations tested, a reduction in bacterial adhesion was observed. One way ANOVA 
analysis indicated that these biological data differed significantly (p = 0.009). Further, Tukey 
post hoc analysis indicated that the activity observed at 25, 100 and 250 µm is significantly 
different to the inhibitor-free control.  The highest inhibition was achieved at 250 µm were 
bacterial adhesion to the epithelial lung cell significantly decreased to 40% (p = 0.006). As 
expected, the results were inversely proportional and as the glycolipid concentrated decreased 
the% of bacterial adhesion increased. In contrast, the C-3 rigid derivative 4.37 seemed to 
increase bacterial adhesion at all concentrations tested (p = 0.003). Like before, we believe the 
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glycolipid aids adhesion by acting as a “bridge” between the bacteria and the host cell. 
Interestingly, these results indicate that the hydrophobic chain may play a role in the inhibition 
process, maybe by altering the molecule conformation and/or leading to the formation of 
intermolecular assembles and thus influencing the presentation of the carbohydrate moieties. 
Unexpectedly, the results for the more flexible O-glycolipids 4.38 and 4.39 follow an opposite 
pattern. This time, the C-3 flexible derivative 4.39 provides the more promising results. At all 
concentrations (apart from 250 µm) a decrease in bacterial adhesion is observed. The highest 
reduction is observed at 100 µm were the bacterial adhesion decreases to 50% (p = 0.008). 
Again, the results follow an inversely proportional pattern and the bacterial adhesion increases 
with decreased glycolipid concentration. The fact that the bacterial adhesion increases at 250 
µm and decreases at lower concentrations is not unusual. As mentioned previously it is 
believed that when a high concentration of glycolipids is present the bacteria can utilise them 
as a carbon source to provide energy. The C-14 flexible derivative 4.38 shows a dramatic 
increase in bacterial adhesion at 25 and 100 µm (p = 0.01, p = 0.02 respectively), whereas at 
250 and 5 µm a statistically significantly effect is not observed.   
With these contradicting results a direct conclusion is difficult. While it is clear that the rigid   
C-16 derivative 4.36 gave the most promising results, the C-3 flexible derivative 4.39 also led to 
a slight decrease in bacterial adhesion. We can therefore assume that the biggest influence on 
the biological activity lies in the conformation of the molecule, intermolecular interactions and 
thus the presentation of the terminal galactose moieties. In the case of the rigid derivatives 
4.36 and 4.37, the C-16 derivative resulted in a more optimum presentation of the galactose 
moieties and thus an optimum biological acivity. In contrast for the more flexible derivatives 
4.38 and 4.39 the C-3 derivative led to a more optimum presentation of the galactose moieties 
and therefore an increased biological activity. It is also possible that the shorter distance 
between the galactose moieties is more optimum for the rigid derivative 4.36 and rigidity does 
not play as big a role as believed.  
Inhibitory concentration studies were also carried out, and the results are shown in Figure 
5.12. The results indicate that the inhibition of bacterial adhesion observed was a real effect as 
statistically significantly differences in bacterial survival were not observed at the relevant 
concentrations.  
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Figure 5.12 Survival of bacteria after overnight incubation with glycolipids 4.36, 4.37 and 4.39. Bars 
represent the mean% survival relative to inhibitor free control (100%) from three separate experiments 
for each bivalent glycolipid. Error bars represent the standard error of the mean (SEM).  
5.8.2 1,2,3-Triazole-containing O-glycolipids 4.40 and 4.41 and N-glycolipids 4.42  
As before, we wanted to examine how introducing a triazole moiety into the molecule would 
influence the biological activity. For this analysis, the more flexible O-glycolipids 4.40-4.41 and 
rigid N-glycolipid 4.42 (Figure 5.13) were chosen as representative examples. The presence of a 
triazole moiety can aid binding to the bacterial receptor, as aromatic stacking can occur with 
aromatic moieties present on the lectin. It is also important to highlight that introducing the 
triazole moiety alters the distance between the aromatic core and the carbohydrate epitope.  
This results in an increased distance between the carbohydrate epitopes and thus can 
influence how they are presented to the bacterial receptor and therefore the biological result.  
We also wanted to investigate how hydrophobic chain length alters the biological activity, so 
both short (4.41) and long (4.40) chain derivatives were synthesised. 
Figure 5.13 Structure of aromatic flexible O-glycolipids 4.40 and 4.41, and rigid N-glycolipids 4.42 
selected for biological evaluation. 
 
The assay was performed as before and the results are presented in Figure 5.14. 
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Figure 5.14 Adhesion of LMG13010 bacteria to lung epithelial cell upon treatment with either O-
glycolipid 4.40 or 4.41, or N-glycolipid 4.42. Bars represent the mean% binding relative to inhibitor-free 
control (100%) from four separate experiments for each bivalent glycolipid. Error bars represent the 
standard error of the mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 using a one-way ANOVA and 
Tukey’s post-test, compared to inhibitor free control. 
The results indicate that the C-14, flexible, triazole-containing derivative 4.40 exhibited the 
best biological activity, as bacterial adhesion to the epithelial cells decreased at all 
concentrations tested. However, at some concentrations (5 and 100 µm) the reduction was 
not statistically significant. The highest reduction was observed at 250 µm (bacterial adhesion 
decreased to 58% (p = 0.001)).  
In comparison, the C-3, flexible, triazole-containing derivative 4.41 exhibited the least 
biological activity as treatment with the compound led to a statistically significant increase in 
bacterial adhesion at all concentrations tested. In fact, when the bacteria was treated with 250 
µm of glycolipid 4.41, bacterial adhesion to the epithelial cell increased to 170% (p = 0.004). 
For the more rigid C-16 N-glycolipid 4.42 the results were also poor. As with derivative 4.41, 
the presence of the compound led to an increase in bacterial adhesion at the majority of 
concentrations tested. However, in this case, the increase in bacterial adhesion to the host cell 
is fairly minimal and not statistically significant.  
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Again, these contradictory results led to difficulties in reaching an obvious conclusion. In the 
case of the more flexible O-glycolipid 4.40, the presence of the triazole moiety does lead to an 
improved biological activity, as a decrease in bacterial adhesion was observed at all 
concentrations investigated. At both 250 and 25 µm concentrations the decrease is fairly 
significant (58% and 62% respectively). These results also highlight the importance of the 
hydrophobic chain, as the C-3 glycolipid 4.41 performed much worse than its C-14 counterpart 
4.40. In fact, 4.41 promotes a significant increase in bacterial adhesion at all concentrations 
tested. For the more rigid N-glycolipid 4.42, introducing the triazole moiety into the molecule 
does not lead to an improved biological result. In fact, it actually had a poorer biological 
activity. Treatment of the bacteria with glycolipid 4.42 led to an increase in bacterial adhesion 
at most of the concentrations tested, however, the increase is fairly minimal.  
All of this information points to the conclusion that the glycolipid conformation and how they 
interact with each other in solution are the most important factors, as these factors influence 
how the galactose moieties are presented to the cell and ultimately the biological activity. 
As before, inhibitory concentration studies were also carried out, and the results are shown in 
Figure 5.15. The graph clearly shows that a real adhesion inhibition effect was in fact observed 
as high survival rates were obtained after overnight incubation with the desired glycolipid.  
 
 
Figure 5.15 Survival of bacteria after overnight incubation with glycolipids 4.41, and 4.42. Bars represent 
the mean% survival relative to inhibitor-free control (100%) from three separate experiments for each 
bivalent glycolipid. Error bars represent the standard error of the mean (SEM).  
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5.8.3 Biological evaluation of O-glycolipid 4.43 and N-glycolipid 4.44 
In an attempt to distinguish between linker length and flexibility/rigidity, the biological 
evaluation of glycolipid 4.43 (Figure 5.16) was carried out. We also wanted to determine if 
multivalency was important for the biological activity of glycolipid 4.36. With this is mind, the 
rigid, monovalent N-glycolipid 4.44 was also evaluated as a potential inhibitor of bacterial 
adhesion. The assay was performed as before and the results are presented in Figure 5.17.  
 
Figure 5.16 Structure of aromatic O-glycolipid 4.43 and, and monovalent N-glycolipid 4.44 selected for 
biological evaluation. 
  
Figure 5.17 Adhesion of LMG13010 bacteria to lung epithelial cell upon treatment with either O-
glycolipid 4.43, or N-glycolipid 4.44. Bars represent the mean% binding relative to inhibitor-free control 
(100%) from four separate experiments for each bivalent glycolipid. Error bars represent the standard 
error of the mean (SEM). *P < 0.05, **P < 0.01, ***P < 0.001 using a one-way ANOVA and Tukey’s post-
test, compared to inhibitor free control. 
As can be seen from the graph, the biological activity of the elongated O-glycolipid derivative 
4.43 is concentration dependent. At the higher concentrations of 250 and 100 µm, a decrease 
in bacterial adhesion to the epithelial lung cells is observed (74% and 84%, respectively, 
compared to 100% for the control).  However, at the lower concentrations of 25 and 5 µm an 
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increase in bacterial adhesion is clearly seen (127% and 177% respectively). From these data it 
is evident that concentration plays an important role in the biological activity of glycolipid 4.43. 
For the monovalent N-glycolipid 4.44, the results are a bit more promising. As with its bivalent 
counterpart 4.36, the presence of glycolipid 4.44 leads to a reduction in bacterial adhesion at 
all concentrations investigated. Interestingly, unlike the bivalent glycolipid 4.36, the results are 
not inversely proportional to the glycolipid concentration, the largest reduction in bacterial 
adhesion is actually observed at 25 µm (37%, p= 0.000). 
As with previous glycolipids, inhibitory concentration studies were carried out, and the results 
are shown in Figure 5.18. From these data, we can conclude that monovalent glycolipid 4.44 
was in fact inhibiting bacterial adhesion as nearly 100% bacterial survival is observed at all 
concentrations after overnight incubation. 
 
 
Figure 5.18 Survival of bacteria after overnight incubation with glycolipids 4.43 and 4.44. Bars represent 
the mean% survival relative to inhibitor-free control (100%) from three separate experiments for each 
bivalent glycolipid. Error bars represent the standard error of the mean (SEM). 
5.9. Conclusions based on structural-activity relationship 
5.9.1 Multivalent versus monovalent: 
For glycolipids 2.26 and 2.29, which were based around aspartic acid scaffolds, the bivalent 
derivative 2.29 displayed increased biological activity in comparison to the monovalent 
glycolipid 2.26. However, for the glycolipids based around an aromatic scaffold, the results are 
not so clear (Figure 5.19). 
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Figure 5.19 Comparison of how bivalent derivative 4.36 and monovalent derivative 4.44 influence 
bacterial adhesion to epithelial cells. 
For both bivalent glycolipid 4.36 and monovalent glycolipid 4.44, the bacterial adhesion 
decreases at all concentrations examined. It is clear from Figure 5.19 that the biological activity 
of bivalent derivative 4.36 is concentration dependent, and the% adhesion is inversely 
proportional to the glycolipid concentration. This is not the case for the monovalent derivative 
4.44, which shows the best biological activity at 25 µm. With both glycolipid 4.36 and 4.44, 
having optimum activities at different concentrations the effect of multivalency is difficult to 
determine. Nevertheless, statistical analysis shows glycolipid 4.44 to be the better inhibitor of 
bacterial adhesion, as a more statistically significant difference to the control is observed at all 
concentrations examined. 
5.9.2 Flexibility versus rigidity: 
In Figure 5.20, the flexible compounds 4.38 and 4.40 are denoted in red, and the rigid 4.36 and 
4.42 compounds are shown in blue. The more transparent colours refer to the triazole-
containing compounds, 4.40 and 4.42.   
The non-triazole-containing rigid N-glycolipid 4.36 exhibited the best biological activity of all 
compounds tested. However, when a triazole moiety was introduced into the molecule 4.42, a 
reduction in biological activity was observed. In comparison the non-triazole-containing 
flexible glycolipid 4.38 generally led to increased levels of bacterial adhesion, or at least only 
minimal levels of decreased bacterial adhesion. With this glycolipid, 4.38, introducing a triazole 
moiety (4.40) did lead to an increase in biological activity. In fact, glycolipid 4.40 displayed a 
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high level of biological activity and inhibition of bacterial adhesion was observed at all 
concentrations. 
 
Figure 5.20 Comparison of how rigidity (blue) and flexibility (red) influences the biological activity of the 
glycolipid. 
In summary, for the rigid N-glycolipid 4.36, the introduction of the triazole moiety results in a 
decrease in biological activity. In contrast, for the more flexible O-glycolipid 4.38, introducing 
the triazole moiety results in an improved biological activity. All this information leads to the 
conclusion that rigidity, and thus the “locking” of compound conformation, may be beneficial. 
This may lead to a more optimum presentation of the galactose moieties and thus increased 
biological activity. Introducing the triazole moiety will also alter the length of the linker 
between the scaffold and the carbohydrate epitope. This increase in length will alter the 
distance between the two galactose moieties and again could influence the presentation of 
the galactose moieties and thus the biological activity. 
5.9.3 Importance of hydrophobic chain 
The effect of hydrophobic chains is somewhat conflicting. Our studies indicated that, generally, 
for the more rigid derivatives, the longer chain analogues 4.36 gave the more promising 
results. Whereas, for the more flexible derivatives, the shorter chain analogues 4.39 appeared 
to exhibit a higher biological activity. However, overall it is clear that the presence of 
hydrophobic chains does influence the biological activity (Figure 5.21 and 5.22). 
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Figure 5.21 Comparison of how C-14 4.36 (blue) and C-3 4.37 (red) hydrocarbon chains influence the 
biological activity of the flexible O-glycolipids. 
 
 
 
Figure 5.22 Comparison of how C-14 4.38 (red) and C-3 4.39 (blue) hydrocarbon chains influence the 
biological activity of the rigid N-glycolipids. 
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5.10 Conclusions 
We have examined the structure-activity relationship of a variety of glycolipids based around 
either an aspartic acid, aliphatic or aromatic core. The inhibition ability of the glycoconjugates 
appears to be very specific for each compound. For the majority of the compounds, the ability 
to influence adhesion is not concentration dependent. For example some compounds 
promoted inhibition at lower concentrations, but at higher concentrations bacterial adhesion 
is promoted.  
Preliminary results have revealed ligands which can reduce bacterial adhesion to the host 
epithelial cell in the µm range. It is believed they achieve this by binding to the bacterial 
receptors thus inhibiting subsequent binding to the host cells. The best inhibitors were 
identified as the rigid, bivalent N-glycolipid 4.36 and the rigid, monovalent N-glycolipid 4.44. 
Overall, the results are extremely difficult to rationalise and conformational analysis on the 
glycolipids, as well as more structural information on the lectins of interest, is required in order 
to establish trends. This highlights the complex nature of the adhesion process. Furthermore, 
the investigation of micelle formation is also crucial in order to rationalise the results. 
In order to improve the anti-adhesion effect, more definite structural information on the 
receptors involved in the adhesion process is required. This would allow for a more rational 
design of synthetic ligands. 
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6.1 General Procedure and Instrumentation 
All chemicals purchased were reagent grade and used without further purification, unless 
stated otherwise. DCM was distilled over CaH2, MeCN over P2O5, THF over Na wire and 
benzophenone. Anhydrous DMF and Pyr were purchased from Sigma Aldrich. Molecular sieves 
(MS) used for glycosylation and coupling were 8-12 Mesh and were flamed dried prior to use. 
Reactions were monitored using thin layer chromatography (TLC) on Merck Silica Gel F254 
plates, using mixtures of Pet Ether/EtOAc, unless otherwise stated. Detection was effected 
either by visualisation in UV light and/or charring in a mixture of 5% sulphuric acid-EtOH or 
phosphomomolybdic acid-EtOH (12 g in 250 mL). Evaporation under reduced pressure was 
always effected with the bath temperature kept below 40 oC. 
NMR spectra were obtained on a Bruker Avance 300 MHz spectrometer operated at 300 MHz 
for 1H NMR analysis and 75 MHz for 13C analysis at 298 K, or a Bruker Avance AV-600 MHz 
spectrometer (Trinity College Dublin) operated at 600 MHz for 1H and 150 MHz for 13C at      
298 K. Proton and carbon signals were assigned with the aid of 2D NMR experiments (COSY, 
HSQC, TOCSY, 14N HSQC, ROESY, NOESY or HCCOSW) and DEPT experiments for novel 
compounds. HCCOSW is a HSQC type of experiment. Chemical shifts for 1H NMR acquired in 
CDCl3 are reported in ppm relative to residual solvent proton (δ 7.26 ppm). Flash 
chromatography was performed according to the method of Still et al. with Merck Silica Gel 
60, using adjusted mixtures of Pet Ether/EtOAc, unless otherwise stated.[228] Optical rotations 
were obtained using an AA-100 polarimeter. [α]25D values are given in 10
1cm2g1. The melting 
points were obtained using a Stuart Scienific SMP1 melting pont apparatus and are 
uncorrected. High resolution mass spectra (HR-MS) were performed on an Agilent-L 1200  
Series coupled to a 6210 Agilent Time-of-Flight (TOF) mass spectrometer equipped with both a 
positive and negative electronspray source. Infrared spectra were obtained in the region 4000-
400 cm-1 on a Nicolet Impact 400D spectrophotometer or using a Perkin Elmer 2000 FTIR 
spectrometer. SEM was performed using a Hitachi S-3200-N with a tungsten filament and the 
sample was coated in gold. 
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6.2 Experimental procedures 
6.2.1 Experimental procedures for Chapter 2 
 
N4-[2-O-(β-D-galactopyranosyl)-ethyl]-N2-decanoyl-L-asparagine tetradecylamide 2.26 
NEt3 (0.1 mL) was added to a stirring solution of N
4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-ethyl]-N2-decanoyl-L-asparagine tetradecylamide 2.55 (120 mg, 0.14 mmol) 
dissolved in DCM/MeOH/H2O (3 mL/6 mL/3 mL) at 40 °C. The mixture was stirred for 18 h. The 
reaction mixture was concentrated under reduced pressure to afford the crude solid which 
was triturated using DCM and EtO2 to give 2.26 as a white solid (80 mg, 83%); [α]
25 
D = -6.0 (c, 
0.33 in Pyr); 1H-NMR (300 MHz, d5-Pyr): δ 8.95 (d, J = 8.1 Hz, 1 H, NHCOC9H19), 8.87 (t, J = 5.4 
Hz, 1 H, CH2CH2NHCO), 8.55 (t, J = 5.7 Hz, 1 H, CONHC14CH29), 7.05, 6.79, 6.63, 6.39 (each bs, 1 
H, OH), 5.55–5.53 (m, 1 H, H-α), 4.79 (d, J = 7.5 Hz, 1 H, H-1), 4.51–4.33 (m, 4 H, overlap of H-2, 
H-4, H-6, H-6'), 4.18–4.07 (m, 3 H, overlap of H-3, H-5, 1 H of OCH2CH2NH), 3.99–3.95 (m, 1 H, 1 
H of OCH2CH2NH), 3.77–3.65 (m, 2 H, OCH2CH2NH), 3.22–3.16 (m, 2 H, NHCH2C13H27), 3.18 (td, J 
= 6.6 Hz, J = 1.2 Hz, 2 H, overlap of H-β, H-β'), 2.36 (t, J = 7.5 Hz, 2 H, COCH2C8H17), 1.79–1.69 
(m, 2 H, COCH2CH2C7H15), 1.60–1.50 (m, 2 H, NHCH2CH2C12H25), 1.28-1.10 (m, 34 H, overlap of 
COC2H4(CH2)6CH3, NHC2H4(CH2)11CH3), 0.85 (m, 6 H, overlap of COC8H16CH3, NHC13H26CH3); 
13C-
NMR (75 MHz, d5-Pyr): δc 175.4, 173.9, 173.0 (each CO), 107.7 (C-1), 78.9, 77.2, 74.5, 72.2 (C-2, 
C-4, C-3, C-5), 71.7 (OCH2CH2NH), 64.5 (C-6), 53.3 (C-α), 42.5 (each OCH2CH2NH), 41.8 
(NHCH2H13H27), 40.7 (C-β), 38.5, 38.4, 34.1, 34.0,32.0, 31.9, 31.9, 31.7, 31.7, 31.6, 31.6, 31.5, 
29.2, 28.1 (each CH2), 18.6 (overlap of COC8H16CH3, NHC13H26CH3); HRMS m/z (ESI+): 688.5099 
(C36H69N3O9: [M+H]
+ requires  688.5107).   
 
N4-[2-O-(β-D-galactopyranosyl)-ethyl]-N2-hexadecanosyl-L-asparagine tetradecylamide 2.27 
Trimethylamine (0.1 mL) was added to a stirring solution of N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-ethyl]-N2-hexadecanosyl-L-asparagine tetradecylamide 2.27 (24 mg, 0.020 
mmol) dissolved in DCM,/MeOH/H2O (2 mL/4 mL/2 mL) at 40 
oC.  The mixture was stirred for 
18 h. The reaction mixture was concentrated under reduced pressure to afford the crude solid 
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which was triturated using DCM and EtO2 to give 2.27 as a white solid (10 mg, 52%); [α]
25 
D = -
20 (c, 0.1 in Pyr); 1H-NMR (300 MHz, d5-Pyr):  8.95 (d, J = 8.1 Hz, 1 H, NHCOC15H31), 8.81 (t, J = 
5.4 Hz, 1 H, CH2CH2NHCO), 8.52 (t, J = 5.7 Hz, 1 H, CONHC14H29), 5.57-5.50 (m, 1 H, H-α), 4.78 
(d, J = 7.5 Hz, 1 H, H-1), 4.51-4.35 (m, 4 H, overlap of H-2, H-4, H-6 and H-6'), 4.17-4.00 (m, 3 H, 
overlap of  H-3, H-5 and 1 H of CH2CH2O), 3.98-3.93 (m,1 H, 1 H of CH2CH2O), 3.80-3.64 (m, 2 H, 
CH2CH2NH), 3.48-3.35 (m, 2 H, NHCH2C13H27), 3.14 (td, J = 6.6 Hz, J = 1.2 Hz, 2 H, H-β, H-β’),  
2.36 (t, J = 7.5  2 H, NHCOCH2C14H29), 1.80-1.72 (m, 2 H, NHCOCH2CH2C13H27), 1.59-1.50 (m, 
NHCH2CH2C12H25), 1.22-1.12 (m, 46 H, overlap of NHCOC2H4(CH2)12CH3, and NHC2H4(CH2)11CH3), 
0.86 (m, 6 H, overlap of NHCOC14H28CH3 and NHC13H26CH3); 
13C-NMR (75 MHz, d5-Pyr): c 175.4, 
173.9 , 173.0 ( each CO), 107.7 (C-1), 78.9, 77.2, 74.5, 72.2 (C-2, C-4, C-3, C-5), 71.7 
(OCH2CH2NH), 64.5 (C-6), 53.3 (C-α), 42.50 (OCH2CH2NH), 41.81 (NHCH2C13H27), 40.7 (C-β), 38.5 
(NHCOCH2C14H29), 34.1, 32.04, 31.9, 31.9, 31.8, 31.7, 31.0, 31.6, 29.2 (each s, 
NHCOCH2(CH2)13CH3 and NHCH2(CH2)12CH3 ), 28.1 (NHCOCH2CH2C13CH27), 24.9 (each s, 
NHCOCH2(CH2)13CH3 and NHCH2(CH2)12CH3 ), 16.2 (NHCOC14H28CH3, NHC13H26CH3); HRMS m/z 
(ESI+): 772.606 (C42H82N3O9: [M+H]
+ requires  772.6046).   
 
N4-[2-O-(β-D-galactopyranosyl)-ethyl]-N2-tetracosanoyl-L-asparagine tetradecylamide 2.28 
NEt3 (0.1 mL) was added to a stirring solution of N
4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-ethyl]-N2-tetracosanoyl-L-asparagine tetradecylamide 2.62 (16 mg, 0.015 
mmol) dissolved in DCM/MeOH/H2O/THF (1 mL/2 mL/1 mL/2 mL) at 40 °C. The reaction 
mixture was stirred and its progress was followed by 1H-NMR spectra of aliquots. The reaction 
was deemed complete after 36 h. The reaction mixture was concentrated under reduced 
pressure to afford the crude solid which was triturated using DCM and EtO2 to give 2.28 as a 
white solid (5 mg, 38%); 1H-NMR (300 MHz, d5-Pyr): δ 9.02–8.96 (m, 1 H, NHCOC23H47), 8.89–
8.79 (m, 1 H, CH2CH2NHCO), 8.54–8.52 (m, 1 H, CONHC14CH29), 5.54 (dd, J = 6.3, 12.9 Hz, 1 H, H-
α), 4.80 (d, J = 7.8 Hz, 1 H, H-1), 4.52–4.36 (m, 4 H, overlap of H-2, H-4, H-6, H-6'), 4.18–4.10 
(m, 3 H, overlap of H-3, H-5, 1 H of OCH2CH2NH), 3.99–3.95 (m, 1 H, 1 H of OCH2CH2NH), 3.77–
3.65 (m, 2 H, OCH2CH2NH), 3.48–3.38 (m, 2 H, NHCH2C13H27), 3.18 (m, 2 H, H-β, H-β'), 2.40–2.35 
(m, 2 H, COCH2C22H45), 1.79–1.69 (m, 2 H, COCH2CH2C21H43), 1.60–1.50 (m, 2 H, 
NHCH2CH2C12H25), 1.20 (bs, 62 H, overlap of COC2H4(CH2)20CH3, NHC2H4(CH2)11CH3), 0.85 (m, 6 
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H, overlap of COC22H44CH3, NHC13H26CH3); HRMS m/z (ESI+): 884.7278 (C50H97N3O9: [M+H]
+ 
requires  884.7298).   
 
N4-[2-O-(2,3,6-tri-O-acetyl-β-D-galactopyranosyl-4-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-
ethyl]-N2-decanoyl-L-asparagine tetradecylamide 2.32 
HOBt (17 mg, 0.48 mmol) was added to a stirring solution of carboxylic acid 2.35 (66 mg, 0.11 
mmol), TBTU (37 mg, 0.11 mmol) and NEt3 (0.035 mL 0.26 mmol) dissolved in DMF (6 mL), 
under N2 at 50
 oC. The mixture was stirred for 10 min and 1-O-(2-aminoethyl)-2,2’,3,3′,4′,6,6′-
hepta-O-acetyl-β-lactoside 2.76 (87 mg, 0.13 mmol) dissolved in DMF (3 mL) was added 
dropwise. The mixture was stirredovernight at rt. The reaction mixture was concentrated in 
vacuo. Flash chromotagraphy (EtOAc) afforded 2.22 as a white solid (42 mg, 29%); Rf = 0.4 
(EtOAc); [α]25 D = +3.6 (c, 1.1 in DCM); IR vmax (NaCl plate, DCM): 3287.3, 2918.6, 2850.5, 1750.9, 
1642.4, 1558.8, 14431.9, 1369.9, 1227.46, 1057.6, 955.0, 903.1, 802.1, 729.8, 719.0, 682.51 
cm-1;  1H-NMR (300 MHz, CDCl3): δ 7.39 (d, J = 6.9 Hz, 1 H, NHCOC15H31), 7.06 (t, J = 5.4 Hz, 1 H, 
CONHC14CH29), 6.34 (t, J = 5.4 Hz, 1 H, CH2CH2NHCO), 5.34 (d, J = 2.7 Hz, 1 H, H-4 Gal), 5.24-5.18 
(m, 1 H, H-3 Gluc), 5.11 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2 Gal), 4.97 (dd, J = 3.3 Hz, J = 10.5 
Hz, 1 H, H-3 Gal), 4.89-4.86 (m, 1 H, H-2, Gluc), 4.68–4.64 (m, 1 H, H-α), 4.57-4.48 (m, 3 H, 
overlap of H-1 Gal, H-1 Gluc and 1 H of H-6 Gluc), 4.15–4.04 (m, 3 H, overlap of H-6 Gal, and 1 
H of H-6 Gluc), 3.89–3.85 (m, 1 H, H-5 Gal), 3.82–3.60 (m, 4 H,  overlap of OCH2CH2NH, H-4 
Gluc and H-5 Gluc), 3.43 (bs, 2 H, OCH2CH2NH), 3.19 (m, 2 H, NHCH2C13H27), 2.77 (dd, J = 3.6 Hz, 
J = 15.3 Hz, 1 H, H-β), 2.45 (dd, J = 6.9, J = 15, 1 H, H-β'), 2.22 (t, J = 7.2 Hz, 2 H, COCH2C14H29), 
2.15, 2.12 2.06, 2.04, 1.96  (each s, 6 H, O(CO)CH3), 1.62–1.60 (m, 2 H, COCH2CH2C13H27), 1.46–
1.45 (m, 2 H, NHCH2CH2C12H25), 1.20-1.31 (m, 46 H, overlap of COC2H4(CH2)12CH3, 
NHC2H4(CH2)11CH3), 0.87 (t, J = 6.6 Hz, 6 H, overlap of COC14H28CH3, NHC13H26CH3); 
13C-NMR (75 
Hz, CDCl3): δc 172.6, 170.6, 169.6, 169.4, 169.3, 169.1, 169.0, 168.9, 168.7, 168.03 (each CO), 
101.0 (C-1 gal), 100.7 (C-1 Gluc), 76.0 (C-5, Gluc), 72.8 (C-4, Gluc), 72.6 (C-3 Gluc), 71.6 (C-2 
Gluc),  70.9 (C3- Gal), 70.7 (C-5 Gal), 69.1 (OCH2CH2NH), 68.8 (C-2 Gal),66.6 (C-4 Gal), 61.7, 60.7 
(C-6 Gal, C-6 Gluc), 49.8 (C-α), 39.6 (NHCH2C13H27), 39.4 (OCH2CH2NH,) 36.9 (COCH2C14H29), 
36.6 (C-β), 31.9, 29.7, 29.5, 29.5, 29.3, 29.3, 26.9, 25.6, 22.6 (overlap of COC2H4(CH2)12CH3, 
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NHC2H4(CH2)11CH3), 20.9, 20.8, 20.7, 20.6, 20.5 (O(CO)CH3), 14.11 (COC14H28CH3, NHC13H26CH3); 
HRMS m/z (ESI+): 1228.7353 (C62H106N3O21: [M+H]
+ requires  1228.7313).   
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-palmitoyl-L-asparagine 
tetradecylamide 2.31 
HOBt (65 mg, 0.48 mmol) was added to a stirring solution of carboxylic acid 2.69 (250 mg, 0.44 
mmol) and TBTU ( 155 mg, 0.48 mmol) dissolved in DMF (20 mL), under N2 at 50
 OC. The 
solution was stirred for 10 min and 2-aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 
2.33 (189 mg, 0.48 mmol) dissolved in DMF (15 mL) was added dropwise. The reaction mixture 
was stirred overnight at rt and concentrated in vacuo. Flash chromotagraphy (EtOAc) afforded 
2.31 as a white solid (274 mg, 63%); Rf = 0.59 (9:1, DCM:MeOH); [α]
25 
D = -1.67 (c, 1.2 in DCM); 
1H NMR (300 MHz, CDCl3):  7.32-7.27 (m, 2 H, overlap of NHCOC15H31 and CONHC14H29), 6.03-
5.97 (m, 1 H, OCH2CH2NH), 5.4-5.37 ( m, 1 H, H-4), 5.21-5.14 (m, 1 H, H-2), 5.04-4.99 (m, 1 H, H-
3), 4.66-4.61 (m, 1 H, H-α), 4.51 (d, J = 7.8 Hz, 1 H, H-1), 4.18-4.10 (m, 2 H, H-6 and H-6’), 3.96-
3.80 ( m, 2 H overlap of H-5 and 1 H of CH2CH2O), 3.65 (m, 3 H, overlap of 1 H of OCH2CH2NH 
and OCH2CH2NH), 3.25-3.16 (m, 2 H, NHCH2C13H27), 2.61 (dd, J = 3.3 Hz, J = 15.3, 1 H, H-β), 2.45 
(dd, J = 6.9, J = 15.6, 1 H, H-β’), 2.27-2.22 (m, 2 H, NHCOCH2C14H29) 2.16, 2.09, 2.04, and 1.9 
(each s, 3 H, O(CO)CH3), 1.64-1.59 (m, 2 H, NHCOCH2CH2C13H27), 1.51-1.46 (m, 
NHCH2CH2C12H25), 1.33-1.24 (m, 46 H, overlap of NHC2H4(CH2)11CH3, NHCOC2H4(CH2)12CH3), 0.88 
(t, J = 6.3 Hz, 6 H, overlap of NHCOC14H28CH3, CONHC13H26CH3);
 13C-NMR (75 MHz, CDCl3): δc 
173.7, 171.7, 170.4, 170.2, 170.1, (each CO), 101.1 (C-1), 70.8, 70.7 (C-5, C-3), 69.0, (C-2), 68.7 
(OCH2CH2NH), 67.0 (C-4), 61.3 (C-6), 50.0 (C-α), 39.7 (OCH2CH2NH), 37.6 (NHCH2C13H27), 36.6 (C-
β), 35.6 (NHCOCH2C14H29), 31.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 26.9, 25.6, 22.6 (overlap 
of NHCOCH2(CH2)13CH3 and NHCH2(CH2)12CH3), 20.8. 20.7, 20.6, 20.5 (each O(CO)CH3), 14.1 
(overlap of COC14H28CH3, NHC13H26CH3); HRMS m/z (ESI+): 940.6532 (C50H90N3O13: [M+H]
+ 
requires  940.6468).   
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N4-[2-O-(6-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-hexadecanosyl-L-asparagine 
tetradecylamide 2.30 
To a solution of 1-O-(2-azidoethyl) -(2,3,4-tri-O-trimethylsilyl, 6-O carboxymethylbromide)-β-D-
galactopyranose 2.89 (138 mg, 0.2 mmol) in absolute EtOH (15 ml), Pd/C (14 mg, 10% w/w) 
was added. The resulting mixture was stirred under H2 for 2.5 h. The mixture was then filtered 
through a Celite cake and the filtrate was concentrated under vacuum to afford the crude 
product as thick clear oil.  An in situ reaction with the aspartic acid derivative 2.35 was then 
carried out. HOBt (16 mg, 0.12 mmol), followed by NEt3 (0.030 mL, 2.2 mmol), were added to a 
stirring solution of the carboxylic acid 2.35 (63 mg, 0.11 mmol) and TBTU (39 mg, 1.2 mmol) 
dissolved in anhydrous DMF (10 mL), under N2 at rt. The mixture was stirred for 15 min and 
2.89 (46 mg, 0.13 mmol) dissolved in anhydrous DMF (1.2 mL) was added dropwise. The 
mixture was stirred for 18 h upon which a precipitate was observed. Filtration and trituration 
of the precipitate yielded the pure product 2.30 as a white solid (55 mg, 55%, over two steps); 
[α]25 D = 3 (c, 0.5 in Pyr); 
1H-NMR (300 MHz, d5-Pyr):  9.02 (d, J = 7.8 Hz, 1 H, NHCOC15H31), 8.92 
(t, J = 5.1 Hz, 1 H, CH2CH2NHCO), 8.57 (t, J = 5.7 Hz, 1 H, CONHC14H29), 5.55-5.50 (m, 1 H, H-α), 
4.86-4.67 (m, 3 H, overlap of  H-1, H-6 and H-6’), 4.40 (dd, J = 7.5 Hz, J = 9.3 Hz, 1 H, H-2), 4.34 
(d, J = 3.3 Hz, 1 H, H-4), 4.23-4.11 (m, 3 H, overlap of  H-3, H-5 and 1 H of CH2CH2O), 3.97-3.89 
(m, 1 H, 1 H of OCH2CH2NH), 3.83-3.64 (m, 2 H, OCH2CH2NH), 3.48-3.35 (m, 2 H, NHCH2C13H27), 
3.13 (d, J = 6.6 Hz, 2 H, H-β, H-β’),  2.41-2.34 (m, 2 H, NHCOCH2C14H29), 2.2 (s, 3 H, O(CO)CH3), 
1.80-1.72 (m, 2 H, NHCOCH2CH2C13H27), 1.57-1.50 (m, NHCH2CH2C12H25), 1.24 (46 H, overlap of 
NHCOC2H4(CH2)12CH3, and NHC2H4(CH2)11CH3), 0.86 (t, J = 6.3 Hz, 6 H, overlap of 
NHCOC14H28CH3 and NHC13H26CH3); 
13C-NMR (75 Hz, CDCl3): c  173.96 , 172.5, 171.6, 171.2 
(each CO), 105.8 (C-1), 75.5 (C-5), 74.0 (C-3), 72.7(C-2), 70.39 (C-4), 69.6 (OCH2CH2NH), 65.1 (C-
6), 55.5 (C-α), 40.7 (OCH2CH2NH), 40.3 (NHCH2C13H27),  39.0 (C-β), 36.9 (NHCOCH2C14H29), 32.6, 
30.5, 30.4, 30.3, 30.2, 30.1, 30.0, 29.7, 28.4 27.7, 27.5, 26.6, 26.4, 23.4 (each s, 
NHCOCH2(CH2)13CH3 and NHCH2(CH2)12CH3 ), 21.2 (O(CO)CH3), 16.24 (NHCOC14H28CH3, 
NHC13H26CH3); HRMS m/z (ESI+): 814.616 (C44H84N3O10: [M+H]
+ requires  814.6151).   
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N4-[2-O-(β-D-galactopyranosyl)-ethyl]-N2- hexadecancosyl-N1-[2-O-(β-D-galactopyranosyl)-
ethyl] L-asparagine 2.29 
Trimethylamine (0.1 mL) was added to a stirring solution of N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-ethyl]-N2-hexadecancosyl-N1-[2-O-(2,3,4,6-tetra-O-acetylβ-D-
galactopyranosyl)-ethyl] L-asparagine 2.29 (37 mg, 0.040 mmol) dissolved in DCM,/MeOH/H2O 
(2 mL/4 mL/2 mL) at 40 oC.  The mixture was stirred for 18 h. The reaction mixture was 
concentrated under reduced pressure to afford the crude solid which was triturated using 
DCM and EtO2 to yield 2.29 as a white solid (15 mg, 86%); [α]
25 
D = 6 (c, 0.8 in Pyr); 
1H-NMR (300 
MHz, d5-Pyr):  8.95 (d, J = 7.8 Hz, 1 H, NHCOC15H31), 8.79-8.85-8.71 (m,  2 H, CH2CH2NHCO), 
5.54-5.48 (m, 1 H, H-α), 4.78 (t, J = 6.9 Hz, 1 H, H-1), 4.53-4.32 (m, 8 H, overlap of H-2, H-4, H-6 
and H-6'), 4.19-4.08 (m, 6 H, overlap of  H-3, H-5 and 1 H of CH2CH2O), 3.94-3.87 (m, 2 H, 1 H of 
CH2CH2O), 3.77-3.60 (m, 4 H, CH2CH2NH), 3.12 (d, J = 5.4 Hz, 2 H, H-β, H-β’), 2.37 (t, J = 7.2 Hz, 2 
H, NHCOCH2C14H29), 1.74-1.70 (m, 2 H, NHCOCH2CH2C13H27),  1.30-1.09 (m, 24 H, 
NHCOC2H4(CH2)12CH3), 0.85-0.82 (m, 3 H, NHCOC14H28CH3); 
13C-NMR (75 MHz, d5-Pyr): c 173.7, 
172.5 , 171.3 (each CO), 105.9, 105.7 (C-1, C-1’), 77.2 (C-5, C-5’), 75.5 (C-3, C-3’), 72.9, 72.8 (C-
2, C-2’), 70.5 (C-4, C-4’), 69.8, 66.0 (OCH2CH2NH), 66.1, 62.8 (C-6, C-6’), 55.3 (C-α), 40.8, 40.6 
(OCH2CH2NH), 39.2 (C-β), 36.7 (NHCOCH2C14H29), 32.4, 30.2, 30.1, 30.0, 29.8, 26.3, 23.2 (each s, 
NHCOCH2(CH2)13CH3 and NHCH2(CH2)12CH3 ), 21.2 (O(CO)CH3), 14.5 (NHCOC14H28CH3, 
NHC13H26CH3); HRMS m/z (ESI+): 782.4620 (C36H68N3O15N3: [M+H]
- requires  782.4645).
Chapter 6:                                                                                                                                    Experimental details 
 
ii A reference preceeding the compound title indicates that an experimental procedure was followed as 
in a publication. It does not implicity indicate that the exact compound in question was synthesised; only 
that reagents and conditions were followed. 
 
183 
 
 
 
2,3,4,6-Tetra-O-acetyl-α/β-D-galactopyranose 2.39 
Dimethylamine (3.83 mL, 7.66 mmol) was added to a stirring solution of 1,2,3,4,6-penta-O-
acetyl-β-D-galactospyranose 2.38 (2 g, 5.12 mmol) in MeCN ( 20 mL). The solution was heated 
to 80 oC and stirred for 24 h. The reaction mixture was concentrated in vacuo, dissolved in 
DCM washed with brine and dried (MgSO4). The solution was filtered, the solvent removed 
under reduced pressure, and the crude product purified using flash column chromatography 
(1:1, EtOAc:Hexane) to yield the title compound 2.39 as a brown oil (1.18 g, 66%); Rf = 0.28 
(1:1, Hexane/EtOAc); IR vmax (NaCl plate, DCM): 3619.6, 3643.1, 3063.3, 2971.8, 2942.7, 
2916.7, 2849.2, 2726.0, 2442.3, 2124.9, 191.9, 1747.7, 1648.1, 1434.4, 1372.2, 1231.2, 1155.4, 
1127.2, 1052.2 cm-1 ; 1H NMR (300 MHz, CDCl3, α-anomer):  5.71-5.72 (m, 1 H, H-1), 5.48 (d, J 
= 3.3 Hz, 1 H, H-4), 5.43 (dd, J = 6.2 Hz, J = 12.0 Hz, 1 H, H-3), 5.15 (dd, J = 3.4 Hz, J = 12.0 Hz, 1 
H, H-2), 4.48 (appt, J = 6.0 Hz,  1 H, H-5), 4.08-4.16 (m, 2 H, H-6, H-6’), 2.09, 2.00, 1.98, 1.92 
(each s, 3 H, O(CO)CH3).  
The NMR data are in agreement with the reported values.[229] 
 
2,3,4,6-Tetra-O-acetyl-α-D-galactopyranosyl-1-trichloroacetimidate 2.40[230]ii 
Trichloroacetonitrile (1.52 mL, 15.18 mmol) and 1,8-diaza bicylco[5.4.0]undec-7-ene (0.12 mL, 
0.792 mmol)  was added to a solution of 2,3,4,6-tetra-O-acetyl-α/β-D-galactopyranose 2.39 
(918 mg, 2.64 mmol) in anhydrous DCM (5 mL) under N2. The reaction miture was stirred for 
3.5 h. The solvent was evaporated under reduced pressure and the residue obtained obtained 
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was purified by column chromatography (4:3, Hexane/EtOAc) to give the title compound 2.40 
as a white solid (1.08 g, 83%); Rf = 0.57 (1:1, Hexane/EtOAc); 
1H NMR (300 MHz, CDCl3, α-
anomer):  8.66 (s, 1 H, NH), 6.58 (d, J = 3.2 Hz, 1 H, H-1), 5.54-5.52 (m, 1 H, H-4), 5.43-5.28 (m, 
2 H, H-2, H-3), 4.42 (t, J = 6.5 Hz,  1 H, H-5), 4.17-4.05 (m, 2 H, H-6, H-6’), 2.1, 2.01, 2.0, 1.99 
(each s, 3 H, O(CO)CH3); 
13C (75 MHz, CDCl3): δc 170.3, 170.1, 170.0, 169.9 (each CO), 160.9 
(CNH) 93.5 (C-1), 90.8 (CCl3), 68.9 (C-5), 67.5 (C-2), 67.4 (C-4), 66.9 (C-3), 61.2 (C-6), 20.7, 20.6, 
20.5, 20.5 (O(CO)CH3). 
The NMR data are in agreement with the reported values.[231] 
 
O-(2-N-carbobenzyloxyaminoethyl)-(2,3,4,6-tetra-O-acetyl)-β-D-galactopyranose 2.41 
2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl-1-trichloroacetimidate (2.7 g, 5.6 mmol) and N-
(tert-Butoxycarbonyl)ethanolamine (1.36 g, 8.4 mmol) were dissolved in anhydrous DCM 
under N2. TMSOTf (0.21 mL, 1.1 mmol) was added and the reaction mixture was stirred 
overnight. The solvent was removed under reduced pressure and the resulting residue 
dissolved in DCM and washed with 1M HCl, aqueous sat. NaHCO3, brine and dried over MgSO4. 
Column chromatography afforded the title compound as a white solid (1.12 g, 40%); Rf = 0.37 
(1:1, Hexane/EtOAc); 1H NMR (300 MHz, CDCl3):  5.38-5.36 (m, 1 H, H-4), 5.21-5.14 (m, 1 H,  
H-2), 5.02-4.97 (m, 1 H, H-3), 4.44 (d, J = 7.9 Hz, 1 H, H-1), 4.14-4.05 (m, 2 H, H-6, H-6’), 3.92-
3.82 (m, 2 H, overlap of H-5 and 1 H of OCH2CH2NH), 3.69-3.59 (m, 1 H, 1 H of OCH2CH2NH), 
3.33-3.25 (m, 2 H, OCH2CH2NH), 2.1, 2.07, 2.05, 1.99 (each s, 3 H, O(CO)CH3), 1.44-1.40 (m, 9 H, 
OC(CH3)3); 
13C (75 MHz, CDCl3): δc 170.5, 170.3, 170.2, 169.7 (each CO), 155.9 (COOC(CH3)3), 
101.6 (C-1), 79.7 (OC(CH3)3), 70.7 (C-5, C-3), 69.8 (OCH2C2NH), 68.8 (C-2), 67.8 (C-4), 60.3 (C-6), 
39.3 (OCH2CH2NH), 27.3 (OC(CH3)3), 20.7, 20.6, 20.5, 20.5 (O(CO)CH3). 
The spectroscopic data are in agreement with the literature.[185] 
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2-(Benzyloxycarbonyl)aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 2.42[92] 
β-D-galactose pentacetate 2.38 (0.57 g, 1.45 mmol) and benzyl N-(2-hydroxyethyl)carbamate 
(0.34 g, 1.7 mmol) were dissolved in dry DCM (6 mL) under N2 and BF3Et2O (546 mg, 4.35 
mmol) was added dropwise at rt. After overnight stirring the reaction mixture was quenched 
using NEt3 (1 mL). The solvent was concentrated under vacuum and the crude mixture was 
acetylated using AcOH (3 mL) and pyridine (9 mL) for 1 h. The solvent was evaporated under 
reduced pressure to yield a yellow oil that was purified by column chromatography (1:1, 
EtOAc: Pet Ether). The title compound 2.42 was obtained as thick clear oil (0.42 g, 57%); Rf = 
0.53 (6:4, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 3394.4, 3065.5, 3034.1, 2953.9, 2888.1, 
1751.6, 1534.1, 1455.7, 1432.5, 1370.9, 1227.1, 1173.2, 1060.4, 965.0, 912.7, 776.6, 737.5, 
590.3 cm-1 ; 1H NMR (300 MHz, CDCl3):  7.35-7.34 (m, 5 H, Ar), 5.37 (dd, J = 0.9 Hz, J = 3.6 Hz, 1 
H, H-4), 5.17 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2) 5.09 (s, 2 H, PhCH2), 4.99 (dd, J = 3.6 Hz, J = 
10.5 Hz, 1 H, H-3), 4.46 (d,  J = 7.8 Hz, 1 H, H-1), 4.11 (d, J = 6.3 Hz, 2 H, H-6 and H-6’), 3.92-3.86 
(m, 2 H, overlapping of H-5 and 1 H of OCH2CH2NH), 3.69 (m, 1 H, 1 H of OCH2CH2NH), 3.41-
3.37 (m, 2 H, OCH2CH2NH), 2.14, 2.03, 2.02, 1.97  ( each s, 3 H, O(CO)CH3); HRMS m/z (ESI+): 
526.1926 (C24H31NO12: [M+H]
+ requires  526.1919).   
The spectroscopic data are in agreement with the literature.[92]  
 
2-Aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33[92] 
To a solution of 2-(Benzyloxycarbonyl)aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 
2.42 (350 mg, 0.6 mmol) in absolute EtOH (20 mL), Pd/C (40 mg, 10% w/w) was added. The 
resulting mixture was stirred under H2 for 3 h. The mixture was then filtered through a Celite 
cake and the filtrate was concentrated under vacuum to afford the pure product 2.33 as thick 
clear oil (242 mg, 91%); Rf = 0.1 (6:4, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 3402.0, 
1750.6, 1655.4, 1550.9, 1372.6, 1227.4, 1048.0, 913.3, 738.4, 602.9, 542.5 cm-1 ; 1H NMR (300 
MHz, CDCl3):  5.32 (d, J = 3. Hz, 1 H, H-4), 5.13 (dd, J = 7.8 Hz, J = 10.2 Hz, 1 H, H-2), 4.96 (dd, J 
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= 3.6 Hz, J = 10.5 Hz, 1 H, H-3), 4.45 (d, J = 7.8 Hz, 1 H, H-1), 4.15-4.03 (m, 2 H, H-6 and H-6’), 
3.89-3.81 (m, 2 H, overlapping of H-5 and 1 H of OCH2CH2NH2), 3.55-3.50 (m, 1 H, 1 H of 
OCH2CH2NH2), 2.86-2.75 (m, 2 H, OCH2CH2NH2), 2.09, 2.00, 1.98, 1.92 (each s, 3 H, O(CO)CH3); 
HRMS m/z (ESI+): 392.157 (C16H26NO10: [M+H]
+ requires  392.1551).   
The spectroscopic data are in agreement with the literature.[92] 
 
2-Chloroethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.43[232] 
A solution of β-D-galactose pentacetate 2.38 (5 g, 12.8 mmol) and 2-chloroethanol (1 mL, 15.3 
mmol) in dry DCM (50 mL)  was stirred under nitrogen and placed on ice. BF3Et2O (4.74 mL, 
38.4 mmol) was added dropwise over 30 min. After overnight stirring the reaction mixture was 
concentrated under vacuum to yield a yellow oil that was purified by column chromatography 
(1:1, hexane/EtOAc).The product 2.43 was obtained as thick clear oil (4.15 g, 78%); Rf = 0.50 
(1:1, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 3469.2, 2968.4, 1747.4, 1432.7, 1372.2, 
1233.7, 1152.4, 1049.6, 952.5, 914.8, 736.8, 663.8 cm-1 ; 1H NMR (300 MHz, CDCl3):  5.36 (d, J 
= 3.3 Hz, 1 H, H-4), 5.20 (dd, J = 8.1 Hz,  J = 10.5 Hz, 1 H, H-2), 4.99 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 
H, H-3), 4.53 (d, J = 8.1 Hz, 1 H, H-1), 4.18-4.08 (m, 2 H, H-6 and H-6’), 4.06-3.98 (m, 1 H, 1 H of 
OCH2CH2Cl), 3.92-3.87 (m, 1 H, H-5), 3.69-3.62 (m, 1 H, 1 H of OCH2CH2Cl), 3.51-3.43 (m, 1 H, 1 
H of OCH2CH2Cl),  3.3-3.23 (m, 1 H, 1 H of OCH2CH2Cl), 2.12, 2.02, 2.01, 1.95  (each s, 3 H, 
O(CO)CH3); HRMS m/z (ESI+): 411.1065 (C16H24ClO10: [M+H]
+ requires  411.1053).   
The spectroscopic data are in agreement with the literature.[233] 
 
2-Azidoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.44[234] 
2-Chloroethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.43 (1.5 g, 3.65 mmol) was 
dissloved in DMF (70 mL) and NaN3 (443 mg, 7.3 mmol) was added. The mixture was heated to 
110 oC and stirred for 4 h. The solvent was removed under reduced pressure and the residue 
dissolved in DCM and washed with H2O and dried over MgSO4. Flash chromatography (1:1, 
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EtOAc:Pet Ether) afforded the pure product 2.44 as an oily solid ( 1.23 g, 81%); Rf = 0.50 (1:1, 
Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 2941.6, 2106.9, 1750.9, 1434.7, 1370.4, 1223.8, 
1173.7, 1134.4, 1061.6, 955.6, 899.8 cm-1 ;1H NMR (300 MHz, CDCl3):   5.38 (d, J = 3.3 Hz, 1 H, 
H-4), 5.21 (dd, J = 7.8 Hz,  J = 10.5 Hz, 1 H, H-2), 5.02 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 H, H-3), 4.53 
(d, J = 7.8 Hz, 1 H, H-1), 4.20-4.07 (m, 2 H,  overlap of H-6, H-6’ and 1 H of OCH2CH2N3), 3.93-
3.88 (m, 1 H, H-5), 3.69-3.79-3.71 (m, 1 H, 1 H of OCH2CH2N3), 3.63-3.60 (m, 1 H, 1 H of 
OCH2CH2N3),  2.14, 2.06, 2.04, 1.97 (each s, 3 H, O(CO)CH3); HRMS m/z (ESI+): 440.1263 
(C16H23N3NaO10: [M+Na]
+ requires  440.1276).   
The spectroscopic data are in agreement with the literature.[93] 
 
N2-tert-butoxycarbonyl-L/D-asparagine tetradecylamide benzyl ester 2.46  
HOBt (230 mg, 1.7 mmol), N-Boc-L-Asp-OBn 2.45 (500 mg, 1.50 mmol) and TBTU (540 mg, 1.7 
mmol) were dissolved in DMF (10 mL), under N2 at rt and NEt3 (0.646 mL, 4.6 mmol) added. 
The solution was stirred for 15 min and tetradecylamine (330 g, 1.5 mmol) dissolved in DMF (3 
mL) was added. The reaction mixture was stirred for 18 h. The solvent was removed under 
reduced pressure, and the residue was diluted with DCM and washed succesively with 0.1 M 
HCl, aqueous sat. NaHCO3 and brine. Flash chromotagraphy (1:1, Pet Ether:EtOAc) afforded 
2.46 (680 mg, 87%); Rf = 0.9 (1:1, Pet Ether:EtOAc); [α]
25 
D = 0 (c, 1.55 in DCM); IR vmax (NaCl 
plate, DCM): 3333.8, 2918.4, 2850.1, 1737.5, 1687.2, 1647.2, 1527.3, 1467.3, 1367.5, 1293.0, 
1168.2, 1058.6, 1028.6, 864.4, 732.0, 695.4 cm-1; 1H NMR (300 MHz, CDCl3):  7.39-7.32 (m, 5 
H, Ar), 6.42 (bs, 1 H, NHCOC(CH3)3), 5.67  (bs, 1 H, NHC14H29), 5.18-5.08 (m, 2 H, PhCH2), 4.47 ( 
bs, 1 H, H-α), 3.27-3.15 (m, 2 H, NHCH2C13H27), 3.07 (dd, J = 4.5 Hz, J = 17.1 Hz, 1 H, H-β), 3.01 
(dd, J =6.6 Hz, J = 17.1 Hz, 1 H, H-β’), 1.45 (bs, 11 H, overlap of NHCH2CH2C12H25 and 
NHCOC(CH3)3), 1.25-1.20 (m, 22 H, NHC2H4(CH2)11CH3), 0.88 (t, J = 6.6 Hz, 3 H, 
NHC2H4(CH2)11CH3); 
13C NMR (75 MHz, CDCl3): c 170.8, 169.4, (each CO), 134.4 (ArC), 128.6, 
128.4, 128.3 (ArCH), 66.8 (PhCH2), 39.7 (NHCH2C13H27), 31.9, 29.7, 29.6, 29.5, 29.4, 29.4, 29.3, 
(NHCH2(CH2)12CH3), 28.3 (COC(CH3)3), 26.8, 22.7 (NHCH2(CH2)12CH3), 14.10 (NHC13H26CH3); 
HRMS m/z (ESI+): 519.3788 (C30H51N2O5: [M+H]
+ requires  519.3792).   
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L-asparagine tetradecylamide benzyl ester 2.47 
A solution of N2-tert-butoxycarbonyl-L-asparagine tetradecylamide benzyl ester 2.46 (358 mg, 
0.69 mmol) in DCM (10 mL) was cooled in an ice bath and 50% TFA in DCM (0.53 ml, 6.9 mmol) 
was added dropwise. The reaction mixture was stirred at 0 oC for 30 min and then warmed to 
rt where The mixture was stirred for a further 2 h. The organic solvent was removed in vacuo 
and the residue obtained was diluted with EtOAc and washed with aqueous sat. NaHCO3 
solution, brine, dried over MgSO4 and concentrated to yield the corresponding deprotected 
amine 2.47  as an off white solid which was used without further purification (267 mg, 93%); 
1H NMR (300 MHz, CDCl3):  7.38-7.29 (m, 5 H, Ar), 5.18-5.09 (m, 2 H, PhCH2), 3.70 (bs, 1 H, H-
α), 3.25-3.18 (m, 2 H, NHCH2C13H27), 2.99 (dd, J = 3 Hz, J = 15.3 Hz, 1 H, H-β’), 2.66 (dd, J = 8.7 
Hz, J = 15.6 Hz, 1 H, H-β’), 1.52-1.42 (m, 2 H, NHCH2CH2C12H25), 1.31-1.22 (m, 22 H, 
NHC2H4(CH2)11CH3), 0.88 (t, J = 6.6 Hz, 3 H, NHC13H26CH3); HRMS m/z (ESI+): 419.3288 
(C25H43N2O3: [M+H]
+ requires  419.3268).   
 
N2-decanoyl-L-asparagine tetradecylamide benzyl ester 2.48 
HOBt (192 mg, 1.4 mmol) and NEt3 (0.54 mL, 3.9 mmol) were added to a stirring solution of 
decanoic acid (54 mg, 0.31 mmol) and TBTU (110 mg, 0.34 mmol) dissolved in DMF (5 mL), 
under N2 at rt. The mixture was stirred for 10 min and L-asparagine tetradecylamide benzyl 
ester 2.47 (543 mg, 1.2 mmol) was dissolved in DMF (5 mL) and added slowly. The mixture was 
stirred for 18 h. The reaction mixture was concentrated in vacuo, diluted with EtOAc, washed 
with brine, dried over MgSO4 and concentrated. The residue obtained was purified by flash 
chromatography (1:1, Pet Ether: EtOAc) to afford 2.48 as a white solid (700 mg, 94%); Rf = 0.80 
(1:1, Pet Ether:EtOAc); [α]25 D = 0 (c, 1.5 in DCM); IR vmax (NaCl plate, DCM): 3294.5, 2920.4, 
2851.4, 1735.4, 1643.9, 1543.5, 1221.7, 772.6 cm-1;  1H NMR (300 MHz, CDCl3):  7.38-7.32 (m, 
5 H, Ar), 6.79 (d, J = 8.1 Hz, 1 H, NHCOC9H19), 6.51 ( bs, 1 H, CONHC14H29), 5.19-5.10 (m, 2 H, 
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PhCH2), 4.80-4.74 (m, 1 H, H-α), 3.22-3.15 (m, 2 H, NHCH2C13H27), 2.95 (dd, J = 3 Hz, J = 15.3 Hz, 
1 H, H-β), 2.66 (dd, J =8.7 Hz, J =15.6 Hz, 1 H, H- β’), 2.22-2.17 (m, 2 H, NHCOCH2C8H17), 1.62-
1.58 (m, J = 6, 2 H, NHCH2CH2C12H25), 1.48-1.49 (m, 2 H, NHCOCH2CH2C7H15), 1.33-1.21 (m, 34 
H, NHC2H4(CH2)11CH3 and NHCOC2H4(CH2)6CH3), 0.88 (t, J = 6.6 Hz, 6 H, NHC13H26CH3 and 
NHCOC9H16CH3); 
13C NMR (75 Mhz, CDCl3): c 173.4, 172.0, 170.2 (each CO), 134.38 (ArC), 
128.6, 128.4, 128.3 (ArCH), 66.9 (PhCH2), 49.2 (C-α), 39.7 (NHCH2C13H27), 36.5 (NHCOCH2C8H17), 
35.8 (C-β), 31.9, 31.8, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 29.2, 29.2, 28.3, 27.5, 26.8 
(NHC2H4(CH2)11CH3 and NHCOCH2(CH2)7CH3), 25.6 (NHCH2CH2(CH2)11CH3), 22.7, 22.6 
(NHC2H4(CH2)11CH3 and NHCOCH2(CH2)7CH3) 14.1, 14.1 (NHC13H26CH3 and NHCOC8H16CH3); 
HRMS m/z (ESI+): 573.4646 (C35H61N2O4: [M+H]
+ requires  573.4626).   
 
N2-decanoyl-L-asparagine tetradecylamide 2.49 
To a solution of N2-decanoyl-L-asparagine tetradecylamide benzyl ester 2.48 (442 mg, 0.77 
mmol) in EtOAc (10 mL), Pd/C (44 mg, 10% w/w) was added. The resulting mixture was heated 
to 50 oC and H2 bubbled through for 4 h. The mixture was then filtered through a Celite cake 
and the filtrate was concentrated under vacuum to afford a white solid which was recrystillised 
in DCM to yield the pure product 2.49 (315 mg, 85%); 1H NMR (300 MHz, CDCl3):   7.03 (d, J = 
7.8 Hz, 1 H, NHCOC9H19), 6.95 (t, J = 5.7 Hz,  1 H, NHC14H29), 4.78-4.72 (m, 1 H, H-α), 3.24-3.17 
(m, 2 H, NHCH2C13H27), 2.91 (dd, J = 3.8 Hz, J = 17 Hz, 1 H, H-β), 2.67(dd, J = 6.6 Hz, J = 16.8 Hz, 
1 H, H- β’), 2.26-2.19 (m, 2 H, NHCOCH2C8H17), 1.64-1.59  (m, 2 H, NHCH2CH2C12H25), 1.49-1.44 
(m, 2 H, NHCOCH2CH2C7H15), 1.34-1.16 (m, 34 H, NHC2H4(CH2)11CH3 and NHCOC2H4(CH2)6CH3), 
0.87 (t, J = 6.3 Hz, 3 H,  NHC13H26CH3 and NHCOC9H16CH3); HRMS m/z (ESI+): 483.4119 
(C28H55N2O4: [M+H]
+ requires  483.4156).   
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N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-decanoyl-L-asparagine 
tetradecylamide 2.50  
 
HOBt (137 mg, 1.0 mmol) and NEt3 (0.387 mL, 3.0 mmol) were added to a stirring solution of 
N2-decanoyl-L-asparagine tetradecylamide 2.49 (446 mg, 0.9 mmol) and TBTU (327 mg, 1.0 
mmol) dissolved in DMF (15 ml), under N2 at 50
 oC. The mixture was stirred for 10 min and the 
O-(2-aminoethyl)-(2,3,4,6-O-tetracetyl)-β-D-galactopyranose 2.33 (435 mg, 1.1 mmol) 
dissolved in DMF (4 ml) was added dropwise. The mixture was stirredovernight at rt. The 
reaction mixture was concentrated in vacuo. Flash chromotagraphy (EtOAc) afforded 2.50 as a 
white solid ( 477 mg, 60%); Rf = 0.46 (EtOAc); [α]
25 
D = -2 (c, 1 in CHCl2); IR vmax (NaCl plate, 
DCM): 3295.6, 2922.1, 2852.1, 1754.7, 1641.1, 1553.9, 1468.3, 1371.8, 1224.9, 1058.1, 721.7 
cm-1;  1H-NMR (300 MHz, CDCl3): δ 7.5 (d, J = 6.9 Hz, 0.5 H, NHCOC9H19), 7.43 (d, J = 6.7 Hz, 0.5 
H, NHCOC9H19), 7.19-7.04 (m, 1 H, CONHC14CH29), 6.42 (t, J = 5.5 Hz, 0.5 H, CH2CH2NHCO), 6.26 
(t, J = 5.3 Hz, 0.5 H, CH2CH2NHCO), 5.39 (d, J = 3.2 Hz, 1 H, H-4), 5.2-5.14 (m, 1 H, H-2), 5.07-
5.01 (m, 1 H, H-3), 4.69–4.63 (m, 1 H, H-α), 4.58 (d, J = 7.8 Hz, 0.5 H, H-1), 4.53 (d, J = 7.8 Hz, 
0.5 H, H-1), 4.21–4.03 (m, 2 H, overlap of H-6, H-6'), 3.96–3.94 (m, 1 H, H-5), 3.92–3.64 (m, 2 H, 
OCH2CH2NH), 3.53–3.36 (m, 2 H, OCH2CH2NH), 3.22–3.15 (m, 2 H, NHCH2C13H27), 2.83-2.74 (m, 
1 H, H-β), 2.49-2.40 (m, 1 H, H-β'), 2.25–2.20 (m, 2 H, COCH2C8H17), 2.16, 2.10, 2.05, 1.98 (each 
s, 3 H, O(CO)CH3), 1.64–1.60 (m, 2 H, COCH2CH2C7H15), 1.50–1.45 (m, 2 H, NHCH2CH2C12H25), 
1.32-1.23 (m, 34 H, overlap of COC2H4(CH2)6CH3, NHC2H4(CH2)11CH3), 0.87 (t, J = 6.6 Hz, 6 H, 
overlap of COC8H16CH3, NHC13H26CH3); 
13C-NMR (75 Hz, CDCl3): δc 173.7, 171.7, 170.6, 170.4, 
170.2, 170.1, 169.9 (each CO), 101.3 (C-1), 70.8, 70.7 (C-5, C-3), 69.0, (C-2), 68.5 (OCH2CH2NH), 
67.0 (C-4), 61.3 (C-6), 49.7 (C-α), 39.7 (OCH2CH2NH), 37.4 (NHCH2C13H27), 36.6 (C-β), 31.9, 29.7, 
29.6, 29.6, 29.5, 29.4, 29.3, 28.3, 26.9, 25.6, 22.6 (each CH2), 20.9–20.8 (overlap of O(CO)CH3), 
14.1 (overlap of COC8H16CH3, NHC13H26CH3); HRMS m/z (ESI+): 856.5507 (C44H78N3O13: [M+H]
+ 
requires  856.5529).   
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N2-tert-butoxycarbonyl-L-asparagine tetradecylamide benzyl ester 2.51 
 
HOBt (230 mg, 1.7 mmol), N-Boc-L-Asp-OBn 2.45 (500 mg, 1.50 mmol), TBTU (540 g, 1.7 mmol) 
and tetradecylamine (330 g, 1.5 mmol) were dissolved in DMF (10 mL), under N2 at rt. The 
reaction mixture was stirred for 18 h and concentrated under reduced pressure. The residue 
obtained was diluted with DCM and washed succesively with 0.1 M HCl, aqueous sat. NaHCO3 
and brine. Flash chromotagraphy (1:1, Pet Ether:EtOAc) afforded the title compound 2.51 as a 
white solid (298 mg, 37%); Rf = 0.9 (1:1, Pet Ether:EtOAc); [α]
25 
D = +2.5 (c, 1.6 in DCM); IR vmax 
(NaCl plate, DCM): 3333.7, 2918.4, 2850.1, 1737.5, 1687.2, 1647.2, 1527.3, 1467.34, 1367.4, 
1293.1, 1168.2, 1058.6, 1028.6 cm-1; 1H NMR (300 MHz, CDCl3):  7.39-7.62 (bs, 5 H, Ar), 6.43 
(bs, 1 H, NHCOC(CH3)3), 5.60  (bs, 1 H, NHC14H29), 5.17-5.08 (m, 2 H, PhCH2), 4.47 ( bs, 1 H, H-α), 
3.25-3.16 (m, 2 H, NHCH2C13H27), 3.04 (dd, J = 4.5 Hz, J = 17.1 Hz, 1 H, H-β), 2.71 (dd, J = 6.3 Hz, 
J = 17.1 Hz, 1 H, H-β’), 1.48-1.41 (m, 11 H, overlap of NHCH2CH2C12H25 and NHCOC(CH3)3), 1.33-
1.22 (m, 22 H, NHC2H4(CH2)11CH3), 0.88 (t, J = 6.6 Hz, 3 H, NHC2H4(CH2)11CH3); 
13C NMR (75 
MHz): c  171.8, 170.4 (each CO), 135.4 (ArC), 128.6, 128.4, 128.2 (ArCH), 66.7 (CH2Ph), 39.6 
(NHCH2C13H27), 31.8, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2 (NHCH2(CH2)12CH3) , 28.2 
(COC(CH3)3), 26.80, 22.7 (NHCH2(CH2)12CH3), 14.1 (NHC13H26CH3); HRMS m/z (ESI+): 541.3602 
(C30H50N2NaO5: [M+Na]
+ requires  541.3612).   
 
L-asparagine tetradecylamide benzyl ester 2.52  
 
A solution of N2-tert-butoxycarbonyl-L-asparagine tetradecylamide benzyl ester 2.51 (216 mg, 
0.4 mmol) in DCM (4 mL) was cooled in an ice bath and 50% TFA in DCM (0.32 mL, 4.1 mmol) 
was added dropwise. The reaction mixture was stirred at 0 oC for 30 min and then warmed to 
rt where The mixture was stirred for a further 2 h. The organic solvent was removed in vacuo 
and the residue obtained was diluted with EtOAc and washed with aqueous sat. NaHCO3 
solution, brine, dried over MgSO4 and concentrated to yield the corresponding deprotected 
amine 2.52 as a white solid which was used without further purification (144 mg, 83%); 1H 
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NMR (300 MHz, CDCl3):  7.39-7.32 (m, 5 H, Ar), 6.77 (bs, 1 H, NHC14H29), 5.20-5.12 (m, 2 H, 
PhCH2), 3.88-3.79 (m, 1 H, H-α), 3.22-3.18 (m, 2 H, NHCH2C13H27), 2.66 (dd, J = 3.6 Hz, J = 15.6 
Hz, 1 H, H-β’), 2.46 (dd, J = 8.6 Hz, J = 15.6 Hz, 1 H, H-β’), 1.48-1.42 (m, 2 H, NHCH2CH2C12H25), 
1.32-1.20 (m, 22 H, NHC2H4(CH2)11CH3), 0.88 (t, J = 6.6 Hz, 3 H, NHC13H26CH3); HRMS m/z (ESI+): 
419.3288 (C25H43N2O3: [M+H]
+ requires  419.3268).   
 
N2-decanoyl-L-asparagine tetradecylamide benzyl ester 2.54  
HOBt (46 mg, 0.34 mmol) was added to a stirring solution of decanoic acid (54 mg, 0.31 mmol) 
and TBTU (110 mg, 0.34 mmol) dissolved in DMF (5 mL), under N2 at rt. The mixture was stirred 
for 10 min and L-asparagine tetradecylamide benzyl ester 2.52 (140mg, 0.31 mmol) was 
dissolved in DMF (5 mL) and added slowly. The reaction mixture was stirred for 18 h, 
concentrated in vacuo and diluted with EtOAc. It was then washed with brine, dried (MgSO4) 
and concentrated. The residue obtained was purified by flash chromatography (1:1, EtOAc:Pet 
Ether) to afford compound 2.54 as a white solid (115 mg, 62%); Rf = 0.82 (1:1, Pet 
Ether:EtOAc); [α]25 D = -20 (c, 1.1 in DCM); IR vmax (NaCl plate, DCM): 3294.5, 2920.4, 2851.4, 
1735.4, 1643.9, 1543.5, 1221.7, 772.6  cm-1;  1H NMR (300 MHz, CDCl3):  7.34-7.32 (m, 5 H, 
Ar), 6.83 (d, J = 8.1 Hz, 1 H, NHCOC9H19), 6.60 ( bs, 1 H, CONHC14H29), 5.18-5.09 (m, 2 H, PhCH2), 
4.82-4.75 (m, 1 H, H-α), 3.22-3.15 (m, 2 H, NHCH2C13H27), 2.95 (dd, J = 3 Hz, J = 15.3 Hz, 1 H, H-
β), 2.66 (dd, J = 8.7 Hz, J =15.6 Hz, 1 H, H-β’), 2.18 (t, J = 7.2 Hz, 2 H, NHCOCH2C8H17), 1.59-1.57 
(m, J = 6 , 2 H, NHCH2CH2C12H25), 1.44 (bs, 2 H, NHCOCH2CH2C6H15), 1.28-1.20 (m, 34 H, 
NHC2H4(CH2)11CH3 and NHCOC2H4(CH2)6CH3), 0.87 (t, J = 6.6 Hz, 6 H, NHC13H26CH3 and 
NHCOC9H16CH3); 
13C NMR (75 MHz, CDCl3): c 173.4, 171.9, 170.2 (each CO), 134.4 (ArC), 128.6, 
128.4, 128.3 (ArCH), 66.9 (PhCH2), 49.2 (C-α), 39.7 (NHCH2C13H27), 36.5 (NHCOCH2C8H17), 35.8 
(C-β), 31.9, 31.9, 29.7, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 29.2, 28.3, 27.5, 26.8 
(NHC2H4(CH2)11CH3 and NHCOCH2(CH2)7CH3), 25.6 (NHCH2CH2(CH2)11CH3), 22.7, 22.6 
(NHC2H4(CH2)11CH3 and NHCOCH2(CH2)7CH3) 14.1, 14.1 (NHC13H26CH3 and NHCOC8H16CH3); 
HRMS m/z (ESI+): 573.4646 (C35H60N2O4: [M+H]
+ requires  573.4626).   
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N2-decanoyl-L-asparagine tetradecylamide 2.53 
To a solution of N2-decanoyl-L-asparagine tetradecylamide benzyl ester 2.53 (115 mg, 0.2 
mmol) in EtOAc (10 mL), Pd/C (12 mg, 10% w/w) was added. The resulting mixture was heated 
to 50 oC and H2 bubbled through for 4 h. The mixture was then filtered through a Celite cake 
and the filtrate was concentrated under vacuum to afford a white solid which was recrystillised 
in DCM to yield the pure product 2.53 (73 mg, 76%); 1H NMR (300 MHz, CDCl3):  7.02 (d, J = 
7.8 Hz, 1 H, NHCOC9H19), 6.96-6.89 (m, 1 H, NHC14H29), 4.84-4.73 (m, 1 H, H-α), 3.24-3.18 (m, 2 
H, NHCH2C13H27), 2.92-2.87 (m, 1 H, H-β), 2.68 (dd, J = 6.6 Hz, J = 16.8 Hz, 1 H, H- β’), 2.24 (t, J = 
7.2 Hz, 2 H, NHCOCH2C8H17), 1.67-1.57 (m, 2 H, NHCH2CH2C12H25), 1.53-1.42 (m, 2 H, 
NHCOCH2CH2C6H15), 1.32-1.19 (m, 34 H, NHC2H4(CH2)11CH3 and NHCOC2H4(CH2)6CH3), 0.87 (t, J 
= 6.3 Hz, 6 H, NHC13H26CH3 and NHCOC9H16CH3); HRMS m/z (ESI+): 483.4147 (C28H55N2O4: 
[M+H]+ requires  483.4156).   
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]- N2-decanoyl-L-asparagine 
tetradecylamide 2.55 
HOBt (230 mg, 0.17 mmol) was added to a stirring solution of N2-decanoyl-L-asparagine 
tetradecylamide 2.53 (73 mg, 0.15 mmol) and TBTU (54 mg, 0.17 mmol) dissolved in DMF (5 
mL), under N2 at 50
 oC. The mixture was stirred for 10 min and 2-Aminoethyl 2,3,4,6-tetra-O-
acetyl-β-D-galactopyranoside 2.33 (71 mg, 0.18 mmol)  was dissolved in DMF (4 mL) and added 
dropwise. The mixture was stirredovernight at rt. The reaction mixture was concentrated in 
vacuo. Flash chromotagraphy (EtOAc) afforded 2.55 as a white solid (87 mg, 69%); Rf = 0.64 
(EtOAc); [α]25 D = +5.8 (c, 0.8 in DCM); IR vmax (NaCl plate, DCM): 3289.5, 3098.3, 2919.3, 2850.8, 
1750.8, 168.1, 1646.5, 1542.4, 1467.4, 1370.4, 1225.5, 1174.9, 1058.5  cm-1;  1H-NMR (300 
MHz, CDCl3): δ 7.43 (d, J = 6.9 Hz, 1 H, NHCOC9H19), 7.08 (t, J = 5.4 Hz, 1 H, CONHC14CH29), 6.26 
(t, J = 5.4 Hz,    1 H, CH2CH2NHCO), 5.40 (d, J = 2.4 Hz, 1 H, H-4), 5.18 (dd, J = 7.8 Hz, J = 10.5 Hz, 
1 H, H-2), 5.04 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 H, H-3), 4.70–4.64 (m, 1 H, H-α), 4.54 (d, J = 7.8 Hz, 
1 H, H-1), 4.22–4.11 (m, 2 H, overlap of H-6, H-6'), 3.97–3.94 (m, 1 H, H-5), 3.92–3.85 (m, 1 H, 1 
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H of OCH2CH2NH), 3.69–3.64 (m, 1 H, 1 H of OCH2CH2NH), 3.57–3.39 (m, 2 H, OCH2CH2NH), 
3.22–3.16 (m, 2 H, NHCH2C13H27), 2.81 (dd, J = 3.3 Hz, J = 15.3 Hz, 1 H, H-β), 2.46 (dd, J = 6.9, J = 
15.6, 1 H, H-β'), 2.25–2.20 (t, J = 7.5 Hz, 2 H, COCH2C8H17), 2.16, 2.09, 2.05, 1.9 (each s, 3 H, 
O(CO)CH3), 1.62–1.60 (m, 2 H, COCH2CH2C7H15), 1.46–1.45 (m, 2 H, NHCH2CH2C12H25), 1.30-1.18 
(m, 34 H, overlap of COC2H4(CH2)6CH3, NHC2H4(CH2)11CH3), 0.87 (t, J = 6.6 Hz, 6 H, overlap of 
COC8H16CH3, NHC13H26CH3); 
13C-NMR (75 Hz, CDCl3): δc 173.7, 171.7, 170.6, 170.4, 170.2, 170.1, 
169.9 (each CO), 101.3 (C-1), 70.8, 70.7 (C-5, C-3), 69.0, (C-2), 68.5 (OCH2CH2NH) 67.0 (C-4), 
61.3 (C-6), 49.7 (C-α), 39.7 (OCH2CH2NH), 39.3(NHCH2C13H27), 37.0 (C-β), 36.6 (COCH2C8H17), 
31.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 28.3, 26.9, 25.6, 22.6 (COC2H4(CH2)6CH3, 
NHC2H4(CH2)11CH3), 20.87–20.85 (overlap of O(CO)CH3), 14.1 (overlap of COC8H16CH3, 
NHC13H26CH3); HRMS m/z (ESI+): 856.5492 (C44H77N3O13: [M+H]
+ requires  856.5529).  
      
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-butoxycarbonyl-L-
asparagine benzylester 2.57 
HOBt (90 mg, 0.68 mmol), followed by NEt3 (0.18 mL, 1.23 mmol), were added to a stirring 
solution of N-Boc-L-Asp-OBn 2.56 (0.2 g, 0.61 mmol) and TBTU (220 mg, 0.6 mmol) dissolved in 
anhydrous DMF (10 mL), under N2 at rt. The mixture was stirred for 30 min and 2-aminoethyl 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33 (290 mg, 0.74 mmol) dissolved in anhydrous 
DMF (1.2 mL) was added dropwise. The mixture was stirred for 18 h. The reaction mixture was 
concentrated under reduced pressure, diluted with EtOAc and washed successively with 0.1 M 
HCl, aqueous sat. NaHCO3 solution and brine. Flash chromotagraphy (1:1, EtOAc:Pet Ether) 
afforded 2.57 as a white solid (330 mg, 76%); Rf = 0.76 (EtOAc); [α]
25 
D = +6.9 (c, 1.35 in DCM); 
IR vmax (NaCl plate, DCM): 3374.7, 2978.0, 1750.7, 1665.8, 1499.3, 1368.8, 1224.3, 1167.9, 
1124.3, 1057.2 cm−1; 1H-NMR (300 MHz, CDCl3) δ 7.34-7.33 (m, 5 H, Ar), 6.01 (t, J = 5.1 Hz, 1 H, 
CH2CH2NHCO), 5.76 (d, J = 8.1 Hz, 1 H, NHCOC(CH3)3), 5.39 (dd, J = 0.6 Hz, J = 3.3 Hz, 1 H, H-4), 
5.20–5.16 (m, 3 H, overlap of H-2, PhCH2), 5.02 (dd, J = 3.3 Hz, J = 10.2 Hz, 1 H, H-3), 4.57–4.54 
(m, 1 H, H-α), 4.44 (d, J = 7.8 Hz, 1 H, H-1), 4.18–4.13 (m, 2 H, overlap of H-6, H-6'), 3.93–3.89 
(m, 1 H, H-5), 3.86–3.80 (m, 1 H, 1 H of OCH2CH2NH), 3.66–3.59 (m, 1 H, 1 H of OCH2CH2NH), 
3.46–3.38 (m, 2 H, OCH2CH2NH), 2.91 (dd, J = 5.7 Hz, J = 17.4 Hz, 1 H, H-β), 2.71 (dd, J = 4.5 Hz, 
J = 15.9 Hz, 1 H, H-β'), 2.15 (s, 3 H, O(CO)CH3), 2.05 (s, 6 H, O(CO)CH3), 1.99 (s, 3 H, O(CO)CH3) 
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1.42 (s, 9 H, COC(CH3)3); 
13C-NMR (75 MHz, CDCl3): δc 171.4, 170.4, 169.8 (each CO), 155.5 (Ar-
C), 128.5, 128.1 (Ar-CH), 101.4 (C-1), 79.0 (COC(CH3)3), 70.9 (C-5), 70.7 (C-2), 68.9 (C-3), 67.2 
(OCH2CH2NH), 67 (C-4), 61.3 (C-6), 50.5 (C-α), 39.2 (each OCH2CH2NH), 37.7 (CH2Ph), 37.1 (C-β), 
28.3 (COC(CH3)3), 20.8, 20.6 (each O(CO)CH3); HRMS m/z (ESI+): 697.2800 (C32H45N2O15: [M+H]
+ 
requires  697.2814).   
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-butoxycarbonyl-L-
asparagine  2.58 
To a solution of N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-
butoxycarbonyl-L-asparagine benzylester 2.57 (120 mg, 0.17 mmol) in EtOAc (6 mL), Pd/C (12 
mg, 10% w/w) was added. The resulting mixture was stirred under H2 gas for 4 h. The mixture 
was then filtered through a Celite cake and the filtrate was concentrated under vacuum to 
afford the corresponding carboxylic acid 2.58 as an off-white solid, which was used without 
further purification (94 mg, 90%); 1H-NMR (300 MHz, CDCl3): δ 6.53 (bs, 1 H, CH2CH2NHCO), 
5.86 (d, J = 5.4 Hz, 1 H, NHCOC(CH3)3), 5.41 (d, J = 3.3 Hz, 1 H, H-4), 5.17 (dd, J = 7.8 Hz, J = 10.2 
Hz, 1 H, H-2), 5.00 (dd, J = 3.3 Hz, J = 10.2 Hz, 1 H, H-3), 4.49 (d, J = 7.8 Hz, 1 H, H-1), 4.45–4.42 
(m, 1 H, H-α), 4.20–4.11 (m, 2 H, overlap of H-6, H-6'), 3.96–3.92 (m, 1 H, H-5) 3.90–3.85 (m, 1 
H, 1 H of OCH2CH2NH), 3.75–3.68 (m, 1 H, 1 H of OCH2CH2NH), 3.54–3.39 (m, 2 H, OCH2CH2NH), 
2.91 (d, J = 15.6 Hz, 1 H, H-β), 2.72 (dd, J = 8.49 Hz, J = 15.9 Hz, 1 H, H-β'), 2.17, 2.13, 2.05, 1.98 
(each s, 3 H, O(CO)CH3), 1.42 (s, 9 H, COC(CH3)3); HRMS m/z (ESI+): 645.1899 (C25H38N2KO15: 
[M+K]+ requires  645.1904).   
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-butoxycarbonyl-L-
asparagine tetradecylamide 2.59 
HOBt (34 mg, 0.25 mmol) was added to a stirring solution of the N4-[2-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-butoxycarbonyl-L-asparagine 2.58 (140 mg, 0.23 
mmol), tetradecylamine (60 mg, 0.28 mmol), and TBTU (81 mg, 0.25 mmol) dissolved in 
anhydrous DMF, (12 mL) at rt. The mixture was stirred for 18 h. The reaction mixture was 
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concentrated in vacuo, diluted with EtOAc and washed with brine. Flash chromotagraphy 
(EtOAc) afforded 2.59 as a white solid (120 mg, 56%); Rf = 0.65 (EtOAc); [α]
25 
D = +8.8 (c, 0.75 in 
DCM); IR vmax (NaCl plate, DCM): 3316.3, 3091.3 2919.9, 2851.3, 1748.0, 1687.1, 1646.1, 
1548.9, 1524.1, 1467.4, 1434.6, 1369.2, 1368.8, 1230.2, 1171.0, 1055.3 cm-1;  1H-NMR (300 
MHz, CDCl3): δ 6.87 (bs, 1 H, CONHC14H29), 6.23 (t, J = 10.5 Hz, 1 H, CH2CH2NHCO), 6.14 (d, J = 
8.1 Hz, 1 H, NHCOC(CH3)3), 5.38 (d, J = 2.7 Hz, 1 H, H-4), 5.15 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-
2), 5.01 (dd, J = 2.7 Hz, J = 10.5 Hz, 1 H, H-3), 4.49 (d, J = 7.8 Hz, 1 H, H-1), 4.40–4.39 (m, 1 H, H-
α), 4.15–4.11 (m, 2 H, overlap of H-6, H-6'), 3.94–3.87 (m, 1 H, H-5), 3.86–3.81 (m, 1 H, 1 H of 
OCH2CH2NH), 3.67–3.60 (m, 1 H, 1 H of OCH2CH2NH), 3.49–3.34 (m, 2 H, OCH2CH2NH), 3.22–
3.15 (m, 2 H, NHCH2C13H27), 2.71 (dd, J = 4.2 Hz, J = 15.6 Hz, 1 H, H-β), 2.51 (dd, J = 6.6 Hz, J = 
15.6 Hz, 1 H, H-β'), 2.14, 2.07, 2.02, 1.96 (each s, 3 H, O(CO)CH3), 1.42 (m, 11 H, overlap of 
COC(CH3)3, NHCH2CH2C12H25), 1.29-1.17 (m, 22 H, NHC2H4(CH2)11CH3), 0.85 (t, J = 6.6 Hz, 3 H, 
NHC13H26CH3); 
13C-NMR (75 MHz, CDCl3): δc 171.2, 170.9, 170.3, 170.2, 170.0, 169.8, 155.7 
(CO), 101.3 (C-1), 80.1 (COC(CH3)3), 70.8, 70.7 (C-5, C-3), 68.9 (C-2), 68.6 (OCH2CH2NH), 67 (C-
4), 61.3 (C-6), 51.1 (C-α), 39.6 (OCH2CH2NH), 39.2 (NHCH2C13H27), 37.5 (C-β), 31.9, 29.7, 29.6, 
29.6, 29.5, 29.4, 29.3, 29.2 (NHC2H4(CH2)11CH3), 28.3 (COC(CH3)3), 26.8, 22.7 
(NHC2H4(CH2)11CH3), 20.8, 20.7,20.6, 20.5 (each O(CO)CH3), 14.93 (NHC13H26CH3); HRMS m/z 
(ESI+): 802.4685 (C39H67N3O14: [M+H]
+ requires  802.4696).   
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-L-asparagine tetradecylamide 
2.60 
A solution of N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-
butoxycarbonyl-L-asparagine tetradecylamide 2.59 (110 mg, 0.13 mmol) in anhydrous DCM, (6 
mL) was cooled in an ice bath and TFA (0.15 mL, 1.37 mmol) was added. The reaction mixture 
was heated to 50 °C and stirred for 1.5 h. The organic solvent was removed in vacuo and the 
residue obtained was diluted with EtOAc and washed with aqueous sat. NaHCO3 solution, 
brine, dried over MgSO4 and concentrated to yield the corresponding deprotected amine 2.60 
as a brown oil, which was used without further purification (71 mg, 74%); 1H-NMR (300 MHz, 
CDCl3): δ 7.41-7.40 (m, 1 H, CONHC14CH29), 6.42 (t, J = 5.1 Hz, 1 H, CH2CH2NHCO), 5.38 (d, J = 
3.3 Hz, 1 H, H-4), 5.16 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2), 5.01 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 H, 
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H-3), 4.48 (d, J = 7.8 Hz, 1 H, H-1), 4.2–4.1 (m, 2 H, overlap of H-6, H-6'), 3.94–3.89 (m, 1 H, H-5) 
3.87–3.82 (m, 1 H, 1 H of OCH2CH2NH), 3.67–3.64 (m, 2 H, overlap of 1 H of OCH2CH2NH, H-α), 
3.42–3.46 (bm, 2 H, OCH2CH2NH), 3.20–3.22 (m, 2 H, NHCH2C13H27), 2.68 (dd, J = 3.9 Hz, J = 15 
Hz, 1 H, H-β), 2.46 (dd, J = 7.8 Hz, J = 15 Hz, 1 H, H-β'), 2.15, 2.07, 2.03, 1.97 (each s, 3 H, 
O(CO)CH3), 1.50–1.43 (m, 2 H, NHCH2CH2C12H25), 1.33-1.20 (m, 22 H, NHC2H4(CH2)11CH3), 0.85 
(t, J = 6.6 Hz, 3 H, NHC13H26CH3); HRMS m/z (ESI+): 702.4159 (C34H59N3O12: [M+H]
+ requires  
702.4172).   
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-decanoyl-L-asparagine 
tetradecylamide 
HOBt (41 mg, 0.3 mmol) was added to a stirring solution of decanoic acid (48 mg, 0.27 mmol) 
and TBTU (98 mg, 0.3 mmol) dissolved in DMF (6 mL), under N2 at rt. The mixture was stirred 
for 10 min and N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-L-asparagine 
tetradecylamide 2.60 (60 mg, 0.28 mmol) dissolved in anhydrous DMF (8 mL) was added 
slowly. The mixture was stirred for 18 h. The reaction mixture was concentrated in vacuo, 
diluted with EtOAc, washed with brine, dried over MgSO4 and concentrated. The residue 
obtained was purified by flash chromotagraphy (EtOAc) to afford 2.55 as a white solid (150 g, 
63%). The spectroscopic data is identical to that discussed earlier for glycolipid 2.55. 
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-hexadecanosyl-L-asparagine 
tetradecylamide 2.61 
NEt3 (0.013 mL, 0.098 mmol) was added to N
4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-ethyl]-N2-L-asparagine tetradecylamide 2.60 (76 mg, 0.108 mmol,) dissolved 
in DCM (6 mL) under Ar. The reaction mixture was allowed to stir for 10 min, and 
hexadecanoyl chloride (0.029 mL, 0.098 mmol) was added. The reaction mixture was stirred at 
rt overnight. The solvent was concentrated in vacuo, diluted with EtOAc, washed with 0.1 M 
HCl, aqueous sat. NaHCO3, brine and dried over MgSO4. Flash chromatography (EtOAc)  
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afforded 2.61 as a white solid (80 mg, 87%); Rf = 0.43 (EtOAc); [α]
25 
D = -3.5 (c, 1.4 in DCM); IR 
vmax (NaCl plate, DCM): 3290.7, 3098.1,  2917.9, 2850.3, 1751.1, 1642.4, 1543.3, 1462.4, 
1370.5, 1225.6, and 1079.9 cm1;  1H NMR (300 MHz, CDCl3):  7.41 (d, J = 6.9 Hz, 1 H, 
NHCOC15H31), 7.08 (t, J = 5.1 Hz, 1 H, CONHC14H29) 6.30 (bs, 1 H, OCH2CH2NH), 5.39 ( d, J = 3.3 
Hz, 1 H, H-4), 5.16 (dd, J = 7.8 Hz,  J = 10.5 Hz, 1 H, H-2), 5.03 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 H, H-
3), 4.68-4.63 (m, 1 H, H-α), 4.52 (d, J = 7.8 Hz, 1 H, H-1), 4.20-4.10 (m, 2 H, H-6 and H-6’), 3.96-
3.84 (m, 2 H overlap of H-5 and 1 H of OCH2CH2NH), 3.70-3.64 (m, 1 H, OCH2CH2NH), 3.53-3.44 
(m, 2 H, OCH2CH2NH), 3.18 ( q, J = 6.6 Hz, 2 H, NHCH2C13H27), 2.76 (dd, J = 3.3 Hz, J = 15.3, 1 H, 
H-β), 2.46 (dd, J = 6.9, J = 15.6, 1 H, H-β’), 2.23 (t, J = 7.5 Hz, 2 H, NHCOCH2C14H29) 2.14, 2.08, 
2.04, and 1.9 ( each s, 3 H, O(CO)CH3), 1.62-1.58 (m, 2 H, NHCOCH2CH2C13H27), 1.46-1.45 (m, 2 
H, NHCH2CH2C12H25), 1.18-1.31 (m, 46 H, overlap of NHC2H4(CH2)11CH3, NHCOC2H4(CH2)12CH3), 
0.87 (t, J = 6.3 Hz, 6 H, overlap of NHCOC14H28CH3, CONHC13H26CH3); 
13C NMR (75 MHz, CDCl3): 
c 172.6, 170.7, 169.6, 169.3, 169.2, 169.0, 168.89 (each CO), 100.3 (C-1), 69.8, 69.7 (C-5 and C-
3), 67.9 (C-2), 67.5 (OCH2CH2NH), 65.9 (C-4), 60.3 (C-6), 48.7 (C-α), 38.6 (OCH2CH2NH), 38.3 
(NHCH2C13H27), 35.9 (C-β), 35.6 (NHCOCH2C14H29), 30.9, 28.7, 28.6, 28.5, 28.5, 28.4, 28.3, 28.3, 
25.9, 24.6, and 21.6 (NHCOCH2(CH2)13CH3 and NHCH2(CH2)12CH3 ),  19.8, 19.6 and 19.5 (each 
O(CO)CH3), 13.1 (overlap of NHCOC14H28CH3, NHC13H26CH3); HRMS m/z (ESI+): 940.650 
(C50H89N3O13: [M+H]
+ requires  940.6468).   
            
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tetracosanoyl-L-asparagine 
tetradecylamide 2.62 
HOBt (220 mg, 0.16 mmol) was added to a stirring solution of tetracosanoic acid (56 mg, 0.15 
mmol) and TBTU (56 mg, 0.16 mmol) dissolved in anhydrous DMF (6 mL), under N2 at rt. The 
mixture was stirred for 10 min and N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-
ethyl]-N2-L-asparagine tetradecylamide 2.60 (128 mg, 0.18 mmol) was dissolved in anhydrous 
DMF (8 mL) and added slowly. The reaction mixture was stirred for 3 h, concentrated in vacuo, 
diluted with EtOAc, washed with brine, dried over MgSO4. The resulting solution was 
concentrated and the residue obtained was purified by flash chromotagraphy (EtOAc) to afford 
2.62 as a white solid, (63 mg, 40%); Rf = 0.51 (EtOAc); [α]
25 
D = +3.8 (c, 0.83 in DCM); IR vmax 
(NaCl plate, DCM): 3423.0, 2918.4, 2850.3, 1749.6, 1644.4,1543.1, 1465.6, 1369.9, 1223.4, 
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1058.3 cm-1;  1H-NMR (300 MHz, CDCl3): δ 7.44 (d, J = 6.9 Hz, 1 H, NHCOC23H47), 7.09 (t, J = 4.8 
Hz, 1 H, CONHC14CH29) 6.26 (bs, 1 H, CH2CH2NHCO), 5.40 (d, J = 2.7 Hz, 1 H, H-4), 5.17 (dd, J = 
7.8 Hz , J = 10.5 Hz, 1 H, H-2), 5.04 (dd, J = 2.7 Hz, J = 10.5 Hz, 1 H, H-3), 4.70–4.64 (m, 1 H, H-α), 
4.53 (d, J = 7.8 Hz, 1 H, H-1), 4.21–4.10 (m, 2 H, overlap of H-6, H-6'), 3.97–3.92 (tm, 1 H, H-5) 
3.90–3.85 (m, 1 H, 1 H of OCH2CH2NH), 3.71–3.64 (m, 1 H, 1 H of OCH2CH2NH), 3.54–3.44 (m, 2 
H, OCH2CH2NH), 3.22–3.15 (m, 2 H, NHCH2C13H27), 2.77 (dd, J = 3.3 Hz, J = 15.3 Hz, 1 H, H-β), 
2.45 (dd, J = 6.9 Hz, J = 15.6 Hz, 1 H, H-β'), 2.23 (t, J = 7.5 Hz, 2 H, COCH2C22 H45), 2.16, 2.09, 
2.04, 1.90 (each s, 3 H, O(CO)CH3), 1.62–1.59 (m, 2 H, COCH2CH2C21H43), 1.46–1.45 (m, 2 H, 
NHCH2CH2C12H25), 1.31-1.22 (m, 62 H, overlap of COC2H4(CH2)20CH3, NHC2H4(CH2)11CH3), 0.87 (t, 
J = 6.3 Hz, 6 H, overlap of NHCOC22H44CH3, NHC13H26CH3); 
13C-NMR (75 MHz, CDCl3): δc 173.6, 
171.7, 170.6, 170.4, 170.2, 170.1, 169.9 (each CO), 101.3 (C-1), 70.8, 70.7 (C-5, C-3), 69.0, (C-2), 
68.5 (OCH2CH2NH), 67 (C-4), 61.3 (C-6), 49.7 (C-α), 39.7 (OCH2CH2NH), 38.5 (NHCH2C13H27), 36.9 
(C-β), 36.6 (NHCOCH2(CH2)21CH3), 31.9, 31.8, 29.6, 29.5, 29.4, 29.3, 29.2, 26.8, 22.6, 22.6 
(NHCOCH2(CH2)21CH3, NHCH2(CH2)12CH3), 20.9 (overlap of O(CO)CH3), 14.1 (overlap of 
COC22H44CH3, NHC13H26CH3); HRMS m/z (ESI+): 1052.775 (C58H105N3O13: [M+H]
+ requires  
1052.7720).   
 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tertbutoxycarbonyl-N1-[2-O-
(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl] L-asparagine 2.63 
HOBt (161 mg, 1.2 mmol) was added to a stirring solution of N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-ethyl]-N2-tert-butoxycarbonyl-L-asparagine  2.58 (673 mg, 1.1 mmol) TBTU 
(391 mg, 1.2 mmol) and and O-(2-aminoethyl)-(2,3,4,6-O-tetracetyl)-β-D-galactopyranose 2.33 
(521 mg, 1.3 mmol) dissolved in DMF (15 mL), under N2 at rt. The mixture was stirred for 18 h. 
The reaction mixture was concentrated under reduced pressure, diluted with EtOAc and 
washed succesively with 0.1 M  HCl, aqueous sat. NaHCO3 solution, and brine. Flash 
chromotagraphy (EtOAc) afforded 2.63 as an oily solid (0.750 g, 61%); Rf = 0.27 (EtOAc); [α]
25 
D 
= +14.9 (c, 1 in DCM); IR vmax (NaCl plate, DCM): 3370.2, 2979.7, 1750.1, 1662.4, 1528.9, 
1369.6, 1224.2, 1171.1, 1057.02 cm-1;  1H NMR (300 MHz, CDCl3):  7.06 (bs, 1 H, CH2CH2NH’), 
6.19 (t, J = 5.1 Hz, 1 H, CH2CH2NH), 5.99 (bs, 1 H, NHCOC(CH3)3), 5.36 (t,  J = 3.3 Hz, 2 H, overlap 
of  H-4 and H-4’), 5.19-5.10 (m, 2 H, overlap of H-2 and H-2’), 5.05-5.01 (m, 2 H, overlap of  H-3 
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and H-3’), 4.54 (d, J =7.8 Hz, 1 H, H-1’), 4.48 (d, J = 8.1, 1 H, H-1), 4.41 (bs, 1 H, H-α), 4.18-4.07 
(m, 4 H, overlap of H-6 and H-6’), 3.92 ( m, 1 H, overlap of H-5 and H-5’) 3.86-3.82 (m, 2 H, 1 H 
of each OCH2CH2NH), 3.67-3.60 (m, 2 H, 1 H of each OCH2CH2NH), 3.54-3.29 (m, 4 H, 
OCH2CH2NH), 2.87-2.80 (m, 1 H, H-β), 2.51 (dd, J = 6.0 Hz, J = 15.6 Hz, 1 H, H-β’), 2.13, 2.12, 
2.07, 2.06, 2.02, 2.01, 1.96 and 1.95 (each s, 3 H, O(CO)CH3), 1.42 (s, 9 H, COC(CH3)3); 
13C NMR 
(75 MHz, CDCl3): c 171.2, 171.1, 170.8, 170.3, 170.3, 170.2, 170.1, 170.0, 169.8, 169.56 (CO), 
101.3 (C-1), 101.1 (C-1’),  80.3 (COC(CH3)3), 70.9, 70.8 (C-5 and C-5’),  70.7, 68.9 ( C-3’ and C-3), 
68.8, 68.6 ( C-2’ and C-2), 68.3 (OCH2CH2NH),  67.1, 66.9 (C-4’ and C-4), 61.3, 60.4 (C-6’ and C-
6), 51.1 (C-α), 39.6 (OCH2CH2NH), 39.2 (C-β), 28.3 (COC(CH3)3), 20.8, 20.8, 20.6 and 20.5 
(O(CO)CH3); HRMS m/z (ESI+): 980.3721 (C41H62N3O24: [M+H]
+ requires  980.3718).   
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-ethyl] L-asparagine 2.64 
A solution of N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-tert-
butoxycarbonyl-N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl] L-asparagine 2.63 
(650 mg, 0.66 mmol) in anhydrous DCM (10 mL) was cooled in an ice bath and 50% TFA in DCM 
(0.260 mL, 3.3 mmol) was added. The reaction mixture was stirred for 30 min at rt, placed on 
ice and 50% TFA in DCM (0.260 mL, 3.3 mmol) was again added. The reaction mixture was 
stirred at rt for 1.5 h, placed on ice and a final portion of 50% TFA in DCM was added (0.260 
mL, 3.3 mmol). The organic solvent was removed in vacuo and the residue obtained was 
diluted with EtOAc and washed with aqueous sat. NaHCO3 solution, brine, dried over MgSO4 
and concentrated to yield the corresponding deprotected amine 2.64 as a white solid, which 
was used without further purification (396 mg, 61%). 1H NMR (300 MHz, CDCl3):  7.06 (bs, 1 H, 
CH2CH2NH’), 6.19 (t, J = 5.1 Hz, 1 H, CH2CH2NH), 5.41 (bs, 2 H, overlap of  H-4 and H-4’), 5.17-
5.02 (m, 4 H, overlap of H-2 and H-2’ and H-3 and H-3’), 4.52-4.57 (m, 2 H, overlap of H-1 and 
H-1’), 4.27-4.10 (m, 4 H, overlap of H-6 and H-6’), 3.96-3.87 (m, 3 H, overlap of H-5, H-5’ and α-
H) 3.66-3.62 (m, 1 H, 1 H of OCH2CH2), 3.67-3.60 (m, 1 H, 1 H of each OCH2CH2), 3.47-3.46 (m, 4 
H, OCH2CH2NH), 2.97 (s, 1 H, H-β), 2.81 (bs, 1 H, H-β’), 2.15 (s, 6 H, O(CO)CH3), 2.06 (s, 12 H, 
O(CO)CH3), 1.99 (s, 6 H, O(CO)CH3); HRMS m/z (ESI+): 880.3206 (C36H54N3O22: [M+H]
+ requires  
880.3193).   
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N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-hexadecancosyl- N1-[2-O-
(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl] L-asparagine 2.65 
N4-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-
D-galactopyranosyl)-ethyl] L-asparagine 2.64 (396 mg, 0.45 mmol) was dissolved in dry THF (15 
mL) under N2 and hexadecanoyl chloride (0.12 mL, 0.40 mmol) was added. The reaction was 
left stirring for 10 min and then NEt3 added (0.057 mL, 0.40 mmol). The reaction mixture was 
stirred at rt overnight. Gradient elution chromatography (EtOAc-MeOH) yielded the pure 
product 2.65 as an off white solid (270 mg, 58%); Rf = 0.20 (EtOAc); [α]
25 
D = +3.8 (c, 0.7 in 
DCM); IR vmax (NaCl plate, DCM): 3291.9, 2924.5, 2853.67, 1751.3, 1645.5, 1543.1, 1370.4, 
1224.1, 1173.5, 1077.07 cm-1;  1H NMR (300 MHz, CDCl3):  7.26 (bs, 2 H, overlap of CH2CH2NH’ 
and NHCOC15H31), 6.25 (t, J = 5.4 Hz, 1 H, CH2CH2NH), 5.40-5.37 (m, 2 H, overlap of  H-4 and H-
4’), 5.19-5.13 (m, 2 H, overlap of H-2 and H-2’), 5.05-4.99 (m, 2 H, overlap of H-3 and H-3’), 
4.73-4.67 (m, 1 H, H-α), 4.52 (d, J = 1.8 Hz, 1 H,  H-1’), 4.50 (d, J = 1.8 Hz, 1 H, H-1), 4.21-4.08 
(m, 4 H, overlap of H-6 and H-6’), 3.96-3.84 (m, 4 H, overlap of H-5, H-5’ and 1 H of OCH2CH2), 
3.70-3.57 (m, 2 H, 1 H of OCH2CH2), 3.53-3.34 (m, 4 H, OCH2CH2NH), 2.79 (dd, J = 3.6 Hz, J = 
15.6 Hz, 1 H, H-β), 2.48 (dd, J = 6.6 Hz, J = 15.6 Hz, 1 H, H-β’), 2.24 (t, J = 6.9 Hz, 2 H, 
NHCOCH2C14H29), 2.16, 2.15, 2.09, 2.08, 2.04, 2.04, 1.98 and 1.97 (each s, 3 H, O(CO)CH3), 1.64-
1.59 (m, 2 H, NHCOCH2CH2C13H27), 1.29-1.18 (m, 24 H, NHCOC2H4(CH2)12CH3), 0.87 (t, J = 6.3 Hz, 
3 H, NHCOC14H28CH3); 
13C NMR (75 MHz, CDCl3): c 173.5, 171.3, 171.0, 170.4, 170.2, 170.2, 
170.1, 170.1, 169.9, 169.72 (CO), 101.3 (C-1), 101.1 (C-1’),  70.9 and 70.8 (C-5 and C-5’),  70.8 
and 70.7 (C-3’ and C-3), 68.9, 68.8 (C-2’ and C-2), 68.6 and 68.1 (OCH2CH2NH),  67.1, 66.9 (C-4’ 
and C-4), 61.3 (C-6’ and C-6), 49.6 (C-α), 39.4 and 39.3 (OCH2CH2NH), 37.2 (C-β), 36.56 
(NHCOCH2C14H29), 39.1, 29.7, 29.7, 29.5, 29.4, 29.3 and 25.6  28.3 (NHCOCH2(CH2)13CH3), 20.9, 
20.9, 20.8 and 20.7 (O(CO)CH3), 14.1 (NHCOC14H28CH3); HRMS m/z (ESI+): 1118.5502 
(C52H84N3O23: [M+H]
+ requires  1118.5490).   
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N2-tert-butoxycarbonyl-L-asparagine tetradecylamide benzyl ester 2.66 
HOBt (680 mg, 5.1 mmol), N-Boc-L-Asp-OBn 2.56( 1.5 g, 4.60 mmol) and TBTU (1.6 g, 5.1 
mmol) were dissolved in DMF (30 mL), under N2 at rt. The mixture was stirred for 15 min and 
tetradecylamine (1.99 g, 5.1 mmol) dissolved in DMF ( 20 mL) was added dropwise. The 
mixture was stirred for 18 h. The reaction mixture was concentrated under reduced pressure, 
diluted with DCM and washed succesively with 0.1 M HCl, aqueous sat. NaHCO3 and brine. 
Flash chromotagraphy (1:1, EtOAc: Pet Ether) afforded the title compound 2.66 (2.03 g, 84%); 
Rf = 0.9 (1:1, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 3332.8, 2918.5, 2850.6, 1737.2, 
1687.4, 1645.2, 1524.4, 1467.3, 1367.4, 1293.1, 1168.7, 1058.3, 1028.3 cm-1; 1H NMR (300 
MHz, CDCl3):  7.34-7.32 (m, 5 H, Ar), 5.80 (d,  J = 7.8 Hz, 1 H, NHCOC(CH3)3), 5.63-5.56 (m, 1 H, 
NH(CH2)13CH3), 5.23-5.12 (m, 2 H, PhCH2), 4,.55-4.49 (m, 1 H, H-α), 3.21-3.13 (m, 2 H, 
NHCH2(CH2)12CH3), 2.89-2.80 (m, 1 H, H-β), 2.75-2.73-2.64 (m, 1 H, H-β), 1.47-1.39 (m, 9 H, 
COC(CH3)3), 1.32-1.23 (m, 22 H, NHCH2CH2(CH2)11CH3), 0.88 (t, J = 6.6 Hz, 3 H, 
NHCH2CH2(CH2)11CH3); HRMS m/z (ESI+): 1075.7058 (C60H100N4O10: [2M+K]
+ requires  
1075.7071).   
 
L-asparagine tetradecylamide benzyl ester 2.67 
A solution of N2-tert-butoxycarbonyl-L-asparagine tetradecylamide benzyl ester 2.66 (576 mg, 
1.1 mmol) in DCM (6 mL) was cooled in an ice bath and 50% TFA in DCM (0.85 mL, 11.1 mmol) 
was added dropwise. The reaction mixture was stirred at 0 oC for 30 min and then warmed to 
rt where The mixture was stirred for a further 2 h. The organic solvent was removed in vacuo 
and the residue obtained was diluted with EtOAc and washed with aqueous sat. NaHCO3 
solution, brine, dried over MgSO4 and concentrated to yield the corresponding deprotected 
amine 2.67 as a white solid which was used without further purification (377 mg, 73%). 1H 
NMR (300 MHz, CDCl3):  7.37-7.32 (m, 5 H, Ar), 6.81-6.73 (m, 1 H, NHC14H29), 5.20-5.12 (m, 2 
H, PhCH2), 3.91-3.67 (m, 1 H, H-α), 3.24-3.17 (m, 2 H, NHCH2(CH2)12CH3), 2.66 (dd, J = 3 Hz, J = 
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15.3 Hz, 1 H, H-β), 2.47 (dd, J = 8.7 Hz, J = 15.6 Hz, 1 H, H-β’), 1.49-1.41 (t, J = 6, 2 H, 
NHCH2CH2(CH2)11CH3), 1.32-1.22 (m, 22 H, NHCH2CH2(CH2)11CH3), 0.88 (t, J = 6.6 Hz, 3 H, 
NHCH2CH2(CH2)11CH3); HRMS m/z (ESI+): 419.3288 (C25H42N2O3: [M+H]
+ requires  419.3268).   
 
N2-hexadecanosyl-L-asparagine tetradecylamide benzyl ester 2.68 
NEt3 (0.129 mL, 0.93mmol,) was added to L-asparagine tetradecylamide benzyl ester 2.67 (357 
mg, 0.8 mmol,) dissolved in DCM (11 mL) under Ar. The reaction mixture was allowed to stir 
for 10 min, placed on ice and hexadecanosyl choride (0.235 mL, 0.77 mmol,) was added. The 
reaction mixture was stirred at rt overnight. The solvent was concentrated in vacuo, diluted 
with EtOAc, washed with 0.1 M HCl, NaHCO3, brine and dried (MgSO4). Column 
chromatography (EtOAc) afforded 2.68 as a white solid (490 mg, 87%); Rf = 0.67 (1:!, Pet 
Ether:EtOAc); [α]25 D = +7.5 (c, 1.75 in DCM); IR vmax (NaCl plate, DCM): 3290.0, 2917.0, 2849.4, 
1738.8, 1651.0, 1545.2, 1433.6, 1377.9, 1240.0, 1128.8, 721.5, 695.2 cm-1;   1H NMR (300 MHz, 
CDCl3):  7.35-7.30 (m, 5 H, Ar), 6.83 (d, J = 7.8 Hz, 1 H, NHCOC15H31), 5.69-5.60 (m, 1 H, 
NHC14H29), 5.23-5.13 (m, 2 H, PHCH2), 4.85-4.79 (m, 1 H, H-α), 3.20-3.12 (m, 2 H, NHCH2C13H27), 
2.89 (dd, J = 4.5 Hz, J = 15.6 Hz, 1 H, H-β), 2.69 (dd, J = 4.5 Hz, J = 15.6 Hz, 1 H, H-β’), 2.20 (t, J = 
7.2 Hz, 2 H, NHCOCH2C14H29), 1.65-54 (m, 2 H, NHCH2CH2C12H25), 1.47-1.39 (m, 2 H, 
NHCOCH2CH2C13H27), 1.35-1.18 (m, 46 H, NHC2H4(CH2)11CH3 and NHCOC2H4(CH2)12CH3), 0.88 (t, J 
= 6.6 Hz, 6 H, NHC13H26CH3 and NHCOC14H28CH3);
 13C NMR(75 MHz, CDCl3): c 173.2, 171.0, 
169.8 (each CO), 135.43 (ArC), 128.5, 128.3, 128.2 (ArCH), 67.4 (PhCH2), 49.1 (C-α), 39.7 
(NHCH2C13H27), 36.6 (NHCOCH2C8H17), 35.8 (C-β), 31.9, 29.7, 29.6, 29.6, 29.5, 29.5, 29.4, 29.3, 
29.2, 29.2, 29.1, 28.3, 26.9, 25.6 and 22.68 (NHCH2(CH2)12CH3 and NHCOCH2(CH2)7CH3), 14.1, 
(NHC13H26CH3 and NHCOC8H16CH3);  HRMS m/z (ESI+): 658.5588 (C41H73N2O4: [M+H]
+ requires  
658.5565).  
 
 
Chapter 6:                                                                                                                                    Experimental details 
 
 
 
204 
 
 
N2-hexadecanosyl-L-asparagine tetradecylamide 2.69 
To a solution of N2-hexadecanosyl-L-asparagine tetradecylamide benzyl ester 2.68 (450 mg, 0.6 
mmol) in EtOAc (35 mL), Pd/C (45 mg, 10% w/w) was added. The resulting mixture was heated 
to 50 oC and H2 bubbled through for 4 h. The mixture was then filtered through a Celite cake 
and the filtrate was concentrated under vacuum to afford a white solid which was recrystillised 
in DCM to yield the product 2.69 as a white solid (366 mg, 94%); 1H NMR (300 MHz, CDCl3):  
6.97 (d, J = 5.1 Hz, 1 H, NHCOC15H31), 6.81-6.77 (m, 1 H, NHC14H29), 4.55-4.49 (m, 1 H, H-α), 
3.34-3.22 (m, 2 H, NHCH2C13H27), 2.96-2.91 (m, 1 H, H-β), 2.66 (dd, J =6.6 Hz, J =16.8 Hz, 1 H, H- 
β’), 2.24 (t, J = 7.2 Hz, 2 H, NHCOCH2C14H29), 1.65-1.49  (m, 4 H, overlap of  NHCH2CH2C12H25 and 
NHCOCH2CH2C13H27), 1.32-1.24 (m, 46 H, NHC2H4(CH2)11CH3 and NHCOC2H4(CH2)12CH3), 0.88 (t, J 
= 6.3 Hz, 6 H, NHC13H26CH3 and NHCOC14H28CH3); HRMS m/z (ESI+): 567.5087 (C34H67N2O4: 
[M+H]+ requires  567.5095).  
 
β-D-Lactose octaacetate 2.73 
D-Lactose (5 g, 13.8 mmol) and NaOAc (1.13 g, 13.8 mmol) was added to a round bottom and 
placed on ice. Acetic anhydride (13 mL, 13.8 mmol) was added and the reaction mixture was 
heated to 110 oC and stirred overnight. The mixture was poured into ice H2O (20 mL) and the 
resulting gum was filtered and columned in (1:1, EtOAc: Pet Ether) to yield the pure product 
2.73 as a white solid (8.5 g, 80%); Mp = 97-95 oC (lit 96-95 oC)[232]; 1H NMR (300 MHz, CDCl3): δ 
5.66 (dd, J = 1.5 Hz, J = 8.1 Hz, 1 H, H-1 Gluc), 5.33 (bs, 1 H, H-4 Gal), 5.26-5.19 (m, 1 H, H-3 
Gluc), 5.14-4.91 (m, 3 H, overlap of H-2 Gluc, H-2 Gal and H-3 Gal), 4.48-4.42 (m, 2 H, overlap 
of H-1 Gal and 1 H of H-6 Gluc), 4.14 (m, 3 H, overlap of  1 H of H-6 Gluc and H-6, H-6’ Gal), 
3.88-3.73 (m, 3 H, overlap of H-4 Gluc, H-5 Gluc and H-5 Gal), 2.13, 2.10, 2.07, 2.04, 2.03, 2.02, 
2.01, 1.94 (each s, 3 H, O(CO)CH3); HRMS m/z (ESI+): 701.1185 (C28H38NaO19: [M+Na]
+ requires  
701.1900).   
Spectroscopic data is in agreement with the literature.[232] 
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2-Chloroethyl 2,2′,3,3′,4′,6,6′-hepta-O-acetyl-β-lactoside 2.74 
A solution of β-D-Lactose octaacetate 2.73 (3.5 g, 5.1 mmol) and 2-chloroethanol (0.415 mL, 
6.1 mmol) in dry DCM (10 mL)  was stirred under N2 and placed on ice.  50% BF3Et2O (4.74 mL, 
38.4 mmol) in DCM was added dropwise over 30 min. The reaction was stirred overnight, 
poured into 15 mL ice H2O, extracted with DCM (3x15 mL) and washed with aqueous sat. 
NaHCO3, H2O and dried over MgSO4. Flash chromatography (1:1, EtOAc:Pet Ether) afforded the 
pure product 2.74 as fluffy white solid (1.7 g, 47%); IR vmax (NaCl plate, DCM): 3448.0, 2114.4, 
1751.1, 1642.3, 1432.0, 1370.8, 1227.6, 1171., 1136.7, 1056.3, 954.3, 902.2, 736.1 cm-1 ; 1H-
NMR (300 MHz, CDCl3): δ 5.34 (d, J = 2.7 Hz, 1 H, H-4 Gal), 5.23-5.17 (m, 1 H, H-3 Gluc), 5.10 
(dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2 Gal), 4.97-4.88 (m, 2 H, overlap of H-2 Gluc and  H-3 Gal), 
4.54-4.47 (m, 3 H, overlap of H-1 Gal, H-1 Gluc and 1 H of H-6 Gluc), 4.15–4.00 (m, 4 H, overlap 
of H-6 Gal, 1 H of H-6 Gluc and 1 H of OCH2CH2NH), 3.89–3.85 (m, 1 H, H-5 Gal), 3.82–3.70 (m, 
2 H,  overlap of OCH2CH2NH and  H-5 Gluc), 3.63-3.58 (m, 3 H, overlap of H-4 Gluc and 
OCH2CH2NH), 2.15, 2.12, 2.06, 2.04, 2.04, 2.03 1.96  (each s, 3 H, O(CO)CH3) ; 
13C-NMR (75 
MHz, CDCl3): δc 100.9 (C-1 gal), 100.7 (C-1 Gluc), 76.2 (C-5, Gluc), 72.7 (C-3, Gluc), 72.6 (C-4 
Gluc), 71.5 (C-2 Gluc),  70.9 (C3- Gal), 70.7 (C-5 Gal), 69.9 (OCH2CH2Cl), 69.1 (C-2 Gal), 66.6 (C-4 
Gal), 61.8, 60.8 (C-6 Gal, C-6 Gluc), 41.9 (OCH2CH2Cl), 20.8, 20.8, 20.7, 20.6 and  20.5 
(O(CO)CH3); HRMS m/z (ESI+): 721.1714 (C28H39ClNaO18: [M+Na]
+ requires  721.1717).   
The spectroscopic data are in agreement with the literature.[235] 
 
2-Azidoethyl 2,2′,3,3′,4′,6,6′-hepta-O-acetyl-β-lactoside 2.75[234] 
2-Chloroethyl 2,2′,3,3′,4′,6,6′-hepta-O-acetyl-β-lactoside 2.74 (1 g, 1.5 mmol) was dissloved in 
DMF (20 mL) and sodium azide (205 mg, 3.1 mmol) was added. The mixture was heated to   
110 oC for 3 h. The solvent was removed under reduced pressure and the residue dissolved in 
EtOAc washed with H2O and dried with MgSO4. Flash chromatography (3:1, EtOAc:Pet Ether) 
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afforded the pure product 2.75 as a fluffy solid (833 mg, 74%); IR vmax (NaCl plate, DCM): 
3443.2, 1750.7, 1642.6, 1433.2, 1370.5, 1226.5, 1170.7., 1132.9, 1055.7, 954.0 cm-1 ;1H-NMR 
(300 MHz, CDCl3): δ 5.31-529 (m, 1 H, H-4 Gal), 5.19-5.13 (m, 1 H, H-3 Gluc), 5.06 (dd, J = 7.8 
Hz, J = 10.5 Hz, 1 H, H-2 Gal), 4.94-4.85 (m, 2 H, overlap of H-2 Gluc and  H-3 Gal), 4.54-4.45 (m, 
3 H, overlap of H-1 Gal, H-1 Gluc and 1 H of H-6 Gluc), 4.10–3.92 (m, 4 H, overlap of H-6 Gal, 1 
H of H-6 Gluc and 1 H of OCH2CH2N3), 3.86–3.75 (m, 2 H, overlap of  H-5 Gal and H-5 Gluc), 
3.68–3.56 (m, 2 H, overlap of OCH2CH2N3 and H-4 Gluc ), 3.47-3.39 (m, 1 H, 1 H of OCH2CH2N3),  
3.47-3.39 (m, 1 H, 1 H of OCH2CH2N3), 2.13, 2.11, 2.08, 2.02 (each s, 3 H, O(CO)CH3) , 2.04 (s, 6 
H, O(CO)CH3), 1.92 (s, 3 H, O(CO)CH3); 
13C-NMR (75 Hz, CDCl3): δc 170.3, 170.1, 170.0, 169.7, 
169.6, 169.0 (each CO), 100.9 (C-1 gal), 100.3 (C-1 Gluc), 76.1 (C-5, Gluc), 72.8 (C-3, Gluc), 72.7 
(C-4 Gluc), 71.4 (C-2 Gluc),  70.9 (C-3 Gal), 70.6 (C-5 Gal), 60.0 (C-2 Gal), 68.6 (OCH2CH2N3), 66.6 
(C-4 Gal), 61.7, 60.8 (C-6 Gal, C-6 Gluc), 50.4 (OCH2CH2N3), 21.0,  20.8, 20.7, 20.7, 20.6 and  
20.4 (O(CO)CH3); HRMS m/z (ESI+): 728.2099 (C28H39N3 NaO18: [M+Na]
+ requires  728.2121).   
The spectroscopic data are in agreement with the literature.[235] 
 
2-Aminoethyl 2,2′,3,3′,4′,6,6′-hepta-O-acetyl-β-lactoside 2.76 
To a solution of 2-azidoethyl 2,2′,3,3′,4′,6,6′-hepta-O-acetyl-β-lactoside 2.75 (100 mg, 0.14 
mmol) in absolute EtOH (20 mL), Pd/C (10 mg, 10% w/w) was added. The resulting mixture was 
stirred under hydrogen gas for 5 h. The mixture was then filtered through a Celite cake and the 
filtrate was concentrated under vacuum to afford the pure product 2.76 as thick clear oil (87 
mg, 73%); 1H-NMR (300 MHz, CDCl3):δ 5.28-5.27 (m, 1 H, H-4 Gal), 5.17-5.10 (m, 1 H,   H-3 
Gluc), 5.07-5.01 (m, 1 H, H-2 Gal), 4.92-4.81 (m, 2 H, overlap of H-2 Gluc and  H-3 Gal), 4.47-
4.43 (m, 3 H, overlap of H-1 Gal, H-1 Gluc and 1 H of H-6 Gluc), 4.10–4.0 (m, 4 H, overlap of H-6 
Gal, 1 H of H-6 Gluc and 1 H of OCH2CH2NH2), 3.85–3.71 (m, 2 H, overlap of  H-5 Gal and H-5 
Gluc), 3.62–3.50 (m, 2 H, overlap of OCH2CH2NH2 and H-4 Gluc ), 2.85-2.73 (m, 2 H, 
OCH2CH2NH2),  2.09, 2.06, 2.0, (each s, 3 H, O(CO)CH3), 1.98 (s, 9 H, O(CO)CH3), 1.90 (3 H, 
O(CO)CH3). 
The spectroscopic data are in agreement with the literature.[234] 
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N2-palmitoyl-L-asparagine tetradecylamide benzyl ester 2.77 
Free amine 2.52 (1.4 g, 3.3 mmol) was dissolved in dry THF (15 mL) under N2 and hexadecanoyl 
chloride (1.01 mL, 3.3 mmol) was added. The reaction was left stirring for 10 min and then 
NEt3 added (0.46 mL, 3.3 mmol). The reaction mixture was left stirring at rt overnight. Flash 
Chromatography (2:1, EtOAc:Pet ether) yielded the pure product 2.77 as a white solid (1.5 g, 
68%); Rf = 0.52 (2:1, Pet Ether:EtOAc); [α]
25 
D = -11.2 (c, 1 in DCM); IR vmax (NaCl plate, DCM): 
3292.9, 2917.0, 2849.7 1733.4, 1642.8, 1656.9, 1642.8, 1544.0, 1468.2,  1373.2, 1355.9, 
1338.6, 1286.6, 1221.0, 113.5, 1145.4, 1113.2, 1100.2, 1030.6, 937.9, 970.5. 740.1, 720.6, 
740.1  cm-1;  1H NMR (300 MHz, CDCl3):  7.34 (bs, 5 H, Ar), 6.95 (d, J = 8.1 Hz, 1 H, 
NHCOC15H31), 6.66-6.64 (m, 1 H, CONHC14H29), 5.17-5.08 (m, 2 H, CH2Ph), 4.83-4.76 (m, 1 H, H-
α), 3.20-3.10 (m, 2 H, NHCH2C13H27), 2.93 (dd, J = 4.5 Hz, J = 16.8 Hz, 1 H, H-β), 2.67 (dd, J =7.2 
Hz, J = 16.8 Hz, 1 H, H- β’), 2.18 (t, J = 7.2 Hz, 2 H, NHCOCH2C14H29), 1.59-1.57 (m, J = 6 Hz, 2 H, 
NHCH2CH2C12H25), 1.44 (bs, 2 H, NHCOCH2CH2C13H27), 1.25 (s, 36 H, NHC2H4(CH2)11CH3 and 
NHCOC2H4(CH2)12CH3), 0.87 (t, J = 6.6 Hz,  6 H, NHC13H26CH3 and NHCOC14H28CH3); 
13C NMR (75 
MHz, CDCl3): c 171.9, 170.3, 135.4 (each CO), 128.6, 128.4, 128.3 (C-Ph), 66.9 (CH2Ph), 49.2  
(C-α), 39.7 (NHCH2C13H27), 36.5 (NHCOCH2C14H29), 35.9 (C-β),  31.9, 29.7, 29.7, 29.6, 29.5, 29.36, 
29.3, 29.2, 29.1, 28.3, 25.6, 22.7 (NHCH2(CH2)12CH3, NHCOCH2(CH2)13CH3), 13.1 (NHC13H26CH3, 
NHCOC14H28CH3); HRMS m/z (ESI+): 657.5577 (C41H73N2O4: [M+H]
+ requires  657.5565).   
 
2-Azidoethyl-β-D-galactopyranoside 2.85 
2-Azidoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.44 (1.00 g, 2.3 mmol) was 
dissolved in MeOH (14 mL) and DCM (20 mL) and placed under N2. 5.40 M NaOMe (0.22 mL, 
1.1 mmol) was added at rt. The reaction was stirred for 1 h, neutralised with Amberlite IR-120, 
filtered and evaporated under reduced pressure to yield the product as a viscous colourless oil 
(0.54 g, 91%). The product was used without further purification; 1H NMR (300 MHz, MeOD):  
4.27 (d, J = 7.2 Hz, 1 H, H-1), 4.06-3.99 (m, 1 H, OCH2CH2NH), 3.3 (d, J= 1.8 Hz, 1 H, H-4), 3.78-
3.67 (m, 3 H, overlap of 1 H of  OCH2CH2NH and H-6, H-6’), 3.57-3.43 (m, 5 H,  overlap of H-3, 
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H-2, H-5 and OCH2CH2NH); 
13C-NMR (75 MHz, MeOD): δc 103.7 (C-1), 75.3, 73.3, 71.1 (C-2, C-3 
and C-5), 68.8 (C-4), 67.8 (OCH2CH2NH), 61.1 (C-6), 50.5 (OCH2CH2NH); HRMS m/z (ESI+): 
272.0867 (C8H15N3NaO6: [M+Na]
+ requires  272.0853).   
The NMR Data is in agreement with the reported values.[236] 
 
2-Azidoethyl 2,3,4,6-tetra-O-trimethylsilyl-β-D-galactopyranoside 2.86[101] 
A mixture of chlorotrimethylsilane (1.6 mL, 13 mmol) and hexamethyl  disilazane (0.98 mL, 4.4 
mmol) was carefully added to a stirred solution of  1-O-(2-azidoethyl)-β-D-galactopyranose 
2.85 (0.540 g, 2.2 mmol) in pyridine (12 mL) at 0 oC. The reaction was allowed to return to rt at 
stirred overnight. The solvent was removed under reduced pressure and the resulting residue 
was dissolved in DCM, washed with H2O, dried (MgSO4) and concentrated to afford the pure 
product 2.86 as a clear oil (0.89 g, 76%); Rf = 0.90 (1:1, Pet Ether:EtOAc); [α]
25 
D = -4 (c, 1 in 
DCM); IR vmax (NaCl plate, DCM): 2958.3, 2879.3, 2104.4, 1439.9, 1399.5, 1374.8 1345.1, 
1251.5, 1170.6, 1105.1, 1076.0, 11014.9, 958.3, 978.3, 877.2, 841.2, 751.0, 686.1, 625.8 cm-1;  
1H NMR (300 MHz, CDCl3):  4.19 (d, J = 7.5 Hz, 1 H, H-1), 4.0-3.93 (m, 1 H, 1 H of OCH2CH2NH), 
3.83 (d, J = 1.8 Hz, 1 H, H-4), 3.70-3.58 (m, 3 H, overlap of 1 H of  OCH2CH2NH, H-2 and H-6, H-
6’), 3.48-3.28 (m, 4 H,  overlap of H-3, H-5 and OCH2CH2NH), 0.16, 0.14, 0.13 and 0.11 (each s, 
9 H, Si(CH3)3); 
13C-NMR (75 MHz, CDCl3):δc 103.4 (C-1), 74.6 (C-5, C-3), 71.0 (C-2) 70.9 (C-4), 
70.6 (C-3), 67.1 (OCH2CH2NH), 60.4 (C-6), 50.1 (OCH2CH2NH), 0.0, -0.2 and -1.1 (Si(CH3)3; HRMS 
m/z (ESI+): 536.2471 (C20H46N3O6Si4: [M-H]
-  requires  536.2469).   
 
2-Azidoethyl 2,3,4-tri-O-trimethylsilyl-β-D-galactopyranoside 2.87[101] 
2-azidoethyl 2,3,4,6-tetra-O-trimethylsilyl-β-D-galactopyranose 2.86 (0.99 g, 1.84 mmol) was 
dissolved in acetone (3 mL) and MeOH (4 mL) and  placed on ice. AcOH (0.210 mL, 3.6 mmol) 
was added and the reaction mixture was allowed to stir for 2 h. NaHCO3 was added and the 
solvent removed under reduced pressure. The residue obtained was dissolved in DCM washed 
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with NaHCO3, dried (MgSO4) and concentrated to afford the pure product 2.87 as a clear oil 
(0.644 g, 75%); Rf = 0.78 (1:1, Pet Ether:EtOAc); [α]
25 
D = -3.7 (c, 0.9 in DCM); IR vmax (NaCl plate, 
DCM): 3441.9, 2957.7, 2104.3, 1729.0, 1399.1, 1373.0, 1249.8, 1168.2, 1117.0, 971.7, 895.9, 
839.9, 751.4 cm-1;  1H NMR (300 MHz, CDCl3):  4.22 (d, J = 7.5 Hz, 1 H, H-1), 4.02-3.95 (m, 1 H, 
1 H of OCH2CH2NH), 3.88-3.81 (m, 1 H, H -6), 3.76 (d, J = 2.1 Hz, 1 H, H-4), 3.70-3.62 (m, 3 H, 
overlap of 1 H of  OCH2CH2NH, H-2 and H-6’), 3.48-3.46 (m, 3 H,  overlap of  H-5 and 
OCH2CH2NH), 3.64 (dd, J = 2.7 Hz,  J = 9 Hz, 1 H, H-3), 0.022, 0.00 and -0.254  (each s, 9H, 
Si(CH3)3); 
13C-NMR (75 MHz, CDCl3): δc 103.5 (C-1), 74.6 (C-5), 74.5 (C-3),  71.7 (C-4) 70.9 (C-2, 
67.1 (OCH2CH2NH), 62.1 (C-6), 50.1 (OCH2CH2NH), 0.3, 0.2, 0.00 (Si(CH3)3; HRMS m/z (ESI+): 
464.2073 (C17H38N3O6Si3: [M-H]
- requires  464.2074).   
 
2-Azidoethyl 2,3,4-tri-O-trimethylsilyl, 6-O carboxymethylbromide)-β-D-galactopyranoside 2.89 
2-Azidoethyl 2,3,4-tri-O-trimethylsilyl-β-D-galactopyranoside 2.87 (151 mg, 0.3 mmol) and 4 Å 
MS was dried on the schlenk, and then dissolved in dry DCM (3 mL) under N2. Bromoacetic acid 
(113 mg, 0.8 mmol) 4 Å MS was also dried on the schlenk, and dissolved in dry DCM (2 mL) 
under N2. DCC (100 mg, 0.4 mmol) and DMAP (3 mg, 0.01 mmol) were added to the 
bromoacetic acid solution. The mixture allowed was stirred for 5 min and then the alcohol was 
added slowly. The reaction mixture was stirred overnight at rt.  The solvent was removed 
under reduced pressure and the resulting residue dissolved in DCM washed with H2O, dried 
(MgSO4). Flash chromatography (3:1, Pet Ether, EtOAc) afforded the pure product 2.89 as 
viscous clear oil (116 g, 61%); Rf = 0.80 (3:1, Pet Ether:EtOAc); [α]
25 
D = 4.3 (c, 1.2 in DCM); IR 
vmax (NaCl plate, DCM): 2958.7, 2924.9, 2104.5, 1745.7, 1441.1, 1402.6, 1344.9, 1373.4, 
1279.1, 1250.6, 1171.2, 1116.1, 1076.6, 1051.9, 1024.3, 957.9, 972.8, 894.9, 840.8, 752.1, 
685.4 cm-1; 1H NMR (300 MHz, CDCl3):  4.36-4.30 (m, 1 H, H-6), 4.26-4.19 (m, 2 H, overlap of 
H-6’ and H-1), 4.00-3.93 (m, 1 H, 1 H of OCH2CH2NH), 3.80 (s, 2 H, COCH2Br), 3.78 (d, J = 2.1 Hz, 
1 H, H-4), 3.70-3.60 (m, 3 H, overlap of 1 H of  OCH2CH2NH, H-2 and H-5), 3.50-3.46 (m, 2 H, 
OCH2CH2NH), 3.41 (dd, J = 2.7 Hz, J = 9 Hz, 1 H, H-3), 0.16 (s, 9 H, Si(CH3)3), 0.14 (s, 18 H, 
Si(CH3)3); 
13C-NMR (75 MHz, CDCl3): δc 166.4 (CO), 103.4 (C-1), 74.3 (C-3), 71.4 (C-5) 71.0 (C-4), 
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70.7 (C-2), 67.3 (OCH2CH2NH), 64.0 (C-6), 50.1 (OCH2CH2NH), 24.7 (COCH2Br), 0.0, 0.02 and -0.2 
(Si(CH3)3; HRMS m/z (ESI+): 664.0535 (C19H40N3O7Si3: [M+Br]
- requires  664.0546).   
 
N-propylhexadecamide 
Propyl amine (396 mg, 0.45 mmol) was dissolved in dry DCM (10 mL) under N2 and 
hexadecanoyl chloride(0.466 mL, 1.5 mmol) was added. The reaction was left stirring for 10 
min and then NEt3 added (0.235 mL, 1.6 mmol). The reaction mixture was left stirring at rt 
overnight. Gradient elution chromatography (1:1, Pet Ether:EtOAc ) yielded the pure product 
2.93 as a white solid (392 mg, 86%); Rf = 0.64 (1:1, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 
3301.23, 2956.39, 2918.75, 2849.61, 2872.27, 1638.20, 1552.66, 1471.83, 1437.1, 1372.54, 
1285.28, 1269.04, 1249.33, 1227.36, 1207.68, 1156.38, 1122.22 and 1080.20  cm-1;  1H NMR 
(300 MHz, CDCl3):   5.73 (bs, 1 H, CONHCH2), 3.24-3.10 (m, 2 H, CONHCH2C2H5), 2.13 (t, J = 7.5 
Hz, 2 H, NHCOCH2C14H29), 1.61-1.51 (m, 2 H, NHCH2CH2C13H27), 1.53-1.45 (m, 2 H, 
CONHCH2CH2CH3), 1.25 (s, 24 H, NHCOC2H4(CH2)12CH3), 0.91-0.82 (m, 6 H, overlap of 
NHCOC14H28CH3 and CONHC2H4CH3); 
13C-NMR (75 Hz, CDCl3): δc 173.2 (CO), 41.1 
(CONHCH2C2H5), 36.9 (NHCOCH2C14H29), 31.9, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3 and 29.3 
(NHCOC2H4(CH2)12CH3), 25.9 (NHCH2CH2C13H27), 22.9 (CONHCH2CH2CH3), 22.7 
(NHCOC2H4(CH2)12CH3), 14.1, 11.3 (NHCOC14H28CH3 and CONHC2H4CH3); HRMS m/z (ESI+): 
298.3126 (C19H40NO: [M+H]
+ requires  298.3104).   
The NMR data is in agreement with the literature.[237] 
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Solubility of selected aspartic acid analogues 
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6.2.2 Experimental procedures for Chapter 3 
 
 
2-Decyl-N1,N2-bis[2-(β-D-galactopyranosyl)ethyl] malonamide 3.33 
NEt3 (0.1 mL) was added to a stirring solution of 2-decyl-N
1,N2-bis[2-(2,3,4,6-O-tetracetyl)-β-D-
galactopyranosyl)ethyl] malonamide 3.38  (64 mg, 0.064 mmol) dissolved in DCM/MeOH/H2O 
(3 mL/6 mL/3 mL) at 40 °C. The mixture was stirred for 18 h. The reaction mixture was 
concentrated under reduced pressure to afford the crude solid which was triturated using 
DCM and EtO2 to afford 3.33 as a white solid (33 mg, 78%); [α]
25 
D = 5 (c, 0.8 in MeOH); 
1H-NMR 
(300 MHz, d5-Pyr): δ 8.85-8.80 (m, 2  H, CONHCH2CH2O), 4.79 (dd, J = 2.0 Hz,  J = 7.6 Hz, 1 H, H-
1), 4.54–4.39 (m, 8 H, overlap of H-2, H-4, H-6, H-6'), 4.18–4.07 (m, 6 H, overlap of H-3, H-5, 1 
H of OCH2CH2NH), 3.99–3.95 (m, 2 H, 1 H of OCH2CH2NH), 3.78–3.62 (m, 5 H, overlap of 
OCH2CH2NH and H-α), 1.54-1.38 (m, 2 H, NHCOCHCH2C9H19), 1.29-1.06 (m, 16 H, 
NHCOCHCH2(CH2)8CH3), 0.84 (t, J = 6.5 Hz, 3 H, NHCOCHCH2(CH2)8CH3);
13C-NMR (75 MHz, d5-
Pyr): δc 171.7, 171.6 (each CO), 105.9 (C-1), 77, 4, 75.6 (C-3, C-5), 72.8, 70.6 (C-2, C-4), 69.9, 
69.7 (OCH2CH2NH), 62.9, 62.8 (C-6), 55.5 (C-α), 40.8 (OCH2CH2NH), 32.4 (NHCOCHCH2C9H19), 
30.2, 30.1, 30.0, 29.9, 28.4, 23.2 (NHCOCHCH2(CH2)8CH3), 14.6 (NHCOCHCH2(CH2)8CH3); HRMS 
m/z (ESI+): 655.364 (C29H55N2O14: [M+H]
+ requires  655.3648).   
 
2-Decyl-N1,N2-bis(β-D-galactopyranosyl) malonamide 3.32 
NEt3 (0.1 mL) was added to a stirring solution of 2-decyl-N
1,N2-bis(2,3,4,6-O-tetracetyl-β-D-
galactopyranosyl) malonamide 3.68 (70 mg, 0.077 mmol) dissolved in DCM/MeOH/H2O (3 
mL/6 mL/3 mL) at 40 °C. The mixture was stirred for 18 h. The reaction mixture was 
concentrated under reduced pressure to afford the crude solid which was triturated using 
DCM and EtO2 to give 3.32 as a white solid (40 mg, 93%); [α]
25 
D = 4.2 (c, 1.2 in MeOH); 
1H-NMR 
(300 MHz, d5-Pyr): δ 10.03 (d, J = 9.3 Hz, 1 H, CONHH-1), 9.92 (d, J = 9 Hz, 1  H, CONHH-1), 5.96 
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(m, 2 H, H-1), 4.74–4.50 (m, 4 H, overlap of H-2, H-4), 4.44-4.32 (m, 4 H, overlap of H-6 and H-
6’), 4.20–4.15 (m, 2 H, overlap of H-3), 3.84–3.77 (m, 1 H, H-α), 2.29-2.23 (m, 2 H, 
NHCOCHCH2C9H19), 1.58-1.33 (m, 2 H, NHCOCHCH2CH2C8H17), 1.19-1.03 (m, 14 H, 
NHCOCHCH2CH2(CH2)7CH3), 0.83 (t, J = 6.5 Hz, 3 H, NHCOCHCH2CH2(CH2)7CH3); 
13C-NMR (75 
MHz, d5-Pyr): δc 172.6, 172.4 (each CO), 82.3, 82.2 (C-1), 79.1, 78.9, 76.6, 76.5 (C-3, C-5), 72.4, 
72.3, 70.8, 70.7 (C-2, C-4),  62.6 (C-6), 55.9 (C-α), 32.3 (NHCOCHCH2C9H19), 30.1, 29.9, 29.8, 
28.4, 23.2 (NHCOCHCH2(CH2)8CH3), 14.6 (NHCOCHCH2(CH2)8CH3); HRMS m/z (ESI+): 567.3125 
(C25H47N2O12: [M+H]
+ requires  567.3124).   
2-Decyl-N1,N2-bis[(β-D-galactopyranosyl)-1,2,3-triazol-4ylmethylamide] malonamide 3.34 
NEt3 (0.1 mL) was added to a stirring solution of 2-decyl-N
1,N2-bis[(2,3,4,6-O-tetracetyl)-β-D-
galactopyranosyl)-1,2,3-triazol-4ylmethylamide] malonamide 3.71 (64 mg, 0.060 mmol) 
dissolved in DCM/MeOH/H2O (3 mL/6 mL/3 mL) at 40 °C. The mixture was stirred for 18 h. The 
reaction mixture was concentrated under reduced pressure to afford the crude solid which 
was triturated using DCM and EtO2 to give to afford 3.34 as a white solid (41 mg, 95%); [α]
25 
D = 
12 (c, 1 in MeOH); 1H-NMR (300 MHz, d5-Pyr): δ 9.59-9.53 (m, 2  H, CONHCH2), 8.41 (d, J = 2.7 
Hz, 1  H, N3CCH), 6.28 (d, J = 9.1 Hz, 2 H, H-1), 5.18-5.12 (m, 2 H, H-2),  4.81-4.78 (m, 2 H, 
CONHCH2), 4.66 (bs, 2 H, H-4),  4.47-4.34 (m, 8 H, overlap of H-3, H-5, H-6 and H-6’), 3.69 (t, J = 
7.2 Hz, 1 H, H-α), 2.16-2.10 (m, 2 H, NHCOCHCH2C9H19), 1.45-1.37 (m, 2 H, 
NHCOCHCH2CH2C8H17), 1.22-1.08 (m, 14 H, NHCOCHCH2CH2(CH2)7CH3), 0.83 (t, J = 6.5 Hz, 3 H, 
NHCOCHCH2CH2(CH2)7CH3); 
13C-NMR (75 MHz, d5-Pyr): δc 171.5 (CO),  146.0 (N3CCH), 122.5 
(N3CCH), 90.5 (C-1), 80.7, 76.1 (C-3, C-5), 71.7, 71.6, 70.6 (C-2, C-4),  62.6 (C-6), 55.6 (C-α), 35.9 
(CONHCH2), 32.4 (NHCOCHCH2C9H19), 30.2, 30.1 29.9, 29.8, 28.4, 23.2 (NHCOCHCH2(CH2)8CH3), 
14.6 (NHCOCHCH2(CH2)8CH3); HRMS m/z (ESI+): 729.3759 (C31H53N812: [M+H]
+ requires  
729.3777).   
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 Dimethyl 2-decylmalonate 3.37[134] 
To a solution of dimethyl malonate 3.35 (0.866 mL, 7.5 mmol) and bromodecane (1.61 mL, 98 
mmols) in MeCN, K2CO3 (4.18 g, 30 mmol) was added and the reaction was refluxed for 24 hrs. 
The K2CO3 was filtered off and the filtrate concentrated under reduced pressure. The resulting 
liquid was taken up in EtOAc and a wash of H2O and brine was carried out. It was then dried 
over MgSO4 and concentrated under reduced pressure to yield a clear liquid. Flash 
chromatography (96:4, Hex:EtOAc) afforded the title compound 3.37 as a clear liquid (1.65 g, 
80%); Rf = 0.65 (96:4, Hex:EtOAc); IR vmax (NaCl plate, DCM): 2954.9. 2925.8, 2855.3, 1739.8, 
1435.8, 1342.3, 1198.8, 1153.5, 1122.9, 1018.3, 804.9, 722.0 cm-1; 1H NMR (300 MHz, CDCl3):  
3.69 (s, 6 H, COOCH3), 3.30 (t, J = 7.5 Hz, 1 H, H-α), 1.85-1.81 (m, 2 H, COCHCH2(CH2)8CH3), 1.29-
1.21 (m, 16 H, COCHCH2(CH2)8CH3), 0.82 (t, J = 6.6 Hz, 3 H, COCHCH2(CH2)8CH3); 
13C NMR (75 
MHz): c 169.8 (CO), 52.2 (OCH3), 51.6 (α-C), 31.8, 29.5, 29.4, 29.2, 29.1, 28.8, 
(COCHCH2(CH2)8CH3), 27.3 (COCHCH2(CH2)8CH3), 22.6 (COCHCH2(CH2)8CH3), 13.90 
(COCHCH2(CH2)8CH3); HRMS m/z (ESI+): 311.1622 (C15H28KO4: [M+K]
+ requires  311.1619).   
NMR data is in agreement with the literature.[124] 
 
2-Decylmalonic acid 3.36 
15% NaOH (0.317 mL) was added to dimethyl 2-decylmalonate 3.37 (100 mg, 0.34 mmol) in 
EtOH (5 mL). The reaction was heated to 80 oC and stirred overnight. H2O (4 mL) and 2 M HCl 
was added dropwise until a pH of 1 was reached. The reaction mixture was concentrated in 
vacuo; diluted with EtOAc, washed with brine and H2O, dried (MgSO4) and concentrated under 
reduced pressure to yield 3.36 as a white solid (44 mg, 50%); Mp = 120-118 oC (lit 119.5-118 
oC)[238]; 1H NMR (300 MHz, CDCl3):  3.44 (t, J = 7.5 Hz, 1 H, H-α), 1.70-1.68 (m, 2 H, 
COCHCH2(CH2)8CH3), 1.30-1.22 (m, 16 H, COCHCH2(CH2)8CH3), 0.85 (t, J = 6.3 Hz, 3 H, 
COCHCH2(CH2)8CH3); HRMS m/z (ESI+): 245.1758 (C13H25O4: [M+H]
+ requires  245.1747).   
This compounds is mentioned in the literature but no NMR data are given.[239] 
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[2-O-(2,3,4,6-O-tetracetyl-β-D-galactopyranose)ethyl]-dodecanamide 3.39 
HOBt (116 mg, 0.859 mmol) and NEt3 ( 0.228 mL, 1.6 mmol) were added to a stirring solution 
of  2-decylmalonic acid 3.36 (100 mg, 0.40 mmol) and TBTU (275 mg, 0.85 mmol) dissolved in 
DMF (12 mL), under N2 at rt. The mixture was stirred for 20 min and O-(2-aminoethyl)-(2,3,4,6-
O-tetracetyl)-β-D-galactopyranose 2.33 (352 mg, 0.9 mmol) dissolved in DMF (10 mL) was 
added dropwise. The mixture was stirredovernight. The reaction mixture was concentrated in 
vacuo diluted with EtOAc and washed with brine. Flash chromotagraphy (1:1, Ethyl acetate: 
Hexane) afforded the title compound 3.39 as an off white solid (180 mg, 78%); Rf = 0.22 (1:1, 
Hex:EtOAc); [α]25 D = -6.6 (c, 1 in CHCl2);  IR vmax (NaCl plate, DCM): 3409.1, 2958.1, 2925.7, 
2854.4, 1751.7, 1547.1, 465.5, 1436.1, 1379.0, 1221.6, 1172.6, 1221.6, 1059.5, 956.7, 900.9, 
799.4, 772.0, 714.1 cm-1; 1H NMR (300 MHz, CDCl3):  5.84 (t, J = 5.1 Hz, 1 H, CONHCH2CH2O), 
5.38 (d, J = 3.3 Hz, 1 H, H-4), 5.17 (dd, J = 7.8, J = 10.5, 1 H, H-2), 5.00 (dd, J = 3.3 Hz, J = 10.5 Hz, 
1 H, H-3), 4.46 (d, J = 7.8 Hz, 1 H, H-1), 4.13 (dd, J = 2.1 Hz, 2 H, H-6, H-6’), 3.93-3.82 (m, 2 H,  
overlap of H-5 and 1 H NHCH2CH2O), 3.70-3.63 (m, 1 H, 1 H of NHCH2CH2O), 3.54-3.34 (m, 2 H, 
NHCH2CH2O), 2.14-1.97 (m, 11 H, overlap of NHCOCH2C10H21 and O(CO)CH3), 1.62-1.55 (m, 2 H, 
NHCOCH2CH2C9H19), 1.29-1.23 (m,  16 H, COCH2CH2(CH2)9CH3), 0.85 (t, J = 6.3 Hz, 3 H, 
(COCH2(CH2)9CH3); 
13C-NMR (75 MHz, CDCl3): δc 173.2 (CO), 170.3, 170.1, 170.0, 169.6 
(O(CO)CH3) 101.4 (C-1), 70.8, 70.7 (C-5, C-3), 69.2, (C-2), 68.9 (OCH2CH2NH), 66.9 (C-4), 61.3 (C-
6), 39.0 (OCH2CH2NH), 36.7 (NHCOCH2C10H21), 31.8, 29.6, 29.5, 29.4, 29.3, 29.3, 25.6, 
(NHCOCH2(CH2)9CH3), 22.6 20.80, 20.6, 20.5 (each O(CO)CH3), 14.1 (NHCO(CH2)10CH3); HRMS 
m/z (ESI+): 574.3231 (C28H48NO11: [M+H]
+ requires  574.3222). 
 
N-propyldodecanamide 3.68 
HOBt (81 mg, 0.60 mmol) and NEt3 ( 0.076mL, 0.548 mmol) were added to a stirring solution of  
2-decylmalonic acid 3.36 (67 mg, 0.27 mmol) and TBTU (190 mg, 0.60 mmol) dissolved in DMF 
(10 mL), under N2 at rt. The mixture was stirred for 20 min and propylamine (0.05 mL, 0.60 
mmol) was added dropwise. The mixture was stirredovernight. The reaction mixture was 
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concentrated in vacuo diluted with EtOAc and washed with brine. Flash chromotagraphy (1:1 
EtOAc:Hex) afforded 3.68 as a whitish solid (35 mg, 53%); Rf = 0.63 (1:1, Hex:EtOAc); 
1H NMR 
(300 MHz, CDCl3):  5.58 (bs, 1 H, NH), 3.22-3.15 (m, 2 H, NHCH2CH2CH3), 2.14 (t, J = 7.5 Hz, 2 
H, COCH2(CH2)9CH3), 1.62-1.57 (m, 2 H, COCH2CH2(CH2)8CH3), 1.53-1.46 (m, 2 H, NHCH2CH2CH3), 
0.92-0.83 (m, 6 H, overlap of NHCH2CH2CH3, COCH2(CH2)9CH3); HRMS m/z (ESI+): 242.2485 
(C15H31NO: [M+H]
+ requires  242.2478). NMR data is in agreement with the literature.[240] 
 
Dimethyl 2-dodecylidenemalonate 3.48 
To a solution of dimethyl malonate 3.35 (0.52 mL, 4.5 mmol) and dodecanal (0.73 mL, 4.5 
mmol) in anhydrous DCM (15 mL) on ice, piperidine (2 drops) and acetic acid (2 drops) were 
added. The reaction was left to stir at 0 oC for 45 min and then 4 Å molecular sieves were 
added. The reaction was stirred at room temperature for 16 h. The reaction mixture was 
diluted with Et2O (40 mL), and washed with H2O (10 mL portions) until the aqueous phase was 
neutral. The collected aqueous phase was extracted with Et2O (15 mL x 3). The combined 
organic layers where washed with, aqueous sat. NaHCO3 and brine. The solution was dried 
over MgSO4 and solvent removed under reduced pressure to yield a clear liquid. Flash 
chromatography (5:1, Hex: EtOAc) afforded the title compound 3.48 as a clear liquid (0.516 g, 
38%); Rf = 0.71 (5:1, Hex:EtOAc); IR vmax (NaCl plate, DCM): 2925.6, 2854.8, 1731.5, 1646.8, 
1436.4, 1369.9, 1261.9, 1222.5, 1062.5, 771.1 cm-1; 1H NMR (300 MHz, CDCl3):  7.04-6.97 (m, 
1 H, C=CH), 3.80-3.74 (m, 6 H, COOCH3), 2.31-2.22 (m, 2 H, CCHCH2(CH2)9CH3), 1.51-1.39 (m, 2 
H, CCHCH2CH2(CH2)8CH3), 1.34-1.19 (m, 16 H, CCHCH2CH2(CH2)8CH3), 0.89-0.82 (m, 3 H, 
CCHCH2CH2(CH2)8CH3); 
13C NMR (75 MHz, CDCl3): c 165.9, 164.4 (CO), 150.5 (C=CH), 127.87 
(C=CH), 52.2, 52.1 (COOCH3), 31.9, 29.8, 29.6, 29.4, 29.3, 29.2, 29.1, 28.2, 22.6 
(C=CH(CH2)10CH3), 14.0 (C=CH(CH2)10CH3); HRMS m/z (ESI+): 299.2232 (C17H31O4: [M+H]
+ 
requires  299.2217). 
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[2-O(2,3,4,6-O-tetracetyl-β-D-galactopyranosyl)ethyl]-acetamide 3.50 
Dimethyl 2-dodecylidenemalonate 3.48 (100 mg, 0.36mmol) was dissolved in anhydrous EtOAc 
(2.5 mL) under Ar. The round bottom was wrapped in tinfoil and LiI (396 mg, 1.47 mmol) 
added. The reaction mixture was heated to 60 oC and stirred overnight. HOBt (148 mg, 1.1 
mmol), TBTU (353 mg, 1.1 mmol) and NEt3 (0.15 mL, 1.1mmol) were added and the reaction 
mixture stirred for 5 min. 2-aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 2.33 (431 
mg, 1.1 mmol) was dissolved in DMF (3 mL) and added and the resulting solution was stirred 
for 10 h. The solvent was removed under reduced pressure. The residue obtained was 
dissolved in DCM and washed with 1M HCl, aqueous sat. NaHCO3, brine and dried over 
MgSO4. Column chromatography afforded the decarboxylated product 3.50 as an oily solid 
(100 mg, 63%); Rf = 0.38 (10:1, DCM:MeOH); [α]
25 
D = 4.2 (c, 0.96 in DCM); IR vmax (NaCl plate, 
DCM): 3388.3, 3087.6, 2962.9, 2940.2, 1749.7, 1661.5, 1539.0, 1432.0, 1371.1, 1225.8, 1173.3, 
1134.7, 1075.9, 956.3, 914.9, 799.9, 753.3, 666.2 cm-1; 1H NMR (300 MHz, CDCl3):  5.98 (bs, 1 
H, CONHCH2CH2O), 5.38 (dd, J = 1 Hz, J = 3.4 Hz, 1 H, H-4), 5.17 (dd, J = 7.8, J = 10.5, 1 H, H-2), 
5.00 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 H, H-3), 4.45 (d, J = 7.8 Hz, 1 H, H-1), 4.19-4.07 (m, 2 H, H-6, 
H-6’), 3.93-3.82 (m, 2 H,  overlap of H-5 and NHCH2CH2O), 3.70-3.64 (m, 1 H, 1 H of 
NHCH2CH2O), 3.54-3.34 (m, 2 H, NHCH2CH2O), 2.14, 2.05, 2.03, 1.97 (each s, 3 H, O(CO)CH3); 
13C-NMR (75 MHz, CDCl3): δc 173.2 (CO), 170.3, 170.1, 170.0, 169.6 (O(CO)CH3) 101.4 (C-1), 
70.8, 70.7 (C-5, C-3), 69.2, (C-2), 68.9 (OCH2CH2NH), 66.9 (C-4), 61.3 (C-6), 39.0 (OCH2CH2NH), 
23.2, 20.80, 20.6, 20.5 (each O(CO)CH3); HRMS m/z (ESI+): 434.1669 (C18H28NO11: [M+H]
+ 
requires  434.1657). 
 
2-Decyl-N1,N3-bis(2-hydroxyethyl)malonamide 3.52 [126b] 
Dimethyl 2-decylmalonate 3.37 (500 mg, 1.8 mmol) and ethanolamine were dissolved in DCM 
(1 mL) under N2. The reaction mixture was stirred at rt for 3 days. The solvent was removed in 
vacuo and the crude residue recrystallised in EtOH and Et2O (1:1) to yield the desired product 
3.52 as white crystals (370 mg, 62%); IR vmax (NaCl plate, DCM): 3332.9, 2915.7, 2848.6, 1673.9, 
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16371, 1557.4, 1463.3, 1421.3, 1332.7, 1214.2, 1088.7, 1056.9, 1044.9, 928.0 cm-1; 1H NMR 
(300 MHz, CDCl3):  7.86 (t, J = 5.4 Hz, 2 H, NH), 4.70 (t, J = 5.3 Hz, 2 H, OH),  3.40-3.35 (m,  4 H, 
NHCH2CH2OH), 3.17-3.06 (m, 4 H, NHCH2CH2OH), 3.30 (t, J = 7.5 Hz, 1 H, H-α), 1.67-1.60 (m, 2 
H, COCHCH2(CH2)8CH3), 1.33-1.11 (m, 16 H, COCHCH2(CH2)8CH3), 0.85 (t, J = 6.6 Hz, 3 H, 
COCHCH2(CH2)8CH3); 
13C NMR (75 MHz, CDCl3): c 169.8 (CO), 59.7 (NHCH2CH2OH), 53.0 (α-C), 
41.1 (NHCH2CH2OH), 31.2, 30.4, 28.3, 28.8, 28.7, 26.8, 22.1 (COCHCH2(CH2)8CH3), 13.90 
(COCHCH2(CH2)8CH3); HRMS m/z (ESI+): 353.2427 (C17H34NaN2O4: [M+Na]
+ requires  353.2411).  
 
N1,N3-bis(2-hydroxyethyl)malonamide 3.54[126b] 
Diethyl malonate 2.53 (476 mL, 3.1 mmol) and ethanolamine (0.386 mL, 6.4 mmol) were 
dissolved in DCM (1 mL) under N2. The reaction mixture was stirred at rt for 2 h. The white 
solid which had crashed out was filtered and recrystillised from EtOH and Et2O (1:1) to yield 
the desired product 3.54 as cream flakes (508 mg, 85%); Mp = 128-125 oC (lit 126-125 oC)[126b]; 
1H NMR (300 MHz, CDCl3):  8.01 (bs, 2 H, NH), 4.68 (t, J = 5.3 Hz, 2 H, OH),  3.42-3.35 (m,  4 H, 
NHCH2CH2OH), 3.15-3.09 (m, 4 H, NHCH2CH2OH), 3.03 (s, 1 H, H-α); HRMS m/z (ESI+): 213.0844 
(C7H15NaN2O4: [M+Na]
+ requires  213.0846) 
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2-Decyl-N1,N2-bis[2-(2,3,4,6-O-tetracetyl)-β-D-galactopyranosyl)ethyl] malonamide 3.38 
The 2-Aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33 (234 mg, 0.59 mmol) and 
2-decylmalonic acid 3.36 (73 mg, 0.29 mmol) were dissolved in THF (3 mL) and DMTMM(ii) (182 
mg, 0.6 mmol) added. The reaction mixture was stirred overnight, and the percipitate filtered 
off. The filtrate was evaporated under reduced pressure and the residue dissolved in CHCl3 and 
washed successively with 0.1 M HCl and H2O. Column chromatography (EtOAc) yielded the bis 
substituted product 3.38 (163 mg, 55%); Rf = 0.45 (EtOAc); [α]
25 
D = 1.8 (c, 1.1 in DCM);  IR vmax 
(NaCl plate, DCM): 3336.49, 2927.4, 2855.9, 1752.0, 1669.7, 1529.4, 1433.7, 1370.1, 1224.1, 
1173.8, 1135.3, 1060.1, 956.2, 901.8, 803.2, 703.3 cm-1; 1H NMR (300 MHz, CDCl3):  6.87-6.81 
(m, 2 H, CONHCH2CH2O), 5.35 (d, J = 3.3 Hz, 2 H, H-4), 5.15 (dd, J = 7.8, J = 10.5, 2 H, H-2), 5.00-
4.95 (m, 2 H, H-3), 4.45 (d, J = 7.8 Hz, 1 H, H-1), 4.15-4.50 (m, 4 H, H-6, H-6’), 3.92-3.80 (m, 4 H,  
overlap of H-5 and 1 H of OCH2CH2NH), 3.63-3.24 (m, 6 H, overlap of 1 H of  OCH2CH2NH and 
OCH2CH2NH), 2.89 (t, J = 7.5 Hz, 1 H, H-α) 2.19 (s, 6 H, O(CO)CH3), 2.06, 2.05 ( each s, 3 H, 
O(CO)CH3), 2.03, 1.97 (each s, 6 H, O(CO)CH3), 1.81-1.75 (m, 2 H, COCHCH2(CH2)8CH3), 1.24-
1.20 (m,  16 H, COCH2(CH2)8CH3), 0.83 (t, J = 6.3 Hz, 3 H, COCH(CH2)9CH3); 
13C-NMR (75 MHz, 
CDCl3) δc 170.7, 170.6, 170.3, 170.1, 170.0, 169.7, 169.5 (CO), 101.4, 100.9 (C-1), 70.6 (C-5, C-
3), 68.6, 68.5 (C-2), 68.2, 68.1 (OCH2CH2NH), 66.8 (C-4), 61.1 (C-6), 55.0 (C-α), 39.2, 
39.1(OCH2CH2NH), 32.6 (NHCOCHCH2C9H19), 31.7, 29.4, 29.3, 29.2, 27.4, 22.6, (each CH2), 20.7, 
20.6, 20.5, 20.4 (each O(CO)CH3), 14.0 (NHCOCHC9H18CH3); HRMS m/z (ESI+): 992.4522 
(C45H71N2O22: [M+H]
+ requires  992.4493). 
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1-Azido-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 3.67[152] 
TMSN3 (2.56 mL, 19.48 mmol) was added to a solution of galactose pentacetate 2.38 (3.04 g, 
7.79 mmol) in DCM (30 mL). SnCl4 (3.90 mL, 3.90 mmol) (1 M solution in DCM) was added to 
this solution and the reaction mixture stirred for 16 h.  Aqueous sat. NaHCO3 (50 mL) was 
added and the suspension extracted with DCM (2 x 50 mL). The combined organic layers were 
dried (MgSO4), filtered and concentrated in vacuo to afford the title compound  3.67 as a white 
solid (2.65 g, 91%); Rf = 0.55 (1:1, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 3476.5, 3022.0, 
2998.2, 2949.7, 2985.9, 2907.2, 2412.9, 2164.2, 2128.3, 1741.3, 1465.4, 1439.2, 1379.9, 
1216.0, 1167.4, 118.5, 1085.8, 1057.5, 1022.1, 997.9, 957.9, 902.2 cm-1 ;1H NMR (300 MHz, 
CDCl3):  5.42 (dd, J = 1 Hz,  J = 3.3 Hz, 1 H, H-4), 5.10 (dd, J = 8.6 Hz, J = 10.3 Hz, 1 H, H-2), 5.03 
(dd, J = 3.3 Hz, J = 10.3 Hz, 1 H, H-3), 4.59 (d, J = 8.6 Hz, 1 H, H-1), 4.18-4.15 (m, 2 H, H-6 and H-
6’), 4.03-3.98 (m, 1 H, H-5), 2.17, 2.09, 2.06, 1.98 ( each s, 3 H, O(CO)CH3); HRMS m/z (ESI+): 
396.1010 (C14H19N3NaO9: [M+Na]
+ requires  396.1019).   
The NMR data is in agreement with the literature.[152] 
 
1-Amino-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 3.66 
H2 gas was bubbled through a suspension of 1-azido-2,3,4,6-tetra-O-acetyl-β-D-
galactopyranose 3.67 ( 500 mg, and Pd (C) (50 mg, 10% w/w) in EtOAc (20 mL) at 1 atm. The 
solution was stirred at rt overnight. The suspension was filtered through Celite and 
concentrated in vacuo to yield the title compound 3.66 as a white foamy solid (450 mg, 
97%);1H NMR (300 MHz, CDCl3):  5.39 (d, J = 1.8 Hz, 1 H, H-4), 5.11-5.09 (m, 1 H, H-2), 5.04-
5.02 (m, 1 H, H-3), 4.16 (d, J = 8 Hz, 1 H, H-1), 4.10-4.08 (m, 2 H, H-6 and H-6’), 3.91-3.89 (m, 1 
H, H-5), 2.14, 2.09, 2.06, 1.98 (each s, 3 H, O(CO)CH3); HRMS m/z (ESI+): 348.1286 (C14H22NO9: 
[M+H]+ requires  348.1289). 
The NMR data is in agreement with the literature.[152] 
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2-Decyl-N1,N2-bis(2,3,4,6-O-tetracetyl-β-D-galactopyranosyl) malonamide 3.77 
1-Amino-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 3.66 (284 mg, 0.81 mmol) and 2-
decylmalonic acid 3.36 (100 mg, 0.40 mmol) were dissolved in THF (3 mL) and DMTMM (249 
mg, 0.9 mmol) added. The reaction mixture was stirred overnight, and the percipitate filtered 
off. The filtrate was evaporated under reduced pressure and the residue dissolved in CHCl3 and 
washed successively with 0.1 M HCl and H2O. Gradient elution chromatography (1:1, EtOAc:Pet 
Ether- 10:3, EtOAc:Pet Ether) yielded the bis substituted product 3.68 (205 mg, 56%); Rf = 0.65 
(10:3, EtOAc:Pet Ether); [α]25 D = 22.4 (c, 0.95 in DCM);  IR vmax (NaCl plate, DCM): 3333.7, 
2927.7, 2855.9, 2478.8, 1751.4, 1686.1, 1530.0, 1433.2, 1369.9, 1225.7, 1169.2, 11224, 
1085.5, 1056.3, 956.1, 907.6 804.7cm-1; 1H NMR (300 MHz, CDCl3):  7.79-7.76 (m, 1 H, CONH), 
7.01 (d, J = 8.7 Hz, 1 H, CONH), 5.39-5.37 (m, 2 H, H-4), 5.22-5.07 (m, 6 H, overlap of H-1, H-2 
and H-3), 4.08-3.99 (m, 6 H, overlap of H-6, H-6’ and H-5), 2.96 (t, J = 7.2 Hz, 1 H, H-α), 2.12, 
2.11 (each s, 3 H, O(CO)CH3), 2.01 and 2.00 (each s, 6 H, O(CO)CH3), 1.99, 1.95  (each s, 3 H, 
O(CO)CH3), 1.79-1.69 (m, 2 H, NHCOCHCH2(CH2)8CH3), 1.29-1.11 (s, 16 H, 
NHCOCHCH2(CH2)8CH3), 0.83 (t, J = 6.3, 3 H, NHCOCHCH2(CH2)8CH3); 
13C NMR (75 MHz, CDCl3) δc 
171.2, 170.7, 170.5, 170.3, 170.0, 169.9, 169.8, 169.8 (each CO), 78.2, 78.1 (C-1), 72.3, 72.1 (C-
5), 70.8, 70.7 (C-3), 67.9, 67.8 (C-2), 66.9, 66.8 (C-4), 60.9, 60.8 (C-6), 54.4 (C-α) 32.5 
(NHCOCHCH2(CH2)8CH3), 31.7, 29.5, 29.4, 29.2,  29.1, 27.0, 22.5 (NHCOCHCH2(CH2)8CH3), 20.5-
20.3 (overlap of O(CO)CH3), 14.0 (NHCOCHCH2(CH2)8CH3); HRMS m/z (ESI+): 941.3534 
(C41H62N2KO20: [M+K]
+ requires  941.3528). 
 
2-Decyl-N1,N3-bis(propargyl)malonamide 3.70 
Propargylamine (0.045 mL, 0.70 mmol) and 2-decylmalonic acid 3.36 (78 mg, 0.32 mmol) were 
dissolved in THF (1.5 mL) and DMTMM (194 mg, 0.7 mmol) added. The reaction mixture was 
stirred overnight, and the percipitate filtered off. The filtrate was evaporated under reduced 
pressure and the residue dissolved in CHCl3 and washed successively with 0.1 M HCl and H2O. 
Gradient elution chromatography (1:1, EtOAc:Pet Ether- EtOAc) yielded the bis substituted 
product 3.70 (79 mg, 78%); Rf = 0.83 (EtOAc); IR vmax (KBr Disc): 3285.2, 3049.5, 2953.3, 2851.3, 
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2929.7, 2125.1, 1661.4, 1532.6, 1465.9, 1444.1, 1373.7, 1334.5, 1274.6, 1255.9, 1232.9, 
1207.3, 1195.2, 1130.2, 1031.7, 1007.8, 921.2, 936.7, 888.7, 847.8, 830.6, 798.2, 721.2, 683.8, 
660.5 cm-1; 1H NMR (300 MHz, CDCl3):  6.97-6.93 (m, 2 H, CONH), 4.50-4.02 (m, 4 H, 
NHCH2CCH), 3.02 (t, J = 7.8 Hz, 1 H, H-α), 2.23 (t, J = 2.4 Hz, 2 H, NHCH2CCH), 1.89-1.84 (m, 2 H, 
NHCOCHCH2C9H19), 1.29-1.11 (m, 16 H, NHCOCHCH2(CH2)8CH3), 0.87 (t, J = 6.3, 3 H, 
NHCOCHCH2(CH2)8CH3); 
13C NMR (75 MHz, CDCl3) δc 170.4 (each CO), 78.9 (NHCH2CCH), 71.8 
(NHCH2CCH), 54.7 (C-α) 32.9 (NHCOCHCH2(CH2)8CH3), 31.9, 29.5, 29.4, 29.2, 27.4, 22.7 
(NHCOCHCH2(CH2)8CH3), 14.1 (NHCOCHCH2(CH2)8CH3); HRMS m/z (ESI+): 319.239 (C19H30N2O2: 
[M+H]+ requires  319.2380). 
 
2-Decyl-N1,N2-bis[(2,3,4,6-O-tetracetyl)-β-D-galactopyranosyl)-1,2,3-triazol-4ylmethylamide] 
malonamide 3.71 
Copper sulphate .5H2O (2 mg, 0.01 mmol) and sodium ascorbate (4 mg, 0.02 mmol) were 
added to a solution of 2-decyl-N1,N3-bis(propargyl)malonamide 3.70 (32 mg, 0.1 mmol) and 
galactosyl azide 3.67 (75 mg, 0.2 mmol) in DCM/Acetone/H2O (2:2:1). The reaction was 
allowed to stir at rt overnight. The solvent was removed in vacuo, the residue dissolved in DCM 
and washed with brine. Column chromtagraphy (EtOAc) afforded the pure product 3.71 as an 
oily solid (64 mg, 58%); Rf = 0.57 (EtOAc); [α]
25 
D = -6.6 (c, 1.1 in DCM);  IR vmax (NaCl plate, 
DCM): 3305.4, 3140.8, 3077.5, 2926.1, 2855.0, 1754.6, 1670.2, 1531.1, 1457.5, 1431.2, 1370.1, 
1219.3, 1161.4, 1092.8, 1063.3, 953.2, 924.0, 88.4, 804.2, 747.9 cm-1; 1H NMR (300 MHz, 
CDCl3):  7.82 (d, J = 3 Hz, 2 H, N3CCH), 7.44-7.39 (m, 2 H, CONHCH2), 5.88 (d, J = 9.3 Hz, 2 H, H-
1), 5.54-5.48 (m, 4 H, overlap of H-2 and H-4), 5.25 (dd, J = 2.4 Hz, J = 9.3 Hz, 2 H, H-3), 4.56-
4.40 (m, 2 H, CONHCH2), 4.28-4.23(m, 2 H, H-5), 4.16-4.11 (m, 4 H, overlap of H-6 and H-6’), 
3.05 (t, J = 7.5 Hz, 1 H, H-α), 2.19, 2.04, 1.97 (each s, 6 H, O(CO)CH3), 1.81-1.80 (m, 8 H, overlap 
of O(CO)CH3 and NHCOCHCH2C9H19), 1.31-1.11 (m, 16 H, NHCOCHCH2(CH2)8CH3), 0.82 (t, J = 6.3 
Hz, 3 H, NHCOCHCH2(CH2)8CH3); 
13C NMR (75 MHz, CDCl3) δc  170.6, 170.5, 170.3, 169.9, 169.7, 
168.8 (each CO), 145.9 (N3CCH), 121.1, 121.0 (N3CCH), 85.9 (C-1), 73.7 (C-5), 70.6 (C-3), 67.8 
66.7 (C-2, C-4), 61.01 (C-6), 54.6 (C-α), 34.8  (CONHCH2), 32.1 (NHCOCHCH2C9H19), 31.7, 29.5, 
29.4, 29.2, 29.1 27.4, 22.4 (NHCOCHCH2(CH2)8CH3), 20.6, 20.5 20.4, 20.1 (each O(CO)CH3), 14.0 
(NHCOCHCH2(CH2)8CH3); HRMS m/z (ESI+): 1065.4642 (C47H68N8O20: [M+H]
+ requires  
1065.4623). 
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Solubility of aliphatic based analgoues 
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6.2.3 Experimental procedures for Chapter 4 
 
 
N1, N2, di-(β-D-galactopyranosyl)-N3-hexadecanosyl-5-aminobenzene 1,3,dicarboxamide 4.36 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1,N2,di-(2,3,4,6-tetra-O-acetyl-
β-D-galactopyranosyl)-N3-hexadecanosyl-5-aminobenzene 1,3,dicarboxamide 4.98 (59 mg, 0.05 
mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 °C. The mixture was stirred for 18 
h. The reaction mixture was concentrated under reduced pressure and triturated with Et2O to 
yield 4.36 as a white solid (10 mg, 93%); [α]25 D = 11.1 (c, 0.72 in MeOH/Pyr); IR vmax (MeOH): 
3706.5, 3680.9, 3441.6, 2966.7, 2923.8, 2819.4, 1590.55, 1484.8, 1438.9, 1215.7, 119.1, 
1053.8, 1032.9, 997.9 cm-1; 1H-NMR (300 MHz, d5-Pyr):  10.87 (d, J = 3.6 Hz, 1 H, NHCOC15H31), 
10.41-10.38 (m, 2 H, H1NHCO), 8.97 (bs, 2 H, Ar), 8.79 (bs, 1 H, Ar), 6.22-6.15 (m, 2 H, H-1), 
4.76-4.70 (m, 2 H, H-2), 4.65-4.60 (m, 2 H, H-4),  4.50-4.41 (m, 4 H, overlap of H-6, H-6’), 4.29-
4.25 (m, 4 H, overlap of H-3 and H-5), 2.53-2.48 (m, 2 H, NHCOCH2(CH2)13CH3), 1.87-1.73 (m, 2 
H, NHCOCH2CH2(CH2)12CH3), 1.41-1.17 (s, 24 H, NHCOCH2CH2(CH2)12CH3), 0.89-0.81 (m, 3 H, 
NHCOCH2CH2(CH2)12CH3); 
13C NMR (75 MHz, d5-Pyr) δc 172.5, 168.7 (CO), 140.9, 137.3 (ArC), 
124.1, 122.8 (ArCH), 82.9 (C-1), 79.1 (C-5), 76.7 (C-3), 71.93 (C-2), 70.9 (C-4), 63.0 (C-6), 37.7 
(NHCOCH2(CH2)13CH3), 32.4, 30.3, 30.2, 30.1, 30.1, 29.9, 26.3, 23.3 (NHCOCH2(CH2)13CH3), 14.6 
(NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 742.4099 (C36H60N3O13: [M+H]
+ requires  742.4121). 
 
N1, N2, di-(β-D-galactopyranosyl)-N3-propyl-5-aminobenzene 1,3, dicarboxamide 4.37 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution N
1,N2,di-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-N3-propyl-5-aminobenzene 1,3, dicarboxamide 4.100 (44 mg, 0.049 mmol) 
dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 °C. The mixture was stirred for 18 h. The 
reaction mixture was concentrated under reduced pressure to afford the crude mixture which 
was triturated with Et2O to yield 4.37 as a white solid (26 mg, 96%); [α]
25 
D = 10 (c, 1 in MeOH); 
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1H-NMR (300 MHz, d5-Pyr):  10.82-10.80 (m, 1 H, NHCOC2H5), 10.39 (d, J = 9.1 Hz, 2 H, 
H1NHCO), 8.91 (bs, 2 H, Ar), 8.79 (bs, 1 H, Ar), 6.23-6.17 (m, 2 H, H-1), 4.82-4.71 (m, 2 H, H-2), 
4.65-4.61 (m, 2 H, H-4),  4.52-4.43 (m, 4 H, overlap of H-6, H-6’), 4.30-4.20 (m, 4 H, overlap of 
H-3 and H-5), 2.49-2.44 (m, 2 H, NHCOCH2CH3), 0.97 (t, 3 H, J = 7.1 Hz, NHCOCH2CH3); 
13C NMR 
(75 MHz, d5-Pyr) δc 173.5, 168.7 (CO), 140.9, 137.3 (ArC), 123.1, 122.8 (ArCH), 82.9 (C-1), 79.1 
(C-5), 76.7 (C-3), 71.9 (C-2), 70.9 (C-4), 63.0 (C-6), 30.7 (NHCOCH2CH3), 10.2 (NHCOCH2CH3); 
HRMS m/z (ESI+): 560.2072 (C23H34N3O13: [M+H]
+ requires  560.2086). 
  
N1, N2, di-[2-O-(β-D-galactopyranosyl)-ethyl]-N3-tetradecyl-benzene 1,3,5 tricarboxamide 4.38 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1, N2, di-[2-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-ethyl]-N3-tetradecyl-benzene 1,3,5 tricarboxamide 4.29 (19 mg, 
0.14 mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 °C. The mixture was stirred 
for 18 h. The reaction mixture was concentrated under reduced pressure to afford and 
triturated with Et2O to yield 4.38 as a white solid (10 mg, 78%); [α]
25 
D = 2.6 (c, 0.75 in MeOH); 
1H-NMR (300 MHz, d5-Pyr): δ 9.37-9.34 (m, 1 H, CONHC14H29), 9.27-9.23  (m, 2 H, OCH2CH2NH), 
9.16 (s, 2 H, Ar), 9.05 (s, 1 H, Ar), 7.38, 6.89, 6.72 and 6.58 (bs, 1 H, OH), 4.85 (d, J = 7.8 Hz, 2 H, 
H-1), 4.55-4.42 (m, 8 H, overlap of H-2, H-4, H-6 and H-6’), 4.36-4.26 (m, 2 H, 1 H of 
OCH2CH2NH), 4.19-4.14 (m, 2 H, H-3), 4.12-4.06 (m, 4 H, overlap of 1 H of OCH2CH2NH and H-
5), 3.98-3.84 (m, 4 H, OCH2CH2NH), 3.72-3.65 (m, 2 H, NHCH2C13H27), 1.78-1.67 (m, 2 H, 
NHCH2CH2C12H25), 1.24 (s, 22 H, NHC2H4(CH2)11CH3), 0.87 (t, J = 6.3 Hz, 3 H, NHC13H26CH3); 
13C 
NMR (75 MHz, d5-Pyr): δc 167.1, 166.9 (CO), 140.9, 136.7 (ArC), 130.0, 129.5 (ArCH), 105.9 (C-
1), 77.4 (C-5), 75.6 (C-3), 72.9 (C-2), 70.6 (C-4), 69.5 (OCH2CH2NH),  62.8 (C-6), 41.4 
(OCH2CH2NH), 32.5 (NHCH2C13H27), 30.4, 30.3,,30.1, 29.9, 23.2 (NHCOCH2(CH2)12CH3), 14.7 
(NHCOCH2(CH2)12CH3);  HRMS m/z (ESI+): 662.2754 (C28H44N3O15: [M+H]
+ requires  662.2767).  
HRMS m/z (ESI+): 816.4525 (C39H66N3O15: [M+H]
+ requires  816.4488).   
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N1, N2, di-[2-O-(β-D-galactopyranosyl)-ethyl]-N3-propyl-benzene 1,3,5 tricarboxamide 4.39 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1,N2,di-[2-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-ethyl]-N3-propyl-benzene 1,3,5 tricarboxamide 4.74 (42 mg, 0.42 
mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 °C. The mixture was stirred for 18 
h. The reaction mixture was concentrated under reduced pressure to afford the crude mixture 
which was triturated with Et2O to yield 4.39 as a white solid (26 mg, 96%); [α]
25 
D = 2.85 (c, 0.7 
in MeOH/Pyr); 1H-NMR (300 MHz, d5-Pyr): δ 9.32-9.22 (m, 3 H, overlap of CONHC3H7 and 
OCH2CH2NH), 9.12 (s, 2 H, Ar), 9.05 (s, 1 H, Ar), 4.83 (d, J = 7.7 Hz, 2 H, H-1), 4.54-4.40 (m, 8 H, 
overlap of H-2, H-4, H-6 and H-6’), 4.33-4.28 (m, 2 H, 1 H of OCH2CH2NH), 4.19-4.14 (m, 2 H, H-
3), 4.08-4.04 (m, 4 H, overlap of 1 H of OCH2CH2NH and H-5), 3.98-3.81 (m, 4 H, OCH2CH2NH), 
3.59-3.54 (m, 2 H, NHCH2C2H5), 1.74-1.61 (m, 2 H, NHCH2CH2CH3), 0.87 (t, J = 7.1, 3 H, 
NHC2H4CH3);
  13C NMR (75 MHz, d5-Pyr): δc 167.2, 166.9 (CO), 140.9, 136.7 (ArC), 130.0, 129.5 
(ArCH), 105.9 (C-1), 77.3 (C-5), 75.6 (C-3), 72.9 (C-2), 70.6 (C-4), 69.5 (OCH2CH2NH),  62.8 (C-6), 
42.5 (CONHCH2C2H5), 41.4 (OCH2CH2NH), 23. 7 ( COCH2CH2CH3), 12.0 (NHCOCH2CH2CH3);  HRMS 
m/z (ESI+): 662.2754 (C28H44N3O15: [M+H]
+ requires  662.2767).   
 
N1, N2, di-[2-O-(β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-ylmethylamide]-N3-tetradecyl-
benzene 1,3,5 tricarboxamide 4.40 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1,N2,di-[2-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-ylmethylamide]-N3-tetradecyl-benzene 1,3,5 
tricarboxamide 4.92  (40 mg, 0.03 mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 
°C. The mixture was stirred for 18 h. The reaction mixture was concentrated under reduced 
pressure and triturated with Et2O to give the deprotected glycolipid 4.40 as a white solid (27 
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mg, 90%);  [α]25 D = 2.2 (c, 0.9 in MeOH); 
1H-NMR (300 MHz, d5-Pyr): δ 10.20-10.14 (m, 2 H, 
NHCH2(CCHN3)), 9.38-9.29 (m, 1 H, CONHC14H29), 9.15 (s, 3 H,  Ar), 8.39 (s, 2 H, , NHCH2(CCHN3), 
6.96-6.81, 6.66-6.62, 6.53-6.52 (each m, 2 H, OH), 4.95 (d, J = 5.7 Hz, 2 H, CONHCH2CN3CH), 
4.77 (d, J = 7.8 Hz, 2 H, H-1), 4.69-4.64 (m, 4 H, OCH2CH2NH), 4.57-4.55 (m, 2 H, H-4), 4.5-4.33 
(m, 8 H, overlap of OCH2CH2NH, H-2, H-6 and H-6’), 4.18-4.04 (m, 4 H, overlap of H-5 and H-3), 
3.70-3.60 (m, 2 H, NHCH2C13H27), 1.72-1.64 (m, 2 H, NHCH2CH2C12H25), 1.24 (s, 22 H, 
NHC2H4(CH2)11CH3), 0.89-0.85 (m, 3 H, NHC13H26CH3);
 13C NMR (75 MHz, d5-Pyr): δc 168.1, 167.9 
(CO), 146.9 (N3CCH), 140.9, 136.7 (ArC), 130.9, 130.8 (ArCH), 125.2, (N3CCH), 105.5 (C-1), 77.5 
(C-5), 75.6 (C-3), 72.5 (C-2), 70.5 (C-4), 68.3 (OCH2CH2NH), 63.6 (C-6), 50.9 (OCH2CH2NH), 40.8 
(CONHCH2C13H27), 36.5 (CONHCH2CN3CH), 33.4, 30.2, 30.1, 30.0, 29.9, 27.7 
(NHCOCH2CH2(CH2)12CH3), 12.1 (NHCOCH2CH2(CH2)12CH3); HRMS m/z (ESI+): 978.5149 
(C45H72N9O15: [M+H]
+ requires  978.5142).    
 
N1, N2, di-[2-O-(β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-ylmethylamide]-N3-propyl-benzene 
1,3,5 ticarboxamide 4.41 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1,N2,di-[2-O-(2,3,4,6-Tetra-O-
acetyl-β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-ylmethylamide]-N3-propyl-benzene 1,3,5 
ticarboxamide 4.95 (42 mg, 0.036 mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 
°C. The mixture was stirred for 18 h. The reaction mixture was concentrated under reduced 
pressure to afford the crude mixture which was triturated with Et2O to yield 4.41 as a white 
solid (27 mg, 93%); [α]25 D = 4.2 (c, 0.95 in MeOH/Pyr); IR vmax (MeOH): 3305.4, 3072.5, 2885.4, 
1650.4, 1541.8, 1026.5, 636.8 cm-1; 1H-NMR (300 MHz, d5-Pyr): δ 10.28-10.05 (m, 2 H, 
CONHCH2CN3CH), 9.29-9.24 (m, 1 H, CONHC3H7), 9.14-9.08 (m, 3 H, Ar), 8.41-8.36 (m, 2 H, 
N3CCH), 4.94 (d, J = 5.4 Hz, 4 H, CONHCH2CN3CH), 4.75 (d, J = 7.7 Hz, 2 H, H-1), 4.70-4.62 (m, 4 
H, OCH2CH2NH), 4.56-4.51 (m, 2 H, H-4), 4.48-4.31 (m, 8 H, overlap of OCH2CH2NH, H-2, H-6 
and H-6’), 4.15-4.11 (m, 2 H, H-3), 4.06-4.02 (m, 2 H, H-5), 3.58-3.52 (m, 2 H, NHCH2C2H5), 1.69-
1.57 (m, 2 H, NHCH2CH2CH3), 0.86-0.81 (m, 3 H, NHC2H4CH3);
  13C NMR (75 MHz, d5-Pyr): δc 
167.2, 166.0 (CO), 146.0 (N3CCH), 140.9, 136.7 (ArC), 130.1, 129.9 (ArCH), 125.2, 124.3 
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(N3CCH), 105.5 (C-1), 77.5 (C-5), 75.6 (C-3), 72.6 (C-2), 70.5 (C-4), 68.4 (OCH2CH2NH), 50.9 
(OCH2CH2NH), 62.7 (C-6), 42.5 (CONHCH2C2H5), 36.5 (CONHCH2CN3CH), 23. 7 ( COCH2CH2CH3), 
12.0 (NHCOCH2CH2CH3); HRMS m/z (ESI+): 824.3417 (C34H50N9O15: [M+H]
+ requires  824.3421).   
N1, N2, di-(β-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-N3-hexadecanosyl-5-
aminobenzene 1,3, dicarboxamide 4.42 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1, N2, di-(2,3,4,6-Tetra-O-acetyl-
β-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-N3-hexadecanosyl-5-aminobenzene 1,3, 
dicarboxamide 4.102 (70 mg, 0.056 mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 
40 °C. The mixture was stirred for 18 h. The reaction mixture was concentrated under reduced 
pressure to afford the crude mixture which was triturated with Et2O to yield 4.42 as a white 
solid (50 mg, 98%); [α]25 D = 5.4 (c, 1.1 in MeOH); 
1H-NMR (300 MHz, d5-Pyr): δ 11.08 (s, 1 H, 
NHCOC15H31), 10.13 (t, J = 5.6 Hz, 2 H, CONHCH2CN3CH), 8.98 (bs, 3 H, Ar), 8.45 (bs, 2 H, 
N3CCH), 6.29 (d, J = 9.1 Hz, 2 H, H-1), 5.10-5.06 (m, 2 H, H-2), 4.93 (d, J = 5.4 Hz, 4 H, 
CONHCH2CN3CH), 4.68 (d, J = 3.0 Hz, 2 H, H-4), 4.52-4.6 (m, 8 H, overlap of H-3, H-5, H-6 and H-
6’), 2.50 (t, J = 7.2 Hz, 2 H, NHCOCH2C14H29), 1.85-1.78 (m, 26 H, NHCO(CH2)13CH3), 0.88-0.84 
(m, 3 H, NHCOCH2(CH2)13CH3);
  13C NMR (75 MHz, d5-Pyr): δc 167.6 (CO), 146.5 (N3CCH), 140.9, 
136.7 (ArC), 130.1, 129.9 (ArCH), 124.7 (N3CCH), 80.9 (C-1), 78.3 (C-5), 76.1 (C-3), 71.6 (C-2), 
70.5 (C-4), 62.8 (C-6), 37.8, 36.4 (CONHCH2CN3CH and NHCOCH2C15H31), 32.5, 30.3, 29.9, 23.3 
(NHCOCH2(CH2)13CH3),  14.8 (NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 904.4758 (C42H66N9O13: 
[M+H]+ requires  904.4775).   
 
N1, N2, di-[2-O-(β-D-galactopyranosyl)-ethyl-glycine]-N3-hexadecanosyl-5-aminobenzene 1,3, 
dicarboxamide 4.43 
 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1, N2, di-[2-O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-ethyl-glycine]-N3-hexadecanosyl-5-aminobenzene1,3, 
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dicarboxamide 4.107 (30 mg, 0.023 mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 
40 °C. The mixture was stirred for 18 h. The reaction mixture was concentrated under reduced 
pressure to afford the crude mixture which was triturated with Et2O to yield 4.43 as a white 
solid (20 mg, 91%); [α]25 D = 6.4 (c, 0.75 in DCM); 
1H-NMR (300 MHz, d5-Pyr): δ 10.95 (bs, 1 H, 
NHCOC15H31),  9.69-9.67 (m, 2 H, NHCOCH2NHCO), 8.94 (s, 3 H, Ar), 8.86 (t, J = 5.34 Hz, 2 H, 
NHCOCH2NHCO), 4.79 (d, J = 7.8 Hz, 1 H, H-1), 4.53-4.37 (m, 10 H, overlap of H-2, H-3, H-4, H-6 
and H-6’, NHCOCH2NHCO), 4.20-4.13 (m, 2 H, 1 H of OCH2CH2NH), 4.08-4.04 (m, 2 H, H-5), 
3.99-3.92 (m, 2 H, 1 H of OCH2CH2NH), 3.76-3.69 (m, 4 H, OCH2CH2NH),  1.84-1.77 (m, 2 H, 
NHCOCH2C14H29), 1.40-1.18 (m, 26 H, NHCOCH2(CH2)13CH3), 0.87 (t, J = 6.3 Hz, 3 H, 
NHCOC14H26CH3); 
13C NMR (75 MHz, CDCl3): δc 172.9, 171.3, 169.1, 168.3, 167.5 (each CO), 
141.1, 140.2 (ArC), 122.8, 121.9 (ArCH), 105.9 (C-1), 77.4 (C-5), 75.6 (C-3), 72.9 (C-2), 70.6 (C-4), 
69.7 (OCH2CH2NH), 62.8 (C-6), 43.5 (NHCOCH2NHCO), 40.4 (OCH2CH2NH), 37.8 
(NHCOCH2C14H29), 32.4, 30.2, 30.0, 29.8, 26.3, 23.2 (NHCOCH2(CH2)13CH3), 14.5 
(NHCOCH2(CH2)13CH3);  HRMS m/z (ESI+): 966.4912 (C44H73N5NaO17: [M+Na]
+ requires  
966.4894).  
 
N1-(β-D-galactopyranosyl)-N2-hexadecanosyl-3-aminobenzene 1-carboxamide 4.44 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution of N
1-(2,3,4,6-tetra-O-acetyl-β-D-
galactopyranosyl)-N2-hexadecanosyl-3-aminobenzene 1-carboxamide 4.115 (50 mg, 0.07 
mmol) dissolved in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 °C. The mixture was stirred for 18 
h. The reaction mixture was concentrated under reduced pressure and triturated with Et2O 
and DCM to yield 4.44 as a white solid (35 mg, 92%); [α]25 D = 2 (c, 1 in MeOH); 
 1H-NMR (300 
MHz, d5-Pyr):  10.88 (bs, 1 H, NHCOC15H31), 10.23 (d, J = 9.2 Hz, 1 H, H1NHCO), 8.83 (bs, 1 H, 
Ar), 8.35-8.32 (m, 1 H, Ar), 7.98-7.95 (m, 1 H, Ar), 7.40-7.35 (m, 1 H, Ar), 6.22 (t, J = 9.1 Hz, 1 H, 
H-1), 4.74 (t, J = 9.1 Hz, 1 H, H-2), 4.65 (d, J = 2.7 Hz, 1 H, H-4),  4.52-4.46 (m, 2 H, overlap of H-
6, H-6’), 4.30-4.22 (m, 2 H, overlap of H-3 and H-5), 2.53 (t, J = 7.3 Hz, 2 H, 
NHCOCH2(CH2)13CH3), 1.89-1.79 (m, 2 H, NHCOCH2CH2(CH2)12CH3), 1.35-1.25 (m, 24 H, 
NHCOCH2CH2(CH2)12CH3), 0.87 (t, J = 6.4 Hz, 3 H, NHCOCH2CH2(CH2)12CH3); 
13C NMR (75 MHz, 
d5-Pyr): δc 172.5, 168.9 (CO), 141.1, 137.2 (ArC), 129.3, 120.4 (ArCH), 82.9 (C-1), 79.1 (C-5), 76.7 
(C-3), 72.2 (C-2), 70.9 (C-4), 63.0 (C-6), 37.7 (NHCOCH2(CH2)13CH3), 32.4, 30.3, 30.2, 30.1, 30.1, 
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29.9, 26.3, 23.3 (NHCOCH2(CH2)13CH3), 14.6 (NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 537.3524 
(C29H49N2O7: [M+H]
+ requires  537.3534). 
 
N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N3-tetradecyl-Benzene 1,3,5 
tricarboxamide 4.48 
Tetradecylamine (63 mg, 0.29 mmol) and NEt3 (0.049 mL, 0.35 mmol) dissolved in THF (15 mL) 
under Ar, was added dropwise over 3 h to 1,3,5-trichloride, tri carbonyl benzene 4.46 (0.052 
mL, 0.293 mmol) in THF (37 mL). This mixture was allowed to stir for 3h. 2-Aminoethyl 2,3,4,6-
tetra-O-acetyl-β-D-galactopyranoside 2.33 (230 mg, 0.587 mmol) and NEt3 (0.09 mL, 0.646 
mmol) dissolved in THF (3 mL) was added quickly to the solution. The reaction was left stirring 
overnight. The solvent was removed under reduced pressure, the residue dissolved in DCM 
and washed with 0.1 M HCl, aqueous sat. NaHCO3 solution, brine and dried over MgSO4. Flash 
chromatography (9:1, Ethyl Acetate, Hexane) afforded the pure product 4.48 as a white solid 
(27 mg, 8%); Rf = 0.23 (8:2, Pet Ether:EtOAc); [α]
25 
D = -10.5 (c, 0.95 in DCM); IR vmax (NaCl plate, 
DCM): 3373.6, 2926.2, 2854.7, 1751.2, 1659.4, 1536.2, 1518.6, 1433.3, 1370.4, 1226.5, 1173.3, 
1134.4 and 1060.07 cm-1;  1H NMR (300 MHz, CDCl3): δ 8.65 (s, 3 H, Ar), 7.07 (t, J = 5.1 Hz, 2 H, 
OCH2CH2NH), 6.83 (t, J = 5.4 Hz, 1 H, CONHC14H29), 5.39-5.37 (m, 2 H, H-4), 5.21 (dd, J = 8.1 Hz, 
J = 10.5 Hz, 2 H, H-2), 5.02 (dd, J = 3.6 Hz, J =10.5, 2 H, H-3), 4.50 (d, J = 8.1 Hz, 2 H, H-1), 4.12-
4.09 (m, 4 H, H-6 and H-6’), 4.01-3.85 (m, 4 H, overlap of H-5 and 1 H of OCH2CH2NH), 3.85-
3.65 (m, 6 H, overlap of 1 H of OCH2CH2NH and OCH2CH2NH), 3.45- 3.42 (m, 2 H, NHCH2C13H27), 
2.17 (s, 6 H, O(CO)CH3), 1.98 (s, 12 H, O(CO)CH3), 1.91 (s, 6 H, O(CO)CH3), 1.62-1.57 (m, 2 H, 
NHCH2CH2C12H25), 1.24 (s, 22 H, NHC2H4(CH2)11CH3), 0.86 (t, J = 6.9 Hz, 3 H, NHC13H26CH3); 
13C 
NMR (75 MHz, d5-Pyr): δc 170.4, 170.3 and 170.1  (OCOCH3), 165.7 (OCH2CH2NHCO) 165.0 
(CONHC14H29), 135.7, 134.9 (ArC), 128.5, 128.7 (ArCH), 101.3 (C-1), 70.9 (C-5), 70.6 (C-3), 69.0 
(C-2) 68.5 (OCH2CH2NH),  66.9 (C-4), 61.3 (C6), 40.4 (NHCH2C13H27), 39.9 (OCH2CH2NH), 31.9, 
29.7, 29.6, 29.5, 29.4, 27.0 and 22.7 (NHCH2(CH2)12CH3), 20.7, 20.7, 20.6, 20.6 (O(CO)CH3), 14.1 
(NHC13H26CH3); HRMS m/z (ESI+): 1152.5291 (C55H81N3O23: [M+H]
+ requires  1152.5334).   
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N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-O-benzoate-Benzene 1,3, 
dicarboxamide 4.56 
Benzyl alcohol (0.042 mL, 0.295 mmol) and DIPEA (0.056 mL, 0.322 mmol) dissolved in THF (8 
mL) under Ar, were added dropwise over 3h to 1,3,5-benzenetricarbonyl, trichloride 4.46 
(0.052 mL, 0.293 mmol) in THF (3.5 mL). This mixture was allowed to stir for 3h. 2-O-(2,3,4,6-
tetra-O-acetyl- β-D-galactopyranosyl)-ethyl 2.33 (0.229 g, 0.587 mmol) and DIPEA (0.112 mL, 
0.646 mmol) dissolved in THF (3 mL) were added quickly to the solution. The reaction was left 
stirring overnight. The solvent was removed under reduced pressure, the residue dissolved in 
DCM and washed with 0.1 M HCl, aqueous sat. NaHCO3 solution, brine and dried over MgSO4. 
Flash chromatography (9:1, Ethyl Acetate, Hexane) afforded the pure product 4.56 as a white 
solid (22 mg, 7%); Rf = 0.57 (1:1, Pet Ether:EtOAc); [α]
25 
D = -3.6 (c, 0.55 in DCM); IR vmax (NaCl 
plate, DCM): 3391.9, 1749.3, 1659.5, 1536.1, 1432.6, 1370.2, 1225.4 cm-1 ; 1H NMR (300 MHz, 
CDCl3): δ 8.65 (d, J = 1.8 Hz, 2 H, Ar), 8.43-8.42 (m, 1 H, Ar), 7.46-7.33 (m, 5 H, Ar), 7.06 (t, J = 
5.4 Hz, 2 H, NH), 5.39 (bs, 4 H, overlapping of H-4 and CH2Ph), 5.20  (dd, J = 7.8 Hz, J = 10.5 Hz, 
2 H, H-2), 5.05 (dd, J = 3.6 Hz, J =10.5 Hz, 2 H, H-3), 4.49 (d, J = 6 Hz, 2 H, H-1), 4.12-4.09 (m, 4 
H, overlap of H-6, H-6’), 4.01-3.85 (m, 6 H, overlap of H-5 and OCH2CH2NH), 3.79-3.66 (m, 4 H, 
OCH2CH2NH), 2.16, 1.98, 1.97, 1.90 (each s, 6 H, O(CO)CH3); 
13C NMR (75 MHz, CDCl3): δc 170.4, 
170.3, 170.1, 170.1 (OCOCH3), 165.5 (CH2NHCO) 165.0 (COOCH2), 135.4, 135.0 (ArC), 131.4, 
131.3 (ArCH), 129.4, 128.7, 128.45 (CH-Ph), 101.4 (C-1), 70.9 (C-5), 70.7 (C-3), 68.9 (C-2), 68.6 
(OCH2CH2NH), 67.4 (CH2Ph), 66.9 (C-4), 61.3 (C-6), 39.9 (OCH2CH2NH), 20.7, 20.7, 20.6, 20.6 
(O(CO)CH3); HRMS m/z (ESI+): 1047.3503 (C48H58N2O24: [M+H]
+ requires  1047.3452).  
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O1, O2-di[(2,3,4,5,6-pentafluorophenyl)ester],N3-tetradecylamide-benzene 1,3 dicarboxylic acid 
4.71 
Trimesic acid 4.65 (200 mg, 0.9 mmol), HOBt (128 mg, 0.9 mmol) and TBTU (305 mg, 0.9 mmol) 
was placed under N2 and dissolved in DMF (20 mL). NEt3 (0.16 mL, 1.1 mmol) was added 
dropwise and the mixture was allowed to stir for 15 min. Tetradecylamine (243 mg, 1.1 mmol) 
dissolved in DMF (15 mL) was then added. The solution was stirred overnight. The solvent was 
removed under reduced pressure, and the residue dissolved in MeOH and dried over MgSO4 to 
yield a cream solid as the crude product. The crude solid (225 mg, 0.48 mmol) and 
pentaflourophenol (265 mg, 1.4 mmol) were dissolved in THF (2 mL) under N2 with 4 A MS. The 
solution was placed on ice and DIC (0.30 mL, 1.9 mmol) was added. The mixture was allowed 
to stir at 0 oC for 1 h and at rt for a further 2 h. The solvent was removed under reduced 
pressure and gradient elution chromatography (95:5, Pet Ether:EtOAc- 80:20, Pet Ether:EtOAc) 
afforded the pure product 4.71 as a white solid (84 mg, 24%); Rf = 0.22 (1:1, Pet Ether:EtOAc); 
mp =159-161 oC; IR vmax (NaCl plate, DCM): 3285.1, 2921.1, 2852.8, 1765.1, 1645.1, 1546.2, 
1519.4, 1470.2, 1278.4, 1196.2, 1152.8, 1099.8 cm-1;  1H NMR (300 MHz, CDCl3): δ 9.09 (s, 1 H, 
Ar), 8.88 (s, 2 H, Ar), 6.46 (t, J = 5.4, 1 H, CONHC14H29), 3.52 (q, J = 2.3 Hz, 2 H, NHCH2C13H27), 
1.71-1.62 (m, 2 H, NHCH2CH2C12H25), 1.24 (s, 22 H, NHC2H4(CH2)11CH3), 0.86 (t, J = 6.6 Hz, 3 H, 
NHC13H26CH3); 
13C NMR (75 MHz, CDCl3): δc 164.5, 160.9 (CO), 139.6, 138.3 (ArC of C6F5) 136.9 
(ArC of C6H3), 134.8, 134.5 (ArCH of C6H3), 128.7 (ArC of C6H3), 40.7 (NHCH2C13H27), 31.9, 29.7, 
29.6, 29.6, 29.5, 29.4, 29.3, 27.0, 22.7 (NHCH2(CH2)12CH3), 14.1 (NHC13H26CH3); HRMS m/z 
(ESI+): 754.2256 (C35H34F10NO6: [M+H]
+ requires  754.377).  
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N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N3-tetradecyl-benzene 1,3,5 
tricarboxamide 4.48 
O1, O2-di[(2,3,4,5,6-pentafluorophenyl)ester],N-tetradecylamide-benzene 1,3 dicarboxylic acid 
4.71 (75 mg, 0.1 mmol), was dissolved in THF (5 mL) under N2 with 4Å molecular sieves. 2-
Aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33 (120 mg, 0.3 mmol) dissolved in 
THF (5 mL) under N2 and NEt3 (0.042 ml, 0.3 mmol) was added and the reaction mixture stirred 
at rt overnight. The solvent was removed in vacuo and the resulting residue purified by flash 
chromatography (80:20 EtOAc: Pet Ether) to yield compound 4.48 as a clear oily solid (56 mg, 
47%). 
Characterisation as stated previously (pg 229) 
 
O1, O2, di-[(2,3,4,5,6-pentafluorophenyl)ester]-N3-propyl-benzene 1,3, dicarboxylic acid 4.72 
Propylamine (0.092 mL, 1.1 mmol) and DIPEA (0.214 mL, 1.2 mmol) dissolved in THF (10 mL) 
under Ar, were added dropwise over 3.5 h to 1,3,5- benzenetricarbonyl trichloride 4.46 (0.200 
mL, 1.1 mmol) in THF (10 mL). Pentaflourophenol (0.143 mL, 2.2 mmol) and DIPEA (0.427 mL, 
2.6 mmol) dissolved in THF (4 mL) were added quickly to the solution. The reaction was left 
stirring overnight. The solvent was removed under reduced pressure, the residue dissolved in 
DCM and washed with 1 M HCl, aqueous sat. NaHCO3 solution, brine and dried over MgSO4. 
Flash chromatography (10:1-1:1, EtOAc:Pet Ether) and recrystillisation in ethyl acetate 
afforded the pure product 4.72 as a white solid (135 mg, 20%); Rf = 0.67 (1:1, EtOAc: Pet 
Ether); IR vmax (KBr Disc): 3427.0, 2094.9, 1765.7, 1645.3, 1519.4, 1274.4, 1196.5, 1150.3, 
1078.0, 995.4 cm-1;  1H NMR (300 MHz, CDCl3): δ 9.09 (t, J = 1.8 Hz, 1 H, Ar), 8.88 (s, 2 H, Ar), 
6.38 (bs, 1 H, CONHC3H7), 3.5-3.46 (m, 2 H, NHCH2C2H5), 1.71-1.62 (m, 2 H, NHCH2CH2CH3), 
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1.02 (t, J = 7.2 Hz, 3 H, NHC2H4CH3); 
13C NMR (75 MHz, CDCl3): δc 164.4, 160.9 (CO), 139.6, 138.3 
(ArC of C6F5) 136.9 (ArC), 134.8, 134.4 (ArCH), 128.7 (ArC), 42.3 (NHCH2), 22.8 (NHCH2CH2), 11.4 
(NHCH2CH2CH3); HRMS m/z (ESI+): 600.0562 (C24H12F10NO6: [M-H, +H2O]
- requires  600.0589) or 
HRMS m/z (ESI+): 252.0871 (C12H14NO5: [M+H, -PFP ester]
+ requires  252.0866). 
 
N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N3-propyl-benzene 1,3,5 
tricarboxamide 4.74 
O1,O2,di-[(2,3,4,5,6-pentafluorophenyl)ester]-N3-propyl-benzene 1,3, dicarboxylic acid 4.72 (63 
mg, 0.1 mmol), was dissolved in THF (5 mL) under N2 with 4Å molecular sieves. 2-Aminoethyl 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33 (105 mg, 0.27 mmol) dissolved in THF (5 mL) 
under N2 and DIPEA (0.047 ml, 0.27 mmol) was added and the reaction mixture was stirred at 
rt overnight. The solvent was removed in vacuo and the resulting residue purified by flash 
chromatography (1:1 EtOAc:Pet Ether) to yield compound 4.74 as a clear oil that turned into a 
solid (43 mg, 40%); Rf = 0.42 (EtOAc); [α]
25 
D = 7.2 (c, 1 in DCM); IR vmax (NaCl plate, DCM): 
3374.9, 2964.5, 2937.9, 2879.5, 1750.8, 1659.2, 1535.5, 1518.5, 1431.6, 1370.2, 1226.9, 
1173.3, 1134.6, 1059.5 cm-1 ;1H NMR (300 MHz, CDCl3): δ 8.38-8.36 (m, 3 H, Ar), 7.09 (t, J = 5.1 
Hz, 2 H, OCH2CH2NH), 6.83 (t, J = 5.4 Hz, 1 H, NHC3H7), 5.37 (m, 2 H, H-4), 5.14 (dd, J = 8.1 Hz, J 
= 10.5 Hz, 2 H, H-2), 5.01 (dd, J = 3.3 Hz, J = 10.5, 2 H, H-3), 4.50 (d, J = 7.8 Hz, 2 H, H-1), 4.13-
4.03 (m, 4 H, H-6 and H-6’), 3.99-3.89 (m, 4 H, overlap of H-5 and 1 H of OCH2CH2NH), 3.85-
3.63 (m, 6H, overlap of  OCH2CH2NH and  1 H of OCH2CH2NH), 3.46- 3.36 (m, 2 H, NHCH2C2H5), 
2.15 (s, 6 H, O(CO)CH3), 1.97 (s, 12 H, O(CO)CH3), 1.91 (s, 6 H, O(CO)CH3), 1.65-1.58 (m, 2 H, 
NHCH2CH2CH3), 0.95 (t, J = 7.5 Hz, 3 H, NHC2H4CH3); 
13C NMR (75 MHz, CDCl3): δc 170.4, 170.3, 
170.0  (OCOCH3), 165.8, 165.0 (CO), 135.6, 134.9 (C-Ar), 128.5, 128.3 (CH-Ar), 101.3 (C-1), 70.9 
(C-5), 70.6 (C-3), 69.1 (C-2) 68.4 (OCH2CH2NH), 66.9 (C-4), 61.3 (C-6), 40.4 (NHCH2C2H5), 39.9 
(OCH2CH2NH), 22.7 ( NHCH2CH2CH3), 20.7, 20.6, 20.5, 20.6 (O(CO)CH3), 11.4 (NHC2H4CH3); 
HRMS m/z (ESI+): 998.3652 (C44H60N3O23: [M+H]
+ requires  998.3652). 
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N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N3-propyl-O-[(2,3,4,5,6 
pentafluorophenyl)ester]-benzene 1,5 dicarboxamide 4.75 
O1,O2,di-[(2,3,4,5,6-pentafluorophenyl)ester]-N3-propyl-benzene 1,3, dicarboxylic acid 4.72 
(207 mg, 0.35 mmol), was dissolved in THF (7 mL) under Ar and 2-aminoethyl 2,3,4,6-tetra-O-
acetyl-β-D-galactopyranoside 2.33 (173 mg, 0.44 mmol) dissolved in THF (5 mL) under Ar was 
added. The reaction mixture was stirred for 5 min and DIPEA (0.077 ml, 0.44 mmol) was added. 
The resulting solution was stirred at rt overnight. The solvent was removed in vacuo and the 
resulting residue purified by flash chromatography (1:1 EtOAc: Pet Ether) to yield compound 
4.75 as an clear waxy solid (101 mg, 36%); Rf = 0.75 (EtOAc); [α]
25 
D = -8.7 (c, 1.15 in DCM); IR 
vmax (NaCl plate, DCM): 3343.6, 3078.0, 2966.4, 2938.6, 2878.8, 1754.4, 1656.7, 1522.5, 
1439.7, 1370.4, 1232.2, 1162.3, 1080.8, 1061.4, 995.9, 956.5, 916.5, 801.7, 735.1, 706.3, 677.1, 
629.3  cm-1;  1H NMR (300 MHz, CDCl3): δ 8.78-8.76 (m, 2 H, Ar), 8.49 (s, 1 H, Ar), 6.95 (t, J = 5.4 
Hz, 2 H, CONHC3H7), 5.38 (d, J = 2.7, 1 H, H-4), 5.20 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2), 5.02 
(dd, J = 3.3 Hz, J = 10.5, 1 H, H-3), 4.50 (d, J = 7.8 Hz, 1 H, H-1), 4.16-4.02 (m, 2 H, H-6 and H-6’), 
3.95-3.90 (m, 2 H, overlap of H-5 and 1 H of OCH2CH2NH) 3.8-3.62 (m, 3 H, overlap of 1 H of 
OCH2CH2NH and OCH2CH2NH), 3.45- 3.40 (m, 2 H, NHCH2C2H5), 2.14, 2.02, 1.97, 1.93 (each s, 3 
H, O(CO)CH3), 1.68-1.61 (m, 2 H, NHCH2CH2CH3), 0.98 (t, J = 7.2 Hz, 3 H, NHC2H4CH3); 
13C NMR 
(75 MHz, CDCl3): δc 171.3 (CO), 170.5, 170.4, 170.3, 170.0  (OCOCH3), 165.1, 161.15 (CO), 
142.8, 139.7 (ArC of C6F5), 136.2, 135.4 (ArC), 132.4, 131.9, 130.6 (ArCH), 128.1 (ArC), 101.3 (C-
1), 70.9 (C-5), 70.5 (C-3), 69.2 (C-2) 68.4 (OCH2CH2NH), 66.9 (C-4), 61.3 (C-6), 42.1 (NHCH2C2H5), 
39.9 (OCH2CH2NH), 22.7 ( NHCH2CH2CH3), 21.1, 20.8, 20.6, 20.5 (O(CO)CH3), 11.4 (NHC2H4CH3). 
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N1, N2, di-(propargyl)-O-benzoate-benzene 1,3, dicarboxamide 4.88 
Benzyl alcohol (0.291 mL, 2.8 mmol) and DIPEA (0.538 mL, 3.0 mmol) dissolved in THF (50 mL) 
under Ar, was added dropwise over 3 h to 1,3,5- benzenetricarbonyl trichloride 4.46 (0.5 mL, 
2.8 mmol) in THF (30 mL) at 0 oC. This mixture was allowed to stir for 3 h. Propargylamine  
(0.359 mL, 5.6 mmol) and DIPEA (1.06 mL, 6.1 mmol) dissolved in THF (10 mL) was added 
quickly to the solution. The reaction was left stirring overnight. The solvent was removed 
under reduced pressure, the residue dissolved in DCM and washed with HCl (0.1 M), aqueous 
sat. NaHCO3 solution, brine and dried over MgSO4. Flash chromatography (1:1, EtOAc; Pet 
Ether) afforded the pure product 4.88 as a white solid (206 mg, 20%); Rf = 0.59 (1:1, EtOAc:Pet 
Ether); IR vmax (NaCl plate, DCM): 3275.0, 3064.9, 1725.2, 1649.7, 1633.3, 1544.0, 1444.4, 
1431.3, 1363.9, 1319.9, 1282.9, 1258.8, 1238.7, 1187.6, 1201.9,1065.0, 1014.9, 926.8, 914.8, 
900.4, 777.2, 748.8, 731.8, 694.2, 645.3, 661.4 cm-1; 1H NMR (300 MHz, CDCl3): δ 8.58 (s, 2 H, 
Ar), 8.46 (s, 1 H, Ar), 7.46-7.33 (m, 5 H, H-Ph), 6.62 (bs, 2 H, NHCH2CCH), 5.44 (s, 2 H, CH2Ph), 
4.28-4.26 (m, 4 H, NHCH2CCH), 2.31 (t, J = 2.4 Hz, 2 H, NHCH2CCH); 
13C NMR (75 MHz, CDCl3): δc 
165.0 (CONH), 164.9 (COOCH2), 135.3, 134.7 (ArC), 131.0, 130.2, 128.7, 128.7, 128.6 (ArCH and 
PhCH), 128.6 (Ph-C), 78.83 (NHCH2CCH), 72.4 (NHCH2CCH), 67.6 (CH2Ph), 30.0 (CONHCH2CCH); 
HRMS m/z (ESI+): 375.133 (C22H19N2O2: [M+H]
+ requires  375.1339).    
 
N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-
ylmethylamide]-O-benzoate-benzene 1,3, dicarboxamide 4.90 
Copper sulphate .5H2O (11 mg, 0.047 mmol) and sodium ascorbate (18 mg, 0.094 mmol) were 
added to a solution of N1,N2,di-(propargyl)-O-benzoate-benzene 1,3, dicarboxamide 4.88 (88 
mg, 0.2 mmol) and O-(azidoethyl)-(2,3,4,6-O-tetracetyl)-β-D-galactopyranose 2.44 (215 mg, 
0.51 mmol) in DCM/Acetone/H2O (3:1:1). The reaction was allowed to stir at rt overnight. The 
solvent was removed in vacuo, the residue dissolved in DCM and washed with brine. Column 
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chromtagraphy (8:1:1, DCM:MeOH:Toluene) afforded the pure product 4.90 as an waxy solid 
(164 mg, 58%); Rf = 0.52 (8:1:1, DCM:Toluene:MeOH); [α]
25 
D = -5 (c, 0.8 in DCM); IR vmax (NaCl 
plate, DCM): 3317.1, 2925.5, 2854.3, 1750.9, 1660.0, 1536.4, 1432.8, 1370.1, 1223.1, 1174.4, 
1057.2 cm-1; 1H NMR (300 MHz, CDCl3): δ 8.67 (s, 2 H, Ar), 8.50-8.40 (m, 1 H, Ar), 7.82-7.72 (m, 
2 H, NHCH2), 7.67 (s, 2 H, CCHN3), 7.46-7.33 (m, 5 H, H-Ph), 5.37-5.33 (m, 4 H, overlap of CH2Ph 
and H-4), 5.14 (dd, J = 7.8 Hz, J =10.5 Hz, 2 H, H-2), 5.00-4.95 (m, 2 H, H-3), 4.71-4.69 (m, 4 H, 
CONHCH2), 4.58-4.50 (m, 4 H, OCH2CH2NH), 4.44 (d, J = 8.1 Hz, 2 H, H-1), 4.25-4.20 (m, 2 H, 1 H 
of OCH2CH2N), 4.17-4.03 (m, 4 H, H-6 and H-6’), 3.97-3.97 (m, 4 H, overlap of 1 H of OCH2CH2N 
and H-5), 2.12, 2.02, 1.95, 1.94 (each s, 6 H, O(CO)CH3); 
13C NMR (75 MHz, CDCl3): δc 170.5, 
170.2, 170.1, 169.7 (OCOCH3), 165.6 (CONHCH2), 164.5 (COOCH2), 144.1 (CCHN3), 135.4, 134.6, 
134.6 (ArC, PhC), 131.3, 129.8 (ArCH), 128.7, 128.5, 128.4, 128.3 (PhCH) 123.9 (CCHN3), 100.9 
(C-1), 70.9 (C-5), 70.5 (C-3), 68.6 (C-2), 67.6 (OCH2CH2NH), 67.4 (CH2Ph), 66.9 (C-4), 61.2 (C-6), 
50.1 (OCH2CH2NH), 35.6 (CONHCH2), 20.7, 20.6, 20.6, 20.53 (O(CO)CH3); HRMS m/z (ESI+): 
1209.4106 (C54H65N8O24: [M+H]
+ requires  1209.4106).    
 
N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-
ylmethylamide]-N3-tetradecyl-benzene 1,3,5 tricarboxamide 4.92 
Tetradecylamine (0.251 g, 1.1 mmol) and DIPEA (0.214 mL, 1.29 mmol) dissolved in THF (10 
mL) under Ar, were added dropwise over 3 h to 1,3,5- benzene tricarbonyl trichloride 4.46 
(0.296 mL, 1.1 mmol) in THF (30 mL). This mixture was allowed to stir for 3 h. Propargylamine  
(0.143 mL, 2.2 mmol) and DIPEA (0.427 mL, 2.6 mmol) dissolved in THF (10 mL) were added 
quickly to the solution. The reaction was left stirring overnight. The solvent was removed 
under reduced pressure, the residue dissolved in DCM and washed with HCl (0.1 M), aqueous 
sat. NaHCO3 solution, Brine and dried over MgSO4. Flash chromatography (1:1, EtOAc:Pet 
Ether) afforded a mixture of products which was used without further purification. Copper 
sulphate .5H2O (4 mg, 0.018 mmol) and sodium ascorbate (7 mg, 0.037 mmol) were added to 
a solution of 4.92 (50 mg, 0.09 mmol) and 2-azidoethyl 2,3,4,6-tetra-O-acetyl-β-D-
galactopyranoside 2.44 (77 mg, 0.2 mmol) in DCM/Acetone/H2O (3 mL, 1 mL, 1 mL). The 
reaction was allowed to stir at rt overnight. The solvent was removed in vacuo, the residue 
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dissolved in DCM and washed with brine. Column chromtagraphy (8:1:1, DCM:MeOH:Toluene) 
afforded the pure product 4.93 as a waxy solid (64 mg, 54% over two steps); Rf = 0.45 (8:1:1, 
DCM:Toluene:MeOH); [α]25 D = -3.5 (c, 0.9 in DCM); IR vmax (NaCl plate, DCM): 3317.1, 2925.5, 
2854.3, 1750.9, 1660.0, 1536.4, 1432.8, 1370.1, 1223.1, 1174.4, 1057.2 cm-1; 1H NMR (300 
MHz, CDCl3): δ 8.26-8.25 (m, 3 H, Ar), 8.02 (bs, 2 H, NHCH2(CCHN3)), 7.67 (s, 2 H, CCHN3), 6.93 
(bs, 1 H, NHC14H29), 5.35 (d, 2 H, J = 3.3 Hz, H-4), 5.14 (dd, J = 7.8 Hz, J = 10.2 Hz, 2 H, H-2), 4.98 
(dd, J = 3.3 Hz, J =10.5, 2 H, H-3), 4.66 (d, J = 4.8 Hz, 4 H, CONHCH2), 4.58-4.50 (m, 4 H, 
OCH2CH2N), 4.45 (d, J = 7.8 Hz, 2 H, H-1), 4.22-4.16 (m, 2 H, 1 H of OCH2CH2N), 4.14-4.04 (m, 4 
H, H-6 and H-6’), 3.97-87 (m, 4 H, overlap of H-5 and 1 H of  OCH2CH2N), 3.40-3.36 (m, 2 H, 
NHCH2C13H27), 2.12, 2.01, 1.95, 1.94 (each s, 6 H, O(CO)CH3), 1.56 (t, J = 6.3, 2 H, 
NHCH2CH2C12H25), 1.23 (s, 22 H, NHCH2CH2(CH2)11CH3), 0.85 (t, J = 6.0 Hz, 3 H, NHC13H26CH3); 
13C 
NMR (75 MHz, CDCl3): δc 170.4, 170.2, 170.0, 169.7 (OCOCH3), 166.0 (CONHCH2), 165.9 
(CONHC14H29), 144.4 (CCHN3) 135.6, 134.6 (ArC), 128.7, 128.0 (ArCH), 123.7 (CCHN3), 100.9 (C-
1), 70.9 (C-5), 70.6 (C-3), 68.6 (C-2), 67.6 (OCH2CH2NH), 66.9 (C-4), 61.2 (C-6), 50.1 
(OCH2CH2NH), 40.4 (NHCH2C13H27), 35.5 (NHCH2(CCHN3), 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.1, 
22.7 (NHCH2(CH2)12CH3), 20.7, 20.7, 20.6 and 20.5 (O(CO)CH3), 14.0 (NHC13H26CH3); HRMS m/z 
(ESI+): 1336.5782 (C61H87N9NaO23: [M+Na]
+ requires  1336.5807).    
 
N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl-1,2,3-triazol-4-
ylmethylamide]-N3-propyl-benzene 1,3,5 ticarboxamide 4.95 
Propylamine (0.092 mL, 1.1 mmol) and DIPEA (0.214 mL, 1.2 mmol) dissolved in THF (10 mL) 
under Ar, was added dropwise over 3 h to 1,3,5- benzenetricarbonyl trichlorie 4.46 (0.200 mL, 
1.1 mmol) in THF (10 mL). The reaction mixture was stirred for 2 h and propargylamine  (0.143 
mL, 2.2 mmol) and DIPEA (0.427 mL, 2.6 mmol) dissolved in THF (4 mL) were added quickly to 
the solution. The reaction was left stirring overnight. The solvent was removed under reduced 
pressure, the residue dissolved in DCM and washed with 1 M HCl, aqueous sat. NaHCO3 
solution, brine and dried over MgSO4. Flash chromatography (EtOAc) afforded a mixture of 
products which was used without further purification (66 mg, 18%). Copper sulphate .5H2O 
(18 mg, 0.072 mmol) and sodium ascorbate (29 mg, 0.14 mmol) were added to a solution of 2-
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azidoethyl  2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 2.44 (166 mg, 0.39 mmol) and alkyne 
4.94 (60 mg, 0.18 mmol) in DCM/Acetone/H2O (3 mL, 1 mL, 1mL). The reaction was allowed to 
stir at rt overnight. The solvent was removed in vacuo, the residue dissolved in DCM and 
washed with brine. Column chromatography (8:1:1, DCM:MeOH:Toluene) afforded the pure 
product 4.95 as a waxy solid (120 mg, 57%); Rf = 0.30 (8:1:1, DCM:Toluene:MeOH); [α]
25 
D = -9 
(c, 1.1 in DCM); IR vmax (NaCl plate, DCM): 3404.1, 1748.1, 1651.9, 1536.1, 1370.1, 1225.6, 
1057.8 cm-1 ; 1H NMR (300 MHz, CDCl3): δ 8.26 (bs, 3 H, Ar), 8.10 (bs, 2 H, NHCH2(CCHN3)), 7.70-
7.69 (m, 2 H, CCHN3), 7.01 (bs, 1 H, NHC3H7), 5.38 (d, 2 H, J = 3 Hz, H-4), 5.15 (dd, J = 8.1 Hz, J = 
10.2 Hz, 2 H, H-2), 4.98 (dd, J = 3.3 Hz, J =10.5, 2 H, H-3), 4.66 (bs, 4 H, NHCH2(CCHN3)), 4.61-
4.51 (m, 4 H, OCH2CH2NH), 4.46 (d, J = 7.8 Hz, 2 H, H-1), 4.25-4.20 (m, 2 H, OCH2CH2NH), 4.16-
4.07 (m, 4 H, H-6 and H-6’), 3.97-3.89 (m, 4 H, overlap of H-5 and OCH2CH2NH), 3.35 (bs, 2 H, 
NHCH2C2H5), 2.13, 2.02 ( each s, 6 H, O(CO)CH3), 1.96 (s, 12 H, O(CO)CH3), 1.63-1.56 (m, 2 H, 
NHCH2CH2CH3), 0.93 (t, J = 6 Hz, 3 H, NHC2H4CH3); 
13C NMR (75 MHz, CDCl3): δc 170.5, 170.2, 
170.1 (OCOCH3), 169.7 (CONHCH2CCHN3), 166.0 (CONHC3H7), 144.4 (CCHN3) 135.6, 134.6 (ArC), 
129.0, 128.2 (ArCH), 125.3 (CCHN3), 100.9 (C-1), 70.9 (C-5), 70.6 (C-3), 68.6 (C-2), 67.5 
(OCH2CH2NH), 66.9 (C-4), 61.2 (C-6), 50.2 (OCH2CH2NH), 41 (NHCH2C2H5), 35.5 (NHCH2(CCHN3), 
22.7 (NHCH2CH2CH3), 20.7, 20.7, 20.6, 20.5 (O(CO)CH3), 11.5 (NHC2H4CH3); HRMS m/z (ESI+): 
1160.4295(C50H66N9NaO23:[M+H]
+requires 1160.4266).  
 
N3-hexadecanosyll-5-aminobenzene-1,3-dicarboxylic acid 4.96 
5-aminoisophatlic acid (1 g, 5.5 mmol) was dissolved in DMF (20 mL) and THF (20 mL) under Ar. 
Hexadecanoyl chloride (1.84 mL, 6 mmol) and NEt3 (0.92 mL, 6.6 mmol) were added and the 
reaction mixture stirred overnight. The solvent was removed under reduced pressure. The 
resulting residue was dissolved in hot MeOH and the insoluble material filtered off. The pure 
product precipitated out upon cooling, to yield the dicarboxylicacid 4.96 as a white solid (1.86 
g, 81%); Mp = Decomposed at 256 oC; IR vmax (KBr): 3270.3, 2918.0, 2848.8, 1726.6, 1663.28, 
1605.1, 1461.87, 1408.3, 1260.2, 1221.9, 1204.7, 967.9, 907.4, 826.1, 751.7 721.7, 671.2 cm-1; 
1H NMR (300 MHz, DMSO): δ 10.26 (s, 1 H, NHCO), 8.45 (s, 2 H, Ar), 8.14 (s, 1 H, Ar) 3.31 (t, J = 
7.2 Hz, 2 H, NHCOCH2C14H29), 1.60-1.56 (m, 2 H, NHCOCH2CH2C13H27), 1.18 (s, 24 H, 
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NHCOC2H4(CH2)12CH3), 0.82 (t, J = 6.3 Hz, 3 H, NHCOC14H28CH3); 
13C NMR (75 MHz, CDCl3): δc 
171.7, 166.5 (CO), 139.8, 131.6 (ArC), 124.3, 123.3 (ArCH), 36.3 (NHCOCH2C14H29), 31.3 
(NHCOCH2CH2C13H26), 29.1, 29.0, 28.9, 28.8, 28.6, 24.9, 24.46, 22.1 (NHCOC2H4(CH2)12CH3), 13.8 
(NHCOC14H29CH3); HRMS m/z (ESI+): 418.2615, (C24H36NO5: [M-H]
- requires  418.2599). 
 
N1, N2, di-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-N3-hexadecanosyl-5-aminobenzene 
1,3,dicarboxamide 4.98 
N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic acid 4.96 (85 mg, 0.2 mmol), was 
dissolved in THF (5 mL) under N2 and placed on ice. DMF (2 drops) was added. Oxalyl chloride 
(0.055 mL, 0.60 mmol) was then added dropwise. The reaction was left stirring for 40 min at    
0 oC and a solution of 1-amino-2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 3.76 (177 mg, 0.5 
mmol) and NEt3 (0.084 mL, 0.60 mmol) in THF (5 mL) under N2 was added. The reaction was 
left stirring overnight at 0 oC . The solvent was removed in vacuo and the residue dissolved in 
DCM and washed successively with 0.1 M HCl, aqueous sat. NaHCO3 solution, brine and dried 
over MgSO4. Flash chromatography (1:1, EtOAc:Pet Ether) afforded the di-substituted product 
4.98 as a cream waxy solid (99 mg, 45%); Rf = 0.26 (95:5 DCM:MeOH); [α]
25 
D = -7.3 (c, 1 in 
DCM); IR vmax (NaCl plate, DCM): 3325.6, 2925, 2853.9, 1750.4, 1671.4, 1537, 1445.6, 1369.6, 
1226.9, 1083.7, 1052.7 cm-1; 1H NMR (300 MHz, CDCl3):  8.19 (bs, 2 H, Ar), 8.00 (s, 1 H, Ar), 
7.88 (s, 1 H, NHCOC15H31), 7.45 (d, J = 9 Hz, 2 H, H1NHCO), 5.57-5.44 (m, 4 H, overlap of H-1 
and H-4), 5.30-5.14 (m, 4 H, overlap of H-2 and H-3), 4.21-4.04 (m, 6 H, overlap of H-6, H-6’ and 
H-5), 2.39 (t, J = 7.5 Hz, 2 H, NHCOCH2(CH2)13CH3), 2.18,  2.03, 2.01 and 2.00  (each s, 6 H, 
O(CO)CH3), 1.77-1.68 (m, 2 H, NHCOCH2CH2(CH2)12CH3), 1.24 (s, 24 H, NHCOCH2CH2(CH2)12CH3), 
0.86 (t, J = 6.3 Hz, 3 H, NHCOCH2CH2(CH2)12CH3); 
13C NMR (75 MHz, CDCl3): δc 172.1, 171.4, 
170.9, 170.4, 170.2, 170.0, 165.9, 169.8, 166.1, 156.4 (CO), 139.4, 134.3 (ArC), 121.8, 121.0 
(ArCH), 79.0 (C-1), 72.4 (C-5), 71.0 (C-3), 68.6 (C-2), 67.3 (C-4), 61.3 (C-6), 37.6 
(NHCOCH2(CH2)13CH3), 31.9, 29.7, 29.5, 29.4,  29.3, 29.3, 25.7 (NHCOCH2(CH2)13CH3), 20.8, 20.7, 
20.6, 20.6 (O(CO)CH3), 14.1 (NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 1078.4966 (C52H76N3O21: 
[M+H]+ requires  418.2599). 
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N3-propyl-5-aminobenzene-1,3-dicarboxylic acid 4.99 
5-Aminoisophatlic acid (1 g, 5.5 mmol) was dissolved in THF (10 mL) and propionyl chloride       
(0.5 mL, 6.0 mmol) was added dropwise. The mixture was allowed to stir for 5 min and NEt3 
(0.9 mL, 6.6 mmol) was added. The solution was stirred at rt overnight. The reaction was left 
stirring overnight. The solvent was removed under reduced pressure, and the residue 
dissolved in hot methanol. The insoluble material was filtered off, and the filtrate recrystillised 
from EtOAc and Et2O to yield the title product 4.99 as a cream solid (1.16 g, 89%);  
1H NMR 
(300 MHz, DMSO): δ 10.48 (s, 1 H, NHCO), 8.47 (s, 2 H, Ar), 8.13 (s, 1 H, Ar), 2.37 (q, J = 7.5 Hz, 
2 H, NHCOCH2CH3), 1.08 (t, J = 7.5 Hz, 3 H, NHCOCH2CH3); 
13C NMR (75 MHz, DMSO): δc 171.6, 
166.5 (CO), 139.9, 131.6 (ArC), 124.2, 123.3 (ArCH), 29.5 (NHCOCH2CH3), 9.4 (NHCOCH2CH3); 
HRMS m/z (ESI+): 238.0722, (C11H12NO5: [M+H]
+  requires 238.071).  
 
N1, N2, di-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-N3-propyl-5-aminobenzene 1,3, 
dicarboxamide 4.100 
N3-propyl-5-aminobenzene-1,3-dicarboxylic acid 4.99 (67 mg, 0.28 mmol), HOBt (84 mg, 0.62 
mmol) and TBTU (200 mg, 0.62 mmol) were placed under N2 and dissolved in DMF (4 mL). NEt3 
(0.16 mL, 1.1 mmol) was added and the mixture was allowed to stir for 15 min. 1-amino-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 3.76(248 mg, 0.7 mmol) dissolved in DMF (5 mL) 
was then added. The solution was stirred overnight. The solvent was removed under reduced 
pressure and the resulting residue was dissolved in DCM washed with 0.1 M HCl, aqueous sat. 
NaHCO3 solution, brine and dried over MgSO4. Column chromatography (EtOAc) yielded the 
pure di-substituted product 4.100 as an oily solid (49 mg, 20%); Rf = 0.36 (EtOAc); [α]
25 
D = -18.1 
(c, 1.1 in DCM); IR vmax (NaCl plate, DCM): 3338.9, 1750.6, 1676.9, 1602.2, 1535.2, 1370.1, 
1228.3, 1083.4, 1052.1, 956.25, 909.15, 802.3 cm-1;  1H NMR (300 MHz, CDCl3):  8.23-8.21 (m, 
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2 H, overlap of Ar and NHCOC2H5), 7.88 (s, 1 H, Ar), 7.43 (d, J = 9.3 Hz, 2 H, H-1NHCO), 5.58-
5.48 (m, 4 H, overlap of H-1 and H-4), 5.29-5.27 (m, 4 H, overlap of H-2 and H-3), 4.20-4.05 (m, 
6 H, overlap of H-6, H-6’ and H-5), 2.43 (q, J = 7.5 Hz, 2 H, NHCOCH2CH3), 2.18,  2.03, 2.01, 1.99  
(each s, 6 H, O(CO)CH3), 1.27-1.21 (m, 3 H, NHCOCH2CH3); 
13C NMR (75 MHz, CDCl3): c 172.7, 
171.4 (CO), 170.5, 170.2, 170.0, 170.1, 170.0 (O(CO)CH3), 166.1 (CO), 139.6, 134.3 (ArC), 121.8, 
121.8 (ArCH), 79.0 (C-1), 72.4 (C-5), 71.0 (C-3), 68.6 (C-2), 67.3 (C-4), 61.3 (C-6), 30.5 
(NHCOCH2CH3), 20.8, 20.7, 20.6, 20.6, 20.5 (O(CO)CH3), 14.20 (NHCOCH2(CH2)13CH3); HRMS m/z 
(ESI+): 896.2956, (C39H50N3O21: [M+H]
+  requires 896.2931). 
 
N1,N2, di-propargyl-N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic acid 4.101 
N3-hexadecanosyll-5-aminobenzene-1,3-dicarboxylic acid 4.96  (200 mg, 0.47 mmol), HOBt 
(142 mg, 1 mmol) and TBTU (337 mg, 1 mmol) were dissolved in DMF under N2 and NEt3 (146 
mL, 1 mmol) was added. The mixture was allowed to stir for 10 min and propargylamine (0.07 
mL, 1.2 mmol) was added. The solution was stirred at rt overnight.  The solvent was removed 
in vacuo, dissolved in DCM washed successively with 0.1 M HCl, aqueous sat. NaHCO3 solution, 
brine and dried over MgSO4. Column chromatography (1:1, EtOAc: Pet Ether) yielded the 
product which was recrystillsed (EtOAc) as an white solid 4.101 (146 mg, 62%); Rf = 0.39 (1:1, 
EtOAc: Pet EtherDCM); mp = 154- 156 oC; IR vmax (KBr): 3269.08, 3067.5, 2919.0, 2849.6, 
2125.93, 1733.94, 1659.0, 1599.1, 1535.7, 1461.3, 1444.6, 1421.6, 1369.2, 1327.4, 1286.6, 
1205.6=7, 1221.3, 1187.3, 1112.8, 1065.5, 1050.8, 1013.7, 966.2, 916.1, 888.8 cm-1; 1H NMR 
(300 MHz, CDCl3): δ 8.54 (s, 1 H, NHCO), 8.28 (s, 2 H, Ar), 7.98 (s, 1 H, Ar) 7.61-7.57 (m, 1 H, Ar), 
6.95 (t, J = 5.1 Hz, 2 H, NHCH2CCH), 4.24-4.21 (m, 4 H, NHCH2CCH), 2.43 (t, J = 7.5 Hz, 2 H, 
NHCOCH2C14H29), 2.27 (t, J =  2.7 Hz, 2 H, NHCH2CCH), 1.73-1.66 (m, 2 H, NHCOCH2CH2C13H27), 
1.31-1.24 (m, 24 H, NHCOC2H4(CH2)12CH3), 0.87 (t, J = 6.6 Hz, 3 H, NHCOC14H28CH3); 
13C NMR (75 
MHz, CDCl3): δc 172.7, 166.1 (CO), 139.5, 134.6 (ArC), 121.2, 120.9 (ArCH), 78.9 (NHCH2CCH), 
72.16 (NHCH2CCH), 37.6 (NHCOCH2C14H29), 31.9 (NHCOCH2CH2C13H26), 29.9, 29.7, 29.7, 29.5, 
29.4, 29.3, 29.2, 245.4, 22.7 (overlap of NHCH2CCH and NHC2H4(CH2)12CH3),14.1 (NHC14H29CH3). 
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N1, N2, di-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-N3-
hexadecanosyl-5-aminobenzene 1,3, dicarboxamide 4.102 
Copper sulphate .5H2O (5 mg, 0.021 mmol) and sodium ascorbate (8 mg, 0.04 mmol) were 
added to a solution of 1-azido-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 3.67 (158 mg, 0.42 
mmol) and N1,N2, di-propargyl-N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic acid 4.101 
(105 mg, 0.21 mmol) in DCM/Acetone/H2O (3 mL, 1 mL, 1mL). The reaction was allowed to stir 
at rt overnight. The solvent was removed in vacuo, the residue dissolved in DCM, washed with 
brine and dried over MgSO4. Gradient elution chromtagraphy (8:1:1, DCM:MeOH:Toluene- 
EtOAc) afforded the pure product as a clear oil 4.102 (145 mg, 56%); Rf = 0.57 (8:1:1, 
DCM:Toluene:MeOH); [α]25 D = -17.4 (c, 0.87 in DCM); IR vmax (NaCl plate, DCM): 3291.4, 2924.3, 
1754.9, 1649.6, 1599.5, 1537.7, 1446.4, 1425.5, 1369.6, 1092.4, 1062.7, 953.1, 924.1, 897.3, 
801.2, 684.3 cm-1; 1H NMR (300 MHz, CDCl3): δ 8.12 (s, 1 H, NHCOC15H31), 8.03 (s, 2 H, Ar), 7.96 
(CHCN3), 7.92 (s, 1 H, Ar), 7.71-6.67 (m, 2 H, CONHCH2), 5.90 (d, J = 9 Hz, 1 H, H-1), 5.60-5.40 
(m, 4 H, overlap of H-4 and H-2), 5.27 (dd, J = 3.3 Hz, J = 10.2 Hz, 2 H, H-3), 4.75-4.59 (m, 2 H, 
CONHCH2), 4.313-4.27 (m, 2 H, H-5), 4.22-4.08 (m, 4 H, H-6 and H-6’), 2.37 (t, J = 7.2 Hz, 2 H, 
NHCOCH2C14H29), 2.21, 2.01, 1.99, 1.82 ( each s, 6 H, O(CO)CH3), 1.71-1.66 (m, 2 H, 
NHCOCH2CH2C13H26), 1.37-1.22 (m, 24 H, NHCOC2H4(CH2)12CH3), 0.86 (t, J = 6.6 Hz, 3 H, 
NHCOC14H29CH3); 
13C NMR (75 MHz, CDCl3): δc 172.2, 170.3, 170.1, 169.8, 169.2, 166.5 (CO), 
145.4 (CCHN3), 139.0, 134.9 (ArC), 121.4, 120.6 (ArCH and CCHN3), 86.18 (C-1), 73.9 (C-5), 70.8 
(C-3), 68.0 (C-2), 66.8 (C-4), 61.2 (C-6), 37.5 (NHCOCH2(CH2)13CH3), 35.4 (CONHCH2), 31.9, 29.7, 
29.6, 29.5, 29.4,  29.3, 25.4, 22.7 (NHCOCH2(CH2)13CH3), 20.7, 20.6, 20.5, 20.2 (O(CO)CH3), 14.1 
(NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 1240.5657, (C58H82N9O21: [M+H]
+  requires  1240.562). 
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N2-[2-O-(2,3,4,6-tetra-O-acetyl- β-D-galactopyranosyl)-ethyl]- N1-tert-butoxycarbonyl-glycine 
4.105 
HOBt (0.09 g, 0.69 mmol), followed by NEt3  (0.12 mL, 0.63 mmol), were added to a stirring 
solution of N-Boc-Glycine-OH 4.104 (0.11 g, 0.63 mmol) and TBTU (0.22 g, 0.69 mmol) 
dissolved in DMF (10 mL), under N2 at rt. The mixture was stirred for 30 min and 2-aminoethyl 
2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33  (0.29 g, 0.75 mmol) dissolved in DMF (2 mL) 
was added. The mixture was stirred for 18 h. The reaction mixture was concentrated under 
reduced pressure, diluted with EtOAc and washed succesively with HCl 0.1 N, aqueous sat. 
NaHCO3 solution, brine and dried over MgSO4. Flash chromotagraphy (5:1, EtOAc: Pet Ether) 
afforded 4.105 (0.22 g, 62%); Rf = 0.41 (5:1 EtOAc: Pet Ether); [α]
25 
D = 1.97 (c, 1.3 in DCM); IR 
vmax (NaCl plate, DCM): 3382, 2978.9, 1752, 1519.7, 1432.6, 1369.3, 1226.3, 1171.1, 1055.8, 
955.9  cm-1; 1H NMR (300 MHz, CDCl3):  6.42 (bs, 1 H, OCH2CH2NH), 5.36-5.35 (m, 1 H, H-4), 
5.26 (s, 1 H, NHCOC(CH3)3), 5.13 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2), 4.98 (dd, J= 3.3 Hz, J= 
10.5 Hz, 1 H, H-3), 4.46 (d, J = 7.8 Hz, 1 H, H-1), 4.18-4.06 (m, 2 H, H-6 and H-6’), 3.95-3.79 (m, 
2 H, overlap of 1 H of OCH2CH2NH and H-5), 3.7 (d, J = 8.1 Hz, 2 H COCH2NHCO), 3.70-3.63 (m, 1 
H, 1 H of OCH2CH2NH), 3.51-3.40 (m, 2 H, OCH2CH2NH), 2.12, 2.03, 2.01, 1.95 (each s, 3 H, 
O(CO)CH3), 1.42 (s, 9 H, COC(CH3)3); 
13C NMR (75 MHz, CDCl3): δc 170.4, 170.2, 170.0 
(O(CO)CH)3, 169.7, 169.5 (CO), 101.3 (C-1), 76.7 (COC(CH3)3), 70.9 (C-5), 70.72 (C-3), 68.9 (C-2), 
68.6 (OCH2CH2NH), 67.0 (C-4), 61.4 (C-6), 39.2 (OCH2CH2NH), 28.3 (COC(CH3)3), 20.8, 20.6, 20.6 
and 20.5 (O(CO)CH3); HRMS m/z (ESI+): 571.211 (C23H36N2NaO13: [M+H]
+ requires  571.211). 
 
N2-[2-O-(2,3,4,6-tetra-O-acetyl- β-D-galactopyranosyl)-ethyl]-glycine 4.106 
A solution of N2-[2-O-(2,3,4,6-tetra-O-acetyl- β-D-galactopyranosyl)-ethyl]- N1-tert-
butoxycarbonyl-glycine 4.105 (0.11 g, 0.21 mmol) in DCM (6 mL) was cooled in an ice bath and 
TFA (0.17 mL, 2.15 mmol) added. The reaction mixture was stirred at 0 oC for 30 min, and for a 
further 4 h at rt. The organic solvent was removed in vacuo and the residue obtained was 
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diluted with ethyl acetate and washed with aqueous sat. NaHCO3 solution and brine, dried 
(MgSO4) and concentrated to yield the corresponding deprotected amine 4.106 as a brown oil 
that was used without further purification (0.073 g, 74%); 1H NMR (300 MHz, CDCl3):  7.43 
(bs, 1 H, CH2NHCO), 5.36-5.35 (m, 1 H, H-4), 5.16 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2), 4.98 (dd, 
J = 3.3 Hz, J= 10.5 Hz, 1 H, H-3), 4.46 (d, J = 7.8 Hz, 1 H, H-1), 4.18-4.05 (m, 2 H, H-6 and H-6’), 
3.91-3.83 (m, 2 H, overlap of 1 H of OCH2CH2NH and H-5), 3.68-3.61 (m, 2 H, OCH2CH2NH), 
3.54-3.40 (m, 2 H, OCH2CH2NH), 3.37-3.31 (m, 2 H, COCH2NH2) 2.12, 2.03, 2.01, 1.95 (each s, 
3H, O(CO)CH3).  
 
O1,O2,di-(2,3,4,5,6-pentafluorphenyl) ester -N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic 
acid 4.108 
N3-hexadecanosyll-5-aminobenzene-1,3-dicarboxylic acid 4.96 (200 mg, 0.47 mmol) and 
pentaflourophenol (263 mg, 1.4 mmol) was dissolved in THF (5 mL) under N2 and placed on ice. 
DIC (0.298 mL, 1.9 mmol) was added and the reaction was stirred for 1 h at 0 oC. The reaction 
was stirred for a further 4 h at rt. The solvent was removed in vacuo and the residue was 
purified by flash chromatography (10:1, Pet Ether:EtOAc) to yield a white solid which was 
crystillised in EtOAc to yield the pure product 4.108 as a white solid (167 mg, 46%); Rf = 0.66 
(7:1, Pet Ether: EtOAc); mp = 151-153 oC; IR vmax (KBr Disc): 3407.5, 2920.0, 2850.7, 1764.4, 
1665.3, 1519.1, 1454.7, 1468.8, 1454.7, 1339.4, 1310.4, 1192.8, 1097.3, 1077.32cm-1; 1H NMR 
(300 MHz, CDCl3): δ 8.70 (s, 3 H, Ar), 7.47 (s, 1 H, CNHCOC15H31), 2.43 (t, J = 7.5 Hz, 2 H, 
NHCOCH2C14H29), 1.81-1.71 (m, 2 H, NHCOCH2CH2C13H27), 1.24 (s, 24 H, NHCOC2H4(CH2)12CH3), 
0.86 (t, J = 6.6 Hz, 3 H, NHCOC14H28CH3); 
13C NMR (75 MHz, CDCl3): δc 171.8, 160.9 (CO), 139.6, 
138.3 (ArC of C6F5) 136.8 (ArC), 134.8, 134.5 (ArCH), 128.7 (ArC), 37.7 (NHCOCH2C14H29), 31.9, 
29.7, 29.5, 29.4, 29.2, 25.3, 22.7 (NHCOCH2(CH2)14CH3), 14.1 CONHC14H28CH3); HRMS m/z 
(ESI+): 750.2279 (C36H35F10NO5: [M-H]
- requires  750.2283). 
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N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-ethyl-glycine)-O-(2,3,4,5,6 
pentafluorophenol) ester-N3-hexadecanosyl-5-aminobenzene 1,3, dicarboxamide 4.109 
O1,O2,di-(2,3,4,5,6-pentafluorphenyl) ester -N3-hexadecanosyl-5-aminobenzene-1,3-
dicarboxylic acid 4.108 (17 mg, 0.02 mmol), was dissolved in THF (5 mL) under N2 with 4Å 
molecular sieves. N2-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-glycine 4.106 
(25 mg, 0.06 mmol) and DIPEA (0.009 mL, 0.06 mmol) dissolved in THF (2 mL) under N2 were 
added and the reaction mixture was stirred at rt overnight. The solvent was removed in vacuo 
and the resulting residue purified by flash chromatography (1:1, EtOAc:Pet Ether) to yield 
compound 4.109 as a clear oil (10 mg, 45%); Rf = 0.57 (EtOAc); [α]
25 
D = -2 (c, 0.9 in DCM); IR 
vmax (NaCl plate, DCM): 3324.9, 3094.0, 2959.1, 2925.7, 2854.5, 1754.3, 1646.9, 1600.2, 
1554.2, 1521.0, 1453.5, 1369.1, 1225.5, 1170.9, 1078.9, 997.3, 956.3, 888.6, 802.0, 745.7 cm-1; 
1H NMR (300 MHz, CDCl3):  8.90 (s, 1 H, NHCOC15H31), 8.87 (s, 1 H, Ar), 8.34 (t, J = 2.7 Hz, 1 H, 
Ar), 8.17 (t, J = 3.6 Hz, 2 H, Ar) 7.65 (t, J = 10.2 Hz 1 H, COCH2NHCO), 6.74-6.72 (t, J = 11.1 Hz, 1 
H, OCH2CH2NH), 5.41-5.40 (m, 1 H, H-4), 5.17 (dd, J = 7.8 Hz, J = 10.2 Hz, 1 H, H-2), 5.05 (dd, J = 
3.0 Hz, J = 10.2 Hz, 1 H, H-3), 4.55 (d, J = 7.8 Hz, 1 H, H-1), 4.23-4.08 (m, 4 H, overlap of H-6, H-
6’ and COCH2NHCO), 3.98-3.94 (m, 1 H, H-5), 3.90-3.84 (m, 1 H, 1 H of OCH2CH2NH), 3.78-3.70 
(m, 1 H, 1 H of OCH2CH2NH),  3.57-3.40 (m, 2 H, OCH2CH2NH), 2.44 (t, J = 7.5 Hz 2 H, 
NHCOCH2C14H29), 2.14, 2.07, 2.05, 1.99 (each s, 3 H, O(CO)CH3), 1.78-1.70 (m, 2 H, 
NHCOCH2CH2C13H27), 1.24 (s, 24 H, NHCOC2H4(CH2)12CH3), 0.86 (t, J = 6.6, 3 H, NHCOC14H28CH3); 
13C NMR (75 MHz, CDCl3): δc 170.6, 170.2, 170.2, 169.9 (O(CO)CH)3), 168.9, 166.1, 161.8, 157.2 
(CO), 140.0, 135.0, 128.1 (ArC), 124.4, 124.1, 124.0 (ArCH), 101.2 (C-1), 70.9 (C-5), 70.76 (C-3), 
69.01 (C-2), 68.46 (OCH2CH2NH), 67.0 (C-4), 61.4 (C-6), 43.7 (COCH2NHCO), 39.6 (OCH2CH2NH), 
37.6 (NHCOCH2(CH2)13CH3), 31.9, 29.7, 29.7, 29.5, 29.4, 29.4, 29.3, 28.3, 25.4, 22.7 
(NHCOCH2(CH2)13CH3), 21.1, 20.9, 20.7, 20.6 (O(CO)CH3), 14.1 (NHCOCH2(CH2)13CH3); HRMS m/z 
(ESI+): 1016.4182 (C48H63F5N3O15: [M+H]
+ requires  1016.4174). 
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N1,N2, di-(glycine-benzyl ester) –N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic acid 4.11 
N3-hexadecanosyll-5-aminobenzene-1,3-dicarboxylic acid 4.96  (300 mg, 0.7 mmol), HOBt (212 
mg, 1.5 mmol) and TBTU (505 mg, 1.5 mmol) was placed under N2 and dissolved in DMF (10 
mL). NEt3 (0.20 mL, 1.4 mmol) was added and the mixture was allowed to stir for 15 min. 
Glycine benzyl ester. HCl salt (432 mg, 2 mmol) and NEt3 (0.298 mL, 2.1 mmol) were dissolved 
in DMF (5 ml) and added to the reaction mixture, which was stirred overnight. The solvent was 
removed under reduced pressure, and the resulting residue was dissolved in DCM, washed 
with 0.1 M HCl, aqueous sat. NaHCO3 solution, brine and dried over MgSO4. Recrystillisation in 
1:1 (EtOAc:Pet Ether) yielded the pure product 4.11 as a white solid (269 mg, 54%); Rf = 0.9 
(1:1, EtOAc:Pet Ether); IR vmax (KBr Disc): 3368.8, 3315.2, 2923.9, 2852.6, 1735.8, 1659.3, 
1602.1, 1561.3, 1499.0, 145.5, 1443.3, 1432.3, 1405.6, 1390.2, 1293.0, 1251.3, 1195.8, 1112.9, 
1094.7, 1080.8, 1027.03 cm cm-1; 1H NMR (300 MHz, CDCl3): δ 8.52 (bs, 1 H, NHCOC15H31), 7.09 
(s, 1 H, Ar), 7.80 (s, 2 H, CONHCH2), 7.69 (s, 1 H, Ar), 7.35 (s, 10 H, PhH), 5.20 (s, 4 H, CH2Ph), 
4.20 (d, J = 5.4, 4 H, COCH2NHCO), 2.29 (t, J = 6.9, 2 H, NHCOCH2(CH2)13CH3), 1.64 (bs, 2 H, 
NHCOCH2CH2(CH2)12CH3), 1.24 (s, 24 H, NHCOCH2CH2(CH2)12CH3), 0.87 (t, J = 6.3, 3 H, 
NHCOCH2CH2(CH2)12CH3); 
13C NMR (75 MHz, CDCl3): δc 172.8, 170.8, 167.4 (CO), 139.0, 135.2, 
134.5 (ArC) 128.7, 128.5, 128.2 (PhCH), 120.9, 120.6 (ArCH), 67.3 (PhCH2), 40.4 (COCH2NHCO), 
37.4 (NHCOCH2(CH2)13CH3), 31.9, 29.7, 29.7, 29.6, 29.5, 29.4, 23.3, 22.7, 22.3 
(NHCOCH2(CH2)13CH3), 14.3 (NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 714.4077 (C42H56N3O7: 
[M+H]+ requires  714.4113). 
 
N1,N2,di-(glycine)-N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic acid 4.112 
To a solution of N1,N2,di-(glycine-benzyl ester)–N3-hexadecanosyl-5-aminobenzene-1,3-
dicarboxylic acid 4.11  (53 mg, 0.07 mmol) in absolute ethanol (5 mL), Pd/C 10% w/w (6 mg) 
was added. The resulting mixture was stirred under H2 gas overnight. The mixture was then 
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filtered through a Celite cake and the filtrate was concentrated under vacuum to afford the 
pure product 4.112 as a white solid (32 mg, 78%); IR vmax (KBr disc): 3326.2, 2922.1, 2853.4, 
1732.7, 1714.5, 1682.8, 1638.9, 1600, 1570.7, 1417.7, 1354.8, 1328.3, 1301.1, 1210.84, 1029 
cm-1; HRMS m/z (ESI+): 532.3023 (C28H42N3O7: [M-H]
- requires  532.3028). 
 
N1, N2, di-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl-glycine]-N3-hexadecanosyl-
5-aminobenzene 1,3, dicarboxamide 4.107 
N1,N2,di-(glycine)-N3-hexadecanosyl-5-aminobenzene-1,3-dicarboxylic acid 4.112 (28 mg, 0.05 
mmol), HOBt (15 mg, 1.1 mmol) and TBTU (36 mg, 1.1 mmol) was placed under N2 and 
dissolved in DMF (5 mL). NEt3 (0.016 mL, 1.1 mmol) was added and the mixture was allowed to 
stir for 15 min. 2-Aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33 (61mg, 0.15 
mmol) dissolved in DMF (5 mL) was then added. The solution was stirred overnight. The 
solvent was removed under reduced pressure and the residue was dissolved in DCM washed 
with 0.1 M HCl, aqueous sat. NaHCO3 solution, brine and dried over MgSO4. Gradient elution 
chromatography (98:2-95:5, DCM: MeOH) yielded the pure product 4.107 as an oily solid (11 
mg, 15%); Rf = 0.26 (95:5 DCM:MeOH); [α]
25 
D = -7 (c, 0.9 in DCM); IR vmax (NaCl plate, DCM): 
3326.2, 2922.1, 2853.4, 1732.7, 1714.5, 1682.8, 1638.9, 1600, 1570.7, 1417.7, 1354.8, 1328.3, 
1301.1, 1210.8, 1029 cm-1; 1H NMR (300 MHz, CDCl3):  8.69 (bs, 1 H, NHCOC15H31), 8.07 (s, 2 H, 
COCH2NH), 8.01 (s, 2 H, Ar), 7.83 (s, 1 H, Ar), 6.97 (s, 2 H, CH2CH2NH), 5.39 (d, J = 3.3 Hz, 2 H, H-
4), 5.16 (dd, J = 7.8 Hz, J = 10.5 Hz, 2 H, H-2), 5.06 (dd, J = 3.3 Hz, J = 10.5 Hz, 2 H, H-3), 4.58 (d, 
J = 7.8 Hz, 1 H, H-1), 4.21-4.07 (m, 6 H, overlap of H-6, H-6’ and COCH2NH), 4.0-3.95 (m, 2 H, H-
5), 3.93-3.85 (m, 1 H, 1 H of CH2CH2O), 3.81-3.69 (m, 1 H, 1 H of OCH2CH2NH), 3.57-3.50 (m, 2 
H, OCH2CH2NH),  2.37-2.30 (m, 2 H, NHCOCH2(CH2)13CH3), 2.13 (s, 6 H, O(CO)CH3), 2.09 (s, 6 H, 
O(CO)CH3), 2.04 (s, 6 H, O(CO)CH3), 1.98 (s, 6 H, O(CO)CH3), 1.74-1.61 (m, 2 H, 
NHCOCH2CH2(CH2)12CH3), 1.24 (s, 24 H, NHCOCH2CH2(CH2)12CH3), 0.87 (t, J = 6.3, 3 H, 
NHCOCH2CH2(CH2)12CH3); 
13C NMR (75 MHz, CDCl3): δc 178.1, 172.5 (CO), 170.6, 170.2, 170.1, 
170.1 (O(CO)CH)3), 169.9, 167.3 (CO), 135.2, 134 (ArC), 121.9, 121.4 (ArCH), 101.3 (C-1), 70.8 
(C-5), 70.8 (C-3), 69.0 (C-2), 68.5 (OCH2CH2NH), 67.1 (C-4), 61.3 (C-6), 43.8 (COCH2NHCO), 39.7 
(OCH2CH2NH), 37.5 (NHCOCH2(CH2)13CH3), 31.9, 29.7, 29.7, 29.6, 29.5, 29.5,  29.4, 25.4, 22.7 
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(NHCOCH2(CH2)13CH3), 20.8, 20.7, 20.6, 20.5 (O(CO)CH3), 14.11 (NHCOCH2(CH2)13CH3); HRMS 
m/z (ESI+): 1294.6044 (C61H92N5O25: [M-H]
- requires  1294.6044). 
 
N3-hexadecanosyl-3-aminobenzoic acid 4.114 
3-Aminobenzoic acid (1 g, 7.2 mmol) was dissolved in DMF (25 mL) and THF (5 mL) under Ar. 
Hexadecanoyl chloride (2.23 mL, 8 mmol) and NEt3 (1.2 mL, 8.7 mmol) were added and the 
reaction mixture stirred overnight. The solvent was removed under reduced pressure. The 
resulting residue was dissolved in MeOH and the precipitate filtered off. The filtrate was then 
crystillsed in EtOAc to yield the monoacid 4.114 as a cream solid (2.05 g, 75%); Mp = 210- 212 
oC; IR vmax (KBr): 3294.1, 2956.8, 2848.7, 2675.7, 1691.2, 1655.9, 1591.9, 1539.4, 1428.3, 
1470.7, 1456.3, 1325.7, 1272.5, 1180.6, 1198.4, 1161.6, 111.5, 963.8, 944.4, 894.4, 816.5, 
757.4, 718.7, 670.1, cm-1; 1H NMR (300 MHz, DMSO): δ 10.06 (s, 1 H, NHCO), 8.423 (s, 1 H, Ar), 
7.83-7.77 (s, 1 H, Ar) 7.61-7.57 (m, 1 H, Ar), 7.40 (t, J = 7.7 Hz, 1 H, Ar), 2.30 (t, J = 6.9 Hz, 2 H, 
NHCOCH2C14H29), 1.62-1.55 (m, 2 H, NHCOCH2CH2C13H27), 1.32-1.19 (m, 24 H, 
NHCOC2H4(CH2)12CH3), 0.85 (t, J = 8.1 Hz, 3 H, NHCOC14H28CH3); 
13C NMR (75 MHz, DMSO): δc 
171.5, 167.1 (CO), 139.5, 131.1 (ArC), 128.9, 123.7, 123.0, 119.7 (ArCH), 36.3 (NHCOCH2C14H29), 
31.3 (NHCOCH2CH2C13H26), 29.0, 28.9, 28.8, 28.7, 28.6, 28.5, 24.9, 22.1 (NHC2H4(CH2)12CH3), 
13.9 (NHC14H29CH3); HRMS m/z (ESI+): 374.2715, (C23H36NO3: [M-H]
-  374.2701). 
 
N1-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-N2-hexadecanosyl-3-aminobenzene 1-
carboxamide 4.115 
N3-hexadecanosyl-3-aminobenzoic acid 4.114 (157 mg, 0.41 mmol), HOBt (61 mg, 0.45 mmol) 
and TBTU (145 mg, 0.45 mmol) were placed under N2 and dissolved in DMF (8 mL). NEt3 (0.11 
mL, 0.82 mmol) was added and the mixture was allowed to stir for 15 min. The 1-amino-
2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 3.76 (215 mg, 0.62 mmol) dissolved in DMF (5 mL) 
was then added. The solution was stirred overnight. The solvent was removed under reduced 
pressure and the residue was dissolved in DCM washed with 0.1 M HCl, aqueous sat. NaHCO3 
Chapter 6:                                                                                                                                   Experimental details 
 
 
250 
 
solution, brine and dried over MgSO4. Column chromatography  ( 1:1, EtOAc: Pet Ether) yielded 
the pure monovalent derivative 4.115  as a waxy solid (190 mg, 65%); Rf = 0.71 (1:1, Pet Ether: 
EtOAc); [α]25 D = 0 (c, 1.1 in DCM); IR vmax (NaCl plate, DCM): 3317.3, 2923.9, 2853.4, 1751.1, 
1665.6, 1610.65, 1592.8, 1547.8, 1486.1, 1467.15, 1433.3, 1369.9, 1227.4, 1084.1, 1053.6, 
957.0, 909.3, 805.4, 750.8, 688.3 cm-1;  1H NMR (300 MHz, CDCl3):  7.98-7.95 (m, 2 H, Ar), 7.84 
(s, 1 H, Ar), 7.37 (s, 1 H, NHCOC15H31), 7.22 (d, J = 9 Hz, 2 H, H1NHCO), 5.56-5.47 (m, 2 H, 
overlap of H-1 and H-4), 5.32-5.20 (m, 2 H, overlap of H-2 and H-3), 4.17-4.05 (m, 3 H, overlap 
of H-6, H-6’ and H-5), 2.37-2.32 (m, 2 H, NHCOCH2(CH2)13CH3), 2.14,  2.01, 2.0 and 1.98  (each s, 
3 H, O(CO)CH3), 1.71-1.66 (m, 2 H, NHCOCH2CH2(CH2)12CH3), 1.36-1.15 (s, 24 H, 
NHCOCH2CH2(CH2)12CH3), 0.85 (t, J = 6.6 Hz, 3 H, NHCOCH2CH2(CH2)12CH3); 
13C NMR (75 MHz, 
CDCl3): δc 172.0, 171.8, 170.3, 170.4, 170.2, 170.1, 166.8 (CO), 138.9, 133.3 (ArC), 129.5, 123.6, 
121.9, 118.7 (ArCH), 79.0 (C-1), 72.2 (C-5), 70.9 (C-3), 68.5 (C-2), 67.3 (C-4), 61.3 (C-6), 37.7 
(NHCOCH2(CH2)13CH3), 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.3, 25.5, 22.7 (NHCOCH2(CH2)13CH3), 
20.8, 20.7 (O(CO)CH3), 14.1 (NHCOCH2(CH2)13CH3), HRMS m/z (ESI+): 705.3993, (C37H57N2O11: 
[M+H]+  requires 705.3957) . 
 
N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-propargyl-N3-propyl-Benzene 
1,5 dicarboxamide 4.124 
Monovalent derivative 4.75 (99 mg, 0.14 mmol), was dissolved in THF (5 mL) under Ar and 
propargyl amine (0.016 mL, 0.20 mmol) was added. The reaction mixture was stirred for 5 min 
and DIPEA (0.036 ml, 0.21 mmol) was added. The resulting solution was stirred at rt for 3 h. 
The solvent was removed in vacuo and the resulting residue purified by column 
chromatography (EtOAc) to yield compound 4.124 as a clear waxy solid (54 mg, 66%); Rf = 0.47 
(EtOAc); [α]25 D = -9.2 (c, 1.3 in DCM); IR vmax (NaCl plate, DCM): 3296.0, 3071.9, 2965.3, 2937.5, 
2877.76, 2122.6, 1751.2, 1659.2, 1532.0, 1431.4, 1369.5, 1226.1, 1173.0, 1135.4, 1058.7, 
997.5, 955.9, 914.6, 800.0, 737.3, 706.8, 683.41 cm-1;  1H NMR (300 MHz, CDCl3): δ 8.43 (s, 1 H, 
Ar), 8.35-8.33 (m, 2 H, Ar), 7.52 (t, J = 5.1 Hz, 1 H, NHCH2CCH), 7.06-6.97 (m, 2 H, overlap of 
NHC3H7 and OCH2CH2NH), 5.38-5.36 (m, 1 H, H-4), 5.18 (dd, J = 7.8 Hz, J = 10.5 Hz, 1 H, H-2), 
5.01 (dd, J = 3.6 Hz, J = 10.5 Hz, 1 H, H-3), 4.49 (d, J = 7.8 Hz, 1 H, H-1), 4.21-4.19 (m, 2 H, 
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NHCH2CCH), 4.13-4.05 (m, 2 H, H-6 and H-6’), 3.99-3.82 (m, 2 H, overlap of H-5 and 1 H of 
OCH2CH2NH) 3.8-3.55 (m, 3 H, overlap of 1 H of OCH2CH2NH and OCH2CH2NH), 3.41-3.34 (m, 2 
H, NHCH2C2H5), 2.24 (t, J = 2.7, 1 H NHCH2CCH), 2.16, 2.02, 1.97, 1.91 (each s, 3 H, O(CO)CH3), 
1.63-1.56 (m, 2 H, NHCH2CH2CH3), 0.94 (t, J = 7.2 Hz, 3 H, NHC2H4CH3); 
13C NMR (75 MHz, 
CDCl3): δc 171.3 (CO), 170.6, 170.5, 170.3, 170.1 (OCOCH3), 165.9, 161.6 (CO), 135.7, 134.8, 
134.6 (ArC), 129.2, 128.5, 128.1 (ArCH), 101.2 (C-1), 79.32 (NHCH2CCH), 71.78 ( NHCH2CCH), 
70.9 (C-5), 70.5 (C-3), 69.2 (C-2) 68.3 (OCH2CH2NH), 66.8 (C-4), 61.3 (C-6), 42.13 (NHCH2C2H5), 
39.9 (OCH2CH2NH), 29.8 (NHCH2CCH), 22.7 ( NHCH2CH2CH3), 21.1, 20.8, 20.6, 20.5 (O(CO)CH3), 
11.5 (NHC2H4CH3); HRMS m/z (ESI+): 663.2614, (C31H40N3O13: [M+H]
+ requires  663.2588). 
 
N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-ethyl]-N2-[2-O-(2,3,4,6-Tetra-O-acetyl-β-
D-galactopyranosyl)-ethyl-1,2,3-triazol-4-ylmethylamide]-N3-propyl-benzene 1,5 dicarboxamide 
4.116 
Copper sulphate .5H2O (2 mg, 0.008 mmol) and sodium ascorbate (3 mg, 0.016 mmol) were 
added to a solution of 2-aminoethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside 2.33 (34 mg, 
0.082 mmol) and O-(azidoethyl)-(2,3,4,6-O-tetracetyl)-β-D-galactopyranose 2.44 (54 mg, 0.082 
mmol) in DCM/Acetone/H2O (3 mL, 1 mL, 1mL). The reaction was allowed to stir at rt 
overnight. The solvent was removed in vacuo, the residue dissolved in DCM and washed with 
brine. Column chromatography (8:1:1, DCM:MeOH:Toluene) afforded the pure product 4.116 
as an clear oily solid (68 mg, 72%); Rf = 0.34 (8:1:1, DCM:MeOH:Toluene); [α]
25 
D = -12 (c, 1 in 
DCM); IR vmax (NaCl plate, DCM): 3382.3, 2964.8, 2938.3, 2879.1, 1749.5, 1659.4, 1536.2, 
1432.2, 1370.3, 1226.6, 1173.7, 1135.3, 1057.9, 955.7 cm-1;  1H NMR (300 MHz, CDCl3): δ 8.39-
8.35 (m, 2 H, Ar), 8.29 (s, 1 H, Ar), 7.94-7.87 (m, 1 H, NHCH2CN3CH), 7.67 (s, 1 H, CN3CH), 7.1 (t, 
J = 5.1 Hz, 1 H, OCH2CH2NH), 7.0 (t, J = 5.4 Hz, 1 H, CONHC3H7), 5.37-5.34 (m, 2 H, H-4), 5.19-
5.10 (m, 2 H, H-2), 5.02-4.95 (m, 1 H, H-3), 4.72-4.65 (m, 2 H, CONHCH2CN3CH), 4.50-4.24 (m, 2 
H, H-1), 4.13-4.01 (m, 4 H, H-6 and H-6’), 3.98-3.82 (m, 4 H, overlap of H-5 and 1 H of 
OCH2CH2NH) 3.81-3.6 (m, 6 H, overlap of 1 H of OCH2CH2NH and OCH2CH2NH), 3.39-3.33 (m, 2 
H, NHCH2C2H5), 2.15, 2.12, 2.02, (each s, 3 H, O(CO)CH3) 1.96-1.88 (m, 15 H, O(CO)CH3) , 1.62-
1.55 (m, 2 H, NHCH2CH2CH3), 0.93 (t, J = 7.2 Hz, 3 H, NHC2H4CH3); 
13C NMR (75 MHz, CDCl3): δc 
171.2 (CO), 170.5, 170.4, 170.3, 170.3, 170.2, 170.11, 170.1 (OCOCH3), 169.75, 165.83 (CO), 
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144.3 (CN3CH),  135.6, 134.8 (ArC), 128.9, 128.3, 128.2 (ArCH), 101.2, 101.9 (C-1), 123.95 
(CN3CH), 70.9 (C-5), 70.5 (C-3), 69.1 (C-2), 68.5, 68.4 (OCH2CH2NH), 66.9 (C-4), 61.3, 61.2 (C-6), 
42.13 (NHCH2C2H5), 39.9 (OCH2CH2NH), 35.6 (NHCH2CN3CH), 22.7 ( NHCH2CH2CH3), 20.7, 20.7 
20.6, 20.6 20.5 (O(CO)CH3), 11.5 (NHC2H4CH3); HRMS m/z (ESI+): 540.7049, (C47H64N6O23: 
[M+2H]+2  requires 540.7022)  
N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-ethyl-glycine)-N2-propargyl-N2-
hexadecanosyl-5-aminobenzene 1,3, dicarboxamide 4.125 
Compound 4.109 (20 mg, 0.019 mmol), was dissolved in THF (3 mL) under Ar and propargyl 
amine (0.016 mL, 0.0018 mmol) added. The reaction mixture was stirred for 5 min and NEt3 
(0.004 ml, 0.029 mmol) was added. The resulting solution was stirred at rt for 3 h. The solvent 
was removed in vacuo and the resulting residue purified by column chromatography (EtOAc) 
to yield compound 4.125 as a waxy solid (11 mg, 65%); Rf = 0.29 (EtOAc); [α]
25 
D = -3.7 (c, 0.85 
in DCM); IR vmax (NaCl plate, DCM): 3287.4, 3086.2, 2924.0, 2853.0, 2140.9, 2119.9, 1751.6, 
1648.2, 1549.4, 1447.0, 1369.1, 1259.1, 1227.4, 1070.2, 956.2, 899.9, 800.9 cm-1; 1H NMR (300 
MHz, CDCl3):  8.39 (s, 1 H, CNHCOC15H31), 8.21 (s, 1 H, Ar), 8.05 (s, 1 H, Ar), 7.93 (s, 1 H, Ar) 
7.79 (bs, 1 H, COCH2NHCO), 7.32 (bs, 1 H, NHCH2CCH), 6.85-6.82 (m, 1 H, OCH2CH2NH), 5.39-
5.38 (m, 1 H, H-4), 5.17 (dd, J = 7.8 Hz, J = 10.2 Hz, 1 H, H-2), 5.08 (dd, J = 3 Hz, J = 10.2 Hz, 1 H, 
H-3), 4.57 (d, J = 7.8 Hz, 1 H, H-1), 4.22-4.06 (m, 6 H, overlap of H-6, H-6’, COCH2NHCO and 
CONHCH2CCH), 4.01-3.96 (m, 1 H, H-5), 3.91-3.87 (m, 1 H, 1 H of OCH2CH2NH), 3.76-3.73 (m, 1 
H, 1 H of OCH2CH2NH),  3.54-3.50 (m, 2 H, OCH2CH2NH), 2.38 (t, J = 7.5 Hz, 2 H, 
NHCOCH2C14H29), 2.28 (t, J = 4.8 Hz, 1 H, NHCH2CCH), 2.14, 2.07, 2.06, 1.99 (each s, 3 H, 
O(CO)CH3), 1.78-1.70 (m, 2 H, NHCOCH2CH2C13H27), 1.24 (s, 24 H, NHCOC2H4(CH2)12CH3), 0.86 (t, 
J = 6.6, 3 H, NHCOC14H28CH3); 
13C NMR (75 MHz, CDCl3):δc 173 (CO), 170.8, 170.4, 170.3, 170.2 
(O(CO)CH)3), 170.0, 167.4, 166.9 (CO), 139.6, 134.7, 134.2 (ArC), 121.5, 120.6 (ArCH), 101.4 (C-
1), 79.9 (NHCH2CCH), 77.4(NHCH2CCH), 71.8 (C-5), 71 (C-3), 69.2 (C-2), 68.6 (OCH2CH2NH), 67.2 
(C-4), 61.5 (C-6), 60.5 (NHCH2CCH) 44.0 (COCH2NHCO), 39.8 (OCH2CH2NH), 37.7 
(NHCOCH2(CH2)13CH3), 32.1, 30.0, 29.9, 29.8, 29.7, 29.6, 29.5, 25.6, 22.8 (NHCOCH2(CH2)13CH3), 
21.0, 20.9, 20.8 and 20.7 (O(CO)CH3), 14.3 (NHCOCH2(CH2)13CH3); HRMS m/z (ESI+): 887.4642 
(C45H67N4O14: [M+H]
+ requires  887.4648). 
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N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-ethyl-glycine)-N2-(2,3,4,6-tetra-O-acetyl-
β-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-N3-hexadecanosyl-5-aminobenzene 1,3, 
dicarboxamide 4.126 
Copper sulphate .5H2O (2 mg, 0.006 mmol) and sodium ascorbate (3 mg, 0.013 mmol) were 
added to a solution of 1-azido-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 3.67 (29 mg, 0.078 
mmol) and N1-[2-O-(2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-ethyl-glycine)-N2-propargyl-
N3-hexadecanosyl-5-aminobenzene 1,3, dicarboxamide 4.125 (58 mg, 0.065 mmol) in 
DCM/Acetone/H2O (3 mL, 1 mL, 1mL). The reaction was allowed to stir at rt overnight. The 
solvent was removed in vacuo, the residue dissolved in DCM and washed with brine. Gradient 
elution chromtagraphy (EtOAc- 8:1:1, DCM:MeOH:Toluene) afforded the pure product as an 
clear oily solid 4.126 (53 mg, 65%); Rf = 0.46 (8:1:1 DCM:MeOH:Toluene); [α]
25 
D = -10.6 (c, 1 in 
DCM); IR vmax (NaCl plate, DCM): 3305.1, 3086.7, 2924.3, 2853.5, 1752.3, 1649.6, 1599.4, 
1548.2, 1446.7, 1427.6, 1370.2, 1226.2, 171.2, 1060.6, 954.6, 900.0, 802.4, 731.5, 682.0 cm-1; 
1H NMR (300 MHz, CDCl3):  8.73 (s, 1 H, CNHCOC15H31), 8.27 (bs, 1 H, COCH2NHCO),  8.05 (s, 2 
H, overlap of CHCN3 and H-Ar), 8.00 (bs, 1 H, NHCH2CN3CH), 7.84 (s, 1 H, Ar), 7.75 (s, 1 H, Ar), 
7.93 (s, 1 H, Ar), 7.00 (bs, 1 H, OCH2CH2NH), 5.9 (d, J = 9.3 Hz, 1 H, H-1’), 5.64 (t, J = 9.9 Hz, 1 H, 
H-2’), 5.53 (m, 1-H, H-4’), 5.39-5.38 (m, 1 H, H-4), 5.27 (dd, J = 3.6 Hz, 1 H, H-3’),  5.15 (dd, J = 
7.8 Hz, J = 10.2 Hz, 1 H, H-2), 5.05 (dd, J = 3.3 Hz, J = 10.5 Hz, 1 H, H-3), 4.68 (bs, 1 H, 
NHCH2CN3CH), 4.56 (d, J = 7.8 Hz, 1 H, H-1), 4.32-4.28 (m, 1 H, H-5’), 4.22-4.06 (m, 6 H, overlap 
of H-6, H-6’ and COCH2NHCO), 3.99-3.95 (m, 1 H, H-5), 3.89-3.86 (m, 1 H, 1H of OCH2CH2NH), 
3.71-3.67 (m, 1 H, 1 H of OCH2CH2NH),  3.49-3.44 (m, 2 H, OCH2CH2NH), 2.33 (t, J = 7.2 Hz, 2 H, 
NHCOCH2C14H29), 2.15, 2.13, 2.07, 2.03, 2.0, 1.98, 1.97 and 1.83 (each s, 3 H, O(CO)CH3), 1.70-
1.64 (m, 2 H, NHCOCH2CH2C13H27), 1.23 (s, 24 H, NHCOC2H4(CH2)12CH3), 0.86 (t, J = 6.6, 3 H, 
NHCOC14H28CH3); 
13C NMR (75 MHz, CDCl3): δc 172.5 (CO), 170.5, 170.3, 170.2, 170.1, 170.1, 
170.0, 169.9 (O(CO)CH)3), 169.3, 167.0, 166.7, 162.61 (CO), 145.6 (NHCH2CN3CH), 139.1, 134.6, 
133.9 (C-Ar), 121.5, 120.3 (CH-Ar), 120.2 (NHCH2CN3CH), 101.2 (C-1), 86.0 (C-1’), 73.9 (C-5’), 
70.8 (C-4’), 70.7 (C-3), 70.6 (C-5), 68.8 (C-2), 68.5 (OCH2CH2NH), 67.9 (C-2’), 66.9 (C-4), 66.7 (C-
4’), 61.2, 61.1 (C-6 and C-6’), 43.6 (COCH2NHCO), 39.4 (OCH2CH2NH), 37.3 
(NHCOCH2(CH2)13CH3), 35.5 (NHCH2CN3CH),31.9, 29.7, 29.6, 29.6 29.5, 29.3, 29.3, 25.4, 22.6 
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(NHCOCH2(CH2)13CH3), 20.8, 20.7, 20.6, 20.6, 20.5, 20.2 (O(CO)CH3), 14.1 (NHCOCH2(CH2)13CH3); 
HRMS m/z (ESI+): 1260.5813 (C59H86N7O23: [M+H]
+ requires  1260.577). 
N1-[2-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-ethyl-glycine)-N2-(2,3,4,6-tetra-O-acetyl-
β-D-galactopyranosyl-1,2,3-triazol-4-ylmethylamide)-N3-hexadecanosyl-5-aminobenzene 1,3, 
dicarboxamide 4.117 
NEt3 (0.1 mL, 0.016 mmol) was added to a stirring solution 4.126 (50 mg, 0.04 mmol) dissolved 
in DCM/MeOH/H2O (1 mL/2 mL/1 mL) at 40 °C. The mixture was stirred for 18 h. The reaction 
mixture was concentrated under reduced pressure and triturated with Et2O to yield compound 
4.117 as a white solid (10 mg, 92%); [α]25 D = 2.3 (c, 0.87 in MeOH); 
1H-NMR (300 MHz, d5-Pyr): 
δ 10.97 (bs, 1 H, NHCOC15H31), 9.88 (t, J = 5.0 Hz, NHCH2CN3CH), 9.76 (t, J = 5.3 Hz, 
NHCOCH2NHCO), 8.97 (s, 1 H, Ar), 8.90 (s, 1 H, AHr), 8.83(t, J = 5.34 Hz, NHCOCH2NHCO), 8.68 
(s, 1 H, Ar), 8.47 (s, 1 H, CN3CH), 6.28 (d, J = 9.15 Hz, H-1’), 5.22-5.13 (m, 1 H, H-2’), 4.93 (d, J = 
5.3 Hz, NHCH2CN3CH), 4.78 (d, J = 7.7 Hz, 1 H, H-1), 4.66 (d, J = 2.8 Hz, 1 H, H-4’), 4.53-4.34 (m, 
11 H, overlap of H-2, H-3, H-3’, H-4, H-5, H-6 and H-6’, NHCOCH2NHCO ), 4.17-4.13 (m, 1 H, 1 H 
of OCH2CH2NH), 4.07-4.7 (m, 1 H, H-5), 4.12-4.06 (m, 1 H, 1 H, OCH2CH2NH), 3.73-3.70(m, 2 H, 
OCH2CH2NH),  1.87-1.77 (m, 2 H, NHCOCH2C14H29), 1.32-1.18 (m, 22 H, NHCOCH2(CH2)12CH3), 
0.87 (t, J = 6.3, 3 H, NHCOC14H26CH3); 
13C NMR (75 MHz, CDCl3): δc 172.8, 170.4, 168.1, 167.5 
(each CO), 151.8 (ArC), 146.5 (CN3CH), 141.1 (ArC), 124.1 (CN3CH), 124.1, 122.8, 121.9 (ArCH), 
105.9 (C-1), 80.9 (C-1’), 77.4 (C-5), 76.1 (C-3’), 75.6 (C-3), 72.9 (C-2), 71.6 (C-2’), 70.6 (C-4, C-4’), 
69.7 (OCH2CH2NH), 62.8, 62.7 (C-6 and C-6’), 44.4 (NHCOCH2NHCO), 40.6 (OCH2CH2NH), 37.7 
(NHCOCH2C14H29), 32.3, 30.2, 30.0, 29.8, 26.3, 23.2 (NHCOCH2(CH2)13CH3), 14.5 
(NHCOCH2(CH2)13CH3);  HRMS m/z (ESI+): 924.4895 (C43H70N7O15: [M+H]
+ requires  924.4924).   
 
p-Tolyl-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactospyranoside 4.133[191] 
β-D-Galactose pentaacetate (5 g, 12.8 mmol) and p-toluenethiol (1.8 g, 14.7 mmol) were 
dissolved in DCM (100 mL) under N2 and BF3Et2O (4.7 mL, 38.4 mmol) added dropwise at 0 
oC. 
The mixture was stirred at rt overnight, diluted with DCM (100 mL) and washed with aqueous 
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sat. NaHCO3 solution, dried over MgSO4, filtered and concentrated. Silica gel column 
chromatography (2:1, Pet Ether:EtOAc) afforded the pure product 4.133 as a white solid (4.1 g, 
69%); Rf = 0.52 (2:1, Pet Ether:EtOAc); IR vmax (NaCl plate, DCM): 3464.4, 3108.1, 
3036.3,3012.4, 2980.4, 2877.9, 1737.7, 1641.4, 1493.8, 1462.8, 1406.4, 1375.4, 1285.1, 
1145.8, 1157.0, 1107.6, 1081.9, 1047.7, 1020.4, 946.1, 897.3, 859.1, 805.9, 748.4, 709.5, 650.3 
cm-1; 1H NMR (300 MHz, CDCl3):  7.40 (d, J = 8.1 Hz, 2 H, Ar), 7.11 (d, J = 8.1 Hz, 2 H, Ar), 5.39 
(d, J = 3.3 Hz, 1 H, H-4), 5.20 (t, J = 9.9 Hz, 1 H, H-2), 5.03 (dd, J = 3.3 Hz, J = 9.9 Hz), 4.64 (d, J = 
9.9 Hz, 1 H, H-1), 4.21-4.07 (m, 2 H, H-6 and H-6’), 3.90 (t, J = 6.4 Hz, 1 H, H-5), 2.33 (s, 3 H, 
SPhCH3), 2.10, 2.09, 2.03, 1.96 (each s, 3 H, O(CO)CH3); HRMS m/z (ESI+): 477.1210 
(C21H26NaO9S: [M+Na]
+ requires  477.1195). 
NMR data is in agreement with the literature.[191, 241] 
 
p-Tolyl-1-thio-β-D-galactospyranoside 4.134[191] 
p-Tolyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactospyranoside 4.133 (980 mg, 2 mmol) was 
dissolved in a mixture of DCM/MeOH (10 mL, 7 mL) and 5.14 M NaOMe (0.19 mL, 1 mmol) was 
added. The mixture was stirred 1 h, neutralised with Amberlite IR-120, filtered and evaporated 
to dryness to yield the crude product 4.134 as a white solid, which was reacted without further 
purification (500 mg, 85%); 1H NMR (300 MHz, MeOD):  7.38 (d, J = 7.9 Hz, 2 H, Ar), 7.04 (d, J 
= 7.9 Hz, 2 H, Ar), 4.43 (d, J = 9.5 Hz, 1 H, H-1), 3.8-3.80 (m, 1 H, H-4), , 3.68-3.64 (m, 2 H, H-6 
and H-6’), 3.54-3.39 (m, 3 H, overlap of H-2, H-3 and H-5), 2.23 (s, 3 H, SPhCH3); HRMS m/z 
(ESI+): 287.0965 (C13H19O5S: [M+Na]
+ requires  287.0948). 
NMR data is in agreement with the literature.[191] 
 
p-Tolyl-2,3,4,6-tetra-O-benzyl -1-thio-β-D-galactospyranoside 4.129[242] 
p-Tolyl 1-thio-β-D-galactospyranoside 4.134 (500 mg, 1.7 mmol) was dissolved in DMF (10 mL) 
under N2. The solution was cooled to 0 
oC and NaH (419 mg, 17 mmol) was added portionwise. 
The resulting mixture was allowed to stir for 15 min and BnBr (2 mL, 17 mmol) added. The 
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reaction mixture was stirred at rt overnight, diluted with EtOAc (20 mL) and washed with 
aqueous sat. NaHCO3 sol, H2O and dried over MgSO4. Column chromatography (5:1, Pet 
Ether:EtOAc) afforded the pure product 4.129 as a white solid (905 mg, 80%);  Rf = 0.75 (5:1, 
Pet Ether:EtOAc); 1H NMR (300 MHz, CDCl3):  7.51 (d, J = 8.1 Hz, 2 H, Ar), 7.46-7.30 (m, 20 H, 
Ar), 7.03 (d, J = 7.9 Hz, 2 H, Ar), 5.01 (d, J = 11.5 Hz, 1 H, H-1), 4.86-4.76 (m, 1 H, H-4), 4.68-4.62 
(m, 1 H, H-2), 4.53-4.43 (m, 2H, PhCH2), 4.01 (m, 1 H, H-3), 3.95 (t, J = 6.4 Hz, 1 H, H-5), 3.72-
3.61 (m, 2 H, H-6 and H-6’) 2.32 (s, 3 H, SPhCH3); HRMS m/z (ESI+): 646.2754 (C41H43O5S: 
[M+H]+ requires  646.2753). 
NMR data is in agreement with the literature.[242] 
 
1-Azido-4,6-O-benzylidene-β-D-galactopyranose 4.136[193] 
1-Azido-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 3.67 (500 mg, 1.3 mmol) was dissolved in 
DCM and MeOH (10 mL, 7 mL) and 5.14 M NaOMe (0.124 mL, 0.67 mmol) was added. The 
mixture was stirred for 1 h, neutralised with Amberlite IR-120, filtered and evaporated to 
dryness to yield the crude product 4.135 as a white solid. The deprotected galactose azide 
4.135 (100 mg, 0.48 mmol) was dissolved in MeCN (1 mL) under Ar, and p-TsOH (4 mg, 0.024 
mmol) and benzaldehyde dimethyl acetal (370 mg, 2.4 mmol) were added. The reaction 
mixture was stirred for 24 h, and NEt3 (0.02 mL) was added. The solvent was removed under 
reduced pressure and column chromatography (EtOAc) yielded the pure product 4.136 as a 
clear waxy solid (119 mg, 83%);%);  Rf = 0.32 (EtOAc); ); IR vmax (NaCl plate, DCM): 3385.7, 
2911.5, 2860.8, 2116.6, 1452.4, 1405.8, 1364.9, 1343.9, 1331.0, 1295.6, 1249.7, 1174.5, 
1101.6, 1085.8, 1002.4, 963.1, 946.2, 899.4, 820.3, 737.5, 695.7, 597.4 cm-1; 1H NMR (300 
MHz, CDCl3):  7.55-7.42 (m, 2 H, Ar), 7.40-7.35 (m, 3 H, Ar), 5.52 (s, 1 H, COCHPHCO), 4.53 (d, J 
= 8.4 Hz, 1 H, H-1),  4.34 (dd, J = 1.5 Hz, J = 12.6 Hz, 1 H, H-6), 4.19-4.18 (m, 1 H, H-3), 4.05 (dd, 
J = 2.1 Hz, J = 12.9 Hz, 1 H, H-6’), 3.71-3.65 (m, 2 H, overlap of H-2 and H-4), 3.54-3.53 (m, 1 H, 
H-5), 2.89, 2.80 (each bs, 1 H, OH); HRMS m/z (ESI+): 328.0725 (C13H15ClN3O5: [M+Cl]
- requires  
328.0706). 
NMR data is in agreement with the literature.[193] 
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1-Azido-2,3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose 4.137[193] 
1-Azido-4,6-O-benzylidene-β-D-galactopyranose 4.136 (971 mg, 3.3 mmol), was dissolved in 
Pyr (10 mL), placed on ice and benzoyl chloride (0.96 mL, 8.2 mmol) was added dropwise. The 
mixture was allowed to warm to rt and stirred overnight. 1 mL of MeOH was added and the 
solvent was evaporated under reduced pressure. The residue was dissolved in DCM, washed 
with aqueous sat. NaHCO3 and dried MgSO4. Column chromatography (1:1, Pet Ether:EtOAc) 
afforded the title compound 4.137 as a white solid (1.39 g, 84%); Rf = 0.74 (1:1, Pet 
Ether:EtOAc);  IR vmax (NaCl plate, DCM): 3036.0, 2982.6, 2862.9, 2119.8, 1727.5, 1601.9, 
1584.8, 1492.2, 1451.7, 1403.3, 1368.0, 1340.9, 1315.8, 12748, 1248.8, 1178.1, 1109.6, 
1093.8, 1069.8, 1026.2, 999.1, 962.2, 936.8, 835.2, 817.8, 768.9, 738.1, 709.2 cm-1; 1H NMR 
(300 MHz, CDCl3):  8.05-7.95 (m, 4 H, Ar), 7.55-7.47 (m, 4 H, Ar), 7.41-7.33 (m, 7 H, Ar), 5.84 
(dd, J = 8.7 Hz, J = 10.2 Hz, 1 H, H-2), 5.65 (s, 1 H, COCHPHCO), 5.41 (dd, J = 3.3 Hz, J = 10.2 Hz, 
H-3), 4.87 (d, J = 8.7 Hz, 1 H, H-1),  4.63-4.62 (m, 1 H, H-4), 4.44 (dd, J = 1.5 Hz, J = 12.6 Hz, 1 H, 
H-6), 4.17-4.11 (m, 1 H, H-6’), 3.79 (d, J = 0.9 Hz, 1 H, H-5); 13C NMR (75 MHz, CDCl3): δc 166.1, 
165.1 (CO), 137.3 (ArC), 133.5, 133.4, 129.9, 129.8, 129.1 (each ArCH), 129.1, 128.9, (ArC), 
128.5, 128.4, 128.2, 126.3 (ArCH), 101.4 (COCHPHCO), 88.5 (C-1), 73.4, (C-4), 72.5 (C-3),68.7, 
68.4 (C-6’), 68.40 (C-5, C-2);  HRMS m/z (ESI+): 536.1211 (C27H23ClN3O7: [M+Cl]
- requires  
536.123). 
This compound is mentioned in the literature but no experimental data is reported.[189] 
 
1-azido-2,3-di-O-benzoyl-6-O-benzyl-β-D-galactopyranose 4.208[194] 
1-azido-2,3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose 4.137 (190 mg, 0.37mmol) was 
dissolved in fresh anhydrous THF (5 mL) containing 4A molecular sieves (500 mg), and stirred 
for 20 min. NaCNBH3 (238 mg, 3.7 mmol) and a crystal of methyl orange were added. A 
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solution of HCl in Et2O (2 M) was added dropwise until the solution persisted as a pink colour. 
The reaction mixture was stirred for 90 min and an additional portion of HCl solution in Et2O (2 
M, 0.5 mL) was added. The reaction was stirred for a futher 2.5 h. The mixture was filtered into 
a separating funnel containing a 1:1 mixture of DCM andH2O (10 mL of each), and the organic 
layer separated. The aqueous layer was then extracted with DCM (2x5 mL), and the organic 
layers combined. The combined organic layers were washed successively with aqueous sat. 
NaHCO3 and brine, dried over MgSO4, filtered and concentrated. Column chromatography 
afforded title glycosyl acceptor 4.130 as colourless oil (138 mg, 73%); Rf = 0.15 (5:1, Pet 
Ether:EtOAc); [α]25 D = +25.4 (c, 1.1 in DCM); IR vmax (NaCl plate, DCM): 3462.6, 3088.4, 3032.9, 
3064.0 2924.6, 2873.9, 2118.4, 1723.6, 1601.8, 1584.7, 1494.5, 1452.1, 1278.1, 1263.8, 
1179.1, 110.2, 1071.2, 1028.6, 935.5, 802.9, 709.8 cm-1;  1H NMR (300 MHz, CDCl3):  7.99-7.93 
(m, 4 H, Ar), 7.50-7.25 (m, 11 H, Ar), 5.79 (dd, J = 8.8 Hz, J = 10.2 Hz, 1 H, H-2), 5.33 (dd, J = 3.0 
Hz, J = 10.2 Hz, H-3), 4.83 (d, J = 8.8 Hz, 1 H, H-1),  4.61 (s, 2 H, PhCH2), 4.41 (t, J = 3.2 Hz, 1 H, 
H-4), 3.96 (t, J = 5.2 Hz, 1 H, H-5), 3.84 (d, J = 5.2 Hz, 2 H, H-6’), 3.23 (d, J = 3.7 Hz, 1 H, OH); 13C 
NMR (75 MHz, CDCl3): δc 165.9, 165.5 (CO), 137.5 (ArC), 133.7, 133.6, 129.9, (ArCH), 129.1, 
128.9 (ArC), 128.7, 128.6, 128.5, 128.1,128.0 (ArCH), 88.7 (C-1), 75.5, (C-5), 74.3 (C-3), 74.0 
(CH2), 69.4 (C-6), 69.0 (C-2), 68.1 (C-4);  HRMS m/z (ESI+): 504.1774 (C27H26N3O7: [M+H]
+ 
requires  504.1765). 
This compound is mentioned in the literature but no experimental data are reported.[189] 
 
1-azido-2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl-(1 4)-2,3-di-O-benzoyl-6-O-benzyl-β-D-
galactopyranoside 4.131 
1-Azido-2,3-di-O-benzoyl-6-O-benzyl-β-D-galactopyranose 4.130 (372 mg, 0.73 mmol), p-tolyl 
2,3,4,6-tetra-O-benzyl -1-thio-β-D-galactospyranoside 4.129 (620 mg, 0.95 mmol) and NIS (453 
mg, 2 mmol mmol) where placed under Ar and dissolved in DCM (6 mL), and Et2O (12 mL) and 
cooled to -55 oC. TMSOTf (0.03 mL, 0.16 mmol) was added and the mixture was stirred for 1 h. 
NEt3 (1.5 mL) was added, and the mixture was further stirred for 1 h at –55 
oC. The mixture 
was warmed to rt, diluted with DCM and washed successively with aqueous sat. NaHCO3 and 
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brine, dried over MgSO4, filtered and concentrated. Gradient elution column chromatography 
(Pet ether-3:1, Pet Ether:EtOAc) afforded the title glycoside 4.131 as colourless oil (308 mg, 
41%); Rf = 0.63 (3:1, Pet Ether:EtOAc); [α]
25 
D = +63 (c, 0.95 in CHCl2); IR vmax (NaCl plate, DCM): 
3063.4, 3030.7, 2923.9, 2868.7, 2116.8, 1730.3, 1601.8, 1584.9, 1452.7, 1360.1, 1314.4, 
1452.7, 1360.1, 1275.5, 1098.1, 912.9, 803.4, 741.1, 697.8 cm-1;  1H NMR (300 MHz, CDCl3):  
7.97-7.89 (m, 4 H, Ar), 7.51-7.21 (m, 31 H, Ar), 5.78-5.71 (m, 1 H, H-2), 5.26-5.23 (m, 1 H, H-3), 
4.94 (dd, J = 3.1 Hz, 1 H, H-1), 4.88-4.87 (m, 1 H, H-4’), 4.83 (d, J = 6 Hz, H-1’), 4.77 (s, 2 H, 
PhCH2), 4.63-4.59 (m, 1 H, H-2’), 4.49-4.45 (m, 1 H, H-3’), 4.41 (bs, 1 H, H-4), 4.33-4.28 (m, 1 H, 
H-5’), 4.26 (s, 2 H, PhCH2), 4.15-3.92 (m, 8 H, overlap of PhCH2 and H-6), 3.71-3.65 (m, 1 H, H-
5), 3.71-3.65 (m, 1 H, 1 H of H-6’), 3.41-3.35 (m, 1 H, of H-6’); 13C NMR (75 MHz, CDCl3): δc 
171.2, 166.2, 165.3 (CO), 138.8, 138.7, 138.6, 138.2, 137.8 (ArC), 133.4, 133.3, 129.8, 129.7, 
1290, 128.9 (ArCH), 128.4-127.3 (overlap of ArC and ArCH),  100.3 (C-1), 88.7 (C-1’), 78.8, 76.4, 
76.3 (each CH) , 74.9 (PhCH2), 74.8 (CH), 74.7 (C-3), 74.1 (C-3’), 73.8, 73.1, 72.8, 72.5 (each 
CH2), 69.6 (C-2), 69.0 (C-2’) 67.9, 67.4 (each CH2);  HRMS m/z (ESI+): 1048.404 (C61H59N3NaO12: 
[M+Na]+ requires  1048.3991). 
 
1-azido-2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl-(1 4)-6-O-benzyl-β-D-galactopyranoside 
4.138 
1-Azido-2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl-(14)-2,3-di-O-benzoyl-6-O-benzyl-β-D 
galactopyranoside 4.131 (308 mg, 0.3 mmol) was dissolved in MeOH (4 mL) and NaOMe added 
(1 M, 0.094 mL). The solution heated to 90 oC and stirred for 4 h. The mixture was then 
neutralised using HCl (1 M). Column chromatography (4:1, Toluene:Acetone) afforded the pure 
product 4.138 has an oily solid (193 mg, 78%); Rf = 0.22 (4:1, Toluene:Acetone); [α]
25 
D = +63 (c, 
0.95 in CHCl2); IR vmax (NaCl plate, DCM): 3444.1, 3088.1, 3063.5, 3030.3, 2919.3, 2870.7, 
2114.5, 1496.5, 1453.9, 1366.9, 1334.4, 1260.6, 1208.8, 1097.7, 1053.4, 910.7, 802.6, 736.6, 
697.8 cm-1; 1H NMR (300 MHz, CDCl3):  7.41-7.19 (m, 25 H, Ar), 4.95-4.71 (m, 5 H, overlap of 
H-1 and other signals), 4.66-4.53 (m, 2 H), 4.46-4.29 (m, 5 H, overlap of CH2Ph, H-1’ and other 
signals), 4.08-4.03 (m, 3 H), 3.94-3.56 (m, 7 H), 3.40-3.22 (m, 3 H); 13C NMR (75 MHz, CDCl3): δc 
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170.2, 168.3, 165.3 (CO), 138.4, 138.3, 137.9, 137.2 (ArC), 128.6-127.5 (overlap of ArC and 
ArCH),  100.4 (C-1), 90.4 (C-1’), 80.9, 78.8, 77.2, 76.4, 76.2 (each CH) , 74.5 (PhCH2), 74.5, 74.3 
(each CH), 73.9, 73.8, 73.2, 73.1 (each PhCH2), 71.6, 71.4, (each CH), 70.33, 69.3 (each CH2); 
HRMS m/z (ESI+): 840.3489 (C47H51N3NaO10: [M+Na]
+ requires  840.3467). 
 
Solubility of aromatic-based analogues 
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6.2.4 Experimental procedures and materials for Chapter 5 
 
Materials 
 
Phosphate Buffered Saline: 
 
2 PBS tablets were dissolved in 400 mL of distilled H2O to give a 0.01 M solution. This solution 
was then sterilised by autoclaving (at 121 oC for 20 mins). 
 
Quarter Strength Ringers Solution: 
 
Quarter Strength Ringers Solution was prepared by dissolving 1 Ringers tablet in 500 mL of 
distilled H2O, the solution was then sterilised by autoclaving (at 121 
oC for 20 mins). 
Invasion Lysis Buffer: 
PBS was prepared as before except EDTA was added to give a final concentration of 10 mM. 
Triton-X 100 was added to the PBS-EDTA to give a 0.25% vol/vol solution. The solution was 
then autoclaved (at 121 oC for 20 mins). 
Coating Solution: 
Coating solution was required to aid adherence of the CFBE cells to the tissue culture flasks 
and 24 well plates. This prepared used 8.8 mL of plain MEM, 1ml of collagen, 100 μl of 
fibronectin and 100 μl of bovine albinum serum. The 24 well plates and tissue culture flasks 
were coated with coating solution (500 μl and 3 mL respectively) which was left for 1 min and 
removed. The 24 well plates tissue culture flasks were allowed to air dry for 1 hour and stored 
at 4 oC. 
LB medium: 
LB medium was prepared by dissolving 25 g of LB (Sigma) in 1L of deionised H2O, the medium 
was then sterilised by autoclaving (at 121 oC for 20 mins). 
LB Agar: 
LB Agar was prepared by dissolving 35 g of LB Agar (Sigma) in deionised H2O, the agar was 
sterilised by autoclaving (at 121 oC for 20 mins). 
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BCSA (Burkholderia cepacia selective agar): 
BCSA was prepared by adding 5.0 g NaCl, 10.0 g sucrose, 10.0 g lactose, 0.08 g phenol red, 0.02 
g crystal violet, 10.0 g trypticase peptone, 1.5 g yeast extract and  general agar 14 g to 1 L of 
deionised H2O. The media was sterilised by autoclaving, allowed to cool to rt and antibiotics 
added, (600,000U polymixin B and 10 mg of gentamicin). 
Procedures 
Freezing cells: 
Freezing solution of 10% DMSO, 50% FBS and 40% MEM was used. DMSO is a cryo-protectant 
which prevents the formation of ice crystals as cells are frozen which would then cause cell 
lysis upon thawing. It is toxic to cells at rt however, and therefore freezing down and reviving 
cells should be done as quickly as possible. Cells were frozen down during the log-phase of 
growth when flakes are approximately 60-80% confluent and not higher. 1x106 cells were 
frozen in each vial. The cells were trypsinised, centrifuged and the pellet resuspended gently 
but rapidly in the freezing medium above. The vial was frozen at -80 oC and transferred to a 
nitrogen dewar for long term storage. 
Reviving Cells: 
The cells were removed from the liquid nitrogen Dewar and thawed rapidly in a H2O bath at   
37 oC and immediately transferred to a universal containing 5 mL of warm culture medium. 
The cells were centrifuged and and the pellet resuspended in 5ml of warm tissue culture 
medium and transferred to a T25 flask. When this flask was nearly confluent, cells were 
subcultered into a T75 flask. This was then split into 3 T75 flasks. Cells were not used for any 
experiment until after three passages. 
Subculturing of Epithelial cells: 
The cell lines were subcultured once they had reached 80% confluency. Trypsin was warmed to 
37 oC. Supernatant was decanted from the T75 flask and the flask washed well with 10ml of 
sterile PBS to remove any remaining serum. 4ml of trypsin was added to detach the cells from 
the flask and the flask returned to the incubator for 10 min. After 10 min the flask was taken 
from the incubator and hit vigorously on the side to see if all cells had dislodged. Once all cells 
had dislodged the trypsin was inactivated by adding an equvilent amount of tissue culture 
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medium containing 10% FBS. The cells were centrifuged at 2500 g for 5 min, the pellet 
collected and resuspended in fresh tissue culture medium at a 1:2 split. 
Trypan Blue Exclusion Assay (Cell Counting) 
Cells were harvested as usual and resuspended in 5 mL of tissue culture media. Cell suspension 
(20 μl) and trypan blue (20 μl) were added to an eppendorf. 10 μl of this suspension was 
pipetted under a coverslip on a haemocytometer. Only viable cells thay excluded the dye in a 
1mm2 area were counted. The number of cells/ml was calculated using the following 
calculation: 
No. of cells/mm2xdilution factorx104 
No. mls added to cells 
CFBE41o-: 
CFBE cells are transformed bronchial epithelial cells isolated from a CF patient with the 
F508/F508 deletion.[243] CFBE cells require coated flasks and plates. CFBEs can be difficult to 
subculture using trypsin, especially if very confluent. CFBE’s cannot be split very low although 
they should grow very rapidly. CFBE cells can be quite large and a confluent flask might only 
yield 2x106 cells. 
Adhesion Assay: 
Lung epithelial cell lines were grown to confluence in sterile T75 flasks at 37 oC under 5% CO2 
and then seeded onto 24 well plates with FBS in the absence of pen/strep at a density of 
4x105cells/1 mL and incubated overnight at 37 oC in 5% CO2. Bcc strain (LMG13010) were 
inoculated from BCSA selective agar into 10 mL of LB broth and left shaking at 37 oC overnight. 
The following day, 10ml of the LMG13010 was inoculated into 100ml of LB and left shaking to 
reach mid log phase. The bacterial concentration was determined using the growth curve and 
they were grown to an O.D of 0.6. 1 mL solutions of the relevant concentrations or solvent 
controls were made up in sterile eppendorfs and bacteria added to a final concentration of 
2x107 CFU/ml. The bacteria were then pre-incubated with this inhibitor (shaking at 37 oC, no 
CO2, 10 min).  The epithelial cells were rinsed with warm MEM to remove serum and 500 μl of 
bacterial and inhibitor suspension was added. The plate was centrifuged at 700 g for 5 min to 
facilitate attachment and incubated for 15 min (no shaking, 37 oC, 5% CO2). After the 15 mins 
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the medium was removed from the wells and the cells were washed 3 times with sterile PBS to 
remove any bacteria which hadn’t attached to the epithelial cells. 500 μl of cell lysis buffer was 
added for 20 min at room temperature. The resulting lysate was carefully collected with cell 
scraping to ensure all of the cell lysate is obtained. This was then serially diluted in Ringer’s 
solution and quantified by viable counts of bacteria colonies on LB agar after 48 h.  
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